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2Abstract
Serum Response Factor regulates a large array of genes involved in diverse processes 
including  cell  proliferation,  muscle  differentiation  and  development,  and  cytoskeletal 
processes  such  as cell  migration  and  adhesion.  The  specificity  and  versatility of the 
SRF responses is achieved by combinatorial interactions with accessory factors.  SRF 
binds to the CC(A/T)2A(A/T)3GG CArG  box consensus sequence within the promoters 
of its target genes and acts as a docking platform for diverse signal regulated and cell- 
type  specific  cofactors  to  elicit  their  distinct  responses.  In  fibroblasts  two  pathways 
signal through  SRF in a  mutually exclusive  manner.  MAP  kinase signalling  results  in 
transcriptional  activation of a subset of SRF target genes,  via the  interaction  of  SRF 
with  members  of  the  TCF  family  of  Ets  domain  proteins.  In  contrast  Rho-signalling 
induced changes  in  actin dynamics result in the  association  of SRF with  members of 
the Myocardin-related family of SRF cofactors (MAL/MRTF-A/MKL1  and MAL16/MRTF- 
B/MKL2). The results described in this thesis characterise the molecular mechanism of 
MAL-SRF  complex  formation.  MAL  binds  SRF  as  a dimer via  a  seven-residue  core 
sequence  within  the  MAL  B1  region.  Residues  in  the  neighbouring  Q-box  enhance 
MAL-SRF complex formation,  although these do  not contact  SRF directly.  The  MAL- 
SRF  interaction  displays  the  properties  of  a  Rho-regulated  cofactor.  MAL  competes 
with  TCF  for  SRF  binding  due  to  the  interaction  of  both  cofactors  with  the  same 
hydrophobic  groove  and  pocket  on  SRF.  In  contrast  to  TCF,  MAL-SRF  complex 
formation depends on the intact N-terminus of the SRF DNA-binding domain. Mutations 
in the SRF al-helix that reduce DNA bending also impair complex formation with MAL. 
These  mutations  however  do  not  affect  DNA  distortion  in  the  MAL-SRF  complex. 
Efficient MAL-SRF complex formation requires that SRF be bound to its cognate  DNA 
and that MAL directly contacts DNA on either side of the CArG box. My results support 
a  model  in  which  each  MAL  monomer  adds  a  p-strand  consisting  of  the  core  B1 
sequence,  to  the  p-sheet  of  the  SRF  DNA-binding  domain  in  a  similar  way to  TCF, 
while  also  making  direct  DNA  contacts  in  the  ternary  complex  facilitated  by  SRF- 
induced  DNA  distortion.  My  analysis  of  complex  formation  between  MAL  and  SRF 
demonstrates that members of the  MRTF and TCF families of SRF cofactors interact 
with  SRF  using  related  but distinct  mechanisms,  thus  providing  a  molecular rationale 
for their mutually exclusive transcriptional responses and the specificity of signalling to 
SRF.
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1  Introduction
The different cell types of multicellular organisms need to ensure the correct temporal 
and spatial patterns of expression of their genes in order to respond to diverse stimuli 
during growth, differentiation and development and perform their specialised functions. 
To this  end  control  mechanisms  are  in  place  at  different  stages of gene  expression, 
including  RNA  synthesis,  transcript  processing  and  translation.  The  process  of 
transcriptional  activation  is  a  major  point  of  regulation  that  ensures  the  correct 
execution  of  the  transcriptional  programme  of  each  one  of  the  vast  number  of 
eukaryotic genes (Orphanides, G. etal., 2002).
1.1  Transcriptional control of gene expression
Transcription involves the simple principle of the localised action of an enzyme with the 
ability  to  catalyse  the  synthesis  of  RNA  from  a  DNA  template  using  a  pool  of  the 
appropriate  nucleotides.  In  practice  however  transcription  is  a  complex  process 
involving many proteins acting in concert within large multicomponent complexes (Lee, 
T. I. etal., 2000; Lemon, B. etal., 2000).
The  initiation  of  mRNA  synthesis  requires  the  RNA  polymerase  II  complex  with  its 
associated  general  transcription  factors  (GTFs),  including  TFIIF,  TFIIB,  TFIIH,  TFIIE 
and  TFIID,  which  together  comprise  the  basal  transcriptional  machinery  and  are 
involved in  recognition of the core proximal  promoter elements (Woychik,  N.  A.  et al., 
2002).  Formation  of  this  complex  is  sufficient  for  a  basal  level  of  transcription. 
Regulated  transcription  depends  on  a wide  range  of  sequence  specific  DNA-binding 
proteins, which associate with regulatory promoter elements in a controlled  manner to 
elicit specific transcriptional  responses.  Coregulators,  such  as the  Mediator and  GTF 
TFIID complexes,  that bridge the sequence-specific factors with the  basal  machinery 
and transmit the regulatory signals (Malik, S. etal., 2005; Naar, A. M.  etal., 2001), play 
an  important role in this process.  Additionally transcriptional control  is critically linked 
with  the  state  of  chromatin,  with  many  chromatin  remodelling  factors  required  to 
mobilise nucleosomes and expose DNA for transcription factor association (Narlikar, G. 
J.  et a!., 2002), as well as a variety of enzymes that catalyse covalent modifications of
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histones  (including  methylation,  acetyl  at  ion,  phosphorylation,  ubiquitination;
(Khorasanizadeh, S., 2004)) that promote or inhibit transcription.
The correct ordered  recruitment and concerted action of these factors  in  response to 
specific  regulatory  cues  is  necessary  to  ensure  that  only  the  genetic  information 
needed  for  biological  function  and  not  the  full  complement  of  cellular  genes,  is 
expressed at any given time.
1.1.1  Sequence specific transcription factors
Sequence-specific DNA-binding transcription factors are a focal point of transcriptional 
regulation. These proteins bind to their cognate DNA elements that are present in the 
regulatory  regions  (e.g.  enhancers)  of  target  genes  and  in  response  to  particular 
signals orchestrate transcriptional activation through the recruitment and/or stimulation 
of the  activity  of the  basal  transcriptional  complex  or  repression  by  inhibition  of  this 
process (Kadonaga, J. T., 2004). Thus sequence specific factors (which hereafter will 
be  referred  to  as  transcription  factors)  function  as  a  crucial  interface  between  the 
regulatory  information  stored  in  the  promoters  of  genes  and  the  transcriptional 
machinery whose activity depends on the correct interpretation of this information.
Transcription  factors  are  modular  in  structure,  and  usually  contain  a  DNA-binding 
domain  capable  of  sequence  specific  binding  and  discrete  transcriptional  activation 
and/or repression  domains.  In  contrast to the  extensively characterised  DNA-binding 
domains, the transactivation domains of transcription factors remain structurally poorly 
defined,  although  acidic  regions  and  polyglutamine  and  polyproline  stretches  have 
been found to be important for transcriptional activity ((Garvie, C.  W.  et al., 2001) and 
references therein).  Transactivation domains  are thought to transduce transcriptional 
responses by recruiting co-regulatory complexes, which either physically link the DNA- 
specific  transcription  factors  with  the  basal  machinery  complex  via  protein-protein 
interactions or function in chromatin regulation (Garvie, C. W. etal., 2001).
Transcription  factors  may  also  contain  additional  regulatory  modules,  such  as  the 
ligand binding domains of nuclear receptors (Nagy, L. et al., 2004) or the actin binding 
RPEL domain of the MRTFs (see Section 1.2.5.7.1) and dimerisation domains. As will 
be  discussed  in  the  following  sections the  modular character of transcription  factors
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does not preclude multifunctionality of their various domains, as seen in the cases for 
example of basic leucine-zipper (bZIP) factors which  dimerise and  bind  DNA through 
the same domain and also the MADS box transcription factors (see Sections 1.1.1.1.2 
and 1.2.3).
1.1.1.1  Proteln-DNA Interactions
Transcription factors derive their ability to  interact with  specific  DNA sequences from 
the  fact  that  their  DNA-binding  domains  contain  surfaces  that  are  chemically 
complementary to particular patterns of base pairs (Garvie,  C.  W.  et al.,  2001).  Thus 
the DNA-binding surfaces of transcription factors form multiple base-specific hydrogen 
bonds and van der Waals interactions with the functional groups of base pairs,  which 
are  exposed  in the  minor and  major grooves of the  DNA.  DNA binding  also  involves 
non-specific contacts through hydrogen bonds or salt bridges with the highly negatively 
charged  sugar-phosphate  backbone  of the double  helix  (Garvie,  C.  W.  et al.,  2001). 
The  backbone  conformation  which  is  also  sequence  dependent  to  a  certain  degree 
may in some cases affect the protein-DNA interactions,  as exemplified by MADS  box 
transcription  factors  and  their  recognition  of  narrow  minor  grooves  created  by  A-T 
tracts (see Section 1.2.3).
Different  transcription  factors  employ  distinct  modes  of  DNA  recognition  in  which 
different  combinations  of  structural  elements  provide  the  main  DNA-binding 
determinants.  The  most common  interactions  include the  binding  of an  a-helix  in the 
major groove,  although examples also exist of p-strands or loops binding in the minor 
or major groove (Garvie, C. W. etal., 2001). A great variety of DNA-binding motifs have 
been  described to  date  and  major categories  include the  helix-turn-helix,  zinc finger, 
basic region leucine-zipper and helix-loop-helix motifs (Garvie, C. W. etal., 2001).
1.1.1.1.1  The helix-turn-helix motif
The  helix-turn-helix  motif is one of the  most common  DNA-binding  motifs.  The  broad 
range of proteins belonging to this domain superfamily, contain different variations of a 
three-helix bundle in which the conserved second and third helices provide direct DNA 
binding  (Garvie,  C.  W.  et al.,  2001).  The  C-terminal  recognition  helix,  mediates  the 
majority of DNA contacts by binding the major groove, while the second helix is located
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above the recognition helix at a fixed angle and provides additional DNA contacts. The 
homeodomain is a variant type of the  HTH motif, which uses an  N-terminal extension 
from the a1  helix to contact the minor groove (illustrated in the ternary complex of the 
MATa1-MATa2 homeodomain heterodimer; (Li, T. etal.,  1995)). Another variant is the 
winged-HTH motif found in ETS domain proteins, which contains two flexible loops on 
either side of the  main  HTH domain through which it  makes  additional  DNA contacts 
(see also Section 1.2.5.6).
1.1.1.1.2  The basic region leucine-zipper motif
Basic region leucine-zipper (bZIP) proteins contain long a-helices which dimerise by a 
coiled-coil  leucine-zipper  motif  formed  by  their  the  C-terminal  regions,  with  the  N- 
termini spread apart to enter the major groove of DNA, so that the two a-helices adopt 
a scissor-like conformation via which they dimerise and interact with  DNA (Garvie,  C. 
W.  et al.,  2001).  bZIP  proteins  can  interact  with  DNA  as  homo-  or  heterodimers  as 
seen with the Fos and Jun proteins, providing added functional versatility (Chinenov, Y. 
etal., 2001).
1.1.1.1.3  The helix-loop-helix motif
The helix-loop-helix motif is similar to the bZIP since it also mediates DNA-binding and 
dimerisation.  Each  monomer consists of two a-helices connected  by a loop.  These a- 
helical  elements  interact  forming  a  four-helix  bundle  in  which  the  N-terminal  basic 
regions are inserted in the major groove of DNA.  Like bZIP factors bHLH proteins can 
homo- or heterodimerise (Garvie, C. W. etal., 2001).
1.1.1.2  Regulation of transcription factor activity
Regulated transcription depends on the tight control of transcription factor activity,  so 
that the correct genes are active at the right time. Several different ways exist in which 
cells  modulate  transcription  factor  activity  and  these  include  post-translational 
modifications such as phosphorylation, regulation of the subcellular localisation, control 
of transcription  factor  levels  by expression  or degradation,  interaction  with  additional 
regulatory proteins or a combination of these (Calkhoven, C. F. etal., 1996).
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1.1.1.2.1  Regulation of transcription factor activity by phosphorylation
Regulation of transcription factor activity by phosphorylation is exemplified by the TCF 
transcription  factors  which  are  heavily  phosphorylated  in  response  to  MAP-kinase 
signalling  resulting  in  stimulation  of  transactivation  activity  via  interactions  with 
transcriptional  coactivators  (see  Section  1.2.5.6).  The  bZIP  protein  CREB  is  also 
phosphorylated  by  multiple  kinases  resulting  in  the  recruitment  of the  CBP/p300  co­
activator (De Cesare, D. etal., 1999).
1.1.1.2.2  Regulation  of  transcription  factor  activity  by  subcellular 
compartmentalisation
Nuclear  translocation  of  transcriptional  factors  provides  inducibility  to  transcriptional 
regulation  in  response  to  extracellular  stimuli.  For  example,  the  transcription  factor 
NFkB  is  retained  in  the  cytoplasm  by  association  with  the  IkB  inhibitory  protein.  In 
response to extracellular cues IkB is targeted for phosphorylation and is subsequently 
degraded,  resulting in the nuclear translocation of NFkB and transcriptional  activation 
(DiDonato, J. A. etal., 1997). Other transcriptional regulators, such as MRTF and FHL2 
also accumulate in the nucleus as a result of signalling inputs ((Miralles, F. etal., 2003; 
Muller, J. M. etal., 2002); for the regulation of the MRTFs see also Section 1.2.5.7).
1.1.1.2.3  Regulation of transcription factor activity by degradation
Whereas  degradation  of  an  interacting  partner  can  result  in  the  activation  of  a 
transcription factor,  as in the case of IkB-NFkB, direct degradation of the transcription 
factor itself can also provide a means for regulating transcription.  The best understood 
example for this kind of regulation is the activation of Tcf/Lef-1  via protein stabilisation 
of  its  activator  p-catenin  upon  Wnt-signalling  (Molenaar,  M.  et  al.,  1996).  In  the 
absence  of  Wnt-signalling  cytoplasmic  p-catenin  forms  a  complex  with  glycogen 
synthase kinase 3 (GSK3) and adenomatous polyposis coli (APC) (Rubinfeld, B.  et al.,
1996).  This  complex  allows the  phosphorylation  of p-catenin  by GSK3,  which  in  turn 
tags p-catenin for ubiquitination and subsequent degradation  (Aberle,  H.  et al.,  1997). 
Disruption  of the  APC-GSK3-p-catenin  complex  by  Wnt-signalling  prevents  p-catenin 
phosphorylation  by  GSK3  and  inhibits  its  degradation,  resulting  in  p-catenin  nuclear 
translocation and the activation of gene expression.
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1.1.1.2.4  Regulation of transcription factor activity by acetylation
Transcription  factor  activity  can  be  regulated  by  the  post-translational  acetylation  of 
lysines, which may result in modulations in DNA binding affinity, transcriptional activity 
and  protein  stability  (reviewed  in  (Glozak,  M.  A.  et al.,  2005)).  Acetylation  of  a  non­
histone protein was first described for the tumour suppressor p53 (Gu, W. etal., 1997). 
p53  is  acetylated  at  five  lysines  within  its  C-terminal  regulatory  domain,  which 
stimulates its DNA-binding affinity and transcriptional activity. Increased p53-dependent 
gene  expression  by  acetylation  has  been  reported  to  occur  in  vivo  in  response  to 
cellular stresses (Luo, J. etal., 2004).
1.1.1.2.5  Regulation of transcription factor activity by differential expression
Transcription  factors  are  key  mediators  of  the  genetic  programmes  that  underlie 
development.  The  specific  spatial  and temporal  expression  pattern  of  a transcription 
factor  will  dictate  the  cell  growth  and  differentiation  of  particular  tissues  and  their 
morphogenesis  into  organs,  as  well  as  the  maintenance  of  the  differentiation  state. 
There  are  numerous  examples  of  transcription  factors  involved  in  determining 
developmental fate via their specific patterns of expression, such as MyoD-Myf5-MRF4 
in myogenic determination ((Berkes, C. A. et al., 2005) and references therein), GATA- 
1   in erythroid cell differentiation (Pevny, L. etal.,  1991),  Pax6 in eye development (Hill, 
R.  E.  et al.,  1991), or the Drosophila Dorsal transcription factor in determining dorsal- 
ventral axis (Roth, S. etal., 1989).
1.1.1.2.6  Regulation of transcription factor activity by multiple mechanisms
As  inferred  from the examples  presented  in the  previous section,  it  is common for a 
combination  of  mechanisms  to  be  in  place  for  the  regulation  of  transcription  factor 
activity.  One such  example  is the multiple events controlling the activity of the Smad 
protein  mediators  of  TGFp  signalling  (Massague,  J.  et  al.,  2005).  Under  basal 
conditions the Smads are continuously shuttling  between the  nucleus  and cytoplasm. 
Activation  of the  TGFp  pathway  results  in  their  phosphorylation  and  retention  in  the 
nucleus,  where they interact with  additional factors to activate transcription.  A similar 
multi-level  regulatory  mechanism  is  at  place for  members of the  MRTF family,  which 
are  also  subject  to  nucleocytoplasmic  shuttling,  phosphorylation  and  interaction  with 
the SRF transcription factor (see Section 1.2.5.7.3).
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1.1.1.3  Combinatorial  Interactions  -   regulation  of  transcription  by 
multicomponent transcription factor complexes
Unlike  prokaryotic  transcription  factors  that  often  function  individually  to  modulate 
transcription,  eukaryotic  gene  transcription  is  regulated  by  multiple  interacting 
transcription factors. This involves interactions between sequence-specific transcription 
factors  bound  to  adjacent  or  distant  regulatory  promoter  elements  as  well  as 
association  of  DNA-binding  factors  with  cofactors devoid  of  specific  DNA-recognition 
activity (Ogata, K. etal., 2003).
The  regulation  of  transcription  by  combinatorial  interactions  between  diverse 
transcription  factors  contributes  to  the  versatility  of  their  transcriptional  responses, 
since different protein combinations support different transcriptional outcomes.  This is 
exemplified  by  the  interactions  of  MADS  box  transcription  factors  with  their  various 
cofactors which  confer functional  specificity  (analysed  in  detail  in  Sections  1.2.4  and 
1.2.5).  The  NFAT transcription factors  are also involved  in  selective  interactions  with 
Fos/Jun  heterodimers and  FoxP3 in T-cell activation  (Chen,  L.  et al.,  1998;  Wu,  Y.  et 
al., 2006). These interactions are mutually exclusive and controlled by different signals. 
NFAT  cofactor  selectivity  is  thought  to  function  in  T-cell  lineage  determination,  with 
binding to Fos/Jun resulting in effector T-cell differentiation, binding to FoxP3 facilitating 
regulatory T-cell differentiation and lack of signals promoting either interaction leading 
to T-cell anergy (Rudensky, A. Y. et al., 2006; Wu, Y.  et al., 2006). Thus combinatorial 
interactions  of transcription factors  also function  to  integrate  multiple signals at  gene 
promoters  allowing  diverse  modes  of  regulation  of  the  same  gene  depending  on 
different combinations of signalling inputs.
1.1.1.3.1  The enhanceosome
The  significance  of  combinatorial  interactions  between  transcription  factors  in  the 
regulation of transcription is illustrated by the assembly of distinct transcription factor -  
enhancer complexes at gene regulatory regions called enhanceosomes in response to 
specific signals  (reviewed  in  (Carey,  M.,  1998; Courey,  A.  J.,  2001;  Merika,  M.  et al., 
2001)).
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Assembly  of  these  multiprotein  complexes  depends  on  the  cooperative  binding  of 
individual  transcription  factors  to their  enhancer  regions,  which  requires  the  specific 
composition  and  spatial  arrangement  of  their  DNA-binding  sites.  The  prototype 
enhanceosome  model  is  that  assembled  at  the  promoter  region  of  the  interferon  p 
(IFNp) gene  in response to virus infection  (Thanos,  D.  et al.,  1995).  Assembly of this 
enhanceosome involves the cooperative binding of NFkB, c-Jun, ATF-2, and IRF family 
members to a 60  bp  DNA segment containing  specific  DNA-binding  sites.  Binding  of 
these factors critically depends on the architectural protein HMG  I (Y), which alters the 
curvature of the DNA and acts to stabilise the enhanceosome complex ((Thanos, D.  et 
al., 1995); reviewed in (Merika, M. etal., 2001)).
Correct  stepwise  enhanceosome  assembly  results  in  synergistic  transcriptional 
activation, by presenting a surface structure, which is complementary to components of 
the coregulator complexes and the basal transcriptional  machinery (Carey,  M.,  1998). 
The  absence  of  a  single  factor  can  greatly  destabilise  the  complex,  and  thus  the 
enhanceosome  represents  a  transcriptional  switch  which  is  inactive  until  all  the 
necessary components are present (Courey, A. J., 2001).
1.1.2  Summary
In  summary  transcriptional  regulation  depends  on  the  concerted  action  of  multiple 
diverse  transcription  factors.  The  critical  characteristics  of  these  factors  are  their 
abilities  to  bind  DNA  in  a  sequence-specific  manner  and  to  ultimately  decode  the 
regulatory  information  present  in the  promoters  of genes and transmit  it to the  basal 
transcriptional  machinery.  Moreover  combinatorial  interactions  between  transcription 
factors  greatly  impact  on  the  correct  execution  of  the  transcriptional  programme  of 
each  eukaryotic  gene  at different  developmental  stages  and  in  response  to  different 
environmental conditions. The following sections will focus on the MADS box family of 
transcription  factors,  the  properties  of  which  illustrate  the  principles  of  regulatory 
versatility of transcriptional responses.
1.2  The MADS box transcription factor family
The  MADS  box family of eukaryotic transcriptional  regulators  is characterised  by the 
presence of a conserved  56 amino  acid  domain  named  the  MADS  box after the five
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founding  members  of  the  family:  MCM1  (Minichromosome  maintenance  1,  found  in 
yeast, (Passmore, S.  et al., 1989)), AG (agamous, found in plants, (Yanofsky,  M.  F.  et 
at., 1990)) or ARG80 (found in yeast, (Dubois, E.  etal.,  1987)), QEFA (Deficiens found 
in  plants,  (Sommer,  H.  et  al.,  1990))  and  £RF  (Serum  Response  Factor,  found  in 
animals, (Norman, C. etal., 1988)).
Thus  MADS box containing  proteins are found in fungi,  plants and animals,  including 
nematodes,  arthropods,  lower vertebrates  and  mammals.  Four  MADS  proteins  have 
been described in Saccharomyces cerevisiae (MCM1, ARG80, Rlm1  and Smp1), while 
SRF  and  the  Myocyte  Enhancer  2  factors  (MEF2A,  B,  C  and  D)  are  found  in 
metazoans.  In plants the family is greatly expanded and over one hundred  MADS box 
containing  candidate  genes  have  been  identified  by  genomic  sequencing  in 
Arabidopsis thaliana and over 70 in Oryza sativa (De Bodt, S. etal., 2003).
MADS  box  containing  proteins  are  involved  in  diverse  biological  processes  ranging 
from  cell  proliferation  and  muscle  differentiation  in  animals,  to  mating  cell  type 
determination,  stress  response  and  metabolism  in  yeast,  and  reproductive  and 
vegetative development in plants (reviewed in (Messenguy, F. et al., 2003) and (Shore, 
P. etal., 1995b)). The importance of the MADS encoding sequences in mediating these 
functions  has  imposed  a  functional  constraint  on  their  evolution,  resulting  in  a  high 
degree of conservation of the MADS box in all the three major eukaryotic kingdoms.
1.2.1  Classification of MADS box transcription factors
Phylogenetic analysis based on the conservation of the  MADS box sequences reveal 
that  family  members  can  be  assigned  to  two  broad  lineages,  which  have  been 
designated Type I and Type II (Figure 1.1; (Alvarez-Buylla,  E.  R.  et al., 2000)). These 
groups  can  be  further  subdivided  based  on  the  conservation  of  their  sequences  C- 
terminal to the  MADS  box.  The presence of fungal,  animal  and  most  likely also  plant 
members in both Type I and Type II MADS lineages has led to the proposal that these 
arose  by  a  gene  duplication  that  took  place  in  a  common  ancestor  before  the 
divergence of the three major eukaryotic kingdoms (Alvarez-Buylla, E. R. etal., 2000).
Thus Type  II  proteins comprise the  MEF2-like and  MIKC subfamilies.  The  MEF2-like 
class is defined by the presence C-terminally to the MADS box of the MEF2 domain, a
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MADS SRF-like SAM yeasts (MCM1, ARG80), animals (SRF)
MADS SRF-like? plants (AGL30, AGL33, AGL39...)
Type II
MADS MEF2-like MEF2 yeasts (Rlm1, Smp1), animals (MEF2A, -B, -C, -D)
MADS MIKC K C...
plants (AG,DEF, 
GLO, SQUA...)
Figure 1.1. Schematic representation of the domains of plant, animal and fungal Type I  and Type II MADS box proteins. In plant Type I proteins 
the “?” in the MADS box denotes the uncertainty surrounding the classification of their MADS domain and the white box C-terminal to the MADS 
domain indicates domains not well defined and of variable lengths. SRF-like SAM domain proteins and MEF2-like proteins also contain transactivation 
domains that are not pictured for simplicity. (Adapted from [Alvarez-Buylla et. al., 2000] and [Messenguy and Dubois, 2003].Chapter 1 Introduction
stretch  of  32  amino  acids  that  is  highly  conserved  in  the  MEF2  factors  of  animals 
(Pollock, R. etal., 1991; Yu, Y. T. etal., 1992) and to a lesser extent in the yeast Rlm1 
and  Smp1  proteins  (Dodou,  E.  et al.,  1997).  The  Type  II  MIKC  subfamily  contains 
exclusively  plant  proteins  and  is  named  after  the  four  conserved  domains  that 
characterise its  members: the MADS  box,  the  intervening  1  region,  the  keratin-like  K 
domain and the ^-terminal domain (Kaufmann, K. et al., 2005).
Type  I  MADS  proteins  contain  the  SRF-like  subfamily,  which  is  grouped  by  the 
presence of a highly conserved  region  adjacent to the C-terminus of the  MADS  box. 
This  23  amino  acid  region  is  designated  the  SAM  domain,  after the  initials  of  three 
proteins it is found in: £RF, ARG80 and MCM1  (Shore, P. etal., 1995b).
A largely heterogeneous group of putative plant MADS genes has also been classed as 
a  separate  Type  I  subfamily  on  the  basis  of  their  homology  in  the  MADS  box 
sequences (Alvarez-Buylla, E.  R.  et al., 2000).  Putative members of this subfamily are 
largely functionally uncharacterised  and their evolutionary relationships with the other 
MADS box family members are unclear, thus complicating the in depth analysis of the 
MADS phylogenetic tree branching (De Bodt, S. etal., 2003).
1.2.2  Properties of MADS box transcription factors
MADS  box  genes  encode  modular  transcription  factors,  which  bind  specific  DNA 
sequences  in  the  regulatory  regions  of  their target  genes  via  discrete  DNA-binding 
domains  and  exert  their  responses  through  a  combination  of  their  separate 
transactivation  activity  and  interactions  with  other  proteins  (see  below;  reviewed  in 
(Messenguy, F. etal., 2003; Shore, P. etal., 1995b)).
The yeast MCM1  and the metazoan SRF and MEF2 proteins are the most extensively 
studied family members, and will therefore be the focus of the analysis of the properties 
and  functions  of  MADS  box  containing  proteins,  with  references  to  other  yeast  and 
plant family members were appropriate.
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1.2.2.1  DNA binding site specificity of MADS box transcription factors
The  DNA  sites  recognised  by  MADS  box  transcription  factors  are  dyad  symmetric 
sequences approximately  10  bp in  length,  which  contain  an  A/T rich  core flanked  by 
conserved  C-G  base  pairs.  The  DNA  binding  site  specificities  of  various  family 
members  have  been  determined  by  in  vitro  binding  site  selection  assays.  Although 
these  methods  are  designed  to  select  high  affinity  sites,  the  consensus  sequences 
determined  in  vitro for each  protein  usually correlate well  with the naturally occurring 
sites found in target promoters.
The  SRF consensus  DNA  binding  sequence  was  determined  by  in  vitro  binding  site 
selection  as CC(A/T)TATA(A/T)GG  (Pollock,  R.  et al.,  1990).  This is a more stringent 
version  of the  CC(A/T)2A(A/T)3GG  consensus originally  identified  in  the  promoters  of 
SRF controlled genes (Minty, A.  etal., 1986; Treisman,  R.,  1985; Treisman, R.,  1986). 
Non-consensus  changes  in  these  positions  in  SRF  binding  sites  decrease the  DNA 
binding  affinity  of  SRF  by  tenfold  (Leung,  S.  et  al.,  1989;  Wynne,  J.  et al.,  1992). 
Nevertheless mismatched binding sites are frequently found in the regulatory regions of 
SRF target genes, with mismatches often conserved between species suggesting that 
they serve a specific role in vivo (SRF target genes analysed in section 1.2.5.4; (Miano, 
J.  M.,  2003;  Selvaraj,  A.  et al.,  2004;  Zhang,  S.  X.  et al.,  2005)).  The  binding  site 
selection experiments also discovered that the nucleotides flanking the core 10bp SRF 
consensus contribute to binding specificity and identified a degree of asymmetry in the 
flanking sequences selected by SRF (Pollock, R. etal., 1990).
The  same  method  identified  the  consensus  binding  site  of  MCM1  as 
CC(C/T)(A/T)(A/T)(A/T)NN(A/G)G  (Wynne,  J.  et  al.,  1992).  In  vivo  binding  site 
mutagenesis  analysis  determined  a  similar  but  symmetrical  consensus 
(TTACCNAATTNGGTAA) and uncovered the importance of the three residues flanking 
the core 10bp site on either side (Acton, T. B. etal., 1997). Thus the DNA specificity of 
MCM1  is related to that of SRF, but differs in significant ways, the most important being 
a lower stringency for the central A/T sequences. These differences explain the ability 
of SRF and MCM1  to bind subsets of each other’s sites with variable efficiencies, since 
certain SRF sites represent varieties of the MCM1  consensus and vice versa (Wynne, 
J. etal., 1992).
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The  CTA(A/T)4TAG  consensus  binding  sequence  of  the  MEF2  proteins  was  also 
determined by binding site selection and differs significantly from those of its SRF-like 
relatives (Pollock, R.  et al.,  1991). Sequences almost identical to the MEF2 consensus 
are  recognised  by  the  yeast  MEF2-like  proteins  Rlm1  and  Smp1  (Dodou,  E.  et al.,
1997). As a result of their distinct DNA specificities MEF2-like and SRF-like proteins fail 
to  recognise each other’s sites,  reflecting crucial differences in the ways they contact 
DNA ((Pollock, R. etal., 1991); analysed in Section 1.2.3.1).
The consensus  binding  sites of various plant proteins  have  also  been determined  by 
similar  methods.  Thus  the  Arabidopsis  thaliana  proteins  AG  and  AGL1  recognise 
sequences  resembling  the  MCM1  consensus,  while  AGL2  and  AGL3  recognise 
sequences more closely related to MEF2 sites (Huang,  H.  et al.,  1993;  Riechmann, J. 
L. etal., 1996b). Another Arabidopsis protein, SQUA has dual specificity, since it binds 
SRF  and  MEF2  sites  and  a  wide  range  of  intermediate  sites  with  varying  affinities 
(West, A. G. etal., 1998).
Thus  despite their overall  common  characteristics,  significant differences  exist  in  the 
consensus  DNA  binding  sites  recognised  by  different  MADS  box  proteins,  which 
preclude  or  greatly  reduce  binding  of  one  family  member  to  the  recognition  site  of 
another.
1.2.3  The DNA-binding domain of MADS box transcription factors
The minimal DNA-binding domains of many family members have been characterised, 
including  those  of  SRF,  MCM1,  MEF2  and  various  MIKC  plant  proteins.  These 
encompass the MADS box and the conserved sequences C-terminal to it (SAM,  MEF2 
or I  domain)  and  are sufficient for dimerisation  and  high affinity specific  DNA binding 
(Figure  1.2;  (Mueller,  C.  G.  et al.,  1991;  Norman,  C.  et at.,  1988;  Pollock,  R.  et al., 
1991;  Riechmann,  J.  L.  et  al.,  1996a)).  In  this  module  the  primary  DNA  and 
dimerisation  contacts  are  mediated  by  the  MADS  box,  with  the  C-terminal  region 
contributing  to  dimerisation  and  high  affinity  DNA  binding  without  directly  contacting 
DNA (see below).
MADS  box transcription  factors commonly depend  on  combinatorial  interactions  with 
other  proteins  to  fulfil  their  regulatory  roles  and  achieve  target  gene specificity  or
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Figure 1.2. The DNA-binding domains of SRF-like, MEF2-like and MIKC MADS box proteins. The sequences of the MADS boxes from human 
(SRF,  MEF2), yeast (MCM1, ARG80,  Smp1,  Rlm1) and selected plant MIKC proteins are shown, with the C-terminal SAM,  MEF2 and  I- domains 
indicated by grey boxes. The secondary structure shown for SRF- and MEF2-like proteins is based on the solution of their three-dimentional structures 
(Section 1.2.3). The highly homologous MADS boxes of the plant proteins indicate that they adopt similar conformations. The methionine at the begin­
ning of the MEF2-like factors and some MIKC proteins is the initiation codon.Chapter 1 Introduction
integration of different signals (reviewed in (Messenguy, F. etal., 2003; Shore, P. etal., 
1995b).  Many of these  interactions  are  mediated  by the  DNA-binding  domain,  which 
thus  emerges  as  the  most  important  region  of  this  class  of  proteins.  Extensive 
biochemical  and  functional  studies  and  the  solution  of  the  structures  of  MADS  box 
proteins in  binary complexes with their cognate  DNA or ternary complexes with  DNA 
and their cofactors  have elucidated  how this region  integrates such diverse functions 
as DNA-binding, dimerisation and cofactor interaction.
1.2.3.1  Structure of the DNA-binding domain of MADS box transcription 
factors
The  composite  nature  of the  DNA-binding  domain  is  largely  explained  by  its  unique 
fold.  To  date  the  three-dimensional  structures  of  SRF,  SRF-SAP1,  MCM1-MATa2, 
MEF2A and MEF2B-Cabin in complex with their cognate DNA have been solved by X- 
ray crystallography and NMR spectroscopy (Hassler,  M.  et at., 2001; Huang,  K.  et al., 
2000; Mo, Y.  et at., 2001; Pellegrini, L.  etal.,  1995; Santelli,  E. et at., 2000; Tan, S.  et 
al., 1998).  Comparison of the SRF structure with that of MCM1  reveals that the overall 
conformation  of  the  DNA-binding  domain  is  conserved  between  the  two  proteins, 
consistent  with  the  high  degree  of  sequence  homology  (Figure  1.3;  (Tan,  S.  et al.,
1998)).
In the  MEF2 family the basic  MADS  box conformation  is also maintained  (Figure  1.3; 
(Han,  A.  et at.,  2003;  Huang,  K.  et al.,  2000;  Santelli,  E.  et a!.,  2000)).  Significant 
differences exist in the conformation of the divergent MEF2 domain compared to that of 
the SAM domain (Han, A.  et al., 2003; Huang,  K. et al., 2000; Santelli, E.  et al., 2000). 
Nevertheless part of the  MEF2 domain  (residues 61-71)  also forms an a-helix that  is 
located over the central hydrophobic p-sheet, and in that respect the overall fold of the 
MEF2 structures is similar to that of SRF/MCM1.
It is noteworthy that in the crystal structure of the MEF2B-Cabin-DNA ternary complex, 
the  MEF2 domain adopts a more extended conformation than that observed  with the 
shorter sequences  used  in  the  MEF2A structures  (Han,  A.  et al.,  2003).  Thus  in the 
MEF2B crystal apart from the all-helix seen previously in the MEF2A structures, each 
MEF2B  subunit forms  an  additional  p-strand  followed  by a third  a-helix  (Figure  1.4). 
These  elements  reach  over  the  opposing  subunit  so  that  the  plll-strands  of  one
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Figure 1.3. Structures of the DNA-binding domains of SRF, MCM1  and MEF2A on DNA. (A) Sequences and secondary structure of the DNA- 
binding domains (SRF residues 132-222, MCM1  residues 7-97, MEF2A and -B residues 1-91). The MADS box extends from the N-extension to the 
bll-strand and is followed by the SAM (in SRF and MCM1) or MEF2-domain (MEF2 proteins). The additional N-extension regions of SRF and MCM1 
prior to the MADS box are unstructured and shown in lower case letters.The extended MEF2-domain sequence is shown with the secondary structure 
derived from the MEF2B structure in grey (see Section 1.2.3). (B) Three-dimensional structures of SRF, MCM1  and MEF2A bound to their DNA sites 
(produced from PDB files 1SRS, 1MNM and 1EGW). Only the all-helix is ordered in the MEF2A structure (see text in Section 1.2.3).
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monomer interact with the external pll-strands of the other, thus forming  an extended 
six-stranded p-sheet (Figure  1.4). The aill-helix that follows is located  perpendicularly 
to the al-helix of the opposing subunit, with which it makes contacts (Figure 1.4). Thus 
the  dimerisation  of  MEF2B  is  greatly  enhanced  by  both  intra-  and  inter-subdomain 
interactions between the MADS and MEF2 domains of each subunit.
The  MEF2 domain  sequences  are conserved  in  all  MEF2  proteins,  but  although  the 
complete  strand-  and  part  of the  helix-forming  sequences  are  present  in  the  protein 
fragments used in the MEF2A-DNA complexes, these sequences remain unstructured 
(Figure  1.3A; (Huang,  K.  et al., 2000; Santelli,  E.  et al.,  2000)).  It has  been  proposed 
that this is due to the requirement for the complete alll-helix sequence (residues 82-89, 
Figure 1.3A) to stabilise the structure through its interaction with the opposing al-helix 
(Han, A. etal., 2003).
1.2.3.2  Dimerisation specificity of MADS family members
Dimerisation is a prerequisite for MADS box transcription factor function. All MADS box 
proteins characterised to date  have been found to act as homo- or heterodimers and 
mutations that prevent dimerisation  also  prevent  DNA  binding  ((Messenguy,  F.  et al., 
2003;  Shore,  P.  et al.,  1995b)  and  references  therein).  The  extended  dimerisation 
interface formed through all three layers of the DNA-binding domain structures provides 
an explanation for this requirement since  mutations disrupting any of the three layers 
would disrupt the overall conformation of the fold (Figure 1.3B; (Molkentin, J.  D.  et a!., 
1996a; Sharrocks, A. D. etal., 1993a)).
The high degree of sequence homology in the MADS box and the overall conservation 
of the  entire fold  between  subfamily  members  explains the  ability  of  MADS  proteins 
belonging to the same subfamily (MEF2-like or SRF-like) to heterodimerise (Dodou,  E. 
et al.,  1997; Mueller, C. G.  et al.,  1991; Pollock,  R.  et al., 1991; Sharrocks, A.  D.  et at., 
1993a).  The divergent  C-terminal  region  of the  DNA-binding  domain  provides  further 
dimerisation  determinants  and  precludes  interaction  between  proteins  from  different 
subfamilies, so MEF2 factors do not associate with SRF or MCM1, and the yeast Rlm1 
protein does not dimerise with MCM1  (Dodou, E.  et al.,  1997; Pollock,  R.  et al.,  1991). 
The  more  extended  conformation  of the  MEF2  domain  might  also  play  a  role  in  the 
inability of the SRF-  and MEF2-like  proteins to heterodimerise.  On the other hand the
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Figure 1.4. Structure of the Cabin1-MEF2B-DNA ternary complex. (A) The sequences of the DNA-binding domains of the mouse MEF2 proteins. 
The MADS box is indicated by a black line and the MEF2 domain by a grey box. The secondary structure elements are shown in each domain. (B) 
Ribbon representation of the MEF2B DNA-binding domain domains bound to DNA . The two MEF2B subunits are shown in blue and green the DNA 
in magenta.The helix of the Cabinl  repressor that interacts with MEF2B is also shown in red. The secondary structure elements are labeled in each 
MEF2 subunit (S1, S2 and S3 denote the pi, pil, and pill strands and H1, H2, H3 the al, all and alll helices respectively). The sequence of the DNA 
site of MEF2 is shown below. (C) The same complex viewed at 90° to B. Images were taken from (Han et. al., 2003).Chapter 1 Introduction
overall  conservation  of the  DNA-binding  domain  fold  allows  chimeric  MADS  proteins 
comprising  N-terminal  and  C-terminal  regions  derived  from  different  subfamily 
members  to  dimerise  and  bind  DNA  (Mueller,  C.  G.  et al.,  1991;  Pollock,  R.  et al., 
1991).
Although  the  structure  of the  plant  MIKC  proteins  has  not  been  solved  their  MADS 
domains are predicted to adopt similar conformations to those of yeast and metazoan 
proteins  based  on  sequence  conservation  (Kaufmann,  K.  et al.,  2005).  Biochemical 
analysis  of  MIKC  subfamily  members  identified  the  l-region  that  follows  the  MADS 
domain  as  specifying  dimerisation  (Riechmann,  J.  L.  et  al.,  1996a).  This  region  is 
predicted to adopt a helical conformation, and is thus thought to act like the MEF2 and 
SAM domains by dimerising and shielding the hydrophobic central p-sheet from solvent 
(Kaufmann,  K.  et al.,  2005).  Certain  members  of the  MIKC  plant  family such  as  the 
DEF/GLO  heterodimers  of  Antirrhinum  majus  and  the  PI  and  AP3  proteins  of 
Arabidopsis thaliana require the presence of their  K-region  in  addition to the  minimal 
DNA-binding  domain  for  efficient  dimerisation  and  subsequent  DNA  binding 
(Riechmann, J.  L.  et al.,  1996b; West, A.  G.  et al.,  1998). The K-region is predicted to 
mediate  dimerisation  via three  a-helices that form  extended  coiled  coils,  and  is  also 
thought  to  be  involved  in  the  formation  of  higher  order  complexes  between  family 
members (reviewed in (Kaufmann, K. et al., 2005)).
1.2.3.3  DNA binding and sequence recognition
The  elucidation  of  the  three-dimensional  structures  of  the  DNA-binding  domains  of 
SRF- and MEF2-like factors confirmed previous biochemical analyses that mapped the 
DNA-binding  modules  to  the  N-terminal  part  of  the  MADS  domain,  with  conserved 
basic residues mediating crucial DNA contacts (Figure 1.5A and B; (Molkentin, J.  D.  et 
al.,  1996a;  Nurrish,  S. J.  etal.,  1995;  Pollock,  R.  etal.,  1991;  Sharrocks,  A.  D.  et al., 
1993a)).
The antiparallel coiled coil formed by the al-helices of the MADS box of each monomer 
is the primary  DNA binding unit in all the structures described  in the previous section 
(Figure  1.5).  This  coiled  coil  lies  over  the  minor groove  in  the  middle  of  the  dyad- 
symmetric  binding  site  and  interacts  with  the  major  groove  on  either  DNA  half-site, 
allowing the otherwise unstructured N-terminal extension to enter the minor groove and
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Figure 1.5. The interaction of the DNA-binding domains of SRF, MCM1 and MEF2A with their cognate DNA. (A) Sequences and secondary struc­
tures of the DNA-binding domains. Residues that make direct DNA contacts are shown in red. (B) The conserved N-terminal arginine of the MADS box 
adopts  different  conformations  in  different  MADS  proteins.  Three-dimensional  structures  of  SRF,  MCM1  and  MEF2A  bound  to  their  DNA sites 
(produced from PDB files 1SRS,  1MNM and 1EGW). Only the N-extension and al-helix of the DBDs are shown in ribbon representation. The side- 
chains of SRF R143,  MCM1  R18 and  MEF2A R3 are shown  in  red. The sequences DNA sites used  in the crystals are shown below.  Base-pairs 
contacted by the arginine residue are shown in red.
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make specific DNA contacts ((Huang, K. etal., 2000; Pellegrini, L. etal., 1995; Santelli, 
E. etal., 2000; Tan, S.  etal.,  1998); the N-terminal extension of MCM1  is an important 
exception  to this,  as  analysed  below).  This  unusual  recognition  of  the  minor groove 
also explains the preference of MADS transcription factors for DNA sequences with A/T 
rich cores, since stretches of A/T create a narrow minor groove that can accommodate 
the  contacts  formed  by  the  antiparallel  coiled  coil  (Pellegrini,  L.  et  al.,  1995). 
Nonetheless,  apart  from  the  overall  similarities  in  the  way  the  various  MADS  box 
factors contact DNA, a number of critical differences exist that account for their different 
DNA specificities.
1.2.3.3.1  The role of the residues at MADS box positions 1  and 2 in DNA binding 
specificity
An arginine is found at the second position of the MADS box of SRF, MEF2 and MCM1 
(Figure 1.5B; R143 in SRF,  R3 in MEF2 and  R18 in MCM1). Although conserved, this 
residue adopts different conformations in all three structures, a phenomenon attributed 
to the  identity  of the  residue  preceding  it,  as  well  as to the  presence  or absence of 
additional amino acids prior to the MADS sequences (Huang, K.  etal., 2000; Pellegrini, 
L. etal., 1995; Santelli, E. etal., 2000; Tan, S. etal., 1998).
Both SRF and  MEF2 have a glycine preceding the crucial arginine at the beginning of 
their MADS boxes (SRF G142/R143 and MEF2 G2/R3,  Figure 1.5A). The fact that the 
MADS box of the  MEF2-like factors is present at their extreme N-terminus allows the 
GR  residues  to  make  extensive  contacts  in  the  minor  groove  with  the  bases  at 
positions ±3 and ±4 of the  MEF  DNA site specifying  invariant A-T at these  positions 
(Huang, K. etal., 2000; Santelli, E. etal., 2000).
In the case of SRF additional amino acids precede the MADS box and are required for 
high  affinity  DNA  binding  (Norman,  C.  et al.,  1988).  The  presence  of  this  extended 
sequence prior to the GR residues forces them to adopt different conformations and as 
a result the arginine specifies the A/T nucleotides at positions ±1  and ±2 of the SRF 
binding site, while the glycine does not make base specific contacts (Huang,  K.  et al., 
2000;  Pellegrini,  L.  et al.,  1995).  Removal  of the  residues  preceding  the  MADS  box 
allows the SRF GR amino acids to obtain the conformation seen  in  MEF2 and this is 
sufficient to alter the specificity of the resulting truncated protein (METcoreS R F ) from the
37Chapter 1 Introduction
wild-type  SRF  binding  consensus  to  that  of  MEF2  (Nurrish,  S.  J.  et  al.,  1995; 
Sharrocks, A.  D.  etal.,  1993b). Thus the presence of a glycine prior to the conserved 
arginine  specifies  MEF2  DNA  sites,  unless  the  protein  sequence  is  extended  N- 
terminally to the MADS box in which case SRF-specific sites are recognised.
The arginine residue of MCM1  (R18) adopts a different conformation to those seen in 
MEF2 and SRF and does not enter the minor groove thus allowing greater flexibility in 
the  central  DNA  sequences  (Tan,  S.  et al.,  1998).  This  change  in  conformation  is 
attributed to the presence of a glutamate (E17)  in the position occupied by glycine in 
MEF2 and SRF (Huang, K. etal., 2000; Santelli, E. etal., 2000). This residue has been 
found  to  be crucial  for  MCM1  DNA  specificity  since  a G143E  substitution  in  SRF  is 
sufficient to convert its DNA specificity to that of MCM1  (Nurrish, S. J. etal., 1995). This 
property of the N-terminal  MADS box sequences was successfully exploited to create 
altered DNA binding specificity SRF mutant derivatives that could bind MCM1  specific 
sites ((Hill, C. S. etal., 1993); see also Chapter 2).
1.2.3.3.2  The role of the residues at MADS box positions 11-15 on DNA binding 
specificity
Another  important  DNA  specificity  determinant  is  the  identity  of  the  residues  at 
positions  11-15 of the  MADS  box  (SRF residues  152-156,  MCM1  27-31  and  MEF2A 
12-16) (Nurrish, S. J.  et al., 1995).  In SRF substitution of these sequences for those of 
MEF2A  relaxes  its  DNA  specificity  so  it  can  recognise  both  the  SRF  and  MEF2 
consensus sites.  Additional  removal of the sequences  preceding the SRF  MADS  box 
completes the specificity switch from SRF to MEF sites exclusively (Nurrish, S. J. et al., 
1995).  In the case of MCM1  combined substitutions at  positions  E17 and  27-31  with 
the  MEF2  equivalents  change  its  DNA  specificity  to  that  of  MEF2  and  vice  versa 
(Nurrish, S. J.  etal., 1995). The effect of these residues on DNA specificity is not direct 
since  none  of  them  contacts  the  core  10bp  binding  site  (Huang,  K.  et  al.,  2000; 
Pellegrini,  L.  et a!.,  1995; Santelli,  E.  et al., 2000; Tan, S.  et al.,  1998). At least in the 
case of SRF and  MEF2 biochemical analysis of residues within this region has linked 
their effects on DNA binding specificity to their effects on DNA bending (analysed in the 
following section).
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1.2.3.4  DNA bending by MADS box transcription factors
DNA bending is a highly conserved property of MADS box transcription factors through 
the  plant,  fungal  and  animal  kingdoms.  The  ability  of  MADS  proteins  to  distort  their 
DNA  sites  to  varying  degrees  has  been  well  documented  biochemically.  SRF-like 
factors,  including SRF,  MCM1  and ARG80 induce substantial  DNA bending,  whereas 
MEF2-like factors  including the  MEF2 family and  the yeast  Rlm1  and  Smp1  proteins 
have minimal DNA bending effects (Gustafson, T. A. et al.,  1989; Meierhans,  D. et al, 
1997; West, A. G. etal., 1998; West, A. G. etal., 1999; West, A. G. etal,  1997). Many 
plant  MIKC  MADS  proteins  have  also  been  found  to  induce  DNA  bending  including 
SQUA, AP1, AG,  PLENA and also AP3/PI and DEF/GLO heterodimers (Riechmann, J. 
L.  et al.,  1996b; West, A. G.  et al,  1998; West, A.  G.  et al.,  1999).  It is clear however 
that different MADS  proteins employ subtly different  mechanisms to distort their  DNA 
sites.
The difference between the DNA bending abilities of SRF-like and MEF2-like factors is 
apparent in the three-dimensional complexes of these proteins with their cognate DNA, 
in which SRF and MCM1  bend DNA by 72°, while MEF2A only by 15°-17° (Huang, K. et 
al., 2000;  Pellegrini,  L.  et al,  1995; Santelli, E.  etal., 2000; Tan, S.  et al,  1998).  In all 
three complexes there is a 15°-20° bend at the centre of the dyad axis of the DNA, and 
this is the only bend seen in the MEF2A-DNA complex (Huang, K. et al, 2000; Santelli, 
E.  et al., 2000). SRF and MCM1  on the other hand induce further bends on either side 
of their core  binding  site,  which  add  together  resulting  in  significantly  higher overall 
bend angles of the DNA in the complex (Pellegrini, L. etal., 1995; Tan, S.  etal,  1998). 
These additional bends are attributed to the fact that both SRF and MCM1  contact the 
DNA flanking their core binding sites using residues from their al-helices and also the 
p-loop  located  in their middle  layer (Pellegrini,  L.  et al,  1995;  Tan,  S.  et al.,  1998). 
These interactions, which are thought to create a “pull” on the DNA, bending it around 
the N-terminus of the al-helix of each subunit, are absent in the MEF2 structure and as 
a result the DNA is only bent in the middle of the dyad (Huang, K.  etal, 2000; Santelli, 
E. etal., 2000).
In the case of SRF central to the interaction with the flanking DNA sequence is residue 
K154,  which  is located at  position  14 of the  MADS  box within  a sequence  previously 
found to influence DNA-specificity (Figure 1.2; see also section 1.2.3.3.2;(Nurrish, S. J. 
et al,  1995)).  K154 acts in concert with other al-helix residues to facilitate the binding
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of p-loop residues to DNA. In MEF2 factors the position equivalent to K154 is occupied 
by a glutamate (glutamine in the case of MEF2B, see below), which does  not contact 
DNA (Han,  A.  et al., 2003;  Huang,  K.  et al.,  2000; Santelli,  E.  et al.,  2000).  A  K154E 
substitution  in the relaxed specificity METcoreS R F  not only converts its specificity from 
SRF to  MEF2  sites  exclusively  (Nurrish,  S.  J.  et al.,  1995;  Sharrocks,  A.  D.  et al., 
1993b), but also reduces DNA bending (West, A. G. etal., 1997). The reverse mutation 
E14K in MEF2A increases DNA bending and also relaxes its DNA specificity to include 
both MEF2 and SRF consensus sites (West, A. G. etal., 1997). Although these results 
implicate this  position  in the  MADS box in both  DNA  binding and  DNA bending, they 
must be treated with caution since they use the relaxed specificity METcoreS R F .
MEF2B  has  a  glutamine  instead  of  glutamate  at  position  14,  but  retains  the  DNA 
specificity  of  the  other  MEF2  factors  and  also  induces  minimal  DNA  bending 
(Molkentin, J.  D.  etal.,  1996b; West, A. G. etal.,  1999). Thus a link emerges between 
the identity of the residue at SRF position 154 (MEF2 position 14) and the ability of the 
protein  to  bend  DNA,  and  this  correlation  depends  on  whether  the  residue  at  this 
position  is  able to  contact  DNA.  MEF2C,  which  also  has  a glutamate  at  position  14, 
appears  to  be  an  exception,  since  it  has  been  reported  to  bend  DNA  significantly 
(Meierhans,  D.  et al.,  1997). This result is surprising considering that the sequence of 
the  MEF2C  MADS  box  is  almost  identical  to  that  of  MEF2A  and  is  also  very  well 
conserved  with  the  other  MEF2  factors  (Figure  1.2).  It  should  be  noted  that  DNA 
bending  analysis  in  this  study  was  not  done  in  parallel  with  other  MADS  factors  of 
known bending abilities, and it is thus possible that experimental conditions resulted in 
an unusually high apparent bend angle value.
The  correlation  between  the  presence  of  a  DNA  contact  forming  residue  at  position 
K154/E14 with the ability of the protein to induce DNA bending, appears to be context 
dependent, since although a lysine is found at the same position in  MCM1  (K29), this 
residue does not contact DNA and has only a small effect on DNA bending (Lim,  F.  L. 
et  a!.,  2003).  Instead  MCM1  employs  other  al-helix  residues  to  contact  the  DNA 
bordering  its  core  site,  and  aid  the  p-loop  residue-DNA  contacts.  This  is  another 
example of SRF and MCM1  sharing overall similarities in the ways they contact DNA, 
while at the same time exhibiting subtle but crucial differences. Another such difference 
is that while  DNA bending  appears to  be sequence  independent  in  the case  of  SRF 
(West,  A.  G.  et a!.,  1997),  the degree of bending  induced by  MCM1  depends on the
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sequence  of  the  DNA  bordering  its  core  site  (Acton,  T.  B.  et  al.,  1997),  with 
symmetrically placed T:A base pairs at positions ±7 from the centre of the binding site 
increasing the DNA bend (Lim, F. L. et al., 2003).
The Arabidopsis thaliana SQUA protein,  which  binds  DNA sites  ranging  between the 
SRF  and  MEF2  consensus,  also  induces  DNA  bending  in  a  sequence  dependent 
manner (West, A. G.  et al.,  1999). SQUA has a lysine (K14) at the position equivalent 
to SRF  K154,  and this is also involved in  bending  but depends on  residues in the  p- 
loop to specify DNA binding (West, A. G. etal., 1999).
1.2.3.4.1  The significance of DNA bending by MADS box transcription factors
Despite  the  wealth  of  biochemical  information,  the  functional  significance  of  DNA 
bending  by  MADS  box  transcription  factors  in  vivo  remains  unclear.  In  the  case  of 
MCM1,  mutations  have  been  identified  that  impede  DNA  bending  and  exhibit  slow- 
growth phenotypes, hinting at the importance of this property for MCM1  function in vivo 
(Acton, T. B. etal., 2000; Lim, F. L. etal., 2003).
The  correlation  between  the  abilities  of  SRF  and  MEF2  factors  to  recognise  their 
consensus  DNA site and  induce  DNA bending, combined with the fact that in general 
MEF2-like factors induce minimal DNA bending, while SRF-like factors bend their DNA 
sites  significantly  indicates  that  one  of  the  functions  of  DNA  bending  in  MADS  box 
transcription  factors  is to  provide  a  mechanism  of  “indirect  readout” for these  highly 
similar DNA-binding  modules to distinguish  between their DNA sites  (Pellegrini,  L.  et 
al., 1995; West, A. G. etal., 1999).
Sequence  specific  DNA  bending  as  seen  for  MCM1  and  SQUA  also  provides  extra 
specificity  determinants  for  target  gene  selection,  an  important  feature  for  proteins, 
which  regulate  multiple  cell  processes  and  control  the  activity of different  subsets  of 
genes.  Furthermore  at  least for  MCM1  and  SRF the ability to  distort their  DNA sites 
influences cofactor interaction (see section 1.2.4 and Chapter 4; (Lim, F. L. etal., 2003; 
Zaromytidou,  A.  I.  et at.,  2006)),  thus  providing  additional  mechanisms  by  which  to 
ensure  specificity  of  their  responses.  In  the  case  of  the  interaction  of  SRF  with  its 
cofactor MAL the induction of appropriate  DNA distortion in the SRF-DNA complex  is
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critical for MAL binding and this is thought to facilitate direct MAL- DNA contacts (See 
Chapters 4 and 5; (Zaromytidou, A. I. et al., 2006)).
MADS  box  transcription  factors  display  a  startling  diversity  in  the  transcriptional 
responses they elicit in different cell types and in  response to different developmental 
and  environmental  stimuli  (reviewed  in  (Messenguy,  F.  et al.,  2003;  Shore,  P.  et al., 
1995b)).  The  versatility  of  their  functions  is  achieved  mainly  by  combinatorial 
interactions  with  accessory  factors,  which  produce  specific  regulatory  complexes  on 
different target gene  promoters.  Thus  MADS  box  proteins  act  as  docking  sites  for  a 
diverse  array of cofactors  through  which  distinct  and  sometimes  opposing  signalling 
cues  are transduced.  The following  sections will  discuss  the  MCM1  and  SRF  MADS 
box  proteins  focusing  on  the  latter,  and  will  analyse  how  combinatorial  interactions 
contribute to the diverse functional roles of these transcription factors.
1.2.4  MCM1
Mcm1  was originally identified as a Saccharomyces cerevisiae gene necessary for the 
extrachromosomal maintenance of plasmids carrying specific autonomously replicating 
sequences (Minichromosome maintenance 1, ARS; (Maine, G. T.  et al.,  1984)).  It was 
subsequently discovered that this gene coded for a 286 amino acid transcription factor 
responsible for cell-type specific gene expression (Bender, A.  et al.,  1987; Keleher,  C. 
A. etal., 1988; Passmore, S. etal., 1988).
MCM1  contains an  N-terminal  DNA binding domain, which comprises the  MADS  and 
SAM  domains  (see  Section  1.2.3)  and  is  necessary  and  sufficient  for  cell  viability 
(Bruhn,  L.  et al.,  1992;  Primig,  M.  et al.,  1991).  The  MADS  box  is  preceded by a  17 
amino  acid  N-terminal  extension  which  is  phosphorylated  in  vivo  at two  major  sites 
(Kuo, M. H. etal., 1997). Deletion of the N-extension or mutation of the phosphorylation 
sites  impairs  growth  on  high  salt.  A stretch  of  19  acidic  residues  located  directly  C- 
terminal  to  the  SAM  domain  has  been  reported  to  affect  a-cell  type  specific  gene 
expression  (Bruhn,  L.  et al.,  1992).  MCM1  also  contains  a C-terminal transactivation 
domain,  which  is  composed  of  50%  glutamine  residues  and  is  required  for  optimal 
transcriptional activation (Bruhn, L. etal., 1992).
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1.2.4.1  Biological roles and cofactor Interactions of MCM1
MCM1  is expressed in all three yeast cell types (a, a and a/a, see later). This protein is 
involved  in  multiple  functions,  including  cell  type  specification,  the  pheromone 
response,  cell  cycle  control,  minichromosome  maintenance,  osmotolerance  and 
arginine  metabolism.  MCM1  elicits these  diverse  responses through  interactions  with 
different cofactors that are signal regulated, cell-type or promoter- specific (Table  1.1; 
reviewed in (Messenguy, F. et al., 2003)). The following sections will describe some of 
the biological roles of MCM1  and the cofactor interactions that result in specificity of the 
transcriptional response.
Table 1.1  Combinatorial interactions involving MCM1 and its cofactors1
Cofactor Cellular process Experimental evidence
MATal Cell type specification: EMSA,  DNase  I  protection
Activation of a- specific genes (Bender,  A.  et al.,  1987;  Tan, 
S. etal., 1988)
MATa2 Cell type specification: EMSA,  DNase  I  protection
Repression of a-specific genes (Keleher,  C.  A.  et  a!.,  1988; 
Keleher, C. A. etal., 1989) 
Crystal  structure  (Tan,  S.  et 
al., 1998)
STE12 Pheromone response 
Activation of a- and a- genes
EMSA (Errede, B. etal., 1989)
Fkh2 Cell cycle control EMSA (Kumar,  R.  et al., 2000;
Activation  of  CLB2  cluster 
genes
Pic, A. etal., 2000)
Yox1  and Yhp1 Cell cycle control 
Repression of ECB genes
Co-IP (Pramila, T. etal., 2002)
ARG80 Arginine metabolism EMSA (Dubois, E. etal., 1991)
ARG81 Arginine metabolism EMSA (Amar, N. etal., 2000)
ARG82 Arginine metabolism Yeast  2-hybrid,  GST-pulldown 
(El Bakkoury, M. etal., 2000)
1   Table  adapted  from  Messenguy,  F.,  and  Dubois,  E.  (2003).  Role  of  MADS  box 
proteins  and  their  cofactors  in  combinatorial  control  of  gene  expression  and  cell 
development. Gene 316,1-21..
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1.2.4.1.1  Cell type specification
Saccharomyces serevisiae is able to exist in either a haploid or a diploid state.  It has 
two  haploid  cell  types,  a  and  a,  which  produce  different  cell  surface  receptors  and 
pheromones. When one cell-type is exposed to secreted pheromones of the other, the 
a  and a  cells  are  able  to fuse  and  form the diploid  a/a cell  (see  Section  1.2.4.1.2). 
MCM1  is expressed in all three types and is required for establishing the different gene 
expression  patterns  that  define  cell  type  identity  (reviewed  in  (Dolan,  J.  W.  et  al., 
1991)). Thus a- and a-cells express a- and a-specific genes respectively and also a set 
of haploid-specific genes, all of which are repressed in the diploid state.  MCM1  is able 
to orchestrate the expression of different gene networks by engaging cell type-specific 
partners.  Thus,  in  a-cells  MCM1  binds the  MATa2  repressor on  the  promoters  of a- 
specific  genes  and  actively  blocks their transcription  (Keleher,  C.  A.  et al.,  1988).  In 
contrast its association with the MATal  activator on the promoters of a-specific genes 
allows  their  expression  (Bender,  A.  et  al.,  1987).  Neither  MATal  nor  MATa2  are 
present  in  a-cells,  resulting  in the  a-specific genes  being  effectively repressed,  while 
the a-specific genes are transcribed. In a/a cells both the a- and haploid specific genes 
are  repressed  by  the  interaction  of  MATa2  with  MCM1  and  the  MATal  protein 
respectively,  whereas  a-specific  genes  are  repressed  due  to  the  absence  of  the 
MATal  activator.
1.2.4.1.1.1  The MCM1  -  MA Ta2 interaction
Repression  of  a-specific  genes  in  a-  and  a/a-cells  is  achieved  by  the  cooperative 
binding of MCM1  and MATa2 at MCM1  consensus sites called P-sites, flanked by two 
a2-binding sites ((Keleher, C. A.  et al.,  1989; Passmore,  S.  et al.,  1989) and reviewed 
in (Dolan, J. W. etal., 1991)).
The  210  amino  acid  MATa2  protein  contains  a  C-terminal  homeodomain  that  is 
responsible for DNA-binding, preceded by a flexible linker sequence that is required for 
cooperative  binding  to  MCM1.  Transcriptional  repression  depends  on  the  100  amino 
acid  N-terminal  domain  of  MATa2,  which  homodimerises  and  recruits the  Ssn6/Tup1 
repressor complex ((Tan, S. etal., 1998) and references therein).
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Crystallographic analysis has elucidated the structural details of the interactions of the 
MATa2  linker and  homeodomain fragment  with the  MCM1-DNA complex  (Tan,  S.  et 
al.,  1998), which exhibit both striking similarities and contrasts to the TCF-SRF ternary 
complex.  In this structure, the MATa2 homeodomain binds its DNA site on the 5’ side 
of the  MCM1  dimer (Figure 1.6A),  with a second  MATa2 homeodomain unexpectedly 
binding on the other side of MCM1  at the junction of two DNA molecules (not pictured). 
Both  a2  homeodomains  have the same fold and  make similar DNA contacts and for 
clarification  purposes  are  termed  cis-  (bound  on  the  5’  side  of  MCM1)  and  trans- 
(bound at the DNA junction) monomers.
The cis-  MATa2  monomer interacts with  MCM1  via both  its homeodomain and  linker 
regions.  Nevertheless  as  predicted  by  mutagenesis  studies  it  is  the  linker-MCM1 
contacts that define complex formation (Mead, J.  etal.,  1996; Tan, S. etal.,  1998). The 
cis- a2  monomer uses an 8-residue sequence in  its flexible linker to add a parallel p- 
strand to the central  antiparallel  p-sheet of  MCM1  (Figure  1.6A).  This  sequence  had 
been previously identified as necessary for MATa2-MCM1  mediated repression (Mead, 
J. etal., 1996). This study determined that all residues within the p-strand are sensitive 
to alanine substitution, which abolishes MCM1  binding, in contrast to the interaction of 
TCF with SRF ((Hassler,  M.  et at., 2001; Ling,  Y.  et al.,  1997;  Mead, J.  et al.,  1996); 
analysed in Section  1.2.S.6.3). The p-strand addition is achieved by the formation of a 
hydrophobic  interface  between  the  a2-residues  and  a  hydrophobic  groove  on  the 
surface of  MCM1  (the  MCM1  residues  contacting  MATa2  are  summarised  in  Figure 
1.7).  Central  to  this  interaction  is  the  insertion  of  a  phenylalanine  residue  in  a 
hydrophobic pocket created by residues V69, V81, R87 and I90 in the p-sheet and all­
helices of MCM1  (Figure 1.6B; (Tan, S. etal., 1998)). The importance of these contacts 
was  confirmed  by  mutagenesis  studies  where  removal  of the  a2  F116  sidechain  or 
restricting  the  size  of  the  pocket  by  substituting  MCM1  residues  with  bulkier  ones 
abolishes complex formation (Mead, J. etal., 2002; Mead, J. etal., 1996). The residues 
and interactions involving the hydrophobic pocket of MCM1  are conserved in the TCF- 
SRF complex (discussed in Section 1.2.5.6.3)
The significant degree of  DNA bending  induced  by  MCM1  was proposed to facilitate 
the interaction with the cis- MATa2 by bringing the two DNA binding sites closer (Tan, 
S.  et  at.,  1998).  In  vitro  DNA  bending  experiments  however  do  not  support  a
dependence of MATa2 binding on DNA distortion (Lim, F. L. etal., 2003).
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Figure 1.6. Structure of the MATa2 - MCM1 - DNA ternary complex. (A) Ribbon representation of the cis- MATa2 homeodomain and flexible linker 
sequence bound to DNA and MCM1 respectively. The two MCM1 subunits are shown in blue and the DNA in green. MATa2 is shown in red: the flexible 
linker forms a p-hairpin and adds a parallel p-strand to the p-sheet of MCM1. Image was produced from the 1  mnm PDB file. (B) The interaction of the 
F116 MATa2 with the  V69, V81, R87,190 residues (sidechains shown in orange) that form the hydrophobic pocket of MCM1. (C) Model of the interac­
tion of MATa2 and MCM1  on a composite DNA site where two a2-sites are spaced by 3 and 2bp from the MCM1  P-site . Structures are viewed from 
the top. The chameleon sequence of MATa2 is shown in red. Image taken from (Tan and Richmond, 1998).
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Due  to  its  positioning  the  trans  a2  copy does  not  interact  with  the  opposing  MCM1 
subunit, but makes the same 0-strand contacts with a symmetry-related  MCM1  dimer 
bound to a different piece of DNA. This fortuitous interaction uncovered an unexpected 
feature  of  the  MATa2  linker:  the  MCM1  binding  0-strand  is  connected  to  the 
homeodomain  by  a  bistable  “chameleon”  region,  which  can  adopt  either  0-strand  or 
helical conformations (Tan,  S.  et al.,  1998).  Thus  in the cis-monomer this chameleon 
region forms a 0-strand that contacts the  MCM1-binding strand to form a 0-hairpin.  In 
contrast the same region adopts an a-helical conformation in the trans-copy to bridge 
the distance  between  the  a2 homeodomain and  the symmetry  related  MCM1.  It  has 
been  postulated  that  the  chameleon  sequence  functions  to  accommodate  MATa2 
binding to  MCM1  when the spacing of their  DNA sites varies from  2 to 3bp in target 
gene promoters  (Figure  1.6C;  (Tan,  S.  et al.,  1998).  The dependence of the  MCM1- 
MATa2  interaction  on  the  close  spacing  of  their  DNA  sites  is  another  significant 
difference  to  the  TCF-SRF  complex,  formation  of  which  can  tolerate  long  distances 
between their DNA sites due to the extreme flexibility of the TCF linker sequence (see 
Section 1.2.5.6).
1.2.4.1.1.2  The MCM1  -  MA Ta 1 interaction
The promoters of a-specific genes contain a different subclass of MCM1  that deviate 
from the MCM1  binding consensus in one half-site and are designated P\ Adjacent to 
the degenerate side of the P’ site is a binding site for the  MATal  activator named Q. 
MCM1  binds the  P’ sites  weakly  and  a1  binding  to the  Q sites  is  undetectable,  thus 
activation of a-specific genes in a-cells requires cooperative binding of MCM1  and the 
MATal  activator to the P’Q sites ((Bender,  A.  et al.,  1987;  Hagen,  D.  C.  et al.,  1993) 
and references therein).
Analysis  of the  MATal-MCM1  interaction  has  been  restricted to the  MCM1  residues 
involved,  whereas  the  MATal  sequences  required  for  MCM1  binding  remain  poorly 
defined.  MATal  interacts  with  the  DNA-binding  domain  of  MCM1  (Primig,  M.  et al., 
1991)  and  several  residues  within  the  0ll-strand  of  MCM1  are  required  for  complex 
formation,  indicating  that  MATal  contacts  the  same  surface  as  MATa2  (Figure  1.7; 
(Bruhn, L. etal., 1994; Lim, F. L. etal., 2003; Mead, J. etal., 2002)).
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In  contrast  to  MATa2  however,  MATal  binding  to  MCM1  appears  sensitive  to 
mutations in the p-loop (at residues T66 and L68) and al-helix (K40) that also affect the 
degree of  DNA bending  (Lim,  F.  L.  et al.,  2003;  Mead,  J.  et al.,  2002).  Nevertheless 
some  MCM1  derivatives that  harbour  mutations  in the  al-helix  and  are  defective for 
DNA  bending  are still  able to  interact with  MATal  (Carr,  E.  A.  et al.,  2004).  MATal 
binding to these mutant MCM1  proteins alleviates their bending defect and restores the 
overall bend angle in the ternary complex to that observed with the wild-type proteins. 
Furthermore proper DNA bending in the ternary complex correlates with transcriptional 
activity  and  it  has thus  been  proposed  that  the  interaction  of  MATal  with  MCM1  is 
required to impose a bend on the promoter necessary for transcriptional activation.
1.2.4.1.2  The pheromone response
As mentioned previously the a and a cell types secrete different pheromones or mating 
factors (a-factor is the pheromone produced by a-cells and a-factor the a-specific one). 
In addition each cell type expresses different cell-surface receptors,  so that the a-cell 
recognises the a-secreted  mating factor and vice versa.  Exposure  of one cell-type to 
secreted pheromones of the other induces the expression of genes required for mating, 
leading to cell cycle arrest and  morphological changes that culminate in the fusion of 
the a- and a-cells and the formation of the a/a diploid cell (reviewed in (Dolan, J. W.  et 
al., 1991)).
Central  to  the  pheromone  response  is  the  activation  of  a  MAPK  phosphorylation 
cascade  that  targets  the  STE12  transcription  factor  resulting  in  the  expression  of 
pheromone-responsive genes (reviewed in (Banuett, F., 1998)).  In a-cells this depends 
on  cooperative  binding  of  STE12  and  MCM1  at  composite  promoter  elements 
consisting  of  an  MCM1  P-site  and  a  STE12  pheromone  response  element  (PRE) 
(Errede,  B.  et al.,  1989).  On  the  other  hand  the  induction  of  pheromone-responsive 
genes  in  a-cells  is thought to depend on the  interaction  of the  MCM1-bound  MATal 
activator with the STE12 transcription factor (Yuan, Y. O.  et al.,  1993).  It is noteworthy 
that MAPK signalling  also  regulates the activity of the  mammalian  SRF-TCF complex 
(see Section 1.2.5.6).
As with the other  MCM1  cofactors,  STE12  interacts with the  DNA-binding domain  of 
MCM1,  although  its  MCM1  binding  region  is  undefined  (Mueller,  C.  G.  et al.,  1991;
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Primig,  M.  et al.,  1991).  Mutagenesis studies revealed that the STE12 binding surface 
overlaps that of  MATal  and  MATa2,  although the contacts of the  different cofactors 
are not completely conserved (Figure 1.7; (Bruhn,  L.  etal.,  1994; Mueller, C. G.  et al., 
1991)).
1.2.4.1.3  Cell-cycle control
During the cell cycle MCM1  cooperates with the Fkh2 protein to control the expression 
of the CLB2 gene cluster,  a group of about 30 genes required for the G2-M transition 
and then for mitotic progression and cytokinesis (Kumar,  R.  et al., 2000;  Pic, A.  et al., 
2000; Zhu, G. etal., 2000).
Fkh2 belongs to the Forkhead family of winged-helix proteins and contains a C-terminal 
DNA-binding  domain  (FKH  domain)  and  an  N-terminal  Forkhead  Associated  domain 
(FHA) that is also found in the related cell cycle protein FKH1.
Fkh2 binds cooperatively with MCM1  to composite MCM1/FKh2 DNA consensus sites 
in the CLB2 gene promoters (Pic, A.  etal., 2000) and recruits the Ndd1  co-activator in 
a cell-cycle phosphorylation-dependent manner to activate transcription in the G2 and 
M  stages  (Darieva,  Z.  et al.,  2003;  Koranda,  M.  et al.,  2000).  This  complex  is  also 
known as SFF (SWI  Five Factor) since it was first identified as the activity that induces 
transcription of the SWI5 gene, one of the best studied CLB2 cluster members ((Pic, A. 
et al.,  2000)  and  references therein).  It has been  proposed that  Fkh2 and  MCM1  are 
constitutively bound to the CLB2 promoters but in the absence of Ndd1  act to repress 
transcription (Koranda, M. etal., 2000; Pic, A. etal., 2000).
Mutagenesis analysis of Fkh2 identified a stretch of 20 amino acids that are required 
for cooperative MCM1  binding (Boros, J.  et al.,  2003).  This sequence does  not share 
obvious homology to the MATa2 p-strand, and is similar to the mammalian TCF B box 
(see  later)  in  that  it  contains  differently  spaced  hydrophobic  residues  required  for 
complex formation (Boros, J. etal., 2003; Hassler, M. etal., 2001; Ling, Y. etal.,  1997; 
Mead, J.  et al.,  1996; Tan,  S.  et al.,  1988).  Mutation of a tyrosine  residue within this 
stretch  abolishes  the  interaction  with  MCM1,  as  does  mutation  of  the  MCM1  V69 
residue that lines the hydrophobic pocket of MCM1, implicating the hydrophobic pocket 
of MCM1  in the Fkh2 interaction (Figure 1.7).
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The  spacing  and  orientation  of  the  MCM1  and  Fkh2  DNA  sites  are  critical  for  the 
MCM1-Fkh2  interaction  and  thus  the  role  of  DNA  bending  in  the  formation  of  the 
MCM1-Fkh2 complex is thought to involve the correct juxtaposition of the two proteins 
on  DNA (Boros, J.  et al.,  2003;  Lim,  F.  L.  et at.,  2003).  Mutations at MCM1  positions 
T66 and L68 that reduced the apparent bend angle correlated with reduced binding of 
Fkh2  (Lim,  F.  L.  et al.,  2003).  This  correlation  was  not  true  for  all  mutations  tested 
however,  and  the  proximity  of these  residues  to  the  proposed  Fkh2  binding  surface 
cannot exclude effects of certain substitutions on protein-protein interactions.
MCM1  also  interacts  with  the  Yox1  and  Yhp1  homeodomain  proteins  to  repress 
transcription of the early cell-cycle box (ECB) genes at the transition  between the G1 
and M phases of the cell cycle (Pramila, T.  et al., 2002).  MCM1  is constitutively bound 
at the  ECB promoters,  and  it is the periodic expression of the repressor that restricts 
gene expression. Although the two homeodomain proteins display different expression 
patterns  they  function  redundantly  and  the  molecular  mechanism  of their  interaction 
with MCM1  has not been elucidated.
1.2.4.1.4  Arginine metabolism
MCM1  cooperates  with three other proteins,  the  MADS  box  containing  ARG80,  and 
the  unrelated  ARG81  and  ARG82  to  control  arginine  metabolism  by  repressing 
biosynthetic genes and activating catabolic ones in the presence of arginine (reviewed 
in (Messenguy,  F.  etal., 2003)). The interaction of these proteins is poorly understood. 
Although  MCM1  and ARG80 can interact with  both ARG82 and ARG81  the two latter 
proteins do not bind each other. ARG82 acts as a chaperone that stabilises the ARG80 
and  MCM1  MADS  box proteins in the nucleus by binding their a1  helix  (El  Bakkoury, 
M.  et al., 2000). ARG81  is the sensor of arginine and forms a complex with the MCM1 
and ARG80  MADS box proteins on the promoters or arginine regulated genes (Amar, 
N.  et  al.,  2000).  Although  MCM1  and  ARG80  are  both  required  for  the  control  of 
arginine  metabolism  genes,  the  exact  mechanism  of  their  interaction  is  not  known. 
Heterodimerisation  of ARG80  and  MCM1  has  recently  been  proposed  as  a  possible 
mechanism  of  arginine  co-regulation  (Messenguy,  F.  et  a!.,  2003),  this  however 
remains to be substantiated.
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1.2.5  SRF
Serum  Response  Factor  is  a  ubiquitously  expressed  508-amino  acid  protein,  which 
was  initially identified  as  a critical component for the transcription of the c-fos  proto­
oncogene in response to serum stimulation (Gilman,  M. Z.  et al.,  1986; Norman,  C.  et 
al.,  1988;  Prywes,  R.  et al.,  1986; Treisman,  R.,  1986).  SRF is conserved throughout 
the  animal  kingdom  and  is  found  in  nematodes,  arthropods  and  chordates.  It  is 
constitutively  expressed,  although  its  expression  can  be  upregulated  in  response  to 
stimuli in various cell lines (Hela, NIH3T3 and 10T1/2 cells) (Hirschi,  K.  K.  et a/., 2002; 
Norman, C. eta!., 1988; Sotiropoulos, A. etal, 1999; Spencer, J. A. eta!., 1996).
SRF comprises  a  highly conserved  N-terminal  DNA-binding  domain  (Figure  1.8,  see 
Section  1.2.3.1),  and  a  C-terminal  transactivation  domain,  which  is  not  functionally 
conserved between vertebrates and invertebrates (Avila, S.  et al.,  2002; Johansen,  F. 
E. etal., 1993).
1.2.5.1  SRF splice variants
Four  SRF  isoforms  have  been  discovered  to  date:  the  originally  identified  full-length 
SRF protein coded  by seven  exons,  SRF-M,  which  lacks exon 5,  SRF-S  which  lacks 
exons 4 and 5 and  SRF-I  which  lacks exons 3,  4 and 5  (Belaguli,  N.  S.  et al.,  1999; 
Kemp,  P.  R.  et al.,  2000).  SRF-M is  highly expressed  in smooth  and skeletal  muscle 
cells, SRF-S expression is smooth muscle specific and SRF-I is restricted to embryonic 
tissues (Belaguli,  N.  S.  et al.,  1999;  Kemp,  P.  R.  et al., 2000). All three splice variants 
contain the complete DNA-binding domain and can therefore dimerise and bind  DNA, 
but  they  lack  regions  of  the  transactivation  domain.  As  a  result  they  vary  in  their 
transactivation potential, with SRF-M activating SRF reporter genes weakly and SRF-I 
blocking transcription altogether (Belaguli, N. S.  etal.,  1999; Kemp,  P. R.  et al., 2000). 
This  has  led to the hypothesis that the biological  role of the SRF splice variants  is to 
control  SRF  target  gene  expression  in  different  tissues  by  forming  homo-  or 
heterodimers of different activation potentials (Belaguli,  N. S.  et al.,  1999; Kemp,  P.  R. 
et  al.,  2000;  Miano,  J.  M.,  2003).  Nevertheless  the  mechanism  regulating  SRF 
alternative splicing and its functional significance in vivo remains unexplored.
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1.2.5.2  SRF subcellular localisation
A  nuclear localisation  signal  located  N-terminal  to  its  DNA-binding  domain  (residues 
95-100,  Figure  1.8)  renders  SRF constitutively  nuclear  in  most  cell  lines  (Gauthier- 
Rouviere,  C.  et  al.,  1991).  Recent  studies  have  implicated  altered  subcellular 
localisation  in the regulation of SRF gene expression.  Partial  redistribution  of SRF to 
the  cytoplasm  has  been  reported  in  certain  settings,  such  as  upon  differentiation  of 
NIH3T3 cells to adipocytes due to loss of mitogenic  responsiveness  (Ding,  W.  et at.,
1999),  and  also  after  prolonged  serum  starvation  of  airway  myocytes,  due  to 
downregulation of the RhoA pathway (Camoretti-Mercado, B. et al., 2000; Liu, H. W.  et 
al.,  2003).  In  both  cases  cytoplasmic  redistribution  of  SRF  is  accompanied  by 
downregulation of SRF dependent genes and has thus been proposed to be a control 
mechanism  of SRF-dependent gene expression.  The  prevalence of the  phenomenon 
and  the  mechanism  by  which  SRF  redistribution  is  controlled  remains  unclear.  SRF 
was  recently  reported  to  be  predominantly  cytoplasmic  in  round  embryonic 
mesenchymal  cells,  and  to  translocate  to  the  nucleus  following  cell  spreading  and 
differentiation to smooth  muscle (Beqaj,  S.  et al.,  2002),  and it was proposed that the 
decrease of  RhoA activity upon differentiation that drives  SRF to the  nucleus.  In this 
case it was suggested that the low nuclear SRF levels in undifferentiated mesenchymal 
cells were sufficient for the  mitogenic response of SRF,  while the high  nuclear levels 
observed  after  differentiation  were  required  for  smooth  muscle  specific  gene 
expression. This hypothesis however is yet to be substantiated. Although regulation of 
SRF by  alterations  in  subcellular distribution  is  an  intriguing  idea,  further studies  are 
required  to explore the generality and  impact of the observed  phenomena described 
here.
1.2.5.3  SRF post-translatlonal modifications
SRF  is  subject  to  various  post-translational  modifications  including  phosphorylation, 
glycosylation  and  sumoylation.  Several  sites  of  O-linked  glycosylation  have  been 
mapped within the C-terminal activation domain, however the functional implications of 
these modifications  remain  unknown  (Reason, A.  J.  et al.,  1992).  SRF is modified  by 
SUMO-1  at lysine 147 within its DNA-binding domain (Matsuzaki,  K.  et al., 2003). This 
has been suggested to reduce its transcriptional activity in response to RhoA signalling, 
but this aspect of SRF regulation has not been further explored.
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Casein  Kinase II constitutively phosphorylates SRF at multiple sites between residues 
77-85 and substantially increases the on-off rates of SRF-DNA binding without affecting 
binding affinity (Janknecht,  R.  et al.,  1992a; Marais,  R.  M.  et al.,  1992). The functional 
significance  of  SRF  phosphorylation  by  CKII  is  unknown  and  the  CKII  sites  are  not 
conserved in the Drosophila SRF homolog (Affolter, M. etal., 1994)
SRF is also phosphorylated at serine  103 by members of the  MAPKAP-Kinase family 
(Mitogen Activated  Protein  Kinase -  Activated  Protein  Kinase).  In  response to growth 
factors  this  residue  is  targeted  by  RSK  (Ribosomal  S6  Kinase,  also  known  as 
MAPKAP-K1), an event reported to enhance DNA binding rate and affinity (Rivera, V. 
M.  et al.,  1993).  The stress-activated  kinase  MAPKAP-K2  also targets  serine  103  in 
vitro and in vivo thus linking SRF to the stress response (Heidenreich, O.  et al.,  1999). 
This residue can also be phosphorylated in vitro by Calcium Calmodulin  Kinase II and 
IV, and this effect is thought to be linked to the upregulation of SRF dependent genes 
in response to Ca2 +  influx in the cytoplasm (Miranti, C. K. etal., 1995).
Although  serine  103  is  targeted  by  a  multitude  of  kinases  the  significance  of  these 
phosphorylation events in the transcriptional responses of SRF in vivo remains unclear. 
Point  mutations  abolishing these  phosphorylation  sites  do  not  affect growth  factor or 
calcium regulated transcriptional activation through SRF (Hill, C. S. etal., 1994; Miranti, 
C.  K.  etal.,  1995). Furthermore Serine 103 is not conserved in Xenopus (Mohun, T. J. 
etal., 1991).
An  SRF  phosphorylation  event  is  involved  in  the  resistance  of  cultured  senescent 
fibroblasts to mitogenic signals: PKC6 phosphorylates SRF at T160 within the al-helix 
of  the  DNA-binding  domain  and  this  modification  results  in  decreased  SRF-DNA 
binding  and  downregulation  of  SRF-dependent gene  expression  (Wheaton,  K.  et al., 
2004).
The inability of SRF to bind  DNA due to phosphorylation of its al-helix has also been 
implicated in the switch between the mitogenic and muscle programmes.  In this case it 
is  PKCa  that  phosphorylates  Threonine  159  and  Serine  162  abolishing  SRF-DNA 
binding on muscle specific, but not growth-responsive promoters (Iyer, D. etal., 2006).
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The  muscle/neuronal  cell  restricted  Myotonic  Dystrophy  Protein  Kinase  (DMPK)  has 
also  been  reported  to  phosphorylate  Threonine  159  and  Serine  162  within  the  al 
coiled-coil of the DNA-Binding domain (Iyer,  D.  et al., 2003).  In this case however the 
phosphorylation  event  has  been  reported to  activate  SRF dependent transcription  of 
reporter genes, a puzzling result considering that phosphorylation at these positions of 
the MADS box introduces negative charges close to DNA.
Thus  the  literature  on  SRF  phosphorylation  in  response  to  signals  is  uncertain  and 
sometimes contradicting.  Despite the variety of  phosphorylation  events on  SRF  itself 
the  best-characterised  SRF-dependent transcriptional  responses  are  elicited  through 
interactions  with  accessory  factors,  which  are  themselves  targets  of 
signalling/phosphorylation  events.  The  signal-induced  responses  of  SRF  will  be 
discussed in more detail in the following sections.
1.2.5.4  SRF target genes and biological roles
The  first  SRF  dependent  gene  discovered  was  the  c-fos  proto-oncogene.  This  was 
found to contain  a dyad  symmetric sequence  in  its  promoter that was  recognised  by 
SRF and was required for c-fos expression  in response to serum stimulation  (Mohun, 
T.  et al.,  1987; Treisman,  R.,  1985; Treisman,  R.,  1986). This element was therefore 
named the Serum Response Element (SRE).  During the same period a 10bp promoter 
element  was  independently  discovered  in  the  promoters  of  a-cardiac  actin  genes  of 
different  species  and  also  other  muscle  genes  (Minty,  A.  et al.,  1986).  Due  to  the 
conservation of the central A/T rich region and the flanking C-G base pairs this element 
was named the CArG box (£C A-£ich GG;).  It was soon discovered that the CArG box 
corresponded to the core SRF binding site in the centre of the SRE  and  CArG  boxes 
were  subsequently  identified  in  the  promoters  of  many  muscle  specific  and  growth- 
responsive  genes  (Miano,  J.  M.,  2003;  Treisman,  R.,  1995),  including  the  c-fos  and 
egr-1  immediate early genes and also the SRF gene itself (Spencer, J. A. etal., 1996). 
Thus  SRF  is  involved  in  the  growth-response  of  proliferating  cells,  and  also  the 
regulation of the myogenic programme in  post-replicative  myocytes.  In the latter case 
SRF  is  considered  a  central  regulator  of  smooth  muscle  (Miano,  J.  M.,  2003)  and 
cardiac gene expression (Balza,  R. O., Jr.  et al., 2006) and to a lesser extent skeletal 
muscle (see section 1.2.5.4.1; reviewed in (Pipes, G. C. etal., 2006)).
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Approximately  160  SRF target  genes  have  been  identified  to  date  and  over  half  of 
these have been validated (Philippar,  U. et al., 2004; Selvaraj, A.  et al., 2004; Sun, Q. 
et al.,  2006; Zhang,  S.  X.  et al.,  2005).  Although  SRF target genes  have traditionally 
been divided in growth-regulated and muscle specific, the latest studies show a clear 
bias for regulation of genes involved in the actin cytoskeleton (Philippar, U. etal., 2004; 
Selvaraj,  A.  et al.,  2004;  Sun,  Q.  et al.,  2006).  Indeed  Stf-null  Embryonic  Stem  (ES) 
cells display severe cytoskeleton-related abnormalities ((Schratt,  G.  et a!.,  2002); see 
following  section).  Therefore  SRF  emerges  as  a  regulator  of  many  cytoskeletal 
processes such as cytoskeletal architecture, cell migration and cell adhesion.
The fact that SRF controls such  diverse subsets of genes  raises questions  as to the 
contribution of the  CArG  box sequence itself to the specificity of the response.  Many 
natural CArG boxes deviate from the optimal  CC(A/T)6GG consensus by one or more 
mismatched  bases  (Selvaraj,  A.  et al.,  2004;  Sun,  Q.  et al.,  2006).  These  sites,  are 
predicted  to  have  lower  affinities  for  SRF  at  least  in  vitro  (Leung,  S.  et  al.,  1989; 
Wynne, J.  et al.,  1992)  but are often evolutionarily conserved and  are bona fide SRF 
binding sites (Miano, J.  M., 2003; Selvaraj, A.  et at., 2004; Sun, Q.  etal., 2006).  Many 
such  elements  are  found  in  the  promoters  of  muscle  specific  genes  (Sun,  Q.  et al., 
2006),  and in some cases substitution of the low affinity CArG with a high-affinity one 
results in more widespread expression (Hautmann,  M.  B.  etal.,  1998). This lead to the 
hypothesis  that  low-affinity  CArG  boxes  are  a  control  mechanism  of  muscle-specific 
genes that contributes to the specificity of expression. Although intriguing this proposal 
remains largely unsubstantiated, especially since there is no strict correlation  between 
perfect  and  imperfect  CArG  box  sequences  and  muscle-specificity  (Sun,  Q.  et  al., 
2006) and also since many SRF muscle-specific genes are often also muscle cell-type 
restricted.
CArG  boxes  from  growth-responsive  and  muscle-specific  promoters  are 
interchangeable  (Taylor,  M.  et al.,  1989).  Although the sequences flanking the  CArG 
boxes of muscle specific genes have been previously implicated in muscle specificity in 
vivo, this proposal was based on substitution of the sequences flanking muscle-specific 
CArG boxes with those of the growth responsive c-fos CArG element (Chang,  P. S.  et 
al.,  2001;  Santoro,  I.  M.  et al.,  1991).  These  sequences  also  contain  an  Ets  DNA 
binding  site,  recognised  by  members  of  the  TCF  family  of  SRF  cofactors,  which 
respond  to  growth  signals  (see  Section  1.2.5.6).  The  widespread  expression  of  the
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muscle-specific  genes  observed  upon  these  substitution  experiments,  can  thus  be 
attributed to sensitising their promoters to growth signals due to the interaction of the 
TCFs  with  SRF.  As  discussed  in  Section  1.2.2.1,  in  vitro  binding  site  selection 
experiments identify further SRF-DNA binding determinants in the sequences bordering 
the  CArG  box  (Pollock,  R.  et al.,  1990).  The  significance  of these  results  and  their 
possible  implication  in  specificity  of  the  SRF  transcriptional  response  remains 
unknown.
1.2.5.4.1  SRF loss-of-function phenotypes
The  importance  of  SRF  in  regulating  cytoskeletal  processes  and  myogenesis  is 
apparent from SRF loss-of-function studies in mice and also Drosophila melanogaster.
Mutations of the Drosophila melanogaster SRF homologue (DSRF) (Affolter,  M.  et al.,
1994)  reveal  important  roles  of  SRF  in  Drosophila  development.  The  DSRF  allele 
pruned is  required  for development of the tracheal  system,  the  fruit-fly  equivalent  of 
respiratory and vascular systems of vertebrates (Guillemin, K. etal., 1996). The pruned 
mutation  is  homozygous  lethal  with  larvae  exhibiting  severely  impaired  terminal 
branching  of  the  tracheal  system  due  to  inability  of  the  cells  to  extend  cytoplasmic 
outgrowths towards target tissues.
DSRF  is  also  involved  in  wing  formation  where  it  is  expressed  in  intervein  tissue 
promoting  its  terminal  differentiation,  concurrently  suppressing  vein  tissue  formation 
(Montagne,  J.  et  al.,  1996).  Intervein  differentiation  involves  special  cytoskeletal 
arrangements,  which  facilitate  the  adherence  of  the  two  epithelial  layers  that  will 
eventually  form  the  wing.  The  loss-of-function  SRF  allele  blistered  prevents  this 
process resulting in the blistered wing phenotype (Montagne, J.  et al.,  1996).  Both the 
pruned  and  blistered  phenotypes  involve  alterations  in  cell  morphology  and  the 
migratory and/or adherent properties of the cells, consistent with the role of SRF in the 
regulation  of  actin-mediated  cytoskeletal  processes  in  Drosophila  development  (see 
also Section 1.2.5.7.3.3).
Homozygous  Srf-null  mice display a severe  gastrulation  defect and  die at embryonic 
day 7.5  (E7.5)  (Arsenian,  S.  et al.,  1998).  Srf (-/-)  mice also fail to form  mesodermal 
tissue  in  a  non-cell  autonomous  manner,  possibly  due  to  the  downregulation  of  a
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signalling factor required to induce mesoderm (Arsenian, S.  et al.,  1998; Weinhold,  B. 
etal., 2000). Srf (-/-) ES cells display defects in cell migration, adhesion and spreading 
(Schratt, G. etal., 2002) highlighting the importance of SRF in these processes in vivo. 
Furthermore  SRF  has found to  promote cell  survival during  ES cell  differentiation  by 
regulating the Bcl-2 antiapoptotic factor (Schratt, G. etal., 2004), however the extent of 
the involvement of SRF in antiapoptotic gene programmes has not yet been explored. 
The importance of cytoskeletal organisation and cell migration in gastrulation raises the 
possibility that the phenotype observed in Srf-null mouse embryos reflects problems in 
such processes, although Bcl-2 regulation by SRF is likely to contribute in part.
Thus, although SRF was first identified due to its involvement in the growth-response, 
the  SRF-regulated  immediate-early  gene  programme  appears  dispensable  for 
embryonic cellular proliferation since the SRF knock-out  mice develop  normally up to 
E6.5 and Srf-null ES cells do not display proliferative defects (Arsenian, S. etal.,  1998; 
Schratt, G. etal., 2001).
The early embryonic lethality of SRF knockout mice precludes the use of this model to 
study the  role  of  SRF in  differentiation  processes.  Targeted  inactivation  of SRF  has 
shown that it plays important roles in myogenesis and neurogenesis.
Inactivation in murine muscle tissues has been widely used to elucidate the central role 
of  SRF  in  smooth,  cardiac  and  also  skeletal  myogenesis.  Conditional  inactivation  of 
SRF  in  the  developing  heart  leads  to  severe  cardiac  defects  and  lethality  between 
E10.5 and E13.5 due to downregulation of SRF-dependent muscle genes (Miano, J. M. 
et  al.,  2004;  Niu,  Z.  et  al.,  2005;  Parlakian,  A.  et  al.,  2004).  Deletion  of  SRF  in 
embryonic  smooth  muscle  cells  severely  reduces the  smooth  muscle  cell  population 
and  causes  severe  cytoskeletal  defects  in  the  remaining  ones  (Miano,  J.  M.  et a/., 
2004). Selective inactivation of SRF in skeletal muscle resulted in hypoplastic skeletal 
muscles  and  perinatal  lethality  (Charvet,  C.  et  a!.,  2006;  Li,  S.  et  al.,  2005). 
Furthermore  surviving  mice  displayed  growth  retardation  due  to  skeletal  muscle 
hypotrophy (Charvet, C. etal., 2006).
Conditional inactivation of SRF in  neuronal tissues also demonstrated the  importance 
of SRF for normal neuronal development and function.  SRF deletion in adult neuronal 
populations led to downregulation of immediate-early gene expression and showed that
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SRF is  essential for synaptic plasticity in  response to  neuronal  activity-induced  gene 
expression (Ramanan, N. et al., 2005).
The  significance of SRF  in  cytoskeletal  processes  and  especially ceil  migration  was 
highlighted by deletion of SRF in the developing mouse forebrain, which led to severely 
impaired  neuronal  migration  in  the  rostral  migratory  stream  and  impairment  of  axon 
guidance, neuronal outgrowth and synapse formation in the hippocampus (Alberti, S. et 
al.,  2005;  Knoll,  B.  et al.,  2006).  These effects  were  linked to the  downregulation  of 
cytoskeletal SRF dependent genes.
Further  insights  into  the  biological  functions  of  SRF  have  been  gained  by  gene 
targeting  studies  of  its  cofactors  and  are  described  further  below (Sections  1.2.5.7.3 
and 1.2.5.6.6).
1.2.5.5  Specificity of SRF dependent gene expression
How  is  SRF  activity  differentially  controlled  according  to  cell-type  or  signalling 
pathway? SRF is central to many different gene expression programmes that are often 
opposing, the main example being cell proliferation and myogenesis since cells need to 
exit  the  cell  cycle  in  order  to  differentiate  to  muscle  cells.  During  the  proliferative 
programme SRF is able to respond to different signals, transduced either through the 
MAP  kinase  phosphorylation  cascades  or  through  the  effects  of  activated  Rho 
GTPases on the actin  cytoskeleton  (analysed  in  sections  1.2.5.6.5  and  1.2.5.7.3).  In 
contrast during  myogenesis SRF elicits cell-type  specific effects and controls smooth, 
cardiac and skeletal muscle genes.
Despite the various studies on regulation of SRF itself, involving cytoplasmic to nuclear 
translocation,  alternative  splicing,  and  posttranslational  modifications  (see  sections
1.2.5.1  to  1.2.5.3)  it  is  widely acknowledged  that these  effects do  not  constitute  the 
crux of the differential context- and signal-dependent responses of SRF.  SRF derives 
its  versatility  indirectly  by  physically  associating  with  a  range  of  signal-regulated  or 
tissue-specific regulatory cofactors. Thus by engaging different partners SRF acts as a 
platform through which different incoming signals are interpreted.
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This feature of SRF is best described in the fibroblast model of SRF-mediated serum 
response (Figure 1.9). Activation of the MAPK pathway in response to whole serum or 
mitogens such as TPA leads to ternary complex formation between SRF and members 
of the Ternary Complex  Family of transcription factors and subsequent expression of 
immediate-early genes containing both SRF and TCF DNA binding sites such as c-fos 
and egr-1  (see Sectionl.2.5.6).
On  the  other  hand,  activation  of the  RhoA  GTPase  in  response  to  whole  serum  or 
mitogens such  as  LPA induces actin  polymerization and decreases the G-actin  pool. 
These changes in actin dynamics culminate in the association of SRF with members of 
the Myocardin  Related  Family of SRF cofactors and activation of a different subset of 
genes  that  do  not  contain  TCF  binding  sites  (e.g.  vinculin,  actin  and  srf  itself;  see 
Section 1.2.5.7). Thus in this system the ability of SRF to form ternary complexes with 
either the TCFs or MRTFs dictates the MAPK- or Rho-responsiveness of SRF with the 
two pathways being mutually exclusive.
The  following  sections  will  describe  the  two  major  families  of  SRF  cofactors,  the 
Ternary Complex Factor family and the Myocardin Related Transcription  Factor family, 
and briefly discuss other reported SRF partners.
1.2.5.6  The TCFs
The TCF family of SRF cofactors  are one of the  major links of SRF to the  mitogenic 
response and the activation of immediate-early gene expression (Treisman,  R.,  1994). 
They  interact  with  SRF  on  the  promoters  of  their  target  genes  and  regulate  their 
transcription dependent on activation of the Mitogen Activated Protein Kinase pathway.
TCFs form a distinct subgroup within the  ETS-domain transcription factor superfamily 
(reviewed  in  (Sharrocks,  A.  D.,  2001)).  As  denoted  by  their  name  members  of  this 
superfamily  are  characterised  by  the  presence  of  an  ETS  DNA-binding  domain 
(Donaldson,  L.  W.  et al.,  1994).  This  common  characteristic  aside,  the  various  ETS- 
domain  proteins differ greatly in the ways they are  regulated  and the responses they 
elicit,  allowing their subdivision  into various subfamilies based on the conservation of 
the ETS domain and the presence of other functional regions.
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Figure 1.9. Signalling pathways converging at SRF. In the fibroblast model serum 
stimulation activates two distinct pathways that induce SRF-dependent gene expres­
sion  by  regulating  different  cofactors. Activation  of  MAP  kinase  signalling  cascades 
results in the phoshorylation of members of the TCF family  and transcription of genes 
containing TCF Ets binding sites such as egr-1  and c-fos. Activation of Rho GTPases 
induces changes in actin dynamics that activate members of the MRTF cofactor family, 
which  bind  SRF  and  activate  transcription  of  a  different  subset  of  SRF  dependent 
genes. GTPases are shown as black squares, actin is shown in red, SRF in blue, TCF 
in grey with  a P in a red circle indicating phosphorylation. MAL is green and the DNA is 
shown as a black line with white and grey boxes indicating the  Ets and  CArG  sites 
respectively.
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The TCFs were first defined  biochemically as a protein in Hela extracts that formed a 
ternary complex  with  SRF  on the c-fos  SRE  (Shaw,  P.  E.  et al.,  1989).  This  62kDa 
protein,  which was  named  p62T C F  based on  its ability to form ternary complexes with 
SRF and DNA, was later identified as Elk-1  (Ets-like protein-1)  (Hipskind,  R.  A.  et al.,
1991)  a  protein  previously  discovered  as  an  orphan  ETS  protein  by candidate  gene 
studies (Rao, V.  N.  et al.,  1989).  Functional studies identified SAP-1  (SRF-Associated 
protein-1)  (Dalton,  S.  et al.,  1992)  and  the  remaining  family  member  SAP-2/Net/Erp 
was isolated by homology to the other TCFs (Giovane, A. etal., 1994; Lopez, M. etal., 
1994; Price, M. A. etal., 1995).
Sequence comparison of Elk-1  and SAP-1  identified three major regions of homology: 
the N-terminal  ETS domain,  a 21-amino acid sequence designated the B-box and the 
C-terminal domain (Figure 1.10; (Dalton, S.  et al.,  1992)). Comparative analysis of the 
three TCF family members identified their common characteristics: all three are able to 
form ternary complexes with SRF and DNA (Price, M. A. etal., 1995), and this depends 
on TCF-SRF contacts mediated by the B-box and also recognition of TCF specific DNA 
sequences via the  ETS domain  (Dalton,  S.  et al.,  1992; Janknecht,  R.  et al.,  1992b). 
The C-terminal domains of all three are targeted by Mitogen Activated Protein Kinases 
(MAP-Kinases), which stimulate their transactivation activity ((Price, M. A.  etal., 1995); 
see  also  Section  1.2.5.6.5).  Further regions  of homology,  the  D-domain and the  FxF 
motif, flanking the C-terminal domain were later identified as MAP-Kinase docking sites 
(Jacobs,  D.  et al.,  1999; Yang,  S.  H.  et al.,  1998a; Yang,  S.  H.  et al.,  1998b).  Variant 
members of the TCFs exist that lack various parts of their ETS, B or C domains. These 
are  generally  thought  to  antagonise  the  transcriptional  effects  of  their  full-length 
counterparts,  but  these  effects  have  not  been  extensively  studied  (reviewed  in 
(Buchwalter, G. etal., 2004)).
The TCFs also contain repressive domains, the R domain of Elk-1  (Yang, S.  H.  et al., 
2002),  the CID domain of  Net  (Criqui-Filipe,  P.  et al.,  1999)  and the  NID domains  of 
SAP-1  and Net (Maira, S. M. etal., 1996). These will be discussed in Section 1.2.5.6.5.
1.2.5.6.1  DNA binding by the TCFs
The ETS domain is a structural variant of the winged helix-turn-helix motif, the structure 
and  DNA-binding  properties  of  which  have  been  well characterised for many  ETS-
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Figure 1.10. Schematic representation of the TCF family members. The ETS domain binds DNA, the B-box interacts with SRF, the C-domain has 
multiple MAPK phosphorylation sites and acts as a transactivation domain. The D and F (FxF) domains are MAPK docking sites. The R, NID and CID 
green boxes are transcriptional repression domains. (Adapted from Buchwalter et. al. 2004).Chapter 1 Introduction
superfamily  proteins,  including  the  founding  member  Ets-1  (E-26  protein  -1; 
(Donaldson, L. W. etal., 1994; Donaldson, L. W. etal., 1996)).
ETS  domain transcription factors  recognise an  invariant GGA triad  central to  a  more 
extended  motif  designated  the  Ets  binding  site  (EBS),  with  surrounding  nucleotides 
defining  the  DNA-binding  affinity  and  specificity  of  different  family  members,  so  that 
even highly homologous ETS proteins display differences in their DNA contacts (Shore, 
P.  et at.,  1995a).  SAP-1  and  Elk-1  provide one such  example:  although  in vitro  DNA 
binding studies defined similar consensus DNA binding sites (5’-AACCGGAAGT(A/G)- 
3’),  Elk-1  displays a more stringent specificity in the sequences it recognizes whereas 
SAP-1  has  more relaxed  specificity on  either side of the GGA triad  (Shore,  P.  et al., 
1995a).  This difference  is explained  by the three-dimensional  structures of their  ETS 
domains bound to DNA (Mo, Y.  et al.,  1998; Mo,  Y.  et a/., 2000).  Although the overall 
fold of the SAP-1  and  Elk-1  ETS domains are ~80% conserved and the sequence of 
their main DNA-contacting helix is identical, the residues within this helix are forced to 
obtain  different  conformations  due  to  non-conserved  amino-acids  C-terminal  to  the 
DNA-recognition helix.
Autoinhibition of DNA binding is a common mechanism in ETS domain proteins and is 
thought  to  have  evolved  to  prevent  promiscuous  binding  in  the  absence  of  co- 
regulatory partners or regulatory signals (Sharrocks, A.  D.,  2001).  The TCFs are also 
subject to DNA-binding autoinhibition, which is  mediated through the  B and C regions 
of Elk-1  (Dalton, S.  et al.,  1992; Yang,  S.  H.  et al.,  1999), and the  NID (Net Inhibitory 
Domain) domain of SAP-1  (Stinson, J.  etal., 2003) and Net (Maira, S. M.  etal.,  1996). 
In all three cases the inhibitory regions interact with the ETS domain, and inhibition can 
be relieved by MAPK phosphorylation (reviewed in (Buchwalter, G. etal., 2004)).
Although  the  TCFs  are  able  to  bind  DNA  autonomously  in  vitro,  it  remains  unclear 
whether members of this family are able to regulate Ets site containing promoters in an 
SRF independent manner in vivo (reviewed in (Sharrocks, A. D., 2002)). Recent reports 
of Elk-1  interacting with the TNFa and Cctq  promoters autonomously do  not address 
whether these  interactions  involve SRF recruitment to  weak or non-consensus CArG 
boxes (Tsai,  E. Y.  et al., 2000; Yamazaki, Y.  et al., 2003). The ability of SRF and TCF 
to  interact  over  long  DNA  distances  further  complicates  the  search  for  SRF 
independent  TCF-regulated  promoters.  Consequently,  the  best  characterised  TCF
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target  genes  to  date  contain  CArG  elements  and  belong  to  the  immediate-early 
category (Gineitis, D. etal., 2001).
1.2.5.6.2  Ternary complex formation between TCF and SRF
The  Ets  recognition  sequences  of  various  superfamily  members  display  significant 
overlap.  This  raises  the  question  of  how  specificity  of  DNA  binding  is  achieved 
(reviewed  in  (Sharrocks, A.  D.,  2001)).  It is possible that the  interaction of TCFs with 
SRF serves as such a target gene specificity mechanism.  Unlike many  ETS  proteins, 
which associate with their partners via their ETS domains, the TCF-SRF interaction  is 
mediated  by  contacts  external  to  the  ETS  domain.  Thus  ternary  complex  formation 
between TCF and SRF depends on both ETS-DNA and B box-SRF contacts (Dalton, S. 
etal., 1992; Janknecht, R. etal., 1992b).
The combination of protein-DNA and  protein-protein  interactions involved  in the TCF- 
SRF ternary complex allows the recruitment of TCF to low affinity Ets sites as the one 
located on the 5’ side of the CArG  box on the c-fos promoter,  which is not bound  by 
TCFs in the absence of SRF (Dalton, S.  et al.,  1992). The ability of SRF to recruit TCF 
to low affinity sites is illustrated by in vitro binding site selection experiments: when in 
the  presence  of  SRF  bound  to  a  high  affinity  CArG  box,  Elk-1  selects  the 
(G/A)(C/A)(C/A)GGA(A/T)(G/A)(T/C) consensus sequence, which represents a relaxed 
specificity version of that selected by autonomously binding Elk-1  (Treisman,  R.  et al.,
1992). Furthermore the sequences between the ETS and B regions of the TCFs act as 
a flexible linker between the DNA and SRF interaction domains. This linker allows great 
flexibility in the spacing and relative orientations of the Ets and CArG sites contributing 
to the ternary complex, as observed by the non-conservation of the Ets-CArG spacing 
in  different  promoters  and  confirmed  by  in  vitro  DNA-binding  selection  experiments 
((Treisman, R. etal., 1992) and references therein).
1.2.5.6.3  The TCF-SRF interaction
Extensive  biochemical studies have elucidated the molecular mechanism of the TCF- 
SRF  complex  formation  and  the  crystal  structure  of  the  SAP-1  ETS  and  B  regions 
bound to  SRF and  DNA provides further insights  in the  mode  of interaction of these 
proteins (Figure 1.11; (Hassler, M. etal., 2001).
66p-strand
3i0-helix
N-extension
EHsubunit-A  Hsubunit-B  EH DNA  EH SAP-1
Figure 1.11. Structure of the SAP-1 - SRF - DNA ternary complex. Ribbon represen­
tation of the SAP-1  ETS and B domains bound to DNA and SRF repsectively. The two 
SRF subunits are shown in blue and the DNA in green. SAP-1  is shown in yellow: the 
B-box adds an antiparallel p-strand to the p-sheet of SRF, and is flanked by two 310- 
helices that contact the all-helix and al-helix and DNA. The dashed yellow line connect­
ing the ETS and  B domains represents the flexible linker between these two regions 
that is disordered in the crystal. The figure was made from the 1hbx PDB file (Hassler 
et. al. 2001).
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In this structure the  Ets binding site is located on the 5’ side of the CArG  box and the 
two  high  affinity sites are three nucleotides apart as seen  in the c-fos  promoter.  The 
DNA-binding domains of SRF and TCF bind on the opposite planes of the DNA duplex 
and adopt conformations identical to those observed in the respective binary SAP-1  -  
DNA and SRF -  DNA complexes (Mo, Y. etal., 1998; Pellegrini, L. etal., 1995). The N- 
terminus of the SRF al-helix and the C-terminus of the SAP-1  DNA-binding helix make 
minimal contacts, nevertheless these depend on the spacing of the two sites (Hassler, 
M. etal., 2001; Mo, Y. etal., 2001).
Consistent  with  earlier  studies  (Dalton,  S.  et  al.,  1992;  Hill,  C.  S.  et  al.,  1993; 
Janknecht, R. etal., 1992b; Ling, Y. etal., 1997), the TCF B-box is responsible for SRF 
binding. The 21  amino-acids of the B-box are ordered in the unusual conformation of a 
31 0 -helix/p-strand/31 0 -helix, contacting all three layers of the SRF DNA-binding domain 
and also the core of the CArG  DNA sequence (Figure 1.11; (Hassler,  M.  et a!., 2001)). 
The major feature of the SRF-TCF interaction is the ordering of the TCF B-box along a 
hydrophobic  groove  formed  by  the  middle  and  top  layers  of  the  SRF  DNA-binding 
domain (Ling,  Y.  et al.,  1997; Ling,  Y.  et al.,  1998),  resulting  in the p-strand of the  B- 
box  interacting  with the  p-sheet of the SRF middle  layer extending  it by an additional 
antiparallel strand (Hassler, M. etal., 2001). Central to this interaction is the insertion of 
SAP-1  F150  in  a  hydrophobic  pocket formed  by  SRF  residues  V194,  I206  and  1215 
(Figure 1.12).
The 31 0 -helices flanking the p-strand make further crucial contacts: residues R138 and 
N139 of the  N-terminal 31 0 -helix  make phosphate contacts with the core of the CArG 
box, while residue Y141  interacts with the SRF al-helix.  Moreover residues Y141  and 
1142  form  a  hydrophobic  cluster  with  Y147  of  the  p-strand  stabilising  the  overall 
conformation of the B box (Figure 1.12A). The C-terminal 31 0 -helix contributes residues 
L152 and L155, which bind the SRF all-helix.
The importance of many of these residues had been previously pinpointed by alanine 
scanning  mutagenesis  and  in  vitro  binding  studies  of the highly  homologous  Elk-1  B 
box,  which  identified  residues  Y153,  Y159,  F162  and  1164  (corresponding  to  SAP-1 
Y141, Y147,  F150 and L152, see Figure 1.12) as crucial for ternary complex formation 
(Ling, Y. etal., 1997).  Similar  analyses had  also mapped the amino acids forming the
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Figure 1.12. Interactions between the TCF B box and the SRF DNA-binding domain in the ternary complex. (A) Sequence and secondary struc­
ture elements of the SRF DNA-binding domain and the SAP-1 and Elk-1  B boxes. The SRF hydrophobic pocket residues are shown in red. (B)Van der 
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representation. The two SRF subunits are shown in blue and the DNA in green. SAP-1  is shown in yellow, with the side chains of the B-box contacting 
SRF in red, and those interacting with DNA in orange. (C) Van der Waals representation of the SRF DNA-binding domain complexed with the SAP-1 
B box  and DNA. Colour coding is as in B. The SRF residues lining the hydrophobic pocket are shown in red and the phenylalanine inserted into the 
pocket is labeled. Images were produced from the 1hbx PDB file (Hassler and Richmond, 2001).Chapter 1 Introduction
hydrophobic interaction surface of SRF (see Chapter 4 for more details; (Ling, Y. etal.,
1998).
The  interaction of TCF with  SRF by addition of  a p-strand to the  middle  layer of the 
SRF DNA-binding domain  is similar not only to the interaction  of  MATa2  with  MCM1 
(see Section 1.2.4.1.1.1), but also to the mode of homodimerisation of MEF2B where a 
p-strand  belonging  to  the  top  structural  layer  of  each  monomer  interacts  with  the 
exposed  p-strand  of  the  other  (see  Section  1.2.3.1).  As  will  become  apparent  in 
thesubsequent  chapters  this  interaction  mechanism  is  crucial  for  MADS  box 
transcription factors. The implications of this will be analysed in the Discussion.
1.2.5.6.4  DNA bending in the ternary complex
The DNA in the SAP-1 -  SRF -  DNA ternary complex is bent by 77° compared with the 
72° observed in the SRF -  DNA complex.  This discrepancy is explained partly by the 
formation of the  binary complex on  an  incomplete  half-site,  which  lacks  some of the 
CArG box flanking DNA contacts that contribute to the overall bend angle (Pellegrini, L. 
etal.,  1995). The ETS domain also bends DNA by 11°, but in the opposite direction to 
the SRF-induced  bend.  It had  been  previously shown that  Elk-1  binding to the  SRF- 
DNA complex on the c-fos promoter altered the DNA distortion (Sharrocks, A. D.  et al.,
1995).  DNA bending by SRF facilitates the contact of the SAP-1  R138/N139 31 0 -helix 
residues with DNA (Hassler,  M.  et al., 2001).  Nevertheless the extent of DNA bending 
by SRF does not affect the ability of Elk-1  to form a ternary complex,  since it can still 
interact with bending-defective SRF mutants (see Chapter 4; (Zaromytidou, A.  I.  et al., 
2006)).
1.2.5.6.5  Regulation of TCF transcriptional responses
TCFs are direct targets of three major groups of MAPKs, Extracellular signal Regulated 
Kinase  (ERK),  c-Jun  N-terminal  Kinase  (JNK)  and  p38,  that  are  regulated  by 
evolutionarily  conserved  kinase  cascades  (reviewed  in  (Yang,  S.  H.  et al.,  2003b)). 
Upon activation in response to mitogens such as hormones and growth factors (ERK) 
and stress stimuli and cytokines (JNK and p38), these kinases dock on the D and FxF 
motifs of the TCFs and  phosphorylate them on  multiple S/T-P core consensus  motifs 
(Buchwalter, G. et a!., 2004).
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Elk-1  was one of the first transcription factors to be identified as a MAPK substrate and 
can  be phosphorylated by ERK and JNK; SAP-1  can  be phosphorylated by ERK and 
p38, whereas SAP-2 has been reported as an ERK, p38 and JNK target ((Sharrocks, 
A.  D.,  2002)  and  references  therein;  Figure  1.13).  Thus  despite  the  high  sequence 
conservation  of  the  TCF  C-terminal  domains  the  MAPK  cascades  target  the  TCFs 
differentially.  Nevertheless the complexities of MAPK phosphorylation of TCFs  in vivo 
remain  unresolved.  MAPK  phosphorylation  enhances  DNA  binding  of the  TCFs  and 
stimulates their transcriptional  activity  by  recruiting  co-activators  (the  mechanisms  of 
TCF activation are reviewed in (Buchwalter, G. et al., 2004)).
In  addition  to  their transactivation  functions  the  TCFs  are  involved  in  transcriptional 
repression.  Sumoylation of Elk-1  reduces its activity,  as seen with  many transcription 
factors  (Verger,  A.  et al.,  2003).  Sumoylation  involves  covalent  linkage  of  a  SUMO 
(Small Ubiquitin-like Modifier) molecule to lysines within sumo-acceptor motifs of target 
proteins.  Although  the  exact  mechanism  through  which  this  event  attenuates 
transcription  factor  activity  is  still  unclear,  one  of  its  functions  appear  to  be  the 
recruitment of transcriptional co-repressor complexes (Gill, G., 2005). The R domain of 
Elk-1  is a sumoylation motif and when SUMO-conjugated represses its target genes by 
recruiting the HDAC2 histone deacetylase complex (Yang, S. H. etal., 2003a; Yang, S.
H.  etal., 2004)
Studies of the role of phosphorylation and sumoylation in the regulation of Elk-1  activity 
have  led  to  the  following  model  of  transcriptional  regulation  through  Elk-1.  In  the 
absence of activating signals Elk-1  is SU MO-conjugated and bound to the promoters of 
its target genes in ternary complexes with SRF (Yang, S. H. etal., 2003a). Sumoylation 
allows  Elk-1  to  recruit  HDAC  complexes  that  deacetylate  the  chromatin  and  inhibit 
transcription  of  the  Elk-1  target  genes  (Yang,  S.  H.  et al.,  2004).  Activation  of  the 
MAPK  pathway  and  subsequent  phosphorylation  of  the  C-terminal  domain  of  Elk-1 
leads  to  its  rapid  desumoylation  (Yang,  S.  H.  et  a/.,  2003a)  and  transcriptional 
activation by the recruitment of co-activators, such as the Sur2 subunit of the Mediator 
complex  (Stevens,  J.  L.  et  al.,  2002).  Finally  transcription  is  terminated  by  the 
recruitment of histone-deacetylase complexes such as the  mSin3A-HDAC complex to 
the N-terminal region of Elk-1  (Yang, S. H. etal., 2001).
Net displays  limited  transactivation ability and  is thought to act mainly as a  repressor
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through its CID and  NID domains (Buchwalter,  G.  et at., 2004).  The CID domain  also 
represses  target  genes  through  histone  deacetylation  by  recruiting  the  CtBP 
transcriptional  co-repressor  (Criqui-Filipe,  P.  et  al.,  1999).  ERK  activation  and 
phosphorylation of the C-terminal domain relieves this inhibitory effect. The NID domain 
inhibits transcriptional  activity by a poorly understood  mechanism  (Maira,  S.  M.  et al.,
1996)  that involves sumoylation and concurrent increase of the repressive potential of 
Net (Wasylyk, C. etal., 2005). The NID domain and sumoylation motif are conserved in 
SAP-1, which is also thought to utilise them for transcriptional inhibition.
Elk-1  does not contain a NID domain and the Elk-1  sumoylation motif is not conserved 
in  SAP-1  and  Net,  therefore  the  mechanisms  surrounding  sumoylation-mediated 
transcriptional repression through individual TCFs are likely to be different.
1.2.5.6.6  TCF loss-of-function phenotypes
Despite the extensive biochemical  and cultured cell studies the complete spectrum of 
the  biological  roles  of  the  TCFs  is  still  not  fully  understood.  Studies  of  Net  mice 
expressing  a truncated  form  of  the  protein  that  lacks  part  of the  ETS  domain  have 
identified  its  involvement  in the formation of the  vasculature  (Ayadi,  A.  et a!.,  2001). 
These  mice  are viable  but die shortly after birth  from  respiratory failure due to chyle 
accumulation  in  the  thoracic  cavity.  SAP-1  knockout  mice  are  also  viable  but  are 
defective in single-positive T-cell selection and develop a form of Castleman’s disease 
(Costello, P. S.  etal., 2004). Deletion of Elk-1  does not affect mouse development and 
viability and  has  no  negative effect  in  immediate early gene expression  apart from  a 
downregulation of c-fos in certain parts of the brain (Cesari, F. etal., 2004). The lack of 
severe  phenotypes  upon  inactivation  of  individual  TCFs  in  combination  with  their 
overlapping  expression  patterns  (Price,  M.  A.  et al.,  1995)  and  the overall  structural 
similarities suggest a certain degree of functional redundancy.  Nevertheless in light of 
their differences in DNA-sequence recognition, responsiveness to different branches of 
the  MAPK  pathway  and  differing  abilities  to  act  as  transcriptional  activators  or 
repressors  the  lack  of  severe  loss-of-function  phenotypes  is  surprising.  Double  and 
triple knockout studies will help elucidate the functional significance of these proteins in 
vivo.
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1.2.5.7  TheMRTFs
The  Myocardin-related transcription factor (MRTF) family of SRF cofactors consists of 
three members  in  mammals:  Myocardin  (Wang,  D.  et al.,  2001),  MAL/MKL1/MRTF-A 
(Ma, Z. etal., 2001; Mercher, T.  etal., 2001) and MALI6/MKL2/MRTF-B) (Selvaraj, A. 
etal., 2003b; Wang, D. Z. etal., 2002). The MRTFs are conserved through evolution in 
the animal kingdom and are present from arthropods to vertebrates, although no clear 
homolog is found in nematodes.
Myocardin is the founding member of the family and was discovered in a bioinformatics 
screen  for  murine  cardiac  specific  genes  (Wang,  D.  et  al.,  2001).  MAL  had  been 
identified  previously  as  the  product  of  a chromosomal  translocation  between  human 
chromosomes  1   and  22  t(1;22)(p13;q13),  that  leads  to  acute  megakaryoblastic 
leukaemia (AML:M7),  a  rare and  aggressive form  of childhood  leukaemia,  (Ma,  Z.  et 
al.,  2001;  Mercher,  T.  et al.,  2001).  This translocation  product  results  in the  in-frame 
fusion of almost the complete  MAL reading frame C-terminal to a gene  product from 
chromosome  one  that  contains  an  RNA-binding  motif.  Since  neither gene  had  been 
assigned  a  function  at  the  time  of  discovery,  the  t(1:22)  translocation  product  was 
named OTT-MAL (for One-Twenty-Two -  Megakaryocytic Acute Leukaemia; (Mercher, 
T.  et  al.,  2001))  or  RBM15-MKL-1  (RNA-Binding  Motif  15  -   Megakaryoblastic 
Leukemia-1;  (Ma,  Z.  et al.,  2001)).  A  second  MAL  isoform  termed  MAL(BSAC)  and 
containing distinct  N-terminal sequences, was later discovered in a genetic screen for 
antiapoptotic  factors  (Sasazuki,  T.  et  al.,  2002).  The  third  family  member, 
MAL16/MKL2/MRTF-B (Selvaraj, A.  etal., 2003b; Wang,  D. Z.  et a!., 2002),  had been 
originally identified in a lacZ gene trap screen, due to the embryonic lethal effect of the 
gene  trap  insertion  (Skarnes,  W.  C.  et  al.,  1992).  Nevertheless  it  wasn’t  until  the 
characterisation  of  Myocardin  as  an  SRF cofactor  (Wang,  D.  et al.,  2001),  and  the 
identification of  MAL as such  a cofactor (Miralles,  F.  et al.,  2003;  Sasazuki,  T.  et al., 
2002; Wang,  D.  Z.  et al., 2002) that a function was assigned to MALI6.  In contrast to 
Myocardin  whose expression is restricted to the cardiac and smooth  muscle lineages 
(Chen, J.  etal., 2002; Du,  K.  L.  etal., 2003; Wang,  D.  etal., 2001),  MAL and  MALI6 
are more widely expressed (Wang, D. Z.  et al., 2002). Studies in our lab demonstrated 
that  MAL  and  MALI 6  have  the  properties  of  the  elusive  cofactor  mediating  Rho 
signalling ((Miralles,  F. et at., 2003; Zaromytidou, A.  I. et at., 2006) and Cristina Perez- 
Sanchez, personal communication; analysed in detail in section 1.2.5.7.3.1).
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1.2.5.7.1  Functional domains of the MRTFs
The three mammalian proteins share a degree of similarity in  multiple regions (Figure 
1.14; (Miralles, F. etal., 2003; Wang, D. etal., 2001; Wang, D. Z. etal., 2002)).
1.2.5.7.1.1  The RPEL motifs
Their highly conserved  N-termini contain three RPEL motifs, which  have been named 
for their almost invariant central  RPxxxEL sequence (Miralles,  F.  et al.,  2003).  These 
repeats  had  not  been  assigned  a  function  prior  to  their  functional  analysis  in  the 
MRTFs, which established that they represent a novel actin binding structure (Miralles,
F.  et al.,  2003;  Posern,  G.  et al.,  2004).  The  ability  of  the  MRTF  RPEL  domain  to 
interact with actin confers Rho-inducibility to the MRTFs,  since disruption of the  MAL- 
actin  complex  in  response  to  Rho-signalling  activates  MAL-SRF  dependent  gene 
expression  (Miralles,  F.  et al.,  2003).  Functional  analysis  of  the  MAL  RPEL  domain 
indicates  that  this  region  is  necessary  and  sufficient  for  regulation  of  MAL  nuclear 
accumulation in response to Rho activation (Miralles,  F.  et at., 2003; Vartiainen,  M.  K. 
et al., 2006) and that each RPEL motif binds three actin molecules ((Posern, G.  et at., 
2004)  and  Sebastian  Guettler,  personal  communication).  MALI 6  is  also  able to  bind 
actin  through  the  RPELs,  whereas  Myocardin  whose  RPEL  sequences  are  more 
divergent has  negligible affinity for actin and  is refractory to  Rho signalling  (Francesc 
Miralles  and  Sebastian  Guettler,  personal  communication).  The  significance  of  the 
interaction  of  MRTFs with  actin  in their regulation  and the transcription of subsets of 
SRF target genes will be discussed in Section 1.2.5.7.3.
1.2.5.7.1.2  The B1 and Q regions
MRTFs share high homology through a region rich in basic residues designated B1  and
a glutamine-rich region designated Q (Miralles,  F.  et al.,  2003; Wang,  D.  et al.,  2001;
Wang, D. Z. etal., 2002). As will be shown in this thesis, the B1  region mediates MRTF
binding to SRF (Miralles,  F.  et al.,  2003;  Wang,  D.  et al.,  2001).  The  Q region  is  not
required for, but enhances MAL binding to SRF (Miralles,  F.  et al., 2003). Although the
Q box  has been  reported to  be  necessary for the  interaction  of  Myocardin  with  SRF
(Wang, D.  et al., 2001), and was proposed to bind SRF in a manner similar to the TCF
B box (Wang, Z.  et al., 2004), it was later shown that this role is fulfilled by the B1  box
in both  MAL and Myocardin (Zaromytidou, A.  I.  et al., 2006). The results presented in
this thesis analyse the role of the B1  box and support a model in which the MRTFs use
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Figure 1.14. Schematic representation of the MRTF family members. The domain structure of the murine MAL, MALI 6 and Myocardin isoforms 
are shown with the Drosophila DMRTF included.  MAL(fl)  is MKL1/MRTF-A and is translated from a leucine 92 residues prior to the first in-frame 
methionine. The divergent MAL(BSAC) sequences N-terminal to the RREL domain are shown as a striped box. The two MALI 6 isoforms are identical 
apart from their different N-termini prior to the RPEL domain (shown as striped box). Myocardin-935 is identical to Myocardin A (not pictured) which 
contains an extra exon C-terminal to the LZ domain. Note that the original Myocardin cDNA was a predicted open reading frame of 807 amino acids 
that lacked the RPEL domain (Wang et. al., 2001).The  question mark in DMRTF indicates the position of residues resembling the hydrophobic core 
of the mammalian Q box.Chapter 1 Introduction
a conserved predominantly hydrophobic core sequence within their B1  box to contact 
the hydrophobic groove and pocket of SRF via a mechanism analogous to that utilised 
by the TCFs ((Zaromytidou, A. I. etal., 2006); analysed in Chapters 3 and 4).
This model explains the mutually exclusive interactions of the B1  box of MAL and the B 
box of TCF,  however there are significant differences in the way that the two proteins 
form ternary complexes with SRF. Optimal binding of MAL to SRF requires appropriate 
DNA distortion in the SRF-DNA complex, a characteristic not observed in the TCF-SRF 
interaction  ((Zaromytidou,  A.  I.  et  al.,  2006);  analysed  in  Chapter  4),  but  which  is 
reminiscent  of  the  interaction  of  MCM1  with  the  MATal  cofactor  (see  Section 
1.2.4.1.1.1).  Insight into the role of DNA bending  in  MAL-SRF complex formation was 
provided by the analysis of the role of DNA contacts in the complex. This analysis led 
to a model in which SRF-induced DNA bending facilitates direct contacts between MAL 
and DNA, the lack of which greatly impairs ternary complex formation ((Zaromytidou, A. 
I.  et al., 2006); described in Chapter 5).  Despite the importance of MAL-DNA contacts 
in  the  ternary  complex  with  SRF  it  remains  unclear  whether  these  are  sequence 
specific and whether MAL is able to bind DNA autonomously (see Appendix).
1.2.5.7.1.3  The nuclear localisation signals of the MRTFs
The B1  box of the MRTFs also harbours a nuclear localisation signal, but this function 
is  separable  from  SRF  binding,  while the  Q  box  has  been  shown  to  affect  nuclear 
export  (Miralles,  F.  et al.,  2003;  Zaromytidou,  A.  I.  et at.,  2006).  A  second  nuclear 
localisation signal designated B2 is located between RPEL motifs 2 and 3 and both the 
B1  and B2 regions are required for efficient nuclear localisation of MAL (Miralles,  F.  et 
al.,  2003).  MAL  and  MAL  16  shuttle  continuously  between  the  nucleus  and  the 
cytoplasm  in  a signal  regulated  manner,  whereas  Myocardin  is  constitutively  nuclear 
((Miralles, F. etal., 2003); see Section 1.2.5.7.3).
1.2.5.7.1.4  The SAP domain
The MRTFs also contain a SAP domain, named after the first proteins it was identified
in:  SAF-A  and  -B,  Acinous  and  PIAS  (reviewed  in  (Aravind,  L.  et al.,  2000)).  This
domain is found in a variety of proteins involved in diverse processes like recognition of
scaffold-  or  matrix  attachment  regions  on  chromatin,  DNA  repair,  RNA  processing,
chromatin  remodelling  and  apoptotic  degradation  of  chromatin  (Aravind,  L.  et  al.,
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2000). DNA binding appears to be the common characteristic between SAP containing 
proteins  and  in some cases,  such  as  in  SAF-A/B,  Ku70  and  PIAS1  this domain  has 
been  found  to  mediate  recognition  of  A/T  rich  DNA  regions  (Kipp,  M.  et al.,  2000; 
Okubo, S. et al., 2004).
The  role  of the  SAP  domain  in  MRTFs  and  its  ability  to  bind  DNA  remain  unclear. 
Deletion or disruption of this region does not affect ternary complex formation with SRF 
(Miralles,  F.  et  al.,  2003;  Wang,  D.  et  al.,  2001).  Disrupting  the  SAP  domain  of 
Myocardin affects target gene activation in a promoter dependent manner (Wang, D. et 
al., 2001) and deleting it reduces the myogenic potential of the protein in cultured cells 
(Wang,  Z.  et at.,  2003).  This  functional  requirement  of  the  Myocardin  SAP  domain 
suggests a context dependent role either due to specific protein-protein or protein-DNA 
interactions.  Moreover  the  involvement  of  SAP  domain  proteins  in  chromatin 
organisation,  raises  the  possibility that  the  effects  of this  domain  in  the  MRTFs  are 
obscured by the experimental use of naked DNA as opposed to chromatin.
1.2.5.7.1.5  The leuc/ne-zipper m otif and transactlvatlon domains
MRTFs  contain  a  leucine-zipper  motif  that  is  responsible  for  homo-  and 
heterodimerisation, with MAL existing as a stable dimer and Myocardin as a monomer 
in solution ((Miralles,  F.  et al.,  2003; Selvaraj, A.  et al., 2003b; Wang,  D.  et al., 2001; 
Wang,  Z.  et  al.,  2003);  see  Chapter  2).  All  three  family  members  also  contain  C- 
terminal  transactivation  domains,  which  act  as  autonomous  transcriptional  units  and 
which do not appear to be controlled by signalling (Miralles,  F. etal., 2003; Selvaraj, A. 
etal., 2003a; Wang, D. etal., 2001; Wang, D. Z. etal., 2002).
1.2.5.7.2  MRTF isoforms
The original  Myocardin cDNA is a 935-amino acid isoform that contains the complete
RPEL  domain  (Wang,  D.  et  al.,  2001;  Wang,  D.  Z.  et  al.,  2002).  It  later  became
apparent  that  the  Myocardin  open  reading  frame  contained  four  potential  ATG  start
sites in total, the first of which gives rise to Myocardin-935 and is enriched in cardiac
cells  (Creemers,  E.  E.  et at.,  2006).  Alternative  splicing  introduces  a  premature  stop
codon at the N-terminus of Myocardin and translation starts at the third ATG giving rise
to a shorter 856 residue isoform that contains only RPEL 3 and is abundant in smooth
muscle cells  (Figure  1.14;  (Creemers,  E.  E.  et al., 2006).  The  Myocardin-935  isoform
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interacts with both SRF and MEF2 proteins. The interaction with MEF2 is mediated via 
a  short  motif  located  within  the  N-terminal  sequences  and  activates  transcription  of 
MEF2-dependent genes (Creemers,  E.  E.  et al., 2006).  MEF2 binding is not observed 
with the Myocardin-856 isoform, which lacks the N-terminal motif. A third isoform is the 
983  amino  acid  Myocardin  A,  which  contains  an  extra exon  in  its  C-terminal  part,  is 
also  cardiac-enriched  and  is  functionally  identical  to  the  original  Myocardin-935 
(Ueyama, T. etal., 2003)*.
MAL is also present as two isoforms with different N-termini: MAL(fl) which is translated 
from a leucine 92 amino acids upstream of the first in-frame methionine (Miralles, F.  et 
al., 2003),  and  MAL(BSAC) which contains divergent sequences  N-terminal to  its first 
RPEL  motif  (Figure  1.14;  (Sasazuki,  T.  et  al.,  2002).  Both  isoforms  are  widely 
expressed (Sasazuki, T.  et al., 2002; Wang,  D. Z.  et al., 2002) and the significance of 
their diverse  N-termini  is unclear.  Short splice variants of  MAL lacking the  C-terminal 
transcactivation  domains  have also  been  detected  in various tissues,  but these  have 
not  been  characterised  ((Wang,  D.  Z.  et al.,  2002)  and  Francesc  Miralles,  personal 
communication).
Alternative MALI 6 isoforms analogous to MAL(fl) and MAL(BSAC) also exist and have 
been named MRTF-B (Wang, D. Z. etal., 2002) and MKL2 ((Selvaraj, A. etal., 2003b); 
Figure  1.14).  Both  isoforms  contain  all three  RPEL domains  however their  N-termini 
prior to the first RPEL are distinct. Although both are widely expressed the MKL2 form 
is  more  abundant  in  skeletal  muscle  where  the  MRTF-B  type  is  barely  detectable 
(Selvaraj,  A.  et al.,  2003b;  Wang,  D.  Z.  et al.,  2002).  Despite the differences  in their 
expression pattern, the roles of their different N-termini remains unexplored.
1.2.5.7.3  Regulation of MRTF transcriptional activity and signal convergence at 
SRF
Myocardin  was the first  MRTF to  be  identified  as  an  SRF cofactor  (Wang,  D.  et al.,
2001).  Although  Myocardin can activate transcription of SRF target genes in a CArG- 
dependent  manner,  its  expression  is  restricted  to  muscle  lineages  and  its
* The Myocardin isoform used in this thesis is a 977 amino acid version of Myocardin, A 
which lacks six glutamine residues from the polyglutamine stretch of the Q box.
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transcriptional activity appears to be constitutive (Kuwahara, K.  et al., 2005; Wang,  D. 
et al.,  2001;  Wang,  Z.  et  al.,  2003).  In  contrast  the  discovery  of  the  more  widely 
expressed  MAL  and  MALI 6  created  a  breakthrough  in  the  field  of  SRF  dependent 
signal regulated transcription.
As mentioned in Section 1.2.5.5 SRF acts as a platform through which different signals 
can  be transduced.  Signal convergence at SRF  has  been  extensively studied  during 
the serum response of proliferating fibroblasts ((Miralles,  F.  et al., 2003; Treisman,  R., 
1994)  and  references therein).  In  the fibroblast  model  serum stimulation  induces the 
expression of many SRF-dependent genes via pathways initiated by different mitogens 
(Gineitis, D. etal., 2001; Hill, C. S. etal., 1995a). One such pathway is the ERK MAPK 
signalling cascade that results in the phosphorylation of TCF within the ternary complex 
with SRF and DNA (Sectionl .2.5.6).
Early in the dissection of the signalling events leading to activation of transcription by 
SRF it was  discovered that the  MAPK cascades were  not the only pathway inducing 
SRF dependent  gene  expression  (Graham,  R.  et al.,  1991;  Hill,  C.  S.  et al.,  1994). 
More specifically it was discovered that attenuation of TCF binding to SRF on the c-fos 
promoter  did  not  abolish  its  responsiveness  to  serum  indicating  that  a  TCF 
independent pathway was at work (Hill, C. S. etal., 1994; Johansen, F. E.  etal., 1994). 
Furthermore it was shown that the integrity of the SRF DNA-binding domain including 
the sequences  implicated in TCF binding was  instrumental for the  responsiveness of 
SRF to  serum  in  the  absence  of  TCF.  Furthermore  the  TCF-independent  response 
required that the SRF DNA-binding domain be tethered to its cognate DNA site (Hill, C. 
S.  etal.,  1994). This led to a model in which authentic SRF-DNA contact was required 
for the  interaction of wild-type SRF with  a putative “recognition  factor”, that  mediated 
serum  induced  signalling  independently  of  TCF  (Hill,  C.  S.  et al.,  1994).  The  TCF- 
independent  pathway was  later found to  involve  members  of the  Rho family of small 
GTPases ((Hill, C. S. etal., 1995b); analysed in the following section).
Further studies revealed that the Rho and MAPK-TCF pathways are mutually exclusive 
in  their  abilities  to  activate  SRF  dependent  genes  (Gineitis,  D.  et  al.,  2001; 
Sotiropoulos,  A.  et  al.,  1999).  The  differential  sensitivity  of  target  genes  to  each 
pathway  correlates  with  the  presence  or  absence  of  a  TCF  binding  site  in  their 
promoters and the physical interaction of the TCF B box with SRF on target promoters
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is sufficient to inhibit Rho mediated activation, indicating that combinatorial interactions 
of  SRF  with  different  cofactors  at  target  gene  promoters  are  the  root  of  pathway 
selectivity (Murai, K. et al., 2002).
1.2.5.7.3.1  The TCF-independent pathway: Rho-actin signalling to SRF
Rho  GTPases  belong  to  the  Ras  GTPase  superfamily  and  have  major  roles  in  the 
regulation of the actin cytoskeleton and diverse cellular processes including adhesion, 
migration,  morphology,  membrane  trafficking  and  proliferation  (reviewed  in  (Etienne- 
Manneville,  S.  et  al.,  2002)).  Activation  of  RhoA  in  response  to  whole  serum  or 
mitogens such as lysophosphatidic acid (LPA) is necessary and sufficient for activation 
of SRF dependent transcription  in the absence of TCF (Hill,  C.  S.  et al.,  1995a).  The 
related  Rac1  and  Cdc42 GTPases  have the same effect,  however SRF activation  by 
extracellular  signals  that  act  through  these  GTPases  remain  to  be  formally 
demonstrated (Hill, C. S. etal., 1995b).
The function of  Rho GTPases  in TCF independent activation of SRF is also  linked to 
their  role  as  cytoskeletal  regulators.  This  was  initially  revealed  indirectly,  by  a 
mammalian screen for SRF activators, which recovered LIM kinase-1, a regulator of the 
actin treadmilling cycle (Sotiropoulos, A. etal., 1999). LIMK stabilises actin filaments by 
phosphorylating and inactivating cofilin, a protein that promotes the dissociation of actin 
monomers  from  F-actin  pointed  ends  and  induces  F-actin  severing  (Arber,  S.  et at., 
1998;  Yang,  N.  et al.,  1998).  Although  the  requirement  of  LIMK for serum-regulated 
activation  of  SRF  appears  to  be  cell-type  specific  (Geneste,  O.  et  al.,  2002; 
Sotiropoulos,  A.  et  al.,  1999),  its  discovery  was  crucial  since  it  established  a  link 
between the actin cycle and transcription via SRF.
More specifically proteins that promote actin polymerisation,  such  as  members of the 
Diaphanous  and  WASP  families  activate  SRF  in  a  RhoA  dependent  manner,  while 
dominant  negative  forms  of  these  proteins  inhibit  both  F-actin  assembly  and  SRF 
activation (Copeland, J. W. et al., 2002; Grosse,  R.  et al., 2003; Sotiropoulos, A.  et al.,
1999).  Actin  binding  drugs  that  inhibit  polymerisation  such  as  Latrunculin  B,  inhibit 
RhoA  signalling  to  SRF,  while  reagents  that  promote  actin  polymerisation  such  as 
Jasplakinolide activate SRF (Sotiropoulos, A. etal., 1999). Furthermore overexpression 
of  actin  itself  or  non-polymerisable  actin  mutants  inhibits  SRF  activation,  while
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overexpression of actin  mutants that stabilise F-actin has the opposite effect (Posern,
G.  etal., 2002; Sotiropoulos, A. et al.,  1999). Thus RhoA-dependent activation of SRF 
was  shown  to  be  mediated  by  changes  in  actin  dynamics  that  promote  actin 
polymerisation  and G-actin depletion, and  it was the latter that emerged as the event 
leading to SRF activation (Posern, G. etal., 2002; Sotiropoulos, A. etal., 1999).
Taken together these data support a model  according  to  which  RhoA activation  and 
ensuing  changes  in  actin  dynamics  result  in  the  depletion  of  the  G-actin  pool  and 
subsequent activation of an actin-regulated SRF-binding cofactor that interacts with the 
same or overlapping surface on SRF as the TCFs.
In  addition  to  defining  certain  regulatory  behaviours  of  the  putative  cofactor,  the 
functional studies discussed in the previous sections also make clear predictions about 
the abilities  of this  cofactor to  interact with  SRF.  Using these criteria,  soon  after the 
discovery of the MRTFs MAL was identified as the elusive Rho-regulated SRF cofactor 
(Figure 1.15; (Miralles, F. etal., 2003)). MAL cannot bind SRF efficiently in the absence 
of  cognate  SRE  DNA,  and  cannot  interact  with  altered-specificity  SRF  mutants  that 
have heterologous N-terminal sequences in their DNA-binding domains ((Miralles,  F. et 
al.,  2003;  Zaromytidou,  A.  I.  et al.,  2006);  analysed  in  Chapters  2  and  5).  Moreover 
MAL  competes  with  the  TCFs  for  binding  the  same  surface  on  SRF  as  the  TCFs 
((Miralles, F. etal., 2003); see Chapters 2 and 4).
MAL  binding  to  actin  renders  it  predominantly  cytoplasmic  and  inactive  under  basal 
conditions  and  its  nuclear  localisation  and  transcriptional  activity  is  promoted  in 
response  to  Rho  signalling  ((Miralles,  F.  et al.,  2003);  see  below).  Treatment  with 
proteins/reagents that promote F-actin assembly or actin binding drugs that disrupt the 
actin-MAL  complex,  like  Cytochalasin  D  has  the  same  effect,  whereas  proteins  that 
induce  F-actin  disassembly  or  drugs  such  as  Latrunculin  B  that  prevent  actin 
polymerisation  without affecting the actin-MAL interaction inhibit nuclear accumulation 
and transcriptional activation (Miralles, F. etal., 2003).
In the fibroblast system  MAL is continuously shuttling between the cytoplasm and the 
nucleus  under  basal  conditions,  but  its  high  export  rates  result  in  its  predominantly 
cytoplasmic  appearance  (Miralles,  F.  et  al.,  2003)  (Vartiainen,  M.  K.  et  al.,  2006). 
Activation of the Rho-actin pathway promotes MAL accumulation in the nucleus where\
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Figure 1.15. Rho-controlled actin dynamics regulate SRF activity through  MAL.
Signalling through Rho GTPases and their effectors (including Diaphanous and LIMK) 
induces actin polymerisation (shown as a solid red arrow). The depletion of the G-actin 
pool (dashed red arrow) results in the dissociation of actin from the SRF cofactor MAL, 
which then binds SRF and activates transcription.  Rho GTPases are shown as black 
squares,  MAL as a green oval  and SRF as a blue circle. The CArG  site on  DNA is 
shown as a grey box on a black line. Adapted from (Posern and Treisman, 2006).
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after dissociating from actin  it activates transcription of  Rho-  but  not  MAPK-sensitive 
SRF target genes (Figure 1.16; (Miralles, F. et al., 2003)).  Measurement of MAL import 
and export rates following stimulation shows that the  major regulatory step is export, 
and this appears to require actin binding (Vartiainen, M. K. etal., 2006).
Recent  studies  indicate  that  although  it  appears  as  a  major  regulatory  step  in  Rho- 
dependent SRF activity in fibroblasts, nuclear accumulation of MAL is not sufficient for 
activation.  MAL  and  MALI6  are  nuclear  in  many  cell  lines  ((Du,  K.  L.  et al.,  2004); 
Cristina Perez-Sanchez, personal communication) and the forced nuclear accumulation 
of  MAL  by  fusion  to  an  NLS  or  blockade  of  the  Crm1-dependent  nuclear  export 
mechanism  by  Leptomycin  B  treatment,  is  not  sufficient  to  activate  transcription 
(Vartiainen,  M.  K.  et al.,  2006).  MAL is able to interact with  actin  both  in the nucleus 
and the cytoplasm  and  it appears that its dissociation from  actin  is  a prerequisite for 
activation of Rho-dependent SRF transcription, thus revealing a role of nuclear actin in 
the  regulation  of  SRF  (Vartiainen,  M.  K.  et  al.,  2006).  The  exact  mechanism  of 
inhibition  of  MAL  activity  by  nuclear  actin  has  not  been  elucidated,  although  the 
simplest model in support of the current evidence is that interaction of MAL with actin 
prevents MAL-SRF complex formation (Sebastian Guettler, personal communication).
Moreover,  MAL  is  phosphorylated  under  basal  conditions  and  serum  stimulation 
induces  further  phosphorylation  at  multiple  sites  (Miralles,  F.  et  al.,  2003). 
Phosphorylation  appears  to  affect  the  transactivation  potential  of  MAL  (Francesc 
Miralles,  personal  communication),  however  the  kinase  and  upstream  regulators 
involved are not known.
In contrast to Myocardin, which does not respond to Rho signalling, MALI 6 is regulated 
much  like  MAL  in this  system  (Cristina  Perez-Sanchez,  Francesc  Miralles,  Sebastian 
Guettler, personal communication).
While the activation of Rho-regulated transcription via MAL-SRF is well understood the 
means by which MAL activity is down-regulated is less clear.  MAL remains nuclear for 
hours  after the  initial  transcriptional  response  and  the  purpose  of this  localisation  is 
unknown  (Miralles,  F.  et al.,  2003).  MAL has recently been reported to  be a target of 
sumoylation  in  response  to  Rho-signalling  ((Nakagawa,  K.  et  al.,  2005);  Francesc 
Miralles,  personal  communication).  This  event  follows  the  early  MAL-induced
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Figure 1.16. Regulation of MAL localisation and activity by actin in the fibroblast model. (A) Under basal conditions MAL is continuously shut­
tling between the nucleus and cytoplasm, but high export rates maintain it mainly in the cytoplasm and actin binding prevents SRF activation by the 
reduced nuclear population of MAL. (B) Serum stimulation activates Rho signalling and actin polymerisation resulting in the nuclear accumulation of 
MAL due to decreased export rates and activation of SRF-dependent transcription due to the dissociation from actin. The red “?” indicates the uncer­
tainty surrounding the actin-binding state of MAL upon nuclear import and export. MAL is shown in green, SRF in blue and actin in red. Proteins are 
shown as monomers for simplicity. Adapted from (Vartiainen et. al., submitted).Chapter 1 Introduction
transcriptional  response  and  represses  MAL  activity.  Thus  sumoylation  has  been 
proposed as a potential mechanism for MAL-SRF transcription termination, possibly by 
recruitment  of  HDAC  complexes  as  seen  in  other  systems  (see  Section  1.2.5.6.5). 
Nevertheless  this  has  not  been  substantiated  and  although  Myocardin  can  recruit 
HDACs via a region overlapping its Q domain this has not been explored for the other 
MRTFs (Cao, D. etal., 2005).
1.2.5.7.3.2  Target gene specificity of the MRTFs
In fibroblasts the serum-regulated SRF dependent genes can be divided in two groups 
depending on their sensitivity to the MAPK or Rho pathway, which results in differential 
interaction of SRF with members the MRTF or TCF cofactor families (Gineitis, D. etal., 
2001;  Miralles,  F.  et al.,  2003).  Discrimination  between  cofactors appears  at  least  in 
part specified by the presence or absence of a well-defined  Ets binding site at target 
gene  promoters,  with  MAL  preferentially  recruited  to  promoters  lacking  such  sites 
(Miralles, F. etal., 2003; Murai, K. etal., 2002). It has been shown however that certain 
genes  can  be  regulated  by  both  the  MAPK  and  Rho  pathways.  The  srf gene  itself 
belongs  to  this  category  since  it  is  Rho-MAL  dependent  (Gineitis,  D.  et  at.,  2001; 
Miralles, F. etal., 2003), but is also a MAPK-Elk-1  target (Kasza, A. etal., 2005).
Although  it  is  well  established  that the  TCFs  and  MRTFs  all  interact  with  the  same 
surface  on  SRF  the  subtleties  surrounding  ternary  complex  formation  with  different 
cofactors at different promoters in vivo remain unclear. TCF dependence of SRF genes 
is obscured  by the spatial flexibility in the positioning of  Ets  and  CArG  sites  on  DNA 
and  TCF family  members display differential  affinities  for  Ets  sites  (Section  1.2.5.6). 
Moreover,  although  no  significant  sequence  preference  was  found  in  the  MAL- 
dependent genes identified in a recent study ((Selvaraj, A. etal., 2004); see below), the 
MRTFs depend on  DNA contacts for interaction with SRF but it is not known whether 
these  are  sequence  specific  or  affected  by  the  CArG  sequence  itself  or  its  intrinsic 
bending capacity (Chapter 5 and Appendix).
Microarray analysis of SRF-dependent gene expression identified 28 SRF target genes 
that are likely to be regulated by Rho-MAL signalling in response to serum, as defined 
by  sensitivity  to  repression  by  a  MAL  mutant  competent  for  SRF  binding  but  not 
transcriptional  activation  (Selvaraj,  A.  et  a!.,  2004).  Some  of  these  code  for
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transcriptional  regulators and  a small  number is involved in cytoskeletal  processes.  It 
should  be  noted  however,  that  the  genes  identified  in  this  study  are  unlikely  to 
represent the complete spectrum of serum-induced MAL dependent SRF targets, since 
the dominant-negative MAL approach used may block both MRTF and TCF dependent 
targets.
Overexpression of a C-terminally truncated SRF-binding  MAL derivative could  perturb 
the  interaction  of  SRF  with  other  cofactors  at  different  promoters,  with  currently 
unpredictable outcomes on their serum-inducibility. Thus identification of MRTF target 
genes requires more specific methods of cofactor inactivation such as siRNA-targeted 
knockdown.  In addition, as will be discussed in the following sections, the overlapping 
expression  patterns  of  MRTF  family  members  in  various  tissues  and  their  possible 
functional  redundancy as  well  as the similar  modes of regulation  in the case of  MAL 
and  MALI 6 also need to be taken into account when investigating the target genes of 
specific family members.
1.2.5.7.3.3  Biological roles of the MRTFs In cytoskeletal processes
The involvement of SRF in regulating genes involved in cytoskeletal processes is well 
established  (see  Section  1.2.5.4),  and  Rho  signalling  through  the  MRTFs  has  also 
been found  to  regulate expression  of cytoskeletal  genes  such  as  vinculin,  zyxin  and 
actin itself (Gineitis,  D.  et al., 2001;  Miralles,  F.  et al., 2003; Selvaraj, A.  et al., 2004). 
Indeed the cytoskeleton related effects of SRF in neurite outgrowth have been linked to 
Rho-actin signalling through MAL (Knoll, B. etal., 2006).
Further  evidence  on  the  partnership  of  MAL  and  SRF  in  regulating  cytoskeletal 
processes comes from studies in Drosophila melanogaster. There is one MAL isoform 
in fruit flies,  named DMRTF/MAL-D (Figure 1.14; (Han, Z.  et al., 2004; Somogyi,  K.  et 
al.,  2004)).  DMRTF  shares  homology  with  its  mammalian  counterparts  in  the  N- 
terminal  RPEL-,  B1- and SAP domains and also contains a C-terminal transactivation 
domain.  DMRTF  does  not  contain  a  Q-box  equivalent,  although  a  stretch  of 
hydrophobic  residues  resembling  the  hydrophobic  core  of  the  mammalian  Q-box  is 
located C-terminal to the B1  region and a glutamine-rich region exists in the C-terminal 
part of the protein (Han, Z.  et al., 2004; Somogyi, K.  et al., 2004).  It is noteworthy that
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this is the first SRF cofactor identified in Drosophila, since no TCF equivalent has been 
found in this organism.
DMRTF  acts  together  with  SRF  during  fly  development  and  its  deletion  is  lethal  in 
homozygous  larvae  (Han,  Z.  et  al.,  2004;  Somogyi,  K.  et  al.,  2004).  DMRTF-null 
embryos  display  abnormalities  in  tracheal  branching  that  are  similar  to  the  DSRF 
pruned  phenotype,  indicating  that  the  two  proteins  cooperate  during  tracheal 
development  ((Han,  Z.  et al.,  2004);  and  Section  1.2.5.4.1).  Expression  of  dominant 
active  or  negative  DMRTF  derivatives  in  wing  imaginal  discs  results  in  increase  or 
decrease of intervein tissue correlating with the role of SRF in wing development ((Han, 
Z.  et al.,  2004)  and  Section  1.2.5.4.1).  Furthermore expression  of dominant  negative 
DMRTFs in Drosophila embryos affects the migration of mesodermal cells (Han, Z.  et 
al., 2004).
DMRTF activity is also required for cytoskeletal  integrity and  migration of border cells 
during  Drosophila  oogenesis  (Somogyi,  K.  et  al.,  2004).  In  these  cells  DMRTF  is 
activated  in  response  to  perceived  mechanical  tension  or  cell  deformation  and 
translocates  to  the  nucleus  where  it  partners  with  SRF.  Regulation  of  this  system 
appears comparable to the mammalian Rho-actin pathway since an active form of the 
Drosophila Diaphanous protein could induce the translocation of DMRTF to the nucleus 
(Somogyi, K. etal., 2004).
Thus the link of Rho-SRF regulation to the actin treadmilling cycle via the actin-binding 
MRTFs  points  to  a  signalling  feedback  mechanism  through  which  cytoskeletal 
rearrangements  autoregulate  the  expression  of  actin  and  other  cytoskeletal 
components.
1.2.5.7.3.4  Biological roles of the MRTFs In myogenesls
All three  MRTF family members are involved  in  multiple aspects  of myogenesis.  The 
founding  member of the  MRTF family,  Myocardin  is  restricted to smooth  and cardiac 
muscle and is one of the earliest markers of cardiac and smooth  muscle cell lineages 
(Wang,  D.  et  al.,  2001).  The  significance  of  Myocardin  in  cardiomyogenesis  was 
demonstrated in Xenopus embryos were expression of a dominant negative form of the
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protein  and  morpholino-mediated  knockdown  both  inhibited  heart  development  and 
cardiac gene expression (Small, E. M. etal., 2005; Wang, D. etal., 2001).
Surprisingly  Myocardin-null  mice  do  not  display  defects  in  cardiac  development,  but 
instead  die  in the  embryonic stages  due to the  absence  of vascular smooth  muscle 
cells (Li, S. et al., 2003). This severe phenotype combined with studies in which forced 
expression  of  Myocardin  in  cultured  cells  induces  SRF  dependent  expression  of 
smooth  muscle  genes  (Chen,  J.  et al.,  2002;  Du,  K.  L.  et al.,  2003;  Wang,  Z.  et al., 
2003; Yoshida,  T.  et at., 2003)  identified  Myocardin  is an  important component of the 
smooth-muscle gene programme.  Nevertheless this  protein is  not absolutely required 
for smooth muscle differentiation since Myocardin-null ES cells differentiate normally to 
smooth muscle cells in vitro (Pipes, G. C. etal., 2005).
The high expression  levels of  MAL and  MALI 6 in  muscle tissues  (Selvaraj,  A.  et al., 
2003b; Wang, D. Z. et al., 2002) combined with the fact that MAL and MALI 6 are also 
able to induce smooth muscle gene expression when overexpressed in non-muscle cell 
lines including fibroblasts and ES cells (Du, K. L. etal., 2004; Wang,  D. Z. etal., 2002) 
raise  the  possibility  of  functional  compensation  by  other  MRTFs  in  the  absence  of 
Myocardin.
In  support  of  the  involvement  of  the  MRTFs  in  the  smooth-muscle  differentiation 
programme,  inactivation  of  MALI 6  results  in  severe  lethal  phenotypes  related  to 
cardiovascular abnormalities due to defects in the differentiation of neural crest derived 
smooth muscle cells (Li, J. etal., 2005; Oh, J. etal., 2005).
In  contrast  to  the  severe  phenotype  observed  in  MALI 6-inactivated  mice,  MAL 
knockout mice are viable (Li,  S.  et al.,  2006; Sun,  Y.  et at.,  2006).  Furthermore  MAL 
appears dispensable for muscle development in mice, with knockouts only displaying a 
defect in the myoepithelial cells that are required for milk secretion from the mammary 
gland of lactating females. Myoepithelial cells are similar to smooth muscle cells in their 
structure, gene expression pattern, and contractile properties and the  MAL-/- defect is 
related to downregulation of smooth muscle specific genes (Li, S.  et al., 2006; Sun, Y. 
et  al.,  2006).  MALI 6  is  also  expressed  in  myoepithelial  cells,  but  is  not  able  to 
substitute  for the function  of  MAL,  and  although  this  suggests  that  the two  proteins 
have  distinct  roles  it  has  also  been  suggested  that  they  are  indeed  functionally
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redundant and the  inactivation of MAL results  in the decrease of a threshold  level of 
MRTF activity required for normal function (Li, S. etal., 2006).
In one of the two studies of MAL knockout mice published to date approximately 40% 
of  MAL-null  embryos  display  cardiac  defects  and  die  due  to  cardiac  cell  necrosis, 
although the embryos that survive do not display any muscle-related phenotypes (Sun, 
Y. et al., 2006). Although this effect connects MAL with aspects of cardiac development 
the  reasons  behind  the  incomplete  penetrance  of  the  phenotype  and  the  variability 
between the two studies remain unknown.
Although  the  role  of  Myocardin  is  confined  to  cardiac  and  smooth  muscle  the  other 
MRTFs  have  been  implicated  in  skeletal  muscle  differentiation,  since  expression  of 
dominant  negative  MAL  derivatives  or  siRNA  knockdown  of  MAL  and  MALI 6  block 
skeletal muscle gene expression in cultured cells (Kuwahara,  K.  et al., 2005; Selvaraj, 
A. etal., 2003).
Despite the involvement of all three MRTF family members in  myogenic differentiation 
the significant overlap in their expression patterns  in  muscle lineages  (Selvaraj,  A.  et 
al., 2003; Wang, D.  etal., 2001; Wang, D. Z. et al., 2002) and the fact that they interact 
with  SRF  in  the  same  manner  (Zaromytidou,  A.  I.  et  al.,  2006),  make  functional 
redundancy between family  members a central  issue.  Although the differences  in the 
severities  of the  knockout  phenotypes  and  the  inability  in  some  cases  of one family 
member to  replace the other point to at  least some  level  of functional  individuality in 
their  roles,  double  or  triple  knockout  studies  are  needed  to  unravel  the  specific 
contributions  of  each  family  member  to  cardiac,  smooth  and  skeletal  muscle 
development.
1,2.5.8 Interactions of SRF with other cofactors
Although  TCF  and  MRTF family  members  are the  best characterised  SRF cofactors 
involved  in  well-defined complex formation with SRF,  many other proteins  have  been 
reported  to  interact  with  SRF and  to  influence  its  transcriptional  responses.  Many of 
these interactions  lack rigorous biochemical characterisation and  it is  unclear to what 
extent they represent bona fide SRF cofactors. Table 1.2 lists most of the SRF partners
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reported to date. The present section will discuss some of these interactions and their 
effects on SRF dependent transcription.
Table 1.2 Interactions of SRF with other cofactors
Cofactor Cofactor characteristics Experimental evidence
Phoxl Homeodomain EMSA  kinetic  effect 
(Grueneberg,  D.  A.  et al., 
1992)  (Simon,  K. J.  et al., 
1997)
Nkx2.5 Homeodomain 
Cardiac muscle specific
GST-pulldown  (Chen,  C. 
Y. etal., 1996)
Nkx3.1 Homeodomain protein Co-IP (Carson, J. A. etal., 
2000)
Nkx3.2 Homeodomain 
Smooth muscle specific
EMSA kinetic effect, GST- 
pulldown  (Nishida,  W.  et 
al., 2002)
Barx2b Homeodomain GST-pulldown (Herring, B. 
P. etal., 2001)
HOP Homeodomain  protein, 
specific
muscle GST-pulldown,  Co-IP, 
EMSA competition  (Chen, 
F.  et al., 2002; Shin, C. H. 
etal., 2002)
Fhl2 LIM-only FHL family Co-IP,  ChIP  (Philippar,  U. 
etal., 2004)
CRP2, CRP1 LIM-only CRP family 2-hybrid,  GST-pulldown, 
Co-IP,  EMSA  (Chang,  D. 
F. etal., 2003)
TEF-1 TEA/ATTS  transcription  factor  family, GST-pulldown,  Co-IP,  far
involved  in  muscle-specific  gene western  (Gupta,  M.  et al.,
expression 2001)
Myogenin/E12 Basic-helix-loop-helix proteins Yeast  2-hybrid,  GST
My  o D/E 12 involved in myogenesis pulldown (Groisman,  R.  et 
al., 1996)
GATA4 Zinc finger transcription factor,  muscle GST-pulldown,  Co-IP
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Cofactor Cofactor characteristics Experimental evidence
specific (Belaguli,  N.  S.  et  al., 
2000)
EMSA, Co-IP (Morin, S. et 
al., 2001)
GATA6 Zinc finger transcription factor EMSA,  GST-pulldown 
(Nishida, W. etal., 2002)
Fill ETS domain EMSA  (Watson,  D.  K.  et 
al.,  1997) (Dalgleish,  P. et 
al., 2000)
C/EBPp Ras-regulated activation of c-fos Yeast  2-hybrid,  Co-IP 
(Hanlon, M. etal., 1999)
Smad3 Receptor  activated  Smad,  TGFp Co-IP  (Qiu,  P.  et  al.,
regulated cofactor 2003)
Smad7 Inhibitory-Smad,  TGFp  signalling Co-IP  (Camoretti-
repressor Mercado, B. etal., 2006)
P65/NF-kB Rel homology domain GST-pulldown  (Franzoso, 
G. etal., 1996)
YY1 Zinc finger protein EMSA (Natesan,  S.  et al., 
1995)
SRF  has  been  shown  to  functionally  co-operate  with  many  homeodomain  proteins, 
resulting  in  SRF-dependent gene activation.  Most of these interactions are thought to 
involve  binding  of the  homeodomain  to  the  major groove  of the  CArG  site  on  DNA 
(Phoxl,  Nkx2.5,  Barx2b;  (Chen,  C.  Y.  et al.,  1996;  Grueneberg,  D.  A.  et al.,  1992; 
Herring, B. P. etal., 2001)), or to sites adjacent to the CArG box (Nkx3.1; (Carson, J. A. 
et al.,  2000))  and  result  in  increased  SRF-DNA  binding.  Nevertheless  despite  clear 
enhancement of SRF-DNA binding in the presence of these proteins in in vitro binding 
assays, no direct interaction in a ternary complex with DNA has been shown to date.
Binding to the major groove of the SRF-occupied CArG box has also been proposed for 
YY1, a Zinc finger protein that confers significant bend on its DNA sites and can act as 
an activator or repressor depending on promoter context ((Natesan, S. etal., 1995) and 
references therein). YY1  is able to form a ternary complex with SRF and enhances the
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kinetics of SRF-DNA binding on the c-fos promoter, although the biological significance 
of this interaction remains unknown (Natesan, S. etal., 1995).
In the case of the Phox1-SRF interaction a factor named SPIN (£RF-Phox1 -Interacting 
protein)  has  been  identified  that  is  thought  to  bind  both  proteins  forming  an 
SRF/Phox1/SPIN  complex  (Grueneberg,  D.  A.  et  al.,  1997).  The  SPIN  protein  is 
identical to the basal transcription factor TFII-I and its interaction with SRF-Phox1  has 
been implicated in induction of SRF-dependent genes such as c-fos in reporter assays 
(Grueneberg, D. A. et a!., 1997).
A  multicomponent  complex  has  also  been  suggested  to form  between  SRF and  the 
heart  specific  Nkx2.5  and  GATA4  factors  to  enhance  transcription  of  cardiac  genes 
(Belaguli, N. S. etal., 2000; Chen, C. Y. etal.,  1996; Sepulveda, J. L. etal., 2002), and 
between  SRF  and  Nkx3.2  and  GATA6  for smooth  muscle  specific  gene  expression 
(Nishida,  W.  et  al.,  2002).  Although  this  functional  cooperation  has  been  clearly 
demonstrated  with  coexpression  of the  proteins  in  reporter  assays,  the  biochemical 
evidence of the interaction is weaker.
SRF  has  also  been  shown  to  synergise  with  GATA  factors  in  complexes  containing 
members of the LIM-only cysteine-rich protein family (CRP1  and CRP2; (Chang, D.  F. 
etal., 2003)). These proteins contain two LIM domains through which they are thought 
to  mediate  subcellular  protein  targeting  and  assembly  of  multiprotein  complexes,  for 
example cell-adhesion complexes  by binding the actin-binding  proteins  a-actinin  and 
zyxin ((Chang,  D.  F.  et al.,  2003) and references therein).  CRP1  and  CRP2 however 
are  nuclear in  early embryonic stages  and  were  shown  by  GST-pulldown to  interact 
with  SRF  via their  N-terminal  LIM  domain  and  GATA factors  via  the  C-terminal  one 
(Chang, D. F. etal., 2003). Although no in vitro quaternary complex formation or indeed 
recruitment  of  these  factors  to  promoters  in  vivo  has  been  shown,  the  presence  of 
CRP2  increases  SRF  binding  to  DNA  in  vitro  and  cotransfection  of  all  three  factors 
potentiates smooth muscle gene expression in transient transfections (Chang, D.  F.  et 
al.,  2003).  Thus  CRP1/2  have  been  proposed to  act as  bridging  molecules  between 
SRF  and  GATA  factors  that  integrate  their  regulatory  functions  in  target  gene 
expression.
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In addition to these positively acting muscle-restricted  interactions, several  repressors 
of  SRF-dependent  muscle  gene  expression  have  also  been  identified.  HOP 
(Homeodomain  Only  Protein)  is  a  cardiac  specific  protein,  which  unlike  most 
homeodomain  factors  is  incapable  of  specific  DNA  binding  due  to  its  divergent 
sequences  in  the third  homeodomain  helix  (Chen,  F.  et at.,  2002;  Shin,  C.  H.  et al., 
2002).  HOP interacts with SRF and prevents its binding to DNA thus repressing SRF- 
dependent transcription (Chen,  F.  et al., 2002; Shin, C. H.  et al., 2002).  HOP-null mice 
display an embryonic lethal  phenotype due to cardiac defects and thus this protein is 
considered an important regulator of cardiomyogenesis.
FHL2 (Eour and a half LIM domain protein 2) is another LIM domain containing inhibitor 
of SRF activation.  FHL2 was identified by microarray analysis as an SRF target gene 
upregulated in response to RhoA activation and muscle differentiation (Philippar,  U.  et 
al.,  2004).  This  muscle-specific  protein  interacts  with  SRF  in  vitro  and  upon  RhoA 
activation  translocates to the  nucleus  where  it  is  recruited  to the  promoters of  SRF- 
dependent genes such as SM22 and aSM-actin, resulting in inhibition of MAL-induced 
transcriptional  activation  (Philippar,  U.  et al.,  2004).  Furthermore  FHL2  appears  to 
compete  with  MAL for  SRF  binding  in  vitro,  although  this  has  not  been  analysed  in 
detail.  These observations  have  led to  a model  in  which  Rho-MAL signalling to  SRF 
creates a negative feedback loop resulting in  FHL2 production and downregulation of 
MAL-dependent gene expression.
Combinatorial  interactions  with  other  transcription  factors  are  the  crux  of  the 
transcriptional versatility of SRF.  Identifying the ways these interactions are modulated 
temporally  and  spatially,  as  well  as  the  potential  integration  of  different  signalling 
pathways at target gene promoters through multiprotein complexes including SRF and 
other transcription factors will provide necessary insights in the biological significance 
of SRF and the diversity of the roles it fulfils.
This  thesis  will  describe  the  molecular  mechanism  of  the  SRF  interaction  with  the 
downstream  activators  of  the  RhoA  pathway  the  MRTFs,  and  compare  it  to  the 
interaction of SRF with the  MAPK-regulated TCFs  in an attempt to elucidate how the 
physical association of SRF with  members of each family is able to confer differential 
signal-sensitivity to target gene promoters.
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2  The MAL-SRF complex
2.1  Aims
The  identification  of  the  Myocardin-related  transcription  factor  family  established  a 
novel group of SRF coactivators (Ma, Z. et al., 2001; Mercher, T. et al., 2001; Wang, D. 
et al., 2001; Wang, D. Z.  et a!., 2002). Initial studies in our lab showed that in contrast 
to the constitutively active  Myocardin,  the transcriptional  activity of  MAL  was  serum- 
inducible and  RhoA-dependent, thus making it a candidate for the  Rho-actin  pathway 
mediator.  Functional studies had previously identified a number of properties expected 
of the Rho-regulated SRF cofactor. These included that binding of this cofactor to SRF 
and  subsequent transcriptional  activation  required the  intact  N-terminal  region  of the 
SRF DNA-binding domain and also that the cofactor would compete with the TCFs for 
a common surface on the SRF DNA-binding domain (Hill, C. S.  et al.,  1993; Hill, C. S. 
et al.,  1994;  Murai,  K.  et al.,  2002).  My  initial aim was therefore to establish whether 
MAL  interacts  with  SRF on  DNA,  and  subsequently to  investigate  whether the  SRF- 
binding  properties  of  MAL  correlate  with  those  predicted  for  the  Rho-pathway 
coactivator.
2.2  Formation of the MAL-SRF-DNA complex
The open  reading  frame  of the  predominant  MAL  mRNA  present  in  NIH3T3  cells  is 
predicted  to  produce  MAL(met),  a  929  amino-acid  protein  starting  at  the  first  ATG 
codon, N-terminal to the second RPEL motif (Figure 2.1). Indeed many studies on MAL 
and the MRTF protein family, describe  MAL(met) as the full-length form of the protein 
(Cen,  B.  et al., 2003; Sasazuki, T.  et a!., 2002; Wang,  D. Z.  et at., 2002).  However, a 
MAL  cDNA  including  the  5’  UTR  gives  rise  to  a  bigger  protein,  suggesting  that 
translation  begins  upstream  of  the  first  in-frame  methionine.  Mutagenesis  studies 
confirmed this  and  showed  that translation  of  MAL  begins  at or just  N-terminal  to  a 
leucine, 92 amino-acids upstream of the first methionine,  producing  MAL(fl),  a protein 
that contains a third RPEL motif ((Miralles, F. etal., 2003); Figure 2.1).
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Figure 2.1. Sequence alignment of the mouse isoforms of the MRTF family mem­
bers. Myocardin residues 1  to 976, MAL residues -92 to  929 and MALI 6 residues 1  to
1091  were  aligned  using  the  CLUSTALW  programme.  For  simplicity the  N-terminal 
variant isoforms of MAL and MALI 6 are not included in the alignment as their divergent 
sequences  stop  before  RPEL1.  Conserved  motifs  are  labeled  and  indicated  by 
coloured boxes. Identical residues are marked by asterisks and conservative replace­
ments by colons and dots.
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At the time this  study  began,  the  issue  of the  MAL translation  start  site  had  not yet 
been resolved and  MAL(met) was considered the full-length protein. As a result many 
experiments  were  initially  performed  using  MAL(met)  and  its  derivatives,  instead  of 
MAL(fl).  After  the  identification  of  the  non-consensus  translation  start  site  and  the 
cloning  of  MAL(fl),  key  experiments  were  repeated  and  confirmed  using  MAL(fl) 
derivatives.  It should be noted that MAL(met) displays the same properties as MAL(fl) 
when  it  comes  to  regulation  of  activity,  subcellular  localisation  and  SRF  interaction 
(Miralles,  F.  et al.,  2003).  As  a  result  of the  uncertainty  surrounding  the  translation 
initiation site, numbering of the residues of the MAL constructs used in this study starts 
at the first methionine  and the additional  N-terminal  segment of  MAL(fl)  is  numbered 
-92 to -1.
2.2.1  MAL associates with SRF on DNA
Myocardin, the founding member of the MRTF cofactor family, activates transcription of 
muscle-specific  genes  by  interacting  with  the  DNA-binding  domain  of  SRF on  CArG 
box containing  promoters (Wang,  D.  et al., 2001).  To test whether MAL interacts with 
SRF,  whole-cell  extracts  from  cells  transiently  transfected  with  different  MAL 
expression constructs were used in gel-mobility shift assays.
MAL(fl) formed small amounts of a slow moving complex on a c-fos promoter-derived 
probe, that contains a wild-type SRF binding site (Figure 2.2B, lane 2). A similar result 
was  obtained  by  the  MAL(BSAC)  isoform,  contradicting  a  previous  study  in  which 
MAL(BSAC) failed to interact with SRF in gel-mobility shift assays (Sasazuki, T.  et al., 
2002).  MAL(met),  which  lacks  the  N-terminal  sequences  of  the  protein  up  to  and 
including the first RPEL motif, formed increased amounts of complex (Figure 2.2B, lane 
4).  Removal  of  the  N-terminal  sequences  of  MAL  including  all  three  RPEL  motifs 
(residues  1-80,  MALAN)  further  increased  the  amount  of  complex,  suggesting  that 
these sequences exert an inhibitory effect on SRF binding (Figure 2.2B, lane 5).
All  complexes  could  be  supershifted  by  anti-MAL  and  anti-SRF antibodies  indicating 
that both proteins were present in the complex.  Furthermore,  no complexes formed on 
probe  FOS.M,  which  has  a  mutated  CArG  box that cannot  bind  SRF,  indicating that 
complex formation was dependent on the presence of endogenous SRF in the extracts 
(Figure 2.2B, lanes 16-20).
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Figure 2.2. The MAL-SRF complex. (A) The different N-termini of MAL constructs are shown on the left. The sequences of the SRF-binding sites (WT and M) 
are shown on the right. (B) MAL complex formation with endogenous SRF. Gel mobility-shift assays contained the indicated MAL whole-cell extracts and probes, 
and anti-SRF or anti-MAL antibodies. The anti-MAL antibody was raised against MAL(met) residues 1  -170. Positions of the MAL-SRF complex and the supershifted 
complexes are indicated. (C) MAL complex formation with the SRF DNA binding domain. Gel mobility-shift assays as in B, including recombinant SRF (residues 
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No  complex  corresponding  to  endogenous  MAL-SRF  was  visible  in  reactions 
containing  mock-transfected  extract  (Figure  2.2B,  lane  1).  Inclusion  of  the  anti-MAL 
antibody however,  revealed a band at a position equivalent to that of the supershifted 
transfected  MAL derivatives  (lane  11,  compare with  lanes  12-14).  This suggests that 
although the endogenous complex is undetectable under the bandshift conditions used 
(possibly due to the low levels of endogenous MAL in the extract), it becomes apparent 
upon  addition  of  the  anti-MAL  antibody,  which  visibly  enhances  complexes  in  all 
reactions.
Inclusion  of  excess  recombinant SRF  (residues  133-265)  in  the  reactions  generated 
similar  complexes  of  slightly  increased  mobility  relative  to  those  formed  with 
endogenous SRF, showing that MAL, like Myocardin and TCF, interacts with the DNA- 
binding domain of SRF (Figure 2.2C, compare with panel B).
2.2.2  The  role  of  the  N-terminal  domain  of  MAL  in  SRF-complex 
formation
As  shown  in  the  previous  section,  removal  of  the  N-terminal  sequences  of  MAL 
including  the  RPEL motifs  increases  MAL-SRF complex yield.  This  region  of  MAL  is 
also  responsible for regulation  by  RhoA and  interaction  with actin  (Miralles,  F.  et al., 
2003;  Posern,  G.  et  al.,  2004),  thus  raising  the  possibility  that  complex  formation 
between SRF and MAL is also regulated and requires stimulation of the system.
To  investigate  whether  activation  of  the  Rho  pathway  affects  MAL-SRF  complex 
formation,  cells  transiently  transfected  with  MAL  derivatives  were  serum-starved  or 
-stimulated  prior to whole-cell extract preparation.  These extracts were then tested  in 
gel-mobility  shift  assays  for  their  ability  to  interact  with  endogenous  SRF  on  the 
FOS.WT probe.  Complex  formation  between  the  Rho-regulated  MAL(fl),  MAL(BSAC) 
and  MAL(met)  proteins,  as  well  as the constitutively active  MALAN,  and  endogenous 
SRF was unaltered irrespective of serum stimulation (Figure 2.3B). A slight shift in the 
mobility of the complexes could be seen under serum-stimulated conditions, alluding to 
the altered phosphorylation status of MAL upon activation of the pathway (Miralles,  F. 
etal., 2003) (this phosphorylation-induced shift is more visible in Figure 2.4B).
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Figure 2.3. SRF complex formation by N-terminal MAL derivatives is not affected 
by serum stimulation. (A) Structures of the different N-termini of MAL constructs. (B) 
Complex formation of MAL N-terminal derivatives with endogenous SRF. Gel mobility- 
shift  assays  contained  the  indicated  MAL whole-cell  extracts  and  c-fos  ATCF  SRE 
probe. (C) Efficiency of protein extraction by the whole-cell extract technique used for 
bandshifts.  Whole-cell  extracts  were  made  from  Flag-tagged  MAL(met)  transfected 
cells and the recovery of MAL(met) protein in the supernatant and pellet was compared 
to the total MAL(met) extracted by addition to the cells of SDS sample buffer.
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The method employed for making the whole-cell  extracts used in  bandshifts involves 
lysing the cells in a high-salt buffer that causes the cytoplasmic membrane to rupture. 
The  samples  are  then  centrifuged  to  remove  cell  debris  and  the  supernatant  that 
contains the extracted proteins is stored for further experiments. Since low amounts of 
complex  were  consistently generated  by the  proteins  whose  activity  and  subcellular 
localisation  is  regulated,  it  remained  possible that this  reflected  a  problem  in  protein 
extraction.  To verify that all  protein  is extracted  efficiently,  I  compared the amount of 
transfected MAL(met) recovered in the supernatant versus that in the solubilised pellet, 
and contrasted this to the total  MAL(met) recovered in  a parallel experiment by direct 
addition  to  the  cells  of  SDS-sample  buffer  (for  details  see  Materials  and  Methods). 
Under  both  serum-starved  and  -stimulated  conditions  the  amount  of  MAL(met) 
extracted by the high-salt method was equivalent to the total  MAL(met)  recovered  by 
SDS  (Figure  2.3C).  More  importantly  no  MAL(met)  could  be  detected  in  the  pellets 
generated  during  the  whole-cell  protein  extraction  process,  confirming  that  MAL 
proteins are recovered successfully under these conditions and the low yield of MAL- 
SRF complexes is not an artifact of the extraction procedure.
2.2.2.1  A role for actln In MAL-SRF complex Inhibition?
As  previously  mentioned, the  RPEL domain  is  responsible for regulation  by  RhoA by 
mediating the interaction with actin.  SRF activation through the  Rho pathway requires 
the dissociation of G-actin from  MAL (Miralles,  F.  et at., 2003) and expression of wild- 
type actin or non-polymerisable actin mutants inhibits the activation of SRF-dependent 
reporter genes  in  luciferase assays  (Posern,  G.  et al.,  2002).  Conversely transfected 
RPEL domain constructs are able to induce SRF reporter gene activation, probably by 
competing  with  MAL for actin  binding  (Sebastian  Guettler,  personal  communication). 
The exact manner however,  in which these events affect recruitment of  MAL to  SRF 
bound promoters and subsequently transcriptional activation remains unclear.
Taking  into  account that the bandshift experiments  presented  so far were  performed 
with whole-cell extracts, it remained possible that the actin present in the extracts was 
inhibiting MAL-SRF complex formation by binding to the RPEL domain and preventing 
MAL from interacting with SRF. This possibility cast doubt on the suitability of the gel 
mobility-shift  assay  for  investigating  the  interactions  of  full-length  MAL  with  SRF.  If 
actin-bound  MAL is unable to interact with SRF,  it is conceivable that the complexes
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attributed  to  RPEL-containing  MAL  proteins  and  SRF  are  in  fact  formed  by  MAL 
derivatives  that  lack  all  or  part  of  their  RPEL  sequences  (perhaps  due  to  protein 
translation  from  an  internal  start  site,  or  N-terminal  degradation)  and  are  therefore 
unable  to  bind  actin.  To  investigate  whether  the  N-termini  of  the  MAL  proteins 
complexed with SRF in bandshifts were intact I  performed antibody supershift assays 
using  extracts  expressing  5’-Flag-tagged  MAL derivatives  (Figure  2.4).  All  MAL-SRF 
complexes  were  efficiently supershifted  by an  anti-Flag  antibody,  demonstrating that 
the  MAL  derivatives  complexed  with  SRF  contained  their  complete  N-terminal 
sequences.
I  next employed a binding competition approach to investigate the possibility of actin- 
induced inhibition of the MAL-SRF complex: if the actin present in the extracts prevents 
MAL-SRF complex formation by binding to the RPEL domain of MAL, then inclusion of 
excess MAL-RPEL domain in the reactions would be expected to relieve this inhibition 
by competing with the full-length MAL protein for interaction with actin.  Early attempts 
to test this by titrating  GST-RPEL fusion  proteins or coexpressing  RPEL-domain  and 
MAL  constructs  in  cell  extracts,  did  not  affect  MAL-SRF  complex  yield  (data  not 
shown). It remained unclear however whether this was a genuine negative result: actin 
is  very  abundant  in  whole-cell  extracts  and  it  is  conceivable  that  the  concentration 
range  of  titrated  RPEL  domain  or  the  expression  levels  of  the  transfected  RPEL 
construct were not sufficient to relieve an actin-induced inhibition of SRF binding.
Furthermore,  attempts  to  titrate  purified  actin  into  MAL-SRF  reactions  in  order  to 
compete for complex formation were also unsuccessful, since the salt conditions used 
in  the  bandshift  assays  induce  actin  polymerisation.  This  was  clearly  visible  in  the 
samples containing high actin concentrations, were the polymerised actin remained in 
the wells and did not enter the gel (data not shown).
2.2.2.2  The  effect  of  mutations  in  the  RPEL  motifs  on  the  MAL-SRF 
complex
Having established that authentic full-length  MAL-SRF complexes can  be detected by 
the  bandshift  assay,  and  since  addressing  the  role  of  actin  in  complex  formation 
directly was prevented by technical difficulties, I attempted to further explore the role of 
the  RPEL  domain  in SRF-binding. The  RPEL motifs  of MAL were  identified by  their
102RPEL1 B2 RPEL3
(BSAC)
+ 81 em u
B
Ab:
FBS:
MAL:
MAL:
SRF.DBD
mock gflaq
0.3% 15% 0.3% 15%
o O O o
< 4   S '
O)
m
< d
E,
A
N ^   c/>  ©
.  £
A
N ^  if)  © z
<
^  C/)  ©
,  E,
mock  gflaq 
0.3%
fl)  0)
p  Z   c   Z
I  s   ^  <
SRF.DBD
probe
*
Figure  2.4.  N-terminal  derivatives  of  MAL  complexed  with  SRF,  are  not  N- 
terminally degraded.  (A) Structures of the different N-termini of MAL constructs.  (B) 
Supershift of complexes containing MAL N-terminal derivatives and SRF. Gel mobility- 
shift assays contained the indicated N-terminally Flag-tagged MAL whole-cell extracts, 
SRF.DBD (residues 132-223 and 133-265 in the left and right panels respectively), c-fos 
ATCF  SRE  probe  and  anti-Flag  antibody  as  indicated.  The  supershift  of  the 
MAL(met)/SRF complex is shown as an extra panel on the right for clarity.
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homology to the RPEL repeat described in the Pfam protein family database (pfam no. 
PF02755;  Figure  2.1 A  and  Figure  2.5A).  These  motifs  had  no  function  assigned  to 
them  prior to  the  discovery  that  in  MAL they  mediate  Rho-signalling  through  actin- 
binding (Miralles, F. etal., 2003; Posern, G. etal., 2004). Mutations at the core arginine 
and proline RPEL residues of MAL have effects similar to the removal of the whole N- 
terminal  region,  since they abolish  actin-binding  and  render the  protein  constitutively 
nuclear and active (Miralles, F.  et al., 2003).  I therefore used MAL derivatives in which 
the RPEL arginine and  proline residues had been substituted  by alanine or aspartate 
(Figure  2.5A)  in  gel  mobility-shift  assays  to  test  whether they  would  also  resemble 
MALAN in their SRF binding properties.
The (PP/A) MAL(met) derivative formed a complex with SRF similar to that of the wild- 
type  protein,  whereas the  (RR/D)  mutation  increased  the  MAL(met)-SRF complex  in 
serum-starved  or  -stimulated  extracts  (Figure  2.5B  and  data  not  shown).  A  similar 
experiment with MAL(fl) derivatives showed that the triple (RRR/A)  mutation increased 
complex formation,  whereas the  (RPP/A)  derivative had  no effect  (Figure  2.5B).  The 
increase  in  MAL-SRF  complex  seen  upon  mutation  of  the  core  arginine  residues 
cannot be attributed to  removal of actin from the  protein,  since  if that were the case 
similar results would be expected upon mutation of the core proline residues (mutations 
PP/A and  RPP/A).  It appears therefore, that the effect of the RPEL mutations in SRF- 
binding  is  unconnected to their role  in  binding  actin.  Later experiments  revealed that 
removal of the N-terminus of Myocardin, whose affinity for actin is  minimal (Sebastian 
Guettler, personal communication), also increases SRF complex formation (see section 
2.3.2). It therefore remains possible that the N-terminal domains of MAL and Myocardin 
act in similar ways to inhibit SRF binding, perhaps by masking the SRF-binding surface 
or imposing structural constraints on the MAL-SRF interaction (see Discussion).
2.3  The role of the conserved motifs of MAL and Myocardin in 
SRF-binding
MRTF family members share high homology in multiple regions (Figure 2.1). In order to 
identify the regions of  MAL mediating the interaction with  SRF,  MAL constructs were 
created,  in  which  areas  of  significant  homology  to  Myocardin  were  removed.  These 
MAL domain-deletion  derivatives  were then tested for their ability to  bind  SRF in  gel 
mobility shift assays. The amounts of complex formed by MAL(fl) and SRF are very low
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Figure 2.5. Mutations in the RPEL motifs affect the interaction of MAL and SRF.
(A) Structures of the different N-termini of MAL constructs. RPEL motifs are shown as 
red bars. MALAN includes part of RPEL3 whereas MALANs starts directly C-terminal to 
it. The sequence of the consensus RPEL repeat is shown in black with the sequences 
of the three RPELs also shown below.  Framework residues are in blue and residues 
divergent from the consensus in  red. The point mutations at the framework R  and  P 
residues of the motifs are also shown.  (B) Complex formation of MAL RPEL mutants 
with  the  SRF.DBD.  Gel  mobility-shift  assays  contained  the  indicated  N-terminally 
tagged  MAL whole-cell extracts,  SRF.DBD (residues  132-223 and  120-265 in the left 
and right panels respectively),  and c-fos ATCF SRE probe.  Expression levels of the 
MAL derivatives were confirmed by immunoblotting.
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(Figure 2.2), thus increasing the difficulty of detecting low-affinity complexes by MAL(fl) 
derivatives.  These  mutations  were therefore tested  in  the  AN  context  of the  protein, 
which interacts with SRF more efficiently than MAL(fl).
2.3.1  The  effects  of  MAL  domain-deletions  on  SRF  complex 
formation
Deletion of the B1  domain inhibited the ability of MAL to bind SRF, whereas, in contrast 
to what had been reported on Myocardin (Wang, D.  et al., 2001), deletion of the Q box 
of  MAL significantly decreased  but  did  not  abolish  complex  formation  (Figure  2.6B). 
Interestingly, removal of the leucine-zipper motif of MAL resulted in a weaker MAL-SRF 
complex with substantially higher mobility, suggesting a possible role of this region in 
MAL dimerisation  (see Section 2.3.4).  ANALZ MAL derivatives harbouring the B1  and 
Q deletions had similar effects with their AN counterparts, with MALANAB1ALZ unable 
to interact with SRF and MALANAQALZ forming a weaker, fast-moving complex (Figure 
2.6B, compare lanes 2-4 with lanes 7-9).  Removal of the SAP domain had no effect in 
SRF binding.
The  results  obtained  with  the  MALAN  constructs  were  confirmed  with  MAL(met) 
derivatives  (Figure 2.6C).  As observed  with  MALAN,  removal  of the  B1  region  in the 
MAL(met)  context  abolishes  complex  formation  (compare  lanes  4  and  5),  whereas 
removal  of the  Q-box only  impairs  it  (lanes  6 and  7)  and  deletion  of the  LZ domain 
results in lower amounts of complex with increased mobility (lanes 11  and 12).
2.3.2  The effects  of  Myocardin  domain-deletions  on  SRF complex 
formation
Analysis of the equivalent Myocardin derivatives revealed significant differences in the
SRF-binding  properties  of  the  two  proteins.  Although  the  sizes  of  the  MAL  and
Myocardin ORFs are comparable, the Myocardin-SRF complex displayed an inherently
higher  mobility  compared  to  that  of  MAL-SRF  and  appeared  analogous  to  the
MALANALZ-SRF complex (Figure 2.7B, compare lane 1   with lanes 6 and 7). In contrast
to the MALALZ derivatives, deletion of the LZ domain of Myocardin did not change the
mobility of the complex (Figure 2.7B, lane 4), suggesting that the properties of the MAL
LZ region are not shared by that of Myocardin. Deletion of either the B1  and Q domains
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deletion  mutants  and  SRF.  Gel  mobility-shift  assays  contained  the  indicated  MAL 
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abolished the complex  (Figure 2.7B),  consistent with  previous  reports that  binding of 
Myocardin to SRF is  mediated  by both these  regions of the protein  (Wang,  D.  et at., 
2001).
As seen with MAL, the AN form of Myocardin bound SRF more strongly (Figure 2.7C, 
compare  lane  2 with  lane  1   in panel  B).  Interestingly upon  removal  of the  N-terminal 
sequences of Myocardin a second slow-moving complex was discernible. It is not clear 
whether this complex appears due to the deletion of the N-terminus or whether it only 
becomes visible  in the AN form  because the  higher affinity of the  MyocardinAN-SRF 
complex increases the sensitivity of the assay. This low-mobility complex depended on 
the  integrity  of  the  leucine  zipper  of  Myocardin,  since  it  was  absent  in  the  ANALZ 
sample (Figure 2.7C, compare lanes 2 and 5), implicating the Myocardin LZ domain in 
protein  dimerisation  (see Section  2.3.4).  Even though  Myocardin AN  appears to  bind 
SRF more efficiently than the full-length form of the protein, neither the ANAB1  nor the 
ANAQ forms of Myocardin interacted with SRF in this assay (Figure 2.7C, lanes 3 and 
4), highlighting a possible difference in the ways Myocardin and MAL contact SRF.
2.3.3  The effects of MAL and Myocardin domain deletion derivatives 
on SRF-dependent activation of transcription
To investigate whether these domain deletions also affected the functional cooperation 
of  MAL  and  Myocardin  with  SRF  in  intact  cells,  I  tested  the  ability  of the  MAL  and 
Myocardin  constructs  to  activate  SRF-dependent  transcription  in  a  reporter  gene 
assay.  Use of the  MALAN constructs allowed direct evaluation of their contribution to 
transcriptional activation without the interference of endogenous MAL, since MALAN is 
constitutively nuclear and active (Miralles, F. et at., 2003).
Deletion  of the  MAL  B1  region  failed  to  activate  the  reporter and  removal  of the  LZ 
domain impaired reporter activity in accordance with the effects of these constructs on 
complex  formation  (Figure  2.8B).  Removal  of  the  Q-box  however,  did  not  have  a 
significant effect on reporter gene activation. Similar results were described by Cen et 
al. (Cen, B. etal., 2003).
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Expression of the Myocardin AB1  construct failed to activate the reporter, confirming a 
previous report in which an overlapping deletion,  Abasic,  rendered  Myocardin inactive 
in SRF reporter gene assays (Figure 2.8 panels B and C; (Wang,  D.  et al., 2001)).  In 
contrast to the same report however, the equivalent Myocardin AQ derivative reduced 
but  did  not  abolish  reporter  activity  (Figure  2.8,  panels  B  and  C;  (Wang,  D.  et al., 
2001)).  This  result  also  contradicts  the  effect  of  the  MCAQ  construct  on  complex 
formation  (Figure  2.7C  and  (Wang,  D.  et al.,  2001))  and  implies  that  even  though 
complex is not detectable in the bandshift assay, the AQ form of Myocardin retains the 
ability  to  interact  with  SRF  in  vivo.  This  is  not  an  indirect  effect  of  activating 
endogenous  MAL,  since coexpression of MCAQ and C-3 transferase,  an enzyme that 
ADP-ribosylates and  inactivates  RhoA,  did  not alter transcriptional potentiation  of the 
reporter (data not shown).
Expression of MCALZ impaired reporter activity even though complex formation by this 
derivative  appeared  unaffected,  in  agreement  with  the  observations  of  Wang  et.  al. 
(Figure 2.8B; (Wang, Z. etal., 2003)). Similar results were obtained with the equivalent 
deletion mutations in Myocardin AN (data not shown).
Taken  together  these  results  suggest  that  the  B1  region  is  necessary  for  SRF 
interaction in both MAL and Myocardin, whereas the Q-box performs an auxiliary role, 
which is more pronounced in the case of Myocardin. The leucine-zipper region appears 
to affect the stoichiometry of MAL in the SRF complex, while having minimal effects in 
Myocardin  (see  also  section  1.3.4),  but  influences  reporter  gene  activation  by  both 
proteins.
2.3.4  The role of the leucine-zipper domain in MAL and Myocardin
The results described in the previous section  implicate the leucine zipper domains of 
MAL  and  possibly  Myocardin  in  protein  dimerisation.  Protein  association  through 
leucine-zipper domains relies on the interaction of two amphipathic a-helices to form a 
hydrophobic interface. This is achieved  by a slight overtwisting of the  helices,  so that 
the  structure  repeats  itself  after two  helical  turns  or  7  amino-acids  (Alber,  T.,  1992; 
Baxevanis,  A.  D.  et al.,  1993).  The  residues  of  each  heptad  repeat  are  designated 
a,b,c,d,e,f,g (Figure  2.9A).  Residues  a and  d form  the  dimerisation  interface  of the 
zipper and are usually hydrophobic, with leucines most commonly found at position d.
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Residues e and g flank the hydrophobic core of the zipper.  These residues are often 
charged and thus also have the ability to form interhelical salt bridges, which is thought 
to influence dimerisation potential (Baxevanis,  A.  D.  et al.,  1993). This is the basis of 
the “i+5 rule” for the prediction of the specificity of leucine zipper partners:  when the 
charges are compatible, residue g of one helix will form a salt bridge with residue e on 
the opposite helix, 5 amino-acids C-terminal. Repulsive interactions between these two 
positions are predicted to destabilise the dimer (Vinson, C. R. etal., 1993).
Application  of the  “i+5  rule” on the leucine zipper sequences of  MAL and  Myocardin 
predicts that MAL will form homodimers, due to the productive electrostatic interactions 
between two sets of lysine and glutamate residues at positions g and e (Figure 2.9B). 
Myocardin  on  the  other  hand  contains  two  glutatamate  residues  at  key  specificity 
positions, which would result in two repulsive interactions potentially rendering it unable 
to  homodimerise  efficiently.  According  to  the  same  rule  MAL  and  Myocardin  are 
predicted  to  heterodimerise,  since  their  leucine  zippers  can  form  two  productive 
electrostatic interactions versus one unfavourable pairing (Figure 2.9B).
2.3.4.1  The leucine zipper domain of MAL mediates homodimerisatlon
To test whether the  increase  in the  mobility of the  MALANALZ-SRF complex  (Figure 
2.6) reflects a dimer to monomer conversion I mutated one of the conserved leucines of 
the zipper to a proline.  This change is predicted to prevent dimerisation  by disrupting 
the  a-helical  conformation  of  the  zipper.  Moreover,  in  contrast  to  the  LZ  domain 
deletion,  the  proline  substitution  does  not  alter  the  molecular  weight  of  the  protein, 
simplifying the  interpretation  of  its  effects  on  complex  mobility.  Like  MALANALZ,  the 
ANL543P  mutant  displayed  increased  mobility  in  a  gel  shift  assay  (Figure  2.1 OB, 
compare lanes 3 and 4).
To  confirm  that  MAL  is  able  to  homodimerise  I  performed  co-immunoprecipitation 
assays.  Cell extracts co-expressing  HA-tagged  MAL derivatives  with  or without  Flag- 
tagged  MAL(met) were immunoprecipitated with anti-Flag antibodies and analysed for 
the  presence of  HA-tagged  proteins  by  immunoblotting.  Wild-type  HA-MAL(met)  was 
efficiently immunoprecipitated with  Flag-MAL(met) with anti-Flag antibody, but not in a 
control  immunoprecipitation  reaction  using  anti-myc  antiboby  (Figure  2.1 OC,  lanes  2 
and 3).  This  interaction  was  severely  decreased  when HA-MAL(met)ALZ was used,
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Figure 2.9.  The leucine-zipper  domains  of  MAL and  Myocardin.  (A) Sequences of 
the MAL and Myocardin LZ motifs. The top line shows the standard LZ nomenclature. 
Residues at position d predicted to contribute to the hydrophobic dimerisation interface 
are shown in blue. (B) Application of the “i+5” rule of leucine zipper dimerisation specific­
ity on the sequences of MAL and Myocardin. Residues at positions e and g that could be 
participating in interhelical electrostatic interactions are shown in large characters and 
their  charge  is  indicated.  Putative  productive  and  repulsive  electrostatic  interactions 
between these residues are indicated by solid and dashed red lines respectively. Accord­
ing to this rule MAL is predicted to form homodimers, and also heterodimers with Myo­
cardin, whereas Myocardin homodimerision is not favoured.
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confirming that MAL self-association is mediated by the leucine-zipper domain (Figure
2.1 OC, compare lanes 2 and 4). Similar results were obtained with MALAN: HA-MALAN 
was readily detectable in Flag-MALAN immunoprecipitates; this was dependent on the 
integrity of the LZ domain since recovery of HA-MALAN with the  Flag-MALAN  L543P 
mutant  was  greatly  reduced  (Figure  2.10C,  compare  lanes  5  and  6).  Moreover 
bandshift experiments indicate that MAL contacts SRF as a stable dimer (see Section
5.3.2.1 of Chapter 5).
2.3A.2  The role of the Myocardin leucine zipper In homodlmerlsatlon
The  results  described  in  section  2.3.2,  suggest  that  Myocardin  interacts  with  SRF 
predominantly as a monomer, at least under the conditions used in the gel mobility-shift 
assays.  Nevertheless, SRF reporter gene assays indicate that Myocardin requires the 
leucine zipper domain to achieve  its full transactivation  potential  (section  2.3.3).  This 
observation, in conjunction with the results described in the previous section, suggests 
that the Myocardin leucine-zipper also has dimerisation potential.
To  investigate the  possibility  of  Myocardin  self-associating through the  LZ domain,  I 
used  cell  extracts  expressing  wild-type  HA-tagged  Myocardin  with  or  without  Flag- 
tagged  Myocardin  derivatives  in  co-immunoprecipitation  experiments  with  anti-Flag 
antibodies.  A  weak  interaction  could  be  detected  between  the  wild-type  Myocardin 
proteins,  but this  did  not  require  the  presence  of  the  leucine  zipper domain  (Figure
2.1 OD, lanes 4 and 5). It remained unclear whether this represented a bona fide leucine 
zipper  independent  interaction  or  was  due  to  non-specific  binding  under  the  co- 
immunoprecipitation  conditions  used.  Hence,  these  experiments  failed  to  show 
Myocardin  associating  with  itself  through  the  leucine  zipper  domain,  in  contrast  to 
another report in which  Myocardin could be weakly immunoprecipitated with itself in a 
leucine  zipper dependent  manner  (Wang,  Z.  et al.,  2003).  The  discrepancy  between 
these  results  could  be  due  to  the  sensitivity/stringency  of  the  methods  used:  it  is 
conceivable that the self-association of Myocardin is too weak or unstable to be easily 
detectable under the co-immunoprecipitation conditions used.
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the standard  LZ nomenclature.  Residues at position d predicted to contribute to the 
hydrophobic dimerisation interface are shown in blue. An asterisk indicates the position 
of the MAL L543P mutation. (B) Effects of MAL and Myocardin LZ mutations in complex 
formation with SRF. Gel mobility-shift assays contained the indicated MAL and Myocar­
din whole-cell extracts, SRF.DBD (133-265) and c-fos ATCF probe. (C) MAL dimerises 
through the LZ domain. Extracts expressing Flag- and HA-MAL derivatives were immu­
noprecipitated with anti-Flag  beads (anti-myc in lane 3 as a negative control, indicated 
by asterisk) and analysed by immunoblotting.  (D)  Myocardin can  heterodimerise with 
MAL. Extracts expressing HA-tagged Myocardin and Flag-MAL and -Myocardin deriva­
tives were immunoprecipitated with anti-Flag beads and analysed by immunoblotting.
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2.3.4.3 MAL and Myocardin heterodlmerlse through their leucine zippers
To investigate whether MAL and Myocardin are able to heterodimerise as predicted by 
the  “i+5”  rule,  I  performed  co-immunoprecipitation  assays  in  which  cell-extracts 
expressing  HA-tagged  Myocardin  and  Flag-tagged  MAL  derivatives  were 
immunoprecipitated with anti-Flag antibodies and tested for HA-Myocardin recovery by 
immunoblotting. HA-Myocardin was readily detected in immunoprecipitates of wild-type 
Flag-MAL(met)  and this  was  dependent on  the  presence  of the  MAL  leucine-zipper, 
since  the  recovery  of  HA-Myocardin  was  greatly  decreased  when  the  Flag- 
MAL(met)ALZ  derivative  was  used  (Figure  2.10D,  lanes  1   and  2).  Hence  MAL  and 
Myocardin are able to heterodimerise through their leucine-zipper domains.
The ability of the  MAL and  Myocardin  leucine-zipper domains  to  associate  was  also 
demonstrated by the use of chimeric MAL and Myocardin constructs in which their LZ 
domains  had  been  exchanged.  A  Myocardin  derivative  harbouring  the  MAL  leucine- 
zipper  was  able  to  efficiently  associate  with  wild-type  Myocardin  in  co- 
immunoprecipitation experiments, where the recovery levels of HA-tagged Myocardin in 
Flag-MCAN(MAL-LZ) immunoprecipitates, were comparable to those of HA-Myocardin 
with  Flag-MAL(met)  (Figure  2.10D,  lanes  2  and  3).  The  equivalent  MAL  protein  that 
contained  the  Myocardin  leucine-zipper,  MALAN(MC  LZ),  was  also  able  to 
heterodimerise  with  the  wild-type  MAL,  since  HA-MALAN  efficiently  co- 
immunoprecipitated with Flag-tagged MALAN(MC LZ) (Figure 2.10C, lane 6).
2.3.4A  The effects of leucine-zipper “exchange” experiments in MAL and 
Myocardin stoichiometry and Interaction with SRF
To further probe the  properties  of the  leucine-zipper regions,  I  used the chimeric  LZ 
MAL  and  Myocardin  derivatives  in  gel-mobility  shift  assays  with  SRF.  Whole-cell 
extracts expressing  MCAN(MAL-LZ) formed  high  amounts of a slow-moving  complex 
with SRF (Figure 2.1 OB,  lane  12). This complex comigrated with  MALAN-SRF instead 
of  the  MCAN-SRF  complex  (Figure  2.10B,  compare  lane  12  with  lanes  9  and  10), 
indicating that the exchange of the Myocardin leucine-zipper for that of MAL enhances 
the ability of Myocardin to dimerise.
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The  MAL  leucine-zipper chimera  had  a surprising  effect on  SRF-complex formation: 
when used in gel mobility-shift assays, extracts expressing MALAN(MC-LZ) formed two 
complexes with  SRF, one corresponding to the wild-type  MAL-SRF complex and one 
comparable to that formed by the ALZ mutant (Figure 2.1 OB, compare lane 5 with lanes 
2 and 3).  This effect is similar to the two complexes formed by MCAN with SRF,  with 
the important difference that whereas MCAN forms higher amounts of the fast-moving 
complex, in the case of MALAN(MC LZ) formation of the low-mobility complex is more 
efficient (Figure 2.1 OB, compare lanes 5 and 7). Thus this result implies that the ability 
of the  Myocardin  leucine-zipper to self-associate  is  influenced  by the  protein  context 
(MAL or Myocardin). Since the complexes detected in the bandshift assays depend on 
both  the dimerisation  properties  of the  MRTFs  and  their  interactions with  SRF  itself, 
this  could  be  reflecting  fundamental  differences  in  the  ways  MAL  and  Myocardin 
interact with SRF or the presence of other sequences in these proteins able to promote 
or inhibit dimerisation.
Taken  together,  the  data  described  in  this  section  broadly  agree  with  the  "i+5”  rule 
predictions on the dimerisation specificities of the MAL and Myocardin leucine zippers. 
MAL contacts  SRF as  a  dimer and  this  property  is  dependent on  the  integrity of  its 
leucine  zipper  domain.  In  contrast  Myocardin  appears  unable  to  form  stable 
homodimers  and  contacts  SRF  as  a  monomer  at  least  as  measured  by  bandshift 
experiments.  Nevertheless  several  lines  of  evidence  point  to  a  limited 
homodimerisation  ability  of  the  leucine  zipper  of  this  protein.  Finally  MAL  and 
Myocardin are able to heterodimerise through their leucine zipper domains.
2.4  MAL  has  the  SRF-DNA  binding  properties  of  the  Rho- 
controlled SRF cofactor
The  mechanism  by which  Rho-signalling  regulates  SRF  was  not  unravelled  until the
discovery of the actin-MAL link (Miralles,  F.  et al., 2003; Sotiropoulos, A.  et al.,  1999)
and  even  at  present  many  aspects  of the  regulation  of this  system  remain  unclear.
Nevertheless, a wealth of information was compiled over time as to what is required for
SRF to respond to this pathway and a model emerged in which  Rho-induced changes
in actin dynamics  regulate an SRF accessory factor that binds the SRF  DNA-binding
domain and activates transcription of a subset of SRF target genes ((Gineitis, D. et al.,
2001; Hill, C. S.  etal., 1994; Hill, C. S. etal.,  1995b; Sotiropoulos, A.  et al.,  1999); see
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also Introduction).  Moreover a set of predictions were made as to what is required for 
this  cofactor  to  interact  with  SRF  and  activate  transcription  (see  below).  Having 
established  that  MAL  associates  with  SRF,  I  sought  to  examine  whether the  SRF- 
binding  properties  of  MAL  correlate  with  those  expected  of  the  Rho-actin  pathway 
coactivator.
2.4.1  The  N-terminus  of the  SRF  DNA-binding  domain  is  required 
for binding and activation by MAL
The different DNA-binding specificities conferred on the various MADS box proteins by 
the N-terminal sequences of their core domains had been previously exploited to create 
an  altered  DNA-specificity SRF form,  SRF.M2 that contains the  N-terminal  extension 
and al  helix of the SRF-related  yeast protein  MCMI  (Figure  2.11 A;  (Hill,  C.  S.  et al., 
1993)). As a result SRF.M2 recognises MCMI-specific DNA sequences, while retaining 
weak  affinity  for  the  wild-type  SRF  CArG  box  (Figure  2.11B).  Functional  studies 
showed that SRF.M2 does not respond to the Rho pathway when bound to its cognate 
DNA site (FOS.LM; (Hill, C. S. etal., 1993; Hill, C. S. etal., 1994)), and overexpression 
of this altered-specificity mutant also fails to restore activity to a weak SRE site that is 
inducible  in  vivo  by  overexpression  of  the  wild-type  SRF  (Hill,  C.  S.  et  al.,  1994). 
Furthermore SRF does not respond to serum stimulation when tethered to DNA via a 
heterologous  DNA-binding  domain  (Hill,  C.  S.  et al.,  1994).  Thus the  prediction  was 
made  that transcriptional  activation  through  the  Rho-pathway  depended  on  an  SRF- 
binding cofactor,  which required the intact  N-terminal  region of the SRF DNA-binding 
domain  bound  to the  authentic  SRE  site  in  order to  interact  with  SRF.  This cofactor 
would thus be unable to bind SRF.M2 on its cognate site.
To investigate whether this was true for MAL I tested its ability to bind SRF.M2 in gel 
mobility-shift assays. The DNA probes used were constructed from sequences of the c- 
fos promoter: FOS.WT contained the wild-type c-fos CArG box, while the FOS.M probe 
had the CArG  box sequences  mutated to convert its specificity from wild-type SRF to 
SRF.M2 (Figure 2.11B and (Hill, C. S. etal., 1993)).
Whole-cell  extracts  expressing  MALAN  formed  a  discrete  complex  with  endogenous 
SRF  on  the  FOS.WT  probe,  but  not  on  the  mutated  FOS.M  site,  which  is  not 
recognised  by  wild-type  SRF  (Figure  2.12A,  lanes  1   and  2,  see  also  Figure  2.2A).
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Figure 2.11 The altered DNA-specificity SRF.M2 and c-fos derived SRE derivatives. (A) Schematic representation of SRF, with the MADS box 
containing DNA-binding domain shown in blue. The sequence and secondary structure elements of the N-terminal half of the DBD and the substitu­
tions in the SRF.M2 derivative are shown below. (B) Sequences of the intact c-fos SRE (FOS.WT) and its derivatives. In FOS.L the LexA half-site 
(boxed) replaces the Ets motif (underlined). The SRF CArG box is shaded. The base changes in FOS.LM that convert it to a high affinity MCMI site 
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Addition of excess SRF(1-265), gave rise to a similar complex of increased mobility on 
the FOS.WT site, but not on the mutated FOS.M site (Figure 2.12A lanes 3,4 and 7,8). 
Furthermore  MALAN  failed  to  interact  with  SRF.M2  on  its  cognate  DNA site  FOS.M 
(Figure  2.12A,  lanes  9,10).  SRF.M2  has  a  weak  affinity for the  wild-type  CArG  box 
sequence,  however addition of MALAN cell extract to reactions containing SRF.M2(1- 
265)  and the  FOS.WT probe, only gave rise to the complex characteristic of MALAN 
and endogenous SRF (Figure 2.12A, compare the mobility of the MAL-SRF complex in 
lanes 2 and 6). These results confirm that MAL is unable to bind SRF.M2 on the wild- 
type or its cognate  DNA site and suggest that complex formation  between  MAL and 
SRF requires the intact N-terminus of the SRF.DBD.
I next tested the ability of MAL to activate transcription synergistically with SRF.M2 in 
luciferase assays,  using the SRF-responsive FOS.L and the SRF.M2-specific FOS.LM 
reporter genes. These were also constructed from the c-fos promoter and contained a 
Lex-operator half-site instead of the TCF Ets binding site to avoid interference by the 
endogenous TCF proteins (Figure 2.11B and (Hill, C. S. etal., 1993)). As expected the 
SRF  dependent  reporter  FOS.L  was  activated  in  serum-starved  cells  by  increasing 
amounts  of  MAL(met)  and  reporter  activity  was  further  potentiated  upon  serum 
stimulation  of  the  cells  (Figure  2.12B,  left).  Co-transfection  of  wild-type  SRF  with 
MAL(met) activated the reporter to the  levels observed  by  MAL(met)  alone in  serum- 
deprived cells and reduced  their serum inducibility compared to their counterparts that 
were transfected only with  MAL(met),  probably due to the squelching effect observed 
upon  overexpression of SRF in this system  (Figure 2.12B,  (Hill,  C.  S.  et al.,  1993)). 
MAL(met) expression did  not activate the FOS.LM reporter which cannot interact with 
SRF. Co-expression of SRF.M2, which binds the mutated FOS.LM sequence but does 
not respond to  Rho-signalling also failed to potentiate reporter activation  by MAL and 
this was not affected by serum-stimulation (Figure 2.12B, right).
These  results  show  that  MAL  is  unable  to  interact  with  and  activate  transcription 
through  SRF.M2,  confirming  that  as  predicted  for the  Rho-responsive  cofactor  MAL 
interaction with SRF and the subsequent activation of transcription  requires the intact 
N-terminus of the SRF DNA binding domain and the integrity of the authentic SRF DNA 
binding site.
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Figure 2.12. Activation  of SRF through  MAL requires the intact N-terminal sequences of the SRF.DBD. (A)  MAL does not bind the altered- 
specificity SRF.M2. Gel mobility-shift assays contained MALAN and wildtype SRF(residues 1-265) or SRF.M2(1-265) whole-cell extracts, and c-fos 
ATCF wildtype or mutated M probe as indicated. The complexes formed between MALAN and SRF(1-265) or endogenous SRF are indicated. (B) MAL 
does not activate the altered-specificity SRF.M2 on its cognate site. NIH3T3 cells were transfected with the FOS.L or FOS.LM reporter plasmids and 
MAL(met) (0, 5, 50,  100 or 250ng) and SRF.WT or SRF.M2 expression plasmids as indicated. Cells were maintained in 0.5% FBS or stimulated with 
15% FBS prior to being assayed for luciferase activity.Chapter 2 Results
2.4.2  MAL and Elk-1  interact with the same or overlapping regions 
of the SRF DNA-binding domain
Rho-signalling to SRF requires sequences within the SRF DNA binding domain that are 
also involved in the interaction with the TCFs (Hill,  C. S.  et al.,  1993),  however these 
cofactors are not themselves regulated by Rho and can weakly interact with  SRF.M2 
(Gineitis,  D.  et al.,  2001;  Hill,  C.  S.  et al.,  1995b).  Moreover functional  studies  have 
shown that the interaction of TCFs with SRF is sufficient to inhibit the Rho pathway in 
vivo (Hill,  C.  S.  et al.,  1994; Murai,  K.  et at., 2002), suggesting that the TCFs and the 
Rho-regulated  cofactor  are  contacting  a  common  surface  on  the  SRF  DNA-binding 
domain.  Hence the  Rho  pathway  mediator is  predicted to compete with the TCFs for 
SRF binding.
To test whether MAL contacts the same surface on SRF as TCF I  performed binding 
competition  bandshift assays.  Whole-cell extracts  expressing  MALAN  were incubated 
with  the  SRF.DBD  and  complexes  were  challenged  with  synthetic  peptides 
corresponding  to the  Elk-1  B  box,  a 21  amino-acid  sequence conserved  in  all three 
TCFs that mediates their contacts with SRF (Dalton, S.  etal.,  1992; Hassler,  M.  et al., 
2001; Ling, Y.  etal.,  1997; Shore, P.  et at., 1994).  Increasing amounts of the wild-type 
B  box  peptide  efficiently  competed  with  MAL  for  interaction  with  SRF,  whereas  a 
peptide  harbouring the Y159A substitution,  which  abolishes  SRF  binding  (Ling,  Y.  et 
al.,  1997) had  no effect on  MAL-SRF complex formation (Figure 2.13).  The specificity 
of  the  wild-type  peptide  was  further  demonstrated  by  the  fact  that  it  increased  the 
binding of endogenous and core SRF to the probe  (Figure 2.13,  complexes  indicated 
by asterisks).
2.5  Summary
In conclusion, the results described  in this chapter establish  MAL as  an  SRF-binding 
cofactor,  which  contacts  SRF as a dimer via  its  B1  region,  with  the  Q-box  having  a 
lesser contribution to the  interaction.  The  N-terminal  region  of  MAL has  an  inhibitory 
effect on SRF binding that can be alleviated by some but not all mutations in the RPEL 
domain.  Myocardin  also  contacts  SRF  through  the  B1  and  Q  regions, in this case
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Figure 2.13. MAL and Elk-1 compete for the same binding surface on SRF.  Peptide 
competition assay of the MAL-SRF complex with Elk-1  B-box peptides. Gel mobility- 
shift assays contained MALAN whole-cell extract, SRF.DBD (residues 132-265), c-fos 
probe and 0, 0.8, 4 and 20pM wildtype or mutant Elk-1  peptides as indicated.  Peptide 
sequences are shown below. An asterisk indicates the specific SRF-peptide interaction 
revealed  by  the  increased  binding  of  endogenous  SRF  and  of  SRF(132-265).  X 
indicates the position of a complex that is depleted by the wild-type peptide.  It is not 
clear whether this represents the SRF.DBD bound to endogenous TCF or whether it is 
a non-specific effect seen due to the limiting amounts of probe at high peptide concen­
trations.
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however  the  Q-box  appears  to  have  a  more  prominent  role.  The  N-terminus  of 
Myocardin  also limits SRF interaction,  and  Myocardin  appears  unable to form stable 
dimers.  Nevertheless,  its  leucine-zipper  domain  is  likely  to  retain  limited 
homodimerisation  ability,  as  judged  by  its  effects  on  reporter  gene  activation. 
Transcriptional activation by MAL requires the formation of an SRF-dependent complex 
on  the  wild-type  SRE.  Moreover,  the  interaction  of  MAL  with  SRF  requires  the  N- 
terminal sequences of the SRF DNA-binding domain. In addition MAL and TCF interact 
with  the  same  or  overlapping  sequences  on  SRF.  Therefore  MAL  possesses  two 
critical properties expected of the actin-pathway mediator.
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3  The SRF-binding surface of MAL 
3.1  Aims
Having established that MAL is an SRF cofactor that utilises its  B1  and Q  regions to 
interact with SRF, I next sought to characterise the SRF-binding surface of MAL. In this 
chapter  I  describe  the  detailed  analysis  of  the  B1  and  Q  regions  of  MAL  and  their 
respective contributions to SRF complex formation.
3.2  Analysis of the B1  box requirement for SRF-binding
I  initially  focused  my  analysis  on  the  B1  region,  since  it  is  essential  for  complex 
formation (see Chapter 2, section 2.3). Small deletions were introduced into the B1  box 
of MALAN (Figure 3.1 A) and the ability of the resulting MAL derivatives to interact with 
the SRF DNA-binding domain was assessed in gel mobility-shift assays. Removing the 
basic  N-terminal  sequences  of  the  B1  region  slightly  increased  complex  formation, 
whereas  a  small  internal  deletion  (A230-235)  reduced  but  did  not  abolish  it  (Figure
3.1 B,  lanes  4  and  5;  this  will  be  futher  analysed  in  Chapter 5  and  the  Discussion). 
Deletion  of  the  C-terminal  sequences  had  the  same  effect  as  removing  the  entire 
region  (MALAB1)  and completely  abolished complex formation  (Figure  3.1 B,  lane  6), 
implying that the main SRF-contacting residues were present in the C-terminal half of 
B1.
3.2.1  Alanine-scanning mutagenesis of the B1 box
In  order to  investigate which  residues  of the  B1  box form the SRF binding  surface  I 
employed  an  alanine-scanning  mutagenesis  approach,  which  had  been  previously 
successfully applied on both Elk-1  and SRF, in order to map their respective interacting 
surfaces (Ling, Y. etal., 1997; Ling, Y. etal., 1998).
Alanine point-mutations were introduced individually at every position of the B1  region, 
thus  removing  side  chains  that  potentially  participate  in  intermolecular  interactions, 
while at the same time avoiding major structural perturbations. Gel mobility shift assays 
of  the  point  mutants identified  a short stretch of predominantly  hydrophobic residues
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Figure 3.1. Identification of MAL B1 region residues critical for SRF binding. (A) The
sequence of the B1  region is shown in capital letters. The 7-residue critical sequence 
identified by the alanine scan is highlighted in red.  Deletion mutations are indicated by 
blue bars.  (B) Deletion and alanine-scanning mutations in the MAL B1 region affect com­
plex  formation.  Gel  mobility-shift  assays  contained  Flag-tagged  MALAN  B1  region 
derivatives, recombinant SRF.DBD (residues 133-265), and the c-fos ATCF SRE probe. 
Bottom, quantitation of MALAN construct expression by immunoblotting.
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that  are  required  for  interaction  with  SRF.  Alanine  substitutions  at  positions  L236, 
Y238,  H239  and  Y241,  abolished  complex formation  with  SRF,  since they displayed 
<5% wild-type  SRF-binding  activity as calculated  by  phosphorimage  analysis  (Figure
3.1  B, lanes 18, 20, 21  and 23, and data not shown), indicating that these residues are 
directly  involved  with  SRF  contacts.  Mutations  K237A  and  I242A  also  substantially 
reduced  SRF-binding  (Figure  3.1 B,  lanes  19  and  24,  ~25%  wildtype  activity)  and 
removal of the side chains of Q240,  E228 and  D245 resulted in  modest reductions of 
complex  (Figure 3.1B lanes 22,10 and 27, -<50% wildtype activity).  In contrast alanine 
substitutions of  K230,  K232 and  K235  increased  complex formation  by ~30%  (lanes 
12,  14,  17),  implying that these sidechains have an inhibitory effect on the interaction 
with SRF.
I  proceeded to  investigate  whether the  effects of the  B1  region  derivatives  on  SRF- 
complex  formation  correlated  with  their  effects  on  transcriptional  activation  in  intact 
cells. The MAL B1  constructs were cotransfected in NIH 3T3 cells with an SRF reporter 
gene and their ability to stimulate luciferase activity was assessed. The use of MALAN 
derivatives,  which do  not require stimulation to activate SRF-dependent transcription, 
allowed the direct evaluation  of the contribution  of the transiently expressed  MAL B1 
proteins on SRF activation, without the interference of the endogenous MAL.
The results of these functional  studies broadly correlated  with the effects of the  MAL 
mutants in SRF complex formation. The MALAN derivatives L236A, Y238A, H239A and 
Y241A, which did  not interact detectably with  SRF in the gel  mobility-shift assay,  did 
not  activate  an  SRF-controlled  reporter  gene  (Figure  3.2A).  The  Q240A  and  I242A 
substitutions,  which  reduced  SRF  complex  formation,  were  able  to  activate 
transcription  to  almost  wild-type  levels.  The  effects  of  these  mutations  were  more 
pronounced  at lower plasmid  inputs  as shown  by titration experiments  (Figure 3.2B), 
implying that although under the expression conditions used,  MAL-SRF binding is not 
limiting  for  reporter  activation,  the  assay  can  become  easily  saturated  with  higher 
plasmid  amounts.  Furthermore  the  assay  also  suffers  from  the  squelching  effect 
observed  widely  in the  SRF activation  system  at  high  protein  expression  levels  (see 
Chapter 2;  (Hill,  C.  S.  et al.,  1993)),  obscuring the subtler effects of certain  mutants 
such as  I242A. A more marked decrease of SRF activation at lower expression levels 
was also seen with the  K237A substitution  (Figure 3.2B), which affects both complex 
formation with SRF and also MAL nuclear localisation  (Figure 3.1 B and  Section 3.4.1).
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Figure 3.2. Effects of  MAL B1 region mutations on SRF reporter gene activation.
(A) Activation of the SRF-dependent reporter 3DA.Iuc by MALAN B1  region derivatives. 
NIH3T3 cells were transfected with 50ng of the  indicated  plasmids and  maintained  in 
0.3%  FBS  until assayed for luciferase activity.  Results were  normalised to activity by 
SRF.VP16 set to 100 and are presented as ±SEM of three independent experiments. (B) 
Titration of MALAN B1  derivatives (6ng, 18ng, 55ng, 166ng, and 500ng MALAN plasmid 
inputs). Reporter assays were as in A, with results normalised to 55ng input of MALAN set 
to 100. (C) Effects of C3-transferase coexpression on SRF-reporter activation by MALAN 
B1 region derivatives. Reporter assays were as in A, with 25ng C3-transferase plasmids 
cotransfected as indicated.
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Mutations  K234A  and  K235A  also  displayed  lower  SRF  reporter  gene  activation  at 
lower plasmid inputs (data not shown). These derivatives do not reduce SRF complex 
formation but are defective for nuclear import (data not shown; for nuclear import see 
Section  3.4.1).  The  effects  of the  K237A,  K234A  and  K235A derivatives  on  nuclear 
localisation are obscured by high expression levels, which render the localisation of all 
MAL derivatives pancellular. Thus increased expression of K234A,  K235A and K237A 
results in higher SRF reporter gene activation levels, than those expected for nuclear 
import defective derivatives. E228A and D245A also potentiated transactivation to wild­
type levels,  as did the proteins that formed  increased  amounts of complex  with  SRF 
(K230 and  K232),  and this can probably also be attributed to saturation of the system 
(Figure 3.2A). Reporter gene activation by deletions A224-235, A230-235, was reduced 
to a disproportionately  large  degree  compared to their results  on  complex formation 
(compare  Figure  3.2A  with  Figure  3.1 B).  This  however  is  probably  due  to  the 
pronounced negative effects these changes have on nuclear accumulation (see section 
3.4.1).
To  demonstrate  that  the  effects  of  the  MALAN  B1  derivatives  on  reporter  gene 
activation  reflect  their  specific  roles  on  SRF  interaction  and  do  not  involve  indirect 
activation  of  endogenous  MAL,  they  were  co-expressed  with  C3-transferase  in 
luciferase assays (Figure 3.2C). As mentioned previously this enzyme inactivates Rho 
and inhibits activation of the system  by endogenous  MAL.  C3-transferase expression 
reduced transactivation  of the  reporter upon  serum  stimulation,  but  had  no  effect  on 
reporter-gene activation by key MALAN B1  region derivatives,  indicating that these do 
not act indirectly through the endogenous protein.
3.2.2  Mutagenesis of key B1 residues
Having  identified a stretch of residues in the  B1  region that abolish  or greatly reduce 
SRF  binding,  I  proceeded  to  investigate  the  side  chain  requirements  for  MAL-SRF 
complex formation (Figure 3.3A).
The experiments presented in Chapter 2, demonstrate that MAL and TCF must contact 
the same or overlapping surfaces on SRF. Furthermore, alanine scanning mutagenesis 
of the TCF B box established the essential role of an aromatic residue (F162 in Elk-1, 
and  F150 in SAP-1) in SRF-binding, since its bulky aromatic side-chain fits in a deep
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hydrophobic  pocket on  the surface of SRF  ((Hassler,  M.  et at.,  2001;  Ling,  Y.  et al.,
1997); see also Introduction and Chapter 4).
To  test  the  possibility  that  one  of  the  tyrosines  in  the  MAL  B1-box  might  play  an 
analogous  role,  different  hydrophobic  residues  were  inserted  at  positions  Y238  and 
Y241. Substitutions with phenylalanine were expected to increase the binding efficiency 
of  SRF binding  or leave  it  unaffected,  since they would  allow optimal  docking  in the 
pocket (Hassler, M. etal., 2001), whereas non-aromatic substitutions were predicted to 
inhibit  the  interaction.  Indeed  a  Y238F  substitution  increased  complex  formation 
considerably,  while  Y238I  and  Y238L  substantially  reduced  but  did  not  abolish  it, 
apparently implicating this residue in the hydrophobic pocket interaction  (Figure 3.3B, 
lanes 4-6).  Nevertheless, the Y241F mutation also left complex formation  unaffected, 
whereas other  mutations at that  position  had  severe effects  on  SRF  binding  (Figure 
3.3B,  lanes  8-10).  Thus  although  these  observations  establish  the  importance  of 
aromaticity at positions 238 and 241, they preclude a direct correlation of either residue 
with the TCF aromatic position (see Discussion).
At  position  H239  all  substitutions  had  significant  effects  on  SRF  interaction,  with 
conversion  to  phenylalanine  reducing  it,  and  H239L,  H239T,  or  H239K  virtually 
abolishing  it  (Figure  3.3B,  lanes  12-15).  Hence  the  planar  character of  this  residue 
appears to be  important for SRF  binding.  A lysine to arginine substitution  at  position 
237 did not affect complex formation, suggesting that at this position a basic residue is 
important (Figure 3.3B, lanes 18-19).
I  proceeded  to  investigate the effects of these  MALAN  B1  region  derivatives in  SRF 
transcriptional  activity,  by testing  their ability to  activate  an  SRF  reporter  gene.  The 
substitutions at residues Y238,  H239, Y241  and K237 affected reporter activity largely 
in  accordance  to  their  effects  on  complex  formation,  although  for  unclear  reasons 
Y238F impaired rather than enhanced reporter activation (Figure 3.3C).
The seven-residue sequence that is essential for SRF binding is identical in all  MRTF 
family  members  in  vertebrates.  In  contrast  a  related  sequence  is  found  in  MAL 
orthologs in arthropods.  To test whether this sequence could  mediate SRF binding  in 
the context of the mammalian  proteins  I transplanted the  Drosophila heptamer in the 
mouse  MAL  protein  (Figure 3.3A).  The  MAL  (D.BIbox)  derivative  bound SRF very
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Figure 3.3. Analysis of interactions by residues K237, Y238, H239 and Y241. (A) The
sequence of the B1  region is shown in capital letters. The 7-residue critical sequence is 
highlighted  in  red  with  mutated  residues  underlined.  The  sequence  of the  DMAL  B1 
construct  (D.B1) is shown. (B) Gel mobility-shift assays contained Flag-tagged MALAN 
B1  region derivatives, recombinant SRF.DBD (residuesl33-265) (lanes 17-19 contain in 
vitro translated SRF.DBD residues 120-265), and the c-fos ATCF SRE probe.  Bottom, 
quantitation  of  MALAN  construct expression  by  immunoblotting.  (C) Activation  of the 
SRF-dependent reporter 3DA.Iuc by B1 region derivatives. NIH3T3 cells were transfected 
with 50ng of the indicated plasmids and maintained in 0.3% FBS untill assayed for lucifer- 
ase activity.
131Chapter 3 Results
efficiently and also activated the SRF-reporter gene to wildtype levels, showing that the 
Drosophila core  B1  sequence can  replace that of mouse  MAL  (Figure  3.3,  panels  B 
and C).
3.2.3  The B1 region is required for the interaction of intact MAL with 
SRF
The experiments presented in the previous sections identified a role for the B1  box of 
MAL  in  SRF  binding  and  activation.  These  experiments  were  performed  with  the 
MALAN derivative, and I therefore sought to confirm the importance of the B1  region in 
the full-length  protein.  MAL(fl)  formed  a weak complex  with  SRF  in  gel  mobility-shift 
assays, and as seen with MALAN, the MAL(fl) Y238A and Y241A derivatives failed to 
interact  with  SRF  (Figure  3.4A).  To  show that these  mutations  are  relevant  in  SRF 
activation by the intact MAL in vivo,  I exploited the observation that overexpression of 
MAL sensitises SRF reporter genes to activation by low levels of cytochalasin D, which 
are  not sufficient to  activate the  endogenous  MAL  proteins  (Guido  Posern,  personal 
communication).  Expression  of  MAL(fl)  strongly  potentiated  reporter  gene  activation 
upon  stimulation  with  sub-optimal  levels  of this  drug,  whereas the  Y238A  or  Y241A 
derivatives had  no effect, showing that the  intact  B1  is required for SRF activation by 
the full-length MAL protein (Figure 3.4B).
Stimulation of the system with serum or high levels of Cytochalasin D strongly activated 
the  same  SRF  reporter  gene  and  this  was  enhanced  by  overexpression  of  MAL(fl) 
(Figure  3.4C).  Overexpression  of  the  Y238A  or  Y241A  derivatives  however, 
significantly reduced this effect, suggesting that these proteins are able to inhibit SRF 
activation. This may reflect heterodimerisation between wildtype endogenous MAL and 
the  overexpressed  mutant  derivatives,  resulting  in  weak  or  unstable  MAL-SRF 
complexes and hence in inefficient transcriptional activation (see also Discussion).
Considered together, these results demonstrate that the intact B1  region is required for 
potent and efficient activation of SRF by MAL.
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Figure 3.4. The B1  region is necesary for SRF activation by MAL.  (A) SRF complex 
formation  by the  MAL(fl) Y238A and  Y241A derivatives.  Reactions contained  whole-cell 
extracts  transiently  transfected  with  Flag-tagged  MAL(fl)  derivatives,  in  vitro  translated 
SRF.DBD  (residues  120-265),  and the c-fos ATCF SRE  probe.  (B)  Potentiation of SRF 
reporter activity induced by low levels of cytochalasin D requires the integrity of the MAL B1 
region. NIH3T3 cells were transfected with the SRF-dependent 3DA.Iuc reporter and 50ng 
of the indicated plasmids. After 18 hours of serum starvation cells were treated with 0.3% 
FBS or 0.5pM cytochalasin D for 7 hours as indicated. Results are presented as the average 
±SEM of three independent experiments. (C) B1 region mutations that abolish SRF complex 
formation, inhibit activation of the SRF-dependent reporter 3DA.Iuc. Reporter assays were 
as in B.
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3.2.4  The B1  region is required for expression of endogenous SRF 
target genes
To test whether the B1  region is required for activation of endogenous MAL-dependent 
SRF target genes  I  employed  an  immunofluorescence  approach.  NIH3T3  cells  were 
transiently transfected with MALAN or its Y238A and Y241A derivatives and kept under 
starvation  conditions  for  two  days.  The  expression  of  SRF-target  genes  was  then 
detected by antibody staining. Mock-transfected control cells were processed in parallel 
to  provide the  expression  levels  of each  SRF-target gene  under  serum-starved  or -  
stimulated conditions.
Smooth-muscle a-actin  is an SRF-dependent gene normally expressed at high levels 
during  smooth  muscle  differentiation  and  development  (Mack,  C.  P.  et  al.,  1999; 
Shimizu,  R.  T.  et al.,  1995).  Both  Myocardin  and  MAL  have  been  implicated  in  the 
expression  of  this  marker  during  the  SRF-dependent  smooth-muscle  differentiation 
programme  (Du,  K.  L.  et al.,  2004;  Du,  K.  L.  et al.,  2003;  Wang,  Z.  et al.,  2003). 
Moreover,  it  has  been  shown  that  expression  of  smooth  muscle  a-actin  is  serum 
inducible  in  proliferating  fibroblasts  and  can  also  be  induced  by  transient 
overexpression of MAL or Myocardin ((Wang, Z.  et at., 2003), and Franscesc Miralles, 
personal  communication).  Expression  of  MALAN,  but  not  its  Y238A  or  Y241A 
derivatives,  induced  high  levels  of  smooth-muscle  a-actin  expression  in  serum- 
deprived  cells  (Figure 3.5,  panels  A and  B).  In  contrast  MALAN  remained  unable to 
activate the TCF-controlled  egr-1 and c-fos genes,  which are insensitive to  Rho-actin 
signalling  (Figure 3.5,  panels  A  and  B;  (Gineitis,  D.  et al.,  2001)),  indicating that the 
specificity  of  target  gene  expression  is  maintained  under  MAL  overexpression 
conditions.
I  also tested the effects  of  MAL overexpression  in  the  SRE.FOS.HA stable cell  line. 
This  NIH3T3-derived  cell-line  harbours  an  epitope-tagged  c-fos transcript  (HA.FOS), 
controlled by the synthetic 3D.A promoter, (Mohun, T. etal., 1987) (Alberts, A. S. etal.,
1998). This promoter lacks TCF binding sites and this renders  HA.FOS expression in 
this  cell-line  solely  dependent  on  Rho-signalling.  Overexpression  of  MALAN  in  the 
SRE.FOS.HA  cell-line  efficiently  activated  HA.FOS  expression,  as  did  serum- 
stimulation, whereas the Y238A and Y241A mutants had no effect (Figure 3.5, panels 
A and B). Taken together these data show that the integrity of the B1  region of MAL is
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Figure 3.5. Activation of expression of endogenous and stably transfected SRF- 
dependent genes  by  MALAN  derivatives.  (A)  NIH3T3  and  NIH3T3(SRE.FOS.HA) 
cells were transfected with 150ng of the indicated MALAN plasmids and maintained in 
0.3%  serum  for two  days.  Where  indicated,  stimulation  with  15  %  FBS  was for 30 
minutes prior to sample processing.  Gene expression was scored by immunofluores­
cence in 100-200 transfected cells in two independent experiments. (B) Expression of 
SRF-dependent genes induced by serum and MALAN derivatives. Assays were as in A. 
Endogenous smooth muscle a-actin,  Egr-1  and FOS, and stably transfected HA.FOS 
(red) were visualised by staining with the appropriate antibodies, MALAN (green) was 
visualised with anti-Flag antibody and DNA (blue) with DAPI staining.
135Chapter 3 Results
required  for  MAL-dependent  activation  of  endogenous  and  stably-incorporated  SRF 
target genes and confirm that the bandshift assay detects B1-SRF interactions that are 
relevant in vivo.
3.2.5  The B1  region is necessary for SRF binding
In  order to  prove that the  involvement of the critical  B1  region  residues  was  due  to 
direct  protein-protein  interactions  with  SRF  rather  than  involving  additional  proteins 
present in the extracts,  I  used a GST-fusion  protein containing the  B1  and Q regions 
(Figure  3.6A),  in  in  vitro  binding  assays  with  SRF.  GST.MAL(214-298)  effectively 
formed  complexes  on  DNA  with  purified  bacterially  expressed  SRF  DNA-binding 
domain  (Figure  3.6B).  The  same  complex  was  formed  with  in  vitro translated  SRF 
DNA-binding  domain  (Figure  3.6C).  This  interaction  was  specific,  since,  as  in  the 
MALAN  context,  it  was  abolished  by  L236A and  H239A  and  reduced  by the  K237A 
substitution  (Figure 3.6C).  The  Q240A  and  I242A substitutions  had  less  pronounced 
effects in the context of GST. MAL(214-298).
I next tested whether these mutations affect protein-protein interactions with SRF. The 
GST.MAL(214-298)  protein  could  recover  the  wildtype  SRF  DNA-binding  domain  in 
GST-pulldown  experiments.  Even  though  SRF  recovery  was  very  inefficient,  it  was 
abolished  by  the  substitutions  at  residues  required  for  complex  formation  on  DNA 
(Figure 3.6D).
Taken together the results in this section show that the B1  region makes direct protein- 
protein  contacts  in  the  MAL-SRF  complex,  and  these  contacts  are  mediated  by the 
core seven-residue sequence identified by alanine-scanning mutagenesis.
3.2.6  The B1 region is sufficient for SRF binding
The  results  presented  in  the  preceding  sections  are  consistent  with  the  view  that 
residues L236 to I242 of the B1  region represent the primary interaction surface of MAL 
with SRF. To test this directly I  used synthetic  B1  peptides in binding competition gel 
mobility-shift assays with the  MALAN-SRF.DBD complex.  For that purpose  I designed 
a 21-residue peptide comprising the hydrophobic core region flanked by seven N- and 
C-terminal residues (Figure 3.7A, peptide A; residues 229-249). This peptide was able
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to  compete  with  MAL  for  SRF  complex  formation  in  a  dose  dependent  manner, 
whereas peptide Q,  which encompasses the Y238A mutation that abolishes the MAL- 
SRF  interaction  had  no  effect  (Figure  3.7B),  demonstrating  that  the  B1  region  is 
sufficient for SRF-binding. Furthermore the presence of the wild-type but not the mutant 
peptide increased the amounts and slowed the mobility of the complex between  DNA 
and endogenous SRF or the SRF.DBD (Figure 3.7B, complexes indicated by asterisks) 
indicating that the MAL B1 sequence directly contacts the SRF DNA binding domain.
I  therefore explored the possibility of directly visualising the peptide-SRF complex by 
using high-density native gels to resolve SRF-DNA complexes in the presence of MAL 
B1  peptides. This experiment was also aimed at exacting the stoichiometry of peptide 
binding to SRF. Since MAL and TCF contact overlapping regions on SRF, two possible 
docking  surfaces  exist  for  the  B1  region,  one  on  each  SRF  subunit.  Progressive 
increase  of the  B1  peptide concentration  would  therefore  be  expected  to  induce the 
sequential  formation  of  two  distinct  complexes  corresponding  to  monomeric  and 
dimeric peptide-SRF interactions.
Surprisingly,  although  increasing  amounts  of the  peptide A enhanced  the  SRF.DBD- 
DNA  complex,  they  did  not  result  in  the  formation  of  discrete  complexes  with  SRF 
(Figure  3.7C).  Instead  increasing  concentrations  of  the  wild-type  B1  peptide 
progressively  slowed  the  mobility  of  the  existing  SRF-DNA  complex  (Figure  3.7, 
compare lanes 2-7 with lane 1). This “sliding-band” pattern was unchanged when five­
fold  less  SRF.DBD  was  used  (Figure  3.7,  lanes  15-19).  The  reason  for  this 
concentration-dependent decrease in mobility is unclear, but it is possible that it reflects 
peptide oligomerisation, or is a result of the “caging effect” of the gel  matrix: although 
the peptide-SRF complex can dissociate during its passage through the gel, the caging 
effect prevents the peptide from completely escaping the SRF-DNA complex.  Similar 
observations  have  been  made  with  other  systems  (Klejman,  M.  P.  et  al.,  2004). 
Nevertheless, irrespective of the exact reason for the unusual behaviour of the peptide- 
SRF complex, this interaction is specific since it is completely abolished by the Y238A 
mutation (peptide Q; Figure 3.7, lanes 9-14).
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Figure 3.7. The B1  region is sufficient for interaction with SRF. (A) Sequences of 
the MAL B1  peptides used  (A: wild-type;  Q: Y238A mutant).  (B)  Peptide competition 
assay of the MAL-SRF complex with  MAL B1-box peptides.  Gel mobility-shift assays 
contained MALAN whole-cell extract, SRF.DBD (residues 132-265), c-fos probe and 0, 
0.8, 4 and 20pM wildtype or mutant MAL peptides as indicated. An asterisk indicates 
the specific SRF-peptide interaction revealed by the increased binding of endogenous 
SRF and of SRF(132-265). X indicates the position of a complex that is depleted by the 
wild-type peptide. It is not clear whether this represents the SRF.DBD bound to endog­
enous TCF or whether it is a non-specific effect seen due to the limiting  amounts of 
probe at high peptide concentrations. (C) Complex formation between MAL B1 peptides 
and the SRF.DBD.  Binding reactions contained in vitro translated SRF.DBD (residues 
120-265), and c-fos ATCF probe with B1  peptides (0.16, 0.32, 0.63,  1.25, 2.5 and 5 p 
M). Lanes 15-20 contain probe with five times less SRF.DBD and 5, 2.5, 1.25, 0.63 and 
0.32 pM peptide A. Complexes were resolved in 8% native gels.
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3.2.7  The minimal SRF-interacting region of the B1 box
Having  established  that  the  21-residue  peptide  A  is  sufficient  for  SRF  binding,  I 
proceeded to map the minimal SRF interaction surface within this region by testing the 
SRF-binding abilities of a set of nested B1 -peptides (Figure 3.8A). To do that I used a 
binding  competition  approach,  since  challenging  of  a  MAL-SRF  complex  with 
increasing  amounts  of  peptide  is  easier  to  evaluate  than  the  direct  peptide-SRF 
interaction  due  to  the  absence  of  a  discrete  peptide-SRF  complex  (see  previous 
section).
As seen  previously the wildtype peptide A effectively competed  with  MALAN for SRF 
complex formation  (Figure 3.8B),  whereas  introduction of either the Y238A or Y241A 
substitutions in this context failed to inhibit binding (Figure 3.8B; peptides Q and R). C- 
terminal truncations to position 243 did not affect the ability of the peptides to compete 
with  MALAN  for  SRF  binding,  indicating  that  these  sequences  are  not  required  for 
effective  complex  formation  (Figure  3.8B,  peptides  A-G).  In  contrast,  derivatives  of 
peptide  A  lacking  N-terminal  sequences  displayed  reduced  effectiveness  in  the 
competition assay. Removal of residue K230 significantly impaired the ability of peptide 
N to compete with MALAN, and this was further decreased by removing residue K232, 
suggesting that at  least these two basic residues contribute to the affinity of complex 
formation (Figure 3.8B, compare peptide A with peptides M/N and J/K).
Finally,  the  decapeptide  H  (N234-KKLKYHQYIP-C243),  which  contained  the  critical 
residues defined by alanine-scanning, also weakly competed for MALAN-SRF complex 
formation  (Figure  3.8B).  Titration  of  peptide  H  in  the  MALAN-SRF reactions  showed 
that it competed about 30-fold less effectively than peptide A (Figure 3.8C), confirming 
the  contribution  of  the  basic  B1  sequences  in  the  affinity  of  the  interaction,  but 
indicating that they are not essential for complex formation.  Introduction of the Y238A 
substitution  in  the  context  of  peptide  H  failed  to  compete  for  MAL-SRF  complex 
formation, indicating the interaction was specific (Figure 3.8C, compare peptides H and 
S).  Hence,  this  decapeptide  encompasses the  minimal  B1  surface  required  for  SRF 
interaction.
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K232 are shown in red. (B) Peptide competition studies. Gel mobility-shift binding reactions contained MALAN extract, SRF.DBD (residues 132-223) 
and c-fos wildtype SRE probe with 4pM or 20pM peptide competitor as indicated. C-terminally and N-terminally truncated peptides are indicated by 
brackets. Only the SRF.DBD-MAL complex band is shown. (C) The hydrophobic core of the B1  region is sufficient for SRF complex formation. Binding 
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3.3  The role of the Q-box in SRF-binding
The  results  presented  in  the  preceding  section  establish  a  minimal  seven-residue 
sequence  of the  B1  region  of  MAL as  necessary for the formation  of direct contacts 
with  the  SRF  DNA-binding  domain  and  the  activation  of transcription  of  SRF  target 
genes in vivo. Nevertheless, the glutamine-rich region is also required for optimal MAL- 
SRF interaction  (see  Chapter 2;  (Cen,  B.  et a/.,  2003;  Miralles,  F.  et a/.,  2003))  and 
appears to have a  more  prominent role in the  Myocardin-SRF interaction  (Chapter 2; 
(Wang,  D.  et a/.,  2001; Wang,  Z.  et al., 2004)).  I therefore sought to characterise the 
requirement  of  the  Q-box  in  MAL-SRF  complex  formation,  by  testing  the  effects  of 
mutations  within  this  region  and  its  evolutionarily  conserved  N-terminal  flanking 
sequences (Figure 3.9A).
Deletion  of  the  Q-box  hydrophobic  core  (MALANAO)  reduced  MAL-SRF  complex 
formation by 50% in gel mobility-shift assays,  similarly to removal of the entire Q-box 
(MALANAQ), suggesting that the role of the Q box in SRF binding is mediated by these 
sequences and not the stretches of glutamines (Figure 3.9B, compare lanes 3 and 4). I 
therefore focused  my analysis on the conserved  sequences in the Q box,  particularly 
the  hydrophobic  residues  found  in  the  core  of  the  Q-box  and  the  sequences  N- 
terminally to it.
3.3.1  Alanine mutagenesis analysis of the MAL Q box
Double  or  single  alanine  substitutions  were  introduced  at  the  mainly  hydrophobic 
positions  interspersed  amongst  the  glutamines  and  the  ability  of  these  MALAN 
derivatives to  interact with the  SRF.DBD  was tested  in  gel  mobility-shift assays.  The 
I262A/L263A, L270A/L272A and I274A/L275A substitutions reduced complex formation 
by 20-40% (Figure 3.9B, lanes 5-8). Single alanine mutations at each of these residues 
revealed that  L263A,  L270A,  I274A and  L275A all decrease the  interaction  with SRF 
(Figure 3.9B, lanes 10,  11,  13 and  14).  Despite their effects on complex formation, all 
MAL Q-box derivatives  activated the  SRF reporter gene to wildtype levels,  indicating 
that  this  region  of  MAL  is  not  absolutely  required  for  SRF  activation  in  vivo (Figure 
3.9C). These results correlate with the mutagenesis analysis of the  Myocardin Q-box, 
in which  residues  L286,  L293 and  I297 (equivalent to MAL L263,  L270 and  I274) but 
not  L298  (L275inMAL)  were necessary for  SRF binding  (Wang, Z. et al., 2004).  As
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Figure 3.9.  Effects of the Q-box mutations in the MAL-SRF interaction.  (A) The
Q-box sequence and  mutations are shown.  Deletion  mutations are indicated  by blue 
bars and point mutations that affect SRF binding are shown in red. (B) Mutations in the 
Q-box  decrease  but  do  not  abolish  MAL-SRF  complex  formation.  Gel  mobility-shift 
assays  were  performed  using  Flag-tagged  MALAN  Q-box  derivatives,  SRF.DBD 
(residues  133-265),  and  the  c-fos  ATCF  SRE  probe.  Expression  levels  of the  MAL 
derivatives were confirmed by immunoblotting. MAL mutations that affect SRF binding 
are  shown  in  red.  (C)  Q-box  mutations do  not affect activation  of the 3DA.Iuc  SRF 
reporter. NIH3T3 cells were transfected with 50ng of the indicated plasmids and main­
tained in 0.3% FBS until assayed for luciferase activity.
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seen  previously  however,  changes  in  the  Q-box  appear to  have  more  pronounced 
effects in Myocardin than MAL (see section 2.3 of Chapter 2).
3.3.2  Analysis of the Q box by peptide competition assays
Having identified the Q-box residues that affect MAL-SRF complex formation, I wanted 
to test  whether this  region  of  MAL  makes  direct  contacts  with  SRF.  Synthetic  MAL 
peptides  encompassing  both  the  B1  and  Q  regions  were  used  in  gel  mobility-shift 
assays  with  the  SRF  DNA-binding  domain  and  complexes  were  resolved  on  high- 
density  native  gels.  At  low  peptide  concentrations,  the  wildtype  MAL  B1Q  peptide 
generated  a discrete complex of decreased  mobility compared to the SRF.DBD-DNA 
complex,  while  at  higher  peptide  inputs  the  mobility  of  the  complex  was  further 
decreased,  similar to the  behaviour of the  MAL B1  peptide  (Figure 3.1 OB and  Figure 
3.7).  These  complexes  were  specific  since their formation  was  abolished  by the  B1 
Y238A mutation.  A MAL B1Q peptide harbouring three alanine substitutions at Q-box 
residues L263,  L270 and  I274, all of which  individually reduced complex formation  by 
MALAN,  left  SRF-complex  formation  unaffected  (Figure  3.1 OB).  This  suggests  that 
these three residues of the MAL Q-box do not make direct contacts with SRF and their 
effects on SRF binding are only obvious in the context of the wild-type protein.
The formation  of discrete  complexes  by the  B1Q  but  not the  B1  peptides  raises the 
possibility  that  the  B1Q  peptide  contains  further  sequences  that  contribute  to  the 
stability  of  the  complex,  such  as  the  N-terminal  B1  residues  (224-228)  which  are 
missing from  peptide A, or the  presence of the Q box itself.  Further experiments are 
required  in  order  to  explore  these  possibilities,  possibly  by  testing  the  effects  of 
progressively extending the sequences of peptide A on the SRF-DNA complex.
As mentioned previously, Wang and coworkers reported that Myocardin residues L286, 
L293 and I297 (corresponding to MAL positions L263, L270 and I274), were necessary 
for SRF binding by Myocardin (Wang, Z.  et al., 2004).  I therefore tested the analogous 
Myocardin B1Q peptides in the SRF-binding assay (Figure 3.1 OA). As seen with MAL, 
the  wildtype  Myocardin  B1Q  peptide  formed  a  complex  with  the  SRF.DBD,  and  at 
higher peptide inputs a second complex could be discerned, suggesting that individual 
peptides can interact with each SRF monomer (Figure 3.1 OB). These complexes were 
abolished  by the Y261A mutation,  which  is equivalent to MAL Y238A.  The Myocardin
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3xA peptide that contains alanines at positions L286,  L293 and  1297 was also able to 
interact with SRF, suggesting that also in the case of Myocardin these residues do not 
mediate direct protein-protein interactions with SRF.
3.4  The  role  of  the  MAL  B1  and  Q  regions  in  subcellular 
localisation
Both  the  B1  and  Q  regions  of  MAL  have  been  shown  to  affect  the  subcellular 
localisation of the  protein,  with the  B1  region  necessary for nuclear accumulation  of 
MALAN  and  deletion  of  the  Q-box  resulting  in  nuclear  accumulation  of  MAL  in 
unstimulated cells  (Miralles,  F.  et al., 2003).  I therefore used the immunofluorescence 
assay  to  investigate  whether the  B1  and  Q  sequences  involved  in  the  subcellular- 
localisation of MAL correlate with those affecting SRF-interaction.
3.4.1  The role of the B1 region in nuclear localisation of MALAN
NIH3T3  cells  were  transiently  transfected  with  different  MAL  derivatives  and  the 
following  day the  localisation of  Flag-MAL was scored  as  predominantly cytoplasmic, 
diffuse  (designated  c/n)  and  predominantly  nuclear.  As  previously  reported,  MALAN 
was  localised  in the  nucleus  and deletion of the  entire  B1  region  (residues 224-249) 
caused it to become predominantly cytoplasmic (Figure 3.11, panels B and D). Deletion 
of  residues  224-235  and  the  smaller  deletion  of  residues  230-235  also  rendered 
MALAN cytoplasmic (Figure 3.11, panels A, B and C). Removal of the entire C-terminal 
part  of  the  B1  region  also  substantially  reduced  MALAN  nuclear  localisation,  while 
MALAN lacking residues 224-229 remained predominantly nuclear (Figure 3.11, panels 
A,  B and C).  These results suggest that the nuclear localisation function  is contained 
primarily  within  residues  230-235,  but  also  implicate  residues  236-249.  Since  these 
residues also contain the SRF-binding region of MAL,  I tested the nuclear localisation 
of the  alanine  point  mutants,  to  find  out  whether the  nuclear  localisation  and  SRF- 
binding functions of the B1  box overlap.
Alanine  substitutions  K234A  and  K235A  greatly  reduced  nuclear  localisation  of
MALAN, with a K234/235A double mutant having as severe an effect as deletion of the
entire  B1-box  (Figure  3.11  panels  C  and  D).  Mutation  K237A  also  reduced  nuclear
localisation  (Figure 3.11,  panels  C and  D),  but all other substitutions,  including those
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Figure  3.11.  Identification  of  MAL  B1  region  sequences  involved  in  nuclear 
import. (A) B1  region sequence, with deletions in blue and residues K234,  K235 and 
K237 highlighted in red.  (B) Subcellular localisation of the MALAN B1  region deletion 
derivatives. NIH3T3 cells were transfected with 50ng of the indicated MALAN plasmids 
and stained for F-actin (red) and Flag-tagged MALAN (green). (C) Subcellular localisa­
tion of MALAN B1  region point-mutation derivatives, as in B. (D) MALAN B1  mutations 
affect nuclear import.  Subcellular localisation was scored  as predominantly cytoplas­
mic, evenly distributed or nuclear. Results are average of two independent experiments 
(100-200 cells each).
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that completely block complex formation, had no effect on MALAN localisation (Figure 
3.11C,  MALAN  L229A  transfected  cells;  see  also  Figure  3.5B,  MALAN  Y238A 
transfected  cells;  data  not  shown).  These  results  demonstrate  that  nuclear 
accumulation of the MALAN derivatives does not arise indirectly through the occlusion 
of a nuclear export  signal  upon  SRF binding.  Therefore,  these observations suggest 
that the  nuclear localisation  and  SRF-binding functions  of the  B1  box  are separable, 
even though residue K237 plays a role in both activities.
3.4.2  The  effect  of  the  Q  box  mutations  in  the  subcellular 
localisation of MAL(met)
Deletion  of the  Q-box  promotes the  nuclear localisation  of  intact  MAL  under serum- 
starved conditions (Figure 3.12B, (Miralles, F. etal., 2003)). To investigate whether this 
property correlates with the effects of the Q-box mutations on SRF-binding I tested the 
subcellular  localisation  of  various  MAL(met)  Q  derivatives  by  immunofluorescence. 
Deletion  of  the  Q-box  hydrophobic  core  increased  MAL  nuclear  accumulation,  but 
mutation  I274A/L275A  had  no  effect  on  subcellular  localisation  even  though  both 
derivatives affect SRF complex formation (Figure 3.12, compare with  Figure 3.9B). On 
the other hand,  substitution Y259A/K261A increased the proportion of cells exhibiting 
predominantly nuclear MAL, even though it had no effect on the  MAL-SRF interaction 
(Figure 3.12,  compare with  Figure 3.9B).  Additionally,  substitutions  I262A/L263A  and 
L263A both promoted MAL nuclear localisation and reduced complex formation (Figure 
3.12, compare with  Figure 3.9B). These results show that there is no strict correlation 
between  the  effects  of  the  Q-box  mutations  on  subcellular  localisation  of  MAL  and 
complex formation with SRF.
3.5  Summary
The  results  described  in  this  chapter  characterise  the  B1  box  as  the  SRF-binding 
surface of MAL and identify the residues within this surface required for efficient SRF 
interaction and activity. The integrity of the B1  region is required for SRF activation by 
the full-length  MAL protein and is also necessary for expression of endogenous  MAL- 
dependent SRF-target genes, such as smooth muscle a-actin.
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Figure  3.12.  Effects  of  the  Q-box  mutations  in  the  subcellular  localisation  of 
MAL(met).  (A) The Q-box sequence and mutations.  Deletion mutations are indicated 
by  blue  bars  and  point  mutations  that  affect  SRF  binding  are  shown  in  red.  (B) 
MAL(met)  Q-box  mutations  affect  nuclear  import.  Subcellular  localisation  of  the 
MAL(met)  Q-box  region  derivatives.  NIH3T3 cells were transfected with  50ng of the 
indicated MAL(met) plasmids and stained for F-actin and Flag-tagged MAL(met). MAL 
subcellular localisation was scored  as  predominantly cytoplasmic,  evenly distributed 
(c/n) or nuclear.  Results are average of two independent experiments (100-200 cells 
each).
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MAL directly contacts  SRF via a seven-residue  sequence  within the  B1  region.  This 
sequence  is  necessary  and  sufficient  for  SRF-complex  formation,  although  basic 
residues  N-terminal  to  it  are  likely  to  contribute  to  the  affinity  of  binding.  The  SRF- 
contacting  heptapeptide  of  MAL  is  identical  in  all  mammalian  MRTFs  and  can  be 
substituted by the analogous Drosophila sequence.  Moreover the interaction with SRF 
critically depends on the aromatic character of two  residues within this  heptapeptide, 
drawing a parallel to the contacts of the TCFs on the SRF surface.
Although at least four hydrophobic residues within the MAL Q-box affect SRF complex 
formation  in  the  context  of  the  intact  MAL  protein,  these  are  not  required  for  MAL 
induced SRF activity. The B1  and Q regions have opposing effects in MAL subcellular 
localisation,  but the residues  mediating these functions are  largely distinct from those 
responsible for SRF complex formation.
Hence,  a  short  predominantly  hydrophobic  sequence  within  the  B1  box  of  MAL 
represents  the  primary  SRF  contact  surface.  The  Q-box  is  not  required  for  SRF 
interaction and activation, but its presence in the intact MAL protein facilitates complex 
formation.
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4  The MAL-binding surface of SRF 
4.1  Aims
The results presented in the previous chapters established important similarities in the 
properties  that  govern  the  interaction  of  SRF  with  the  MRTF  and  the  TCF  cofactor 
families.  Although  MAL and the TCFs  physically compete for SRF binding,  indicating 
that they contact a common surface on the SRF DNA-binding domain,  MAL unlike the 
TCFs  cannot  interact  with  altered  DNA-specificity  SRF  derivatives,  which  harbour 
mutations in the N-terminal region of the DNA-binding domain. The aim of the present 
chapter  was  to  further  analyse  the  requirements  of  the  MAL-SRF  interaction  by 
mapping the surface of SRF that contacts MAL and investigating the extent to which it 
overlaps with the TCF-binding surface.  Furthermore,  I wished to explore the role of the 
N-terminal  part  of  the  SRF  DNA-binding  domain  in  MAL  complex  formation  and 
determine whether it directly contributes to the MAL-binding surface of SRF.
4.2  Mapping  of  the  MAL-binding  surface  of  SRF  by  point 
mutagenesis
Detailed  biochemical and structural studies identified the TCF-binding surface of SRF 
as a hydrophobic groove formed by the pll-strand, proceeding coil region and all-helix 
of the DNA-binding domain and showed that TCF interacts with this surface by adding 
a p-strand to the 0-sheet of the SRF middle layer (see Introduction; (Hassler,  M.  etal., 
2001;  Ling,  Y.  et  al.,  1998)).  These  studies  pinpointed  the  key  SRF  DNA-binding 
domain  residues,  including  residues  within  this  hydrophobic  groove,  involved  in  TCF 
contacts  Figure  4.1 A  and  B).  Given  that  MAL  and  TCF  physically  compete  for SRF 
binding,  I sought to map the MAL-binding surface of SRF by first analysing the role of 
the hydrophobic groove residues in the MAL-SRF complex.
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Figure 4.1. Residues in the SRF DNA-binding domain involved in TCF binding. (A)
Schematic  representation  of  SRF.  Secondary  structure  elements  in  the  SRF.DBD 
(residues 140- 220) are shown below. Residues involved in interaction with the TCF B 
box are highlighted in red. (B) Van der Waals representation of the DNA-binding domain 
of  SRF  (blue)  complexed  with  DNA (green,  shown  as  ribbon  for simplicity)  and the 
SAP1a B box (yellow, backbone and side-chain representation). Red SRF residues are 
involved in the TCF interaction. E190, V194, Y195, T196, T199, Q203, T207 were origi­
nally identified by mutagenesis analysis (Ling et. al. 1998) and M169, K170, Y173,1206, 
1215, L219, N220 were later identified by crystallographic analysis (Hassler and Rich­
mond, 2001).
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4.2.1  MAL contacts the same hydrophobic groove on the SRF DNA- 
binding domain as the TCFs
To Investigate whether MAL also contacts the hydrophobic groove of SRF and whether 
the same  residues  affect  MAL and TCF binding  I  used  previously characterised SRF 
point  mutation  derivatives  (Ling,  Y.  et  al.,  1998),  and  also  tested  novel  SRF 
substitutions based on the TCF-SRF contacts in the crystal structure (Hassler, M. et al., 
2001).  The  in  vitro translated  SRF derivatives were  used  in gel  mobility-shift  assays 
with  whole-cell  extracts  expressing  MALAN  or  Elk-1  proteins.  Experiments  were 
performed  using  equal  amounts  of  SRF  derivatives,  all  of  which  bound  the  c-fos 
derived wild-type  DNA probe with comparable affinity,  apart from V194E  and T196E, 
for which complex formation was slightly increased (data not shown).
In agreement with the original mutagenesis analysis of the SRF DNA-binding domain, 
changes  V194E  and  T196E  had  the  most  pronounced  effects  on  SRF  complex 
formation  with  Elk-1  on  a  wild-type  c-fos derived  probe,  since  they  abolished  and 
reduced  Elk-1  binding  respectively  (Figure  4.2B,  bottom;  (Ling,  Y.  et al.,  1998));  no 
other substitutions  had  detectable  effects  on  complex formation  in  this  experimental 
set-up (Figure 4.2, bottom).
The effects seen on the  MAL-SRF interaction were more pronounced, especially with 
substitutions in the SRF pil-strand:  mutation V194E abolished complex formation with 
MALAN,  while Y195D and T196E substantially reduced it (Figure 4.2B, top).  Mutation 
H193A  also  significantly  decreased the  MAL-SRF  interaction,  while  not  affecting  the 
Elk-1-SRF complex (Figure 4.2B, this is seen more clearly in Figure 4.7C;  (Ling, Y.  et 
al., 1998)). Mutation V187A increased the efficiency of complex formation implying that 
this side-chain  might interfere with  MAL-SRF complex formation.  Change Q203E  had 
the opposite effect on  MAL binding than that seen with TCF,  since it increased  MAL- 
SRF  complex  formation  (Figure  4.2B  and  Figure  4.1 B;  (Ling,  Y.  et  al.,  1998)), 
suggesting  that the  negative  charge  at  position  203  might  productively  interact  with 
MAL  in  the  complex.  The  other  substitutions  did  not  have  significant  effects.Taken 
together these results suggest that MAL contacts the p-sheet in the middle layer of the 
SRF.DBD.
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Figure 4.2. MAL and TCF contact the same hydrophobic groove on the SRF DNA- 
binding  domain.  (A)  Schematic  representation  of  SRF,  with  the  DBD  in  blue.  The 
sequence  and  secondary  structure  elements  of  the  C-terminal  half of  the  DBD  are 
shown  below,  with  hydrophobic groove residues  in  red.  (B)  SRF  hydrophobic groove 
mutations affect complex formation. MALAN (top), MALANAQ (middle) or Elk-1 (bottom) 
whole-cell extracts were used in gel mobility-shift assays with SRF.DBD (residues 120- 
265), and either ATCF SRE probe (top and middle) or WT SRE probe (bottom).
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In order to investigate whether the loss of binding efficiency previously observed upon 
deletion of the MAL Q-box was due to contacts between this region and the residues 
identified  in the  hydrophobic groove of SRF,  MALANAQ extracts were also tested for 
SRF binding.  The effects  of all  SRF  mutations on  MALANAQ  binding were similar to 
their ability to bind MALAN, indicating that the Q-box is not involved in contacts with the 
hydrophobic groove (Figure 4.2B, middle).
4.2.2  MAL contacts the hydrophobic pocket of SRF
Having established that MAL contacts the hydrophobic groove of SRF,  I  proceeded to 
investigate  whether  other  interactions  in  this  region  were  also  important.  Residues 
V194,1206 and 1215 define a hydrophobic pocket in the hydrophobic groove of the SRF 
DNA-binding  domain  into  which  the  TCFs  insert  an  aromatic  residue  (Figure  4.1 B; 
(Hassler, M. etal., 2001)). The interaction of this residue with the hydrophobic pocket is 
pivotal  in the formation of the TCF-SRF complex.  Furhtermore,  similar use of such  a 
pocket  is  seen  in  the  MATa2-MCM1  complex  (Tan,  S.  et al.,  1998).  In  light  of  the 
importance of the aromatic residues in the MAL B1  box for SRF binding, I proceeded to 
test whether the  hydrophobic pocket was  also central  in  the  MAL-SRF complex.  For 
that  purpose  I  introduced  mutations  at  positions  I206  and  1215 that  are  predicted  to 
alter  the  dimensions  of  the  pocket.  Exchanging  isoleucine  with  bulkier  hydrophobic 
residues such as phenylalanine and tryptophan is expected to reduce the pocket size, 
while  removing  the  side-chain  altogether  by  changing  it  to  alanine  is  expected  to 
increase it. The effects of these substitutions on MAL and TCF binding were tested  in 
gel  mobility-shift assays.  All  SRF derivatives  bound the c-fos DNA probe with similar 
efficiency to the wild-type SRF (data not shown).
An  alanine  substitution  at  position  I206  strongly  enhanced  complex  formation  with 
MAL,  but  left  Elk-1  binding  unaffected,  suggesting  that  this  side-chain  inhibits  MAL 
interaction  (Figure  4.3B).  Conversely  a  change  to  phenylalanine  abolished  complex 
formation with  both  MAL and  Elk-1, whereas I206W had  no effect,  indicating that this 
change  can  be tolerated  in  the  interaction  of  both  MAL  and  Elk-1  with  SRF  (Figure 
4.3B). Substitutions  1215A and  1215W impaired complex formation with both MAL and 
Elk-1 whereas 1215F decreased complex formation by both cofactors to a lesser extent, 
indicating that the aliphatic side-chain is important at this position. Similar results were 
obtained with a MAL derivative lacking the Q-box (Figure 4.3B, middle).
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The results  presented  in this and the preceding  section,  show that  MAL contacts the 
same hydrophobic groove on SRF as TCF, and that the MAL Q box is not responsible 
for this  interaction.  As  with  TCF,  the  MAL-binding  surface  of  SRF  is  defined  by the 
central  presence  of  the  hydrophobic  pocket.  Many  of the  residues  surrounding  this 
pocket are involved  in complex formation with  both MAL and TCF,  although the side- 
chain interactions mediating MAL-SRF and TCF-SRF contacts are subtly different.
4.3  Mutations  in  the al-helix  of the  SRF  DNA-binding  domain 
inhibit MAL binding
The altered DNA binding-specificity SRF derivative SRF.M2, in which the MADS box N- 
terminal  sequences  are  substituted  with those  from the yeast  MCM1  protein,  fails to 
form complexes with MAL on its cognate or the wild-type SRF binding site (Chapter 2). 
I therefore sought to investigate the role of the sequences exchanged in SRF.M2 in the 
formation  of  the  MAL-SRF  complex,  by  using  previously  characterised  and  newly 
designed SRF derivatives in gel mobility-shift assays (Figure 4.4A).
As shown  previously SRF.M2  bound the c-fos CArG  box  weakly and  also  interacted 
weakly with Elk-1, but did not form complexes with MAL (Figure 4.4B;  (Hill, C. S. etal., 
1993)).  Similar  results  were  obtained  with  a  second  altered-specificity  derivative 
SRF.M1, which contains fewer amino acid substitutions in its N-extension (Figure 4.4B 
and (Hill, C. S.  et al.,  1993)).  However the efficiency of DNA binding by this derivative 
was  further  decreased,  precluding  its  use  in  the  analysis  of  MAL-SRF  complex 
formation.  The  residues  of  the  N-terminal  half  of  the  N-extension  including  the 
G142/R143/V144 triad are responsible for the authentic DNA-binding specificity of SRF 
(Figure 4.4A;  (Nurrish,  S. J.  et al.,  1995;  Pellegrini,  L.  et al.,  1995)).  In order to target 
only the  MAL-SRF  interaction  without  perturbing  the  DNA specificity  of the  complex 
these sequences were left intact and two clustered mutations were generated, altering 
the C-terminal part of the N-extension and the al-helix respectively.
The resulting SRF derivatives SRF(N-extension) and SRF(al-helix) bound the wild-type 
c-fos CArG box with efficiencies similar to the wild-type SRF (Figure 4.4A and data not 
shown). The four mutations in the SRF N-extension derivative had no effect on either 
MAL or Elk-1  binding to SRF (Figure 4.4B). The same result was seen with individual 
substitutions  K147E  and  M148I,  while  changes  E149K  and  D152E  caused  small
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reductions in the amounts of complex formed by MAL but not Elk-1  (Figure 4.4B).
Strikingly the SRF al-helix derivative reduced MAL binding to below 10% compared to 
the wild-type activity, as judged by densitometry analysis, while leaving the Elk-1-SRF 
complex unaffected (Figure 4.4B).  Individual substitutions of al-helix residues had less 
pronounced  effects,  with  the  Y158H,  T159V  and  T166H  substitutions  reducing  the 
efficiency of the MAL-SRF complex, without affecting the interaction of SRF with Elk-1 
(Figure 4.4B).
These results show that the grouped L155T/Y158H/T159V/T166H al-helix substitution 
is  sufficient  for  SRF  to  discriminate  between  its  two  cofactors  since  the  al-helix 
mutation  precludes  MAL  binding  but  does  not  affect  the  Elk-1-SRF  interaction.  I 
therefore sought to investigate the role of the four al-helix residues in the formation of 
the MAL-SRF complex.
4.4  The role of DNA bending in MAL-SRF complex formation
There is a correlation between the effect of the MADS box N-terminal changes on MAL 
recruitment and the  migration  properties of the  SRF-DNA complex in the gel-mobility 
shift assay,  since mutations that impair the  MAL interaction also increase the mobility 
of the SRF-DNA complex. Such effects are often indicative of alterations in the degree 
of DNA bending or distortion in a nucleoprotein complex (Figure 4.4; (Wu,  H.  M.  et al., 
1984)).  Given  that  SRF  is  known  to  bend  DNA  upon  binding  (see  Introduction; 
(Gustafson, T. A. et at.,  1989; Pellegrini, L. et al.,  1995; Sharrocks, A.  D. et al., 1995)), 
this observation  raises the  possibility that the al-helix  mutations  affect  DNA bending. 
Indeed,  the  SRF  al-helix  was  previously  implicated  in  DNA  bending  by  a  relaxed- 
specificity  SRF  derivative,  METcoreS R F   (West,  A.  G.  et al.,  1999;  West,  A.  G.  et a!., 
1997).  Furthermore,  the  four  residues  mutated  in  the  al-helix  construct  are  in  close 
proximity to DNA and two of them are known to interact with DNA directly: Y158 makes 
a  phosphate  contact  with  DNA  in  the  SAP1-SRF-DNA crystal,  and  T159  contacts  a 
thymine on the 5’ side of the CArG box in the binary SRF-DNA complex (Hassler, M. et 
al., 2001; Pellegrini, L. et at., 1995). This suggests that the role of these substitutions in 
MAL-SRF complex formation  might  be  indirect,  through their effects  in  the  way SRF 
interacts with DNA.
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To  compare  DNA  bending  by  the  different  SRF  derivatives  I  performed  circular 
permutation analysis (Wu,  H.  M.  et al.,  1984). This technique is based on the fact that 
DNA distortion is a determinant of the electrophoretic mobility of a DNA fragment and 
employs the gel-mobility shift assay to calculate the degree of DNA distortion induced 
in a nucleoprotein complex upon protein binding. This is achieved by generating a set 
of DNA probes of equal lengths, that are circular permutations of the same sequence, 
resulting in the protein binding site being located at different positions along the  DNA 
fragment (Figure 4.5).  Electrophoresis of the protein of interest bound to these probes 
generates complexes of varying mobilities: when the DNA distortion such as a bend is 
present in the middle of the DNA fragment, the nucleoprotein complex migrates through 
the native gel more slowly than an equivalent complex in which the bend is present at 
the end of the DNA fragment.  Calculation of the relative mobilities of these complexes 
and  fitting  of the  data to  a cosine function  allows the  determination  of the  minimum 
(bend in the middle of the fragment) and maximum (bend at the end of the fragment) 
migration points (Figure 4.5). These are then used to estimate the apparent bend angle 
a of the complex from the empirical equation  [f?/m id d le  b in d in g  s tte )/f?/e n d  b in d in g  s ite )= cos(a/2)] 
(Thompson, J.  F. et al., 1988). This value is termed “apparent bend angle” because the 
circular  permutation  technique  cannot  unequivocally  identify directional  DNA  bending 
as  opposed  to  other  DNA  distortions  such  as  locations  of  increased  DNA  flexibility 
(Kerppola,  T.  K.  et al.,  1991).  Moreover,  bend angles calculated with this  method are 
not  absolute  values,  since  their  magnitude  depends  on  experimental  conditions 
including  gel  density,  fragment  length,  electrical  field  strength  and  temperature 
(Kerppola, T. K. et al., 1991).
4.4.1  The  al-helix  mutations  inhibit  MAL  binding  through  their 
effects on DNA bending
Circular permutation analysis of the SRF al-helix derivatives was performed using a set
of circularly permuted  DNA probes,  generated from the c-fos promoter.  The wild-type
SRF  DNA-binding  domain  induced  an  apparent  bend  angle  of  55.5°  ±  1.07°  in  this
assay (Figure 4.6B). This value is lower than the 72° observed in crystallographic and
previous circular permutation studies,  presumably owing to the different experimental
conditions used. The SRF.M2 mutation, which abolished interaction with MAL, reduced
the apparent bend angle  in the binary SRF-DNA complex to 34.  7° ± 0.66°.  A similar
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result was obtained with the al-helix mutation, which also greatly impaired MAL-SRF 
complex  formation  and  which  decreased  the  apparent  bend  angle to  46.8°  ±  1.43° 
(Figure 4.6B). This result confirms the prediction concerning the involvement of the al- 
helix  in  DNA  bending,  which  was  made with the  altered  DNA-specificity  METcoreS R F  
derivative (West, A. G. et al., 1997). Conversely, the N-extension SRF derivative, which 
left the MAL-SRF complex unaffected, did not affect DNA bending by SRF (a=57.2° ± 
0.92°). The individual al-helix changes Y158H and T159V had smaller effects reducing 
the apparent bend angle to 51.6° ±1.19° and 51.7° ± 1.20° respectively, in parallel with 
their lesser effects on MAL-SRF complex formation (Figure 4.6B).
There is therefore a correlation between the effects of the SRF N-terminal  MADS box 
mutations  on  DNA  bending  and  complex  formation  with  MAL,  since  mutations  that 
decrease  MAL  binding  to  SRF  also  reduce  the  DNA  distortion  induced  by  SRF, 
suggesting that the degree of DNA bending is involved in the MAL-SRF interaction.  In 
contrast Elk-1  appears immune to changes in DNA distortion in the SRF-DNA complex, 
since it is able to interact with all the SRF derivatives that display decreased apparent 
bend angles.
4.4.2  The  effects  on  complex  formation  of  mutations  known  to 
affect DNA bending
Previous  reports  identified  a  number  of  other  residues  in  the  DNA-binding  domain 
which are involved in SRF induced DNA bending, amongst which  K154 in the al-helix 
and T191  and H193 in the p-loop region between the pi and pil strands (West, A. G. et 
al.,  1999;  West,  A.  G.  et al.,  1997).  This  group  are  close  together  in  the  crystal 
structure and together with  residue  K165 make  phosphate contacts with the  DNA on 
the 5’ side of the CArG box (Figure 4.7A and B). Given that residue H193 has already 
been  shown to be  necessary for the  association  of  MAL and  SRF (Figure  4.2B)  and 
since the results described in the preceding section implicate DNA bending by SRF in 
complex formation  with  MAL,  I  next investigated  whether there  is  a link between the 
effects of these residues in DNA bending and MAL binding.
Experiments  with  the  altered  DNA  specificity  SRF  mutant  METcoreS R F   previously 
showed  that  negatively  charged  amino  acid  substitutions  at  these  positions  greatly 
reduce the magnitude of the SRF induced  DNA bend,  while changes to alanine affect
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the DNA bend to a lesser degree (West, A.  G.  et al.,  1999; West,  A. G.  et al.,  1997). 
Charge  conversions  at  these  positions  are  probably  also  affecting  the  surrounding 
interactions  with  the  DNA  and  other  SRF  side  chains.  Therefore,  in  order to  avoid 
perturbing  the  other  local  protein-DNA  contacts  I  opted  to  use  the  more  moderate 
alanine substitutions to test the individual effects of each residue on DNA bending and 
MAL binding.
In  contrast  to  the  other  al-helix  mutations  described  in  the  previous  sections,  gel 
mobility-shift  assays  with  the  K154A SRF derivative  affected  complex formation  with 
both  MAL  and  Elk-1  (Figure  4.7B).  Circular  permutation  analysis  of  this  derivative 
reduced  the  apparent  bend  angle  to  49.3°  ±  1.95°,  confirming  that  the  K154A 
substitution  has  moderate  effects on  DNA  bending  (Figure 4.7C;  (West,  A.  G.  et al., 
1999; West, A. G. et al., 1997)). Although K154A has similar small effects on both MAL 
and Elk-1  binding it is not possible to determine whether this is due to the loss of DNA 
distortion in both cases. In the c-fos promoter residue K154 is located close to the Ets 
DNA binding site and is found close to a hydrophobic network formed by SRF al-helix 
and SAP1  ETS domain residues in the SAP1-SRF-DNA crystal structure (Hassler,  M. 
etal., 2001). Even though the residues involved are not completely conserved between 
SAP1  and  Elk-1  and the interactions are likely to be different,  it remains possible that 
removal of the K154 side-chain is affecting Elk-1  binding to SRF due to perturbation of 
interactions between the SRF al-helix and the Elk-1  ETS domain.
Residue K165, which is also located in the SRF al-helix was also mutated and tested in 
gel  mobility-shift assays (Figure 4.7A and B). This residue has not been  implicated in 
DNA bending by SRF, but was tested because alanine mutation of its MCM1 equivalent 
(MCM1  residue  K40)  was  shown  to  greatly  reduce  DNA  bending  (Lim,  F.  L.  et al., 
2003).  The  K165A  SRF  derivative  however  displayed  significantly  reduced  DNA 
binding, probably because it affects both DNA binding and SRF dimerisation (Pellegrini, 
L.  et al.,  1995) and was therefore not included in the circular permutation experiments 
(Figure 4-7C).
In  the  SRF  p-loop  region,  individual  changes  T191A  and  H193A,  both  substantially 
reduced complex formation with  MAL but  not  Elk-1,  but had only marginal effects on 
bending,  decreasing  the  apparent  bend  angle  to  52.2°  ±  0.09°  and  52.8°  ±  1.01° 
respectively (Figure 4.7B and C). A double substitution at these positions, T191/H193A
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had  a  greater  effect  on  DNA  bending  (a=47.4°  ±  0.57°);  however  these  mutations 
abolished both the MAL and Elk-1  interaction with SRF (Figure 4.7B and C). The same 
result  in  cofactor  interaction  was seen  with the  double  T191/H193E substitution,  but 
this  substitution  also  affected  DNA  binding  by  SRF,  probably  due  to  the  charge 
conversion in the vicinity of the DNA (Figure 4.7B).
The V194E  SRF derivative,  which  was  previously shown  not to  be  involved  in  DNA 
bending (Ling, Y.  et al., 1998), was also analysed by circular permutation. As expected 
this mutant abolished complex formation with both MAL and TCF but did not affect the 
degree of  DNA distortion (Figure 4.7C).
Nevertheless, one should keep in mind that residues T191  and H193 are located close 
to the hydrophobic groove, which is the main MAL binding surface of SRF. Therefore, 
even  though  there  appears  to  be  a  correlation  between  loss  of  MAL  binding  and 
decrease of DNA bending with the T191  and H193 alanine derivatives, it is not possible 
to determine whether this is due to loss of DNA contacts and distortion, or due to loss 
of  protein-protein  contacts  with  MAL.  The  significant  effect  of  the  double 
T191/H193Amutation  on  SRF-Elk-1  complex  formation  could  also  be  due  to  the 
proximity of these two residues to the TCF binding surface.
Taken together, these results show that there appears to be a correlation between the 
effects of substitutions  K154A, T191A and  H193A on  DNA bending and  MAL binding. 
Nevertheless, although it is possible that the effects of mutations at positions T191  and 
H193 on the  MAL-SRF interaction are due to alterations in  DNA bending, this cannot 
be determined with certainty due to their proximity to the MAL-binding surface of SRF 
and  their  likely  involvement  in  both  protein-protein  and  protein-DNA  interactions. 
Attempts to resolve this issue by testing the ability of the SRF mutants to interact with 
MAL in co-precipitation  assays  were  not fruitful  due to the  low recovery of MAL-SRF 
complexes in the absence of DNA (see Chapter 5 and Discussion).
4.4.3  DNA bending in the MAL-SRF complex
Having  established  that  the  clustered  al-helix  substitution  decreases  the  degree  of 
DNA  distortion  in  the  binary  SRF-DNA  complex,  I  next  investigated  whether  it  also 
affects  DNA  bending  in  the  ternary  MAL-SRF-DNA  complex  by  performing  circular
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permutation analysis. The different protein composition between the ternary MAL-SRF- 
DNA  complex  and  the  binary  SRF-DNA  complex  prohibits  a  direct  quantitative 
comparison of their apparent DNA bend angles.  Nevertheless, the assay can be used 
to  compare  DNA  bending  by complexes of equivalent  protein  content,  which  include 
different SRF derivatives.
The  location  of  the  MAL-SRF  complex  near  the  top  of  the  native  gels  in  bandshift 
assays  precludes  the  use  of the  full-length  protein  for circular permutation  analysis, 
since  the  loss  of  resolution  at  the  top  of  the  gel  prevents  the  calculation  of  the 
differences  in  the  relative  mobilities  of the  complexes.  I  therefore  used  a small  GST 
fusion  protein  of  the  MAL  B1Q  domains,  GST.MAL(214-298),  complexed  with 
SRF. DBD(120-265) and the c-fos circular permutation DNA probes.
GST.MAL(214-298)  formed  complexes  efficiently  with  SRF on  all  DNA probes,  apart 
from  the  two  probes  (CP1  and  CP6)  in  which  the  SRF  binding  site  was  centred  16 
nucleotides  from  the  end  of  the  fragment  (Figure  4.8;  see  Materials  and  Methods, 
section for CP probe details). This was also observed when full-length MAL was used 
(data not shown; analysed in detail in Chapter 5).  For this  reason the apparent bend 
angles  of the  complexes  in  this  experiment  were  calculated  using  the  data from the 
MAL-SRF complexes formed on the seven  remaining  probes.  This had only  marginal 
effects  on  the  magnitudes  of  the  apparent  bend  angles  of  the  binary  SRF-DNA 
complexes (the apparent bend angle from seven versus nine probes was 54.1° ±0.31° 
versus 55. 5° ±1.07 for wild-type SRF, and 45.39° ±3.01° versus 46.8o ±1.43° for the al- 
helix derivative).
Complexes  between the wild-type SRF DNA binding domain  and GST.MAL(214-298) 
distorted  DNA with an apparent bend of 55.6° ± 0.25°  (Figure 4.8).  The SRF al-helix 
mutation left DNA distortion in the MAL-SRF-DNA complex unaffected, at 57.5° ± 1.25° 
(Figure  4.8,  top),  in  contrast  to  its  effect  on  DNA  bending  in  the  binary  SRF-DNA 
complex, where a reduction of the apparent bend angle is observed (Figure 4.6B). This 
suggests that the interaction of MAL with the SRF(al-helix)-DNA complex increases the 
extent  of  DNA  distortion,  either  through  direct  MAL-DNA  contacts,  or  through 
conformational changes in the complex induced by MAL binding. Thus a simple model 
in  which  MAL  binding  to  SRF  requires  appropriate  DNA  distortion  in  the  SRF-DNA 
complex could explain the inability of MAL to efficiently interact with the al-helix mutant
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Figure 4.8. Optimal MAL-SRF interaction requires the induction of an appropriate 
DNA bend  in the SRF-DNA complex. Circular permutation assays were performed 
using  wildtype  SRF.DBD  or  its  al-helix  derivative  (residues  120-265)  and  either 
GST.MAL(214-298) or transiently expressed Elk-1 as indicated. The data was analysed 
as described in the legend to Figure 4.5. Apparent bend angles for the ternary com­
plexes and representative plots are shown below each panel. Note that MAL complex 
formation is specifically impaired on probes in which the SRF binding site is centred 16 
basepairs from the fragment end.
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since this SRF derivative is impaired for DNA bending.
In  contrast,  the  apparent  bend  in  the  Elk-1-SRF-DNA  complex  was  estimated  at 
51.8°±5,  and  the  SRF  al-helix  mutation  reduced  it  to  40.8°±2  (Figure  4.8,  bottom), 
indicating  that  unlike  MAL,  Elk-1  does  not  require  that  the  DNA  be  distorted  to  a 
specific extent in the ternary complex.
These  results  establish  that  in  contrast  to  TCF  the  interaction  of  MAL  with  SRF 
depends on  appropriate  DNA  bending  and thus  provide  a  rationale for the failure of 
MAL  but  not TCF to  bind the  altered-specificity SRF.M2,  since they  indicate that the 
failure of this mutant to bend DNA to the appropriate degree is what stops recruitment 
of MAL to SRE.M DNA site.
4.5  Summary
The results described in this chapter define the MAL binding surface of SRF. Like TCF 
MAL contacts the hydrophobic groove and pocket of SRF. However, although the areas 
contacted  by the two cofactors  overlap,  the  side-chain  interactions  involved  in  MAL 
and TCF binding are subtly different.
Additionally,  a  link  is  established  between  SRF  induced  DNA  bending  and  MAL 
binding. The requirement of MAL for the intact N-terminal sequences of the SRF DNA- 
binding domain in order to interact with SRF correlates with the ability of residues in the 
al-helix  of  SRF to  bend  DNA  upon  binding.  Other residues  in the  SRF  DNA-binding 
domain known to affect DNA bending also affect the interaction with MAL,  although in 
some  cases  proximity  to  the  MAL-binding  surface  of  SRF  means  that  their  precise 
effect on MAL binding is unclear.
Furthermore,  appropriate  distortion  of the  DNA  in  the  SRF-DNA  binary complex  is  a 
prerequisite  for  MAL  binding,  whereas  the  ability  of  SRF  to  bend  DNA  leaves  the 
interaction with TCF largely unaffected, establishing a major difference in the ways the 
two cofactors bind SRF.
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5  The role of DNA In the MAL-SRF interaction
5.1  Aims
The  results  presented  in  the  previous  chapter  demonstrate  that  appropriate  DNA 
distortion in the SRF-DNA complex is a prerequisite for MAL binding. A simple model to 
explain  this  requirement  is  that  MAL  contacts  DNA  directly,  or  that  appropriate 
distortion  induces  a  conformational  change  on  SRF  necessary  for  MAL  complex 
formation. The aim of the present chapter was therefore to analyse the role of the DNA 
in  the  MAL-SRF  interaction,  by  investigating  how the  presence  of  DNA affects  MAL 
binding  to  SRF  and  studying  whether  the  formation  of  the  MAL-SRF-DNA  complex 
involves direct MAL-DNA interactions.
5.2  Cognate DNA enhances the interaction of MAL and SRF
To  study  the  requirement  for  DNA  in  MAL-SRF  binding  in  detail  I  tested  whether 
binding  of  SRF  to  its  cognate  DNA  facilitates  the  MAL-SRF  interaction  by  a  co- 
immunoprecipitation  approach.  In  vitro  translated  myc-tagged  SRF.WT  and  SRF.M2 
derivatives  were combined  with  whole-cell  extracts  expressing  HA-tagged  MALAN  in 
the  presence  of  either  FOS.WT  DNA  or  the  mutated  FOS.M  DNA.  Reactions  were 
immunoprecipitated  using  myc-beads  and  immunoblotted  for  HA-MALAN  recovery. 
MALAN was efficiently  immunoprecipitated with  wild-type SRF in the  presence of the 
FOS.WT  DNA  that  contains  the  wild-type  SRF  binding  site,  while  its  recovery  was 
greatly reduced in the presence of the mutated SRF binding site FOS.M, which cannot 
bind wild-type SRF (Figure 5.1, compare lanes 2 and 5; (Hill, C. S. et al., 1993)). These 
results demonstrate that MAL  binding to SRF is facilitated  when  SRF is  bound to  its 
cognate DNA. The increased efficiency of MAL-SRF complex formation in the presence 
of DNA also provides a potential explanation for the consistently low recovery of MAL- 
SRF  complexes  in  co-immunoprecipitation  and  GST-pulldown  experiments.  MALAN 
failed  to  immunoprecipitate  with  SRF.M2  in  the  presence  of  either  the  wild-type  or 
mutant c-fos  DNA (Figure 5.1,  lanes 3 and 6),  confirming that MAL does  not interact 
with SRF.M2 even when  its cognate  DNA is present, consistent with the gel  mobility- 
shift assay results (Chapter 2).
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Figure  5.1.  Cognate  DNA  enhances  the  interaction  of  MAL  and  SRF.  Extracts 
containing  HA-tagged  MALAN were incubated with the wild-type or SRF.M2 forms of 
myc-tagged  in  vitro translated  SRF.DBD  (120-265)  as  indicated,  in the  presence or 
absence  of  either the  wild-type  c-fos  DNA probe  (FOS.WT)  or  its  mutated  FOS.M 
derivative generated by PCR. Following immunprecipitation with anti-myc beads, MAL 
AN recovery was detected by HA immunoblotting. The sequences of the SRF binding 
sites are shown below, with the SRF binding site boxed in grey and the Ets binding site 
underlined.
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5.3  MAL makes DNA contacts in the MAL-SRF-DNA complex
5.3.1  DNase I footprinting of the MAL-SRF-DNA complex
To  investigate  whether  MAL  makes  direct  contacts  with  DNA  in  the  MAL-SRF-DNA 
complex,  I  performed  DNase  I  footprinting  analysis.  This  assay  involves  incubating 
nucleoprotein complexes with limiting amounts of the DNase I enzyme, which cuts DNA 
predominantly after pyrimidines (Bernardi, A. et al.,  1975; Bernardi, G. etal., 1973), so 
that each  DNA  molecule  in the  reaction  is cut only once on  average.  Binding of the 
protein of interest to a specific region of the DNA,  protects it from  DNase  I  cleavage. 
After elution  of the  DNA from  the complexes  and denaturing  gel  electrophoresis this 
becomes  apparent  as  a  gap  in  the  DNA  ladder,  creating  a  characteristic  protein 
“footprint”.  Protein  binding to the  DNA  may also change  its conformation  exposing  a 
neighbouring  DNA region and  making  it  more  susceptible to  DNase  I  digestion.  This 
appears in the gel as a DNase I hypersensitive cleavage site.
To  identify  protein-DNA  interactions  in  the  MAL-SRF-DNA  complex,  c-fos  promoter 
probes were radioactively labelled on the 5’ end of their top strand or the 3’ end of the 
bottom strand,  and  were then  combined  with  recombinant SRF  DNA-binding  domain 
(residues  132-223),  either  alone  or  with  increasing  amounts  of  GST.MAL(214-298) 
derivatives. After incubation with limiting amounts of DNase I the DNA was eluted and 
resolved  on  denaturing  gels  alongside  chemical  degradation  products  of  the  probes 
that served as sequence markers.  The SRF DNA-binding domain protected the CArG 
box and its flanking DNA sequences symmetrically to positions ±11  on the 5’, and ±14 
on  the  3*  side  of  each  strand,  consistent  with  the  original  characterisation  of  the 
classical SRE element (Figure 5.2; (Treisman, R., 1986)).
Inclusion  in  the  reactions  of  increasing  amounts  of  wild-type  GST.MAL(214-298) 
induced additional changes in the DNase I digestion pattern symmetrically around the 
SRE dyad (Figure 5.2; summarised in Figure 5.3).
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Figure  5.2.  DNase  I  footprinting  analysis  of  the  MAL-SRF  complex.  Reactions 
contained  c-fos  DNA,  SRF.DBD  (residues  132-223)  as  indicated  and  increasing 
amounts (0.8, 2.5, 7.6 and 22.8 ng) of wild-type or H293A GST.MAL(214-298) proteins. 
The  DNA sequences are aligned with the AG  marker ladders,  the  line  indicates the 
classical SRE and the CArG sequence is boxed. Red dots represent protections from 
and arrowheads enhancements of DNase I cleavage.  Prolonged exposure autoradio­
grams of the footprints are shown below the main experiments.
H239A
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On  the  top  strand,  protections  were  apparent  5'  to  positions  -22,  -21  and  -20,  and 
enhancements 5' to positions -17 and -16; conclusive interpretation of the pattern 3' to 
the SRE was not possible due to a gel compression (Figure 5.2; summarised in Figure
5.3). After prolonged exposure of the autoradiogram further protections were apparent 
on the top strand 5’ to positions -4 and +10 inside the SRF footprint (Figure 5.2, bottom 
panels).  On the  bottom  strand  cleavage  was  enhanced  5'  to  +17,  +16  and  +13  and 
protected 5' to position +20 and +19 (Figure 5.2). High exposure autoradiograms of the 
bottom strand  revealed enhanced cleavage 5’ to  position +3 and +13 inside the SRF 
footprint and also minor enhancements 5’ of positions -18 and -19 and a protection at 
-15 (Figure 5.2 and Figure 5.3).
The  major  alterations  in  the  DNase  I  cleavage  pattern  observed  upon  MAL  binding 
display substantial strand asymmetry, since they appear to be restricted to the 5' side 
of the SRE on each strand. This can be seen clearly for the top DNA strand, although 
the gel compression precludes conclusive analysis of the pattern on the 3’ side of the 
SRE (Figure 5.2 and Figure 5.3).
None  of  these  perturbations  in  the  DNase  I  footprint  pattern  of  SRF  were  seen  by 
increasing  amounts of the  H239A  GST.MAL derivative that is unable to interact with 
SRF (Figure 5.2).
These results establish that the binding of MAL alters the DNase I cleavage pattern in 
the SRF-DNA complex symmetrically  around the  SRE dyad  axis  with  major changes 
focused  at  positions  ±16  to  ±22  from  the  centre  of  the  CArG  box.  A  simple 
interpretation is that MAL is involved in direct DNA contacts within the MAL-SRF-DNA 
complex,  although  it  formally  remains  possible  that  these  contacts  are  mediated  by 
SRF due to conformational  changes  induced  by  MAL  binding.  To  address this  issue 
additional DNA binding studies were performed.
5.3.2  Analysis of the MAL-SRF interaction on nested DNA probes
The DNase I footprinting analysis suggested that sequences outside the classical SRE 
are required for formation of the MAL-SRF complex.  In order to directly investigate the 
role  of these  sequences  in  the  interaction  of  MAL  with  SRF  I  performed  further gel 
mobility-shift assays. MAL was previously shown to be unable to  interact with  SRF  on
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DNA probes where the CArG box was located  16 bp from either the 5’ or 3’ fragment 
end, whereas complex formation was unaffected when the CArG box was centred 27 or 
28  bp  from  the  fragment  end  (see  Figure  4.8,  compare  probes  CP1  and  CP6  with 
probes  CP2  and  CP7).  In  contrast  SRF  itself  bound  all  probes  equally  well.  These 
observations are intriguing  in  light of the DNase  I footprinting results described in the 
preceding section, since they imply that the inability of MAL to interact with SRF-DNA 
complexes when the CArG box is placed 16 nucleotides from the probe end is due to 
the  elimination  of  upstream  DNA contacts,  consistent with the  idea that  MAL  makes 
contacts with the sequences flanking the SRE.
To test this idea I produced two sets of c-fos derived probes, in which the SRF binding 
site was brought progressively closer to one fragment end in 3 base pair increments, 
while the other fragment end was maintained at the same position (Figure 5.4A; termed 
“nested probes” hereafter, for probe design details see Materials and Methods).  None 
of these  probe truncations  affected  binding  of SRF to the  DNA,  as expected  (Figure 
5.4B).
Since  the  symmetric  changes  in  the  DNase  I  accessibility  in  the  MAL-SRF-DNA 
complex were observed with the GST. MAL(214-298) protein,  I tested the ability of this 
protein  to  bind  SRF  with  the  nested  DNA  probes.  Complex  formation  between 
GST.MAL(214-298) and SRF(132-223) was efficient on probes in which the binding site 
was centred 25-28 basepairs from the fragment end (Figure 5.4B, probes -25, -27, +25 
and +28). In contrast truncations to positions ±22 greatly decreased MAL-SRF complex 
formation  and  further deletions to  positions ±19  and  ±16 almost abolished  it  (Figure 
5.4A and  B).  The probe truncations that impair MAL-SRF complex formation coincide 
with the location of the major MAL-induced perturbations in DNase I accessibility to the 
SRF-DNA  complex  (Figure  5.4A).  These  data  provide  further  evidence  that  MAL 
binding to SRF requires not only that SRF is bound to the SRE but also that MAL itself 
contacts the DNA sequences on either side of this site.
Consistent  with  the  results  seen  with  the  GST. MAL(214-298)  protein  on  the  nested 
probes,  MALAN  was  unable to  interact with the ±16 probes and formed  substantially 
reduced amounts of complex on the ±19 probes (Figure 5.4B). This demonstrates that 
the inability of the GST.MAL(214-298) fusion protein to bind SRF on the short probes is 
a bona fide property of the MAL protein.
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The  GST. MAL(214-298)  fusion  protein  only  encompasses  the  B1  and  Q  regions  of 
MAL, thus directly implicating these regions in the MAL-DNA contacts. To test whether 
the Q box was  responsible for the  DNA contacts  MALANAQ whole-cell extracts were 
used  with the nested  probes.  The complexes formed were similar to those seen  with 
the wild-type  MAL protein,  showing that the Q box was not responsible for interacting 
with the DNA flanking the SRE (Figure 5.4B).
To  ascertain that the observations described  above were  not an  artifact  produced  by 
using  the  minimal  SRF  DNA-binding  domain  (residues  132-223),  I  repeated  the 
experiment using full-length SRF whole cell extracts. The combination of MALAN with 
the  wild-type  SRF  protein  gave  similar  results  on  the  nested  probes  as  when  the 
minimal SRF.DBD was used (Figure 5.4C).
Considered  together with  the  DNase  I  footprinting  data,  the  results  presented  in  this 
section  demonstrate  that  the  interaction  of  MAL  with  the  binary  SRF-DNA  complex 
involves direct contacts between MAL and DNA in the vicinity of positions ± 16 to ± 22 
on the  DNA flanking the SRE  and  indirectly  implicate the B1  box in the  interaction of 
MAL  with  DNA.  These  results  also  provide  an  explanation  for  the  requirement  of 
appropriate DNA distortion in the SRF-DNA complex in order for MAL to bind, since this 
distortion would be facilitating the interaction of MAL with DNA.
5.3.2.1  The  role  of MAL  dlmerlsatlon  In  the  formation  of the  MAL-DNA 
contacts
The  alterations  in  DNase  I  accessibility  around  the  SRE  dyad  in  the  MAL-SRF-DNA 
complex and the impairment of MAL-SRF binding by truncations of the DNA bordering 
the  SRE  on  either  the  5’  or  the  3’  side  reveal  a  striking  symmetry  in  the  DNA 
sequences  required for  MAL-SRF binding.  In  light of the fact that both wild-type  MAL 
protein and the GST.MAL(214-298) derivative are dimeric (Chapter 2 and (Ji, X.  et a/., 
1992;  Maru,  Y.  et al.,  1996;  Parker,  M.  W.  et al.,  1990))  and that two  B1  boxes  can 
simultaneously bind to SRF (see Chapter 3) these observations suggest that each MAL 
subunit  contacts  DNA  on  either  side  of the  SRE  in  the  MAL-SRF-DNA complex.  To 
investigate this possibility I tested the effect of monomeric MAL derivatives on complex 
formation with SRF on the nested probes.
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Whole  cell-extracts  expressing  the  monomeric  MALANALZ  (see  Chapter  2),  bound 
SRF efficiently on probes -27, +28, -25 and +25 (Figure 5.5A).  In contrast to what was 
seen with MALAN, further truncations of the DNA probes to positions ±22, ±19 and ±16 
gradually reduced but did not abolish complex formation between MALANALZ and SRF 
(Figure 5.5A),  consistent with each monomer making contacts at only one side of the 
SRE.
Since Myocardin is predominantly monomeric in complex with SRF (see Chapter 2, Fig.
2.4),  I  proceeded  to  test  its  ability  to  interact  with  SRF  on  the  nested  probes. 
Transiently  expressed  full-length  Myocardin  bound  the  nested  probes  with  reduced 
efficiency,  and  complex  formation  was  gradually  decreased  but  not  completely 
impaired, as observed with the MALALZ derivative (Figure 5.5B).
I  next tested the AN  Myocardin derivative, which in gel mobility-shift assays forms two 
SRF  interacting  species,  one  monomeric  co-migrating  with  the full-length  Myocardin- 
SRF  complex  and  one  dimeric  migrating  at  roughly  the  position  of  the  MAL-SRF 
complex  (see  Chapter 2,  Fig.  2.4).  Higher amounts of  MCAN  whole-cell  extract  were 
used in this experiment to adequately visualise both SRF-Myocardin complexes.
Myocardin AN interacted strongly with SRF on the longer probes, and formed a smear 
that covered both the dimer and  monomer positions (Figure 5.5B, compare with  MAL- 
SRF complexes  in  Figure  5.5A).  This was probably due to  a combination of the  high 
amounts of Myocardin in the extracts and the instability of the interaction between the 
dimeric Myocardin and SRF. Sequential truncations of the probes to ±25 and then ±22 
nucleotides from the centre of the SRE decreased the amount of MCAN bound to SRF 
and  induced  the  formation  of  a  discrete  MCAN-SRF  complex  corresponding  to  the 
monomeric  MC position  (Figure 5.5B, compare complexes formed on probes ±25 and 
±22).  Further deletions  of the  probes to  positions ±19 and  ±16  almost abolished  the 
smear corresponding to the dimeric MCAN-SRF interaction, but only slightly decreased 
the amount of the monomeric MCAN-SRF complex (Figure 5.5B).
Thus,  the  monomeric  forms  of  MAL  and  Myocardin  can  tolerate  the  loss  of  DNA
sequences  bordering on one side of the SRE. This implies that when complexed with
the  longer  nested  probes  the  MAL  or  Myocardin  monomer is  able  to  exchange  SRF
subunit  partners  in  the  complex  and  interact  with  DNA  on  either  side  of  the  SRE.
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In contrast the lack of the critical DNA sequences in the shorter probes would constrain 
MAL monomer binding to only one side of the SRF-DNA complex, thus accounting for 
the  gradual  reduction  in  the  amounts  of  MALANALZ-SRF  and  Myocardin-SRF 
complexes. Conversely these results show that binding of dimeric MAL or Myocardin to 
SRF absolutely requires that both subunits interact with SRF and DNA in the complex.
The binding of MAL and Myocardin AN derivatives on the nested probes also provides 
evidence  on  the  stability  of  MRTF  homodimerisation.  In  the  case  of  Myocardin  AN 
gradual truncations of the probes result in the loss of the dimeric complex but not the 
monomeric one  (Figure 5.5B),  showing that homodimerisation  is unstable.  In contrast 
probe  truncations  completely  abolish  the  interaction  of  MALAN  and  SRF  without the 
appearance of a monomeric MAL-SRF complex (Figure 5.5A), demonstrating that MAL 
exists as a stable dimer in solution.
Taken  together,  the  results  presented  in  this  section  indicate  that  the  MAL-DNA 
contacts are formed on either side of the SRE by each MAL subunit of the dimeric wild- 
type  MAL  or  the  dimeric  GST.MAL  derivative,  interacting  with  each  SRF  monomer. 
According to this model  MAL monomers would be unable to bind to very short probes 
ranging  from  -16  to  +16  nucleotides.  Time  constraints  precluded  pursuing  this  point 
further.
5.4  Mapping of the MAL sequences mediating DNA contacts in
the MAL-SRF-DNA complex
The results of the  DNase  I footprinting  and  nested  probe analyses implicate the  MAL 
B1  box  in  the  formation  of  the  MAL-DNA  contacts.  This  is  an  intriguing  possibility 
especially due to the  presence  in the  N-terminal  part of the B1  box of  multiple  lysine 
residues,  which  are found  in  contact with the  DNA in  many  nucleoprotein  complexes 
due to their positive charge.
5.4.1  DNase I footprinting analysis of the MAL B1  peptides
In  order to  explore the  possibility  that the  protein  contacts  with  the  DNA  sequences 
flanking  the  SRE  are  mediated  by  residues  in the  MAL  B1  box  I  performed  DNase  I
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footprinting  experiments  using  different  MAL  peptides  (Chapter  3;  Figure  5.6A)  in 
complex with the SRF DNA-binding domain and c-fos DNA.
The  MAL  B1Q  peptide  (residues 224-283),  which encompasses the intact  B1  region, 
generated  a  footprint  essentially  identical  to  that  produced  by  GST.MAL(214-298) 
(Figure 5.6B).  In contrast,  use of peptide A, which lacks the N-terminal residues of the 
B1  region,  resulted  in alterations in the pattern of DNase I cleavage, the most striking 
of which was an additional enhanced cleavage site on the bottom strand 5’ to position 
-16  (Figure  5.6B,  summarised  in  panel  C;  note  that  cleavage  5’  to  -15  was  also 
observed  after  prolonged  autoradiogram  exposure,  data  not  shown).  Symmetrical 
changes in the DNase I cleavage pattern of the top strand could not be interpreted due 
to a gel compression (Figure 5.6B).
Further  changes  in  the  MAL-SRF footprint  included  the  loss  of the  protections  seen 
with  GST. MAL  and  the  B1Q  peptide  on  the  bottom  strand,  while  only  two  of  the 
previously identified DNase I hypersensitive sites were seen 5’ to positions +17 and +3 
(Figure 5.6B).  On the top strand,  the  peptide  A-SRF footprint lacked  protections 5' to 
positions -22, -21, -20 and -13, but retained the enhanced cleavage sites 5’ to positions 
-17  and  -16  (Figure  5.6B).  Prolonged  autoradiogram  exposure revealed  a loss of the 
protections  5’  to  positions  -4  and  +12  inside  the  SRF  footprint  (data  not  shown). 
Footprinting  of peptides  M and J,  which  are further N-terminally truncated,  generated 
DNase I digestion patterns identical to the one seen with peptide A, indicating that the 
removed residues,  including  K230 and  K232 which were previously seen to affect the 
affinity of the  MAL-SRF interaction in  peptide competition experiments (Chapter 3) do 
not participate in direct  MAL-DNA contacts detectable by DNase  I footprinting  (Figure 
5.6A  and  B).  These  results  imply  that  residues  closer to the core  B1  seven-residue 
sequence,  such  as  K234  or  K235  (see  following  section),  are  responsible  for  the 
perturbed footprint.
The changes in the DNase I footprinting pattern seen with the B1  peptides that lack the 
N-terminal part of the basic region suggest that MAL residues 224-228 are required for 
authentic  MAL-DNA  contacts.  These  data  however  do  not  address  whether  these 
sequences  are themselves  responsible for contacting  DNA,  or whether their absence 
simply perturbs DNA contacts made by other B1  residues (see Discussion).
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Figure 5.6.  DNase I footprinting analysis of the MAL B1  region peptides in com­
plex with SRF. (A) Sequences of the MAL peptides. The B1 and Q regions are boxed in 
grey and the critical B1  residues are red. (B) Footprinting reactions contained c-fos DNA 
and SRF.DBD (residues 132-223) with 7.6ng GST.MAL(214-298), 1.7^iM  peptide B1Q, 
8.5p,M peptides A and  M  and 85^M  peptide J as indicated. The  DNA sequences are 
aligned with the AG marker ladders. (C) Summary of the DNase I footprinting data.The 
c-fos SRE is shown with the CArG sequence boxed. The SRF footprint is shown with a 
line  and  the  MAL  induced  changes  in  DNase  I  cleavage  patterns  with  circles 
(protections) and arrowheads (enhancements); red symbols, GST.MAL (214-298) and 
B1Q peptide; blue symbols, peptides A, M and J.
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5.4.2  Nested probe analysis of MAL B1 deletion derivatives
In  order to  elucidate  the  role of the  N-terminal  half of the  MAL  B1  box  in contacting 
DNA I tested the ability of MAL B1  deletion mutants to bind SRF on the nested probes. 
Of  the  MAL  derivatives  tested,  the  A224-229  mutant  interacted  with  SRF  on  the 
FOS.WT  probe  with  the  efficiency  of  the wild-type  MAL  protein,  while  the  A230-235 
derivative exhibited reduced interaction with SRF and the A224-235 deletion enhanced 
complex formation (Figure 5.7B, also Chapter 3 Figure 3.1).
In  the  nested  probe  assay,  the  MALAN  A224-229  derivative  bound  SRF  on  the 
sequentially truncated  DNA fragments with gradually decreased efficiency.  In contrast 
to the wild-type MAL the A224-229 derivative showed little change in the interaction on 
the ±22 and ±19 probes,  and although binding to the ±16 probes was impaired  it was 
not abolished (Figure 5.7B). This result is intriguing in light of the altered MAL peptide- 
SRF-DNA footprint  observed  upon  the  N-terminal  deletion  of  MAL  residues  224-228 
(Figure 5.6). This footprint displays an additional  DNase I cleavage enhancement 5’ to 
position -16 on the bottom strand, which in conjunction with the increased interaction of 
the A224-229 deletion mutant with the ±19 and ±16 probes compared to wild-type MAL, 
confirms that these residues are likely to affect direct MAL-DNA contacts.
The  reduced  interaction  of  the  MAL  A230-235  derivative  with  SRF  on  the  FOS.WT 
probe  and  the  reduced  affinity  for  SRF  of  peptides  lacking  these  sequences  (Figure 
5.7B  and  Chapter  3)  hinted  at  an  involvement  of  these  residues  in  DNA  contacts 
required for MAL-SRF binding. The A230-235 mutant also displayed gradually reduced 
ability to bind SRF on the nested probes, similar to the MALA224-229 derivative (Figure 
5.7B),  further suggesting  loss  of  direct  DNA  contacts.  The fact that  peptides  lacking 
residues 230-233 generated DNase I footprints with similar alterations to that produced 
by the  longer  peptide  A  (Figure  5.6)  indicates that these  residues  are  unlikely to  be 
involved  in contacting  DNA.  This  however does  not exclude that lysines 234 and 235 
which are also deleted in the A230-235 derivative are involved in DNA interactions.
I  next tested the  MALA224-235 derivative, which lacks the complete  N-terminal  half of 
the  B1  box.  This  MAL  derivative  formed  increased  amounts  of  complex  with  SRF 
(Chapter 3,  Figure  3.1  and  Figure  5.7B).  Use of  MAL  A224-235  in  the  nested  probe
assay generated surprising  results, since this derivative was able to interact efficiently
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with  all  probes,  with  an  only slight decrease  in complex formation on the ±16  probes 
(Figure 5.7).  This  result seems to suggest that removal of the  N-terminal  B1  residues 
either relieves a constraint imposed by this region on the interaction of MAL with SRF 
and  DNA or creates  an additional  MAL-DNA contact closer to the SRE than  positions 
±16, thus allowing  MAL to bind more efficiently.  The multiple lysine residues in the B1 
box,  which  could  be  competing  for  DNA  contacts  and  the  presence  of  an  arginine 
residue at position 222,  which could substitute K234 in the A224-235 derivative make 
both scenarios possible (see Discussion).
Although  the  results  presented  in  this  section  do  not  provide  evidence  as  to  the 
residues  mediating  the  MAL-DNA  contacts,  they  confirm  the  involvement  of  at  least 
part of the  N-terminal  half of the  MAL B1  box in direct DNA contacts.  The analysis of 
the  A224-235  mutant  adds  further  interest to the  already contradicting  effects  of the 
basic  part  of  the  B1  box  in  SRF  complex  formation.  Gel  mobility-shift  assay  and 
footprinting  experiments  designed  to  pinpoint  the  B1  residue  or  residues  contacting 
DNA and to address the issue of B1  box lysine competition for DNA binding could not 
be completed due to time limitations. The role of the basic residues of the MAL B1  box 
in contacting DNA and interacting with SRF is further analysed in the Discussion.
5.5  Summary
The  results  presented  in  this  chapter  establish  that  efficient  MAL-SRF  interaction 
involves  direct  contacts  between  MAL  and  the  DNA  sequences  flanking  the  SRE. 
These  results  also  provide  a  potential  molecular  explanation  for  the  dependence  of 
MAL-SRF complex formation on the ability of SRF to bend its cognate DNA, since such 
distortion  could  aid  the  interaction  of  MAL  with  DNA.  The  MAL-DNA  contacts  are 
shown to  be  mediated  by each  MAL subunit interacting symmetrically with  each  SRF 
monomer and the  DNA on  either side of the SRF-DNA complex.  Finally the  basic  N- 
terminal  region  of  the  B1  box  is  implicated  in  forming  the  DNA  contacts  but  the 
complexity of the B1  sequence  precludes conclusive interpretation of the present data 
and identification of the residues responsible.
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6  Discussion
6.1  Summary
In  the  present  thesis  I  have  analysed  the  interaction  between  the  SRF transcription 
factor and  its  cofactor  MAL,  a  member  of the  Myocardin  related  transcription  factor 
family. The results presented here show that the MAL-SRF complex has the predicted 
properties  of  the  Rho-actin  regulated  SRF  cofactor  and  extend  these  findings.  The 
molecular mechanism of MAL-SRF complex formation has been characterised in detail 
through the analysis of the MAL and SRF interaction surfaces and of the role played by 
DNA contact and distortion in complex formation has been analysed.
In the following  sections the  different aspects of  MAL-SRF complex formation  will  be 
discussed  and  a  model for the  interaction  of  SRF with the  MRTFs  will  be presented. 
Additionally the  importance of cofactor competition  and  exchange in the execution  of 
the diverse transcriptional programmes regulated by SRF will be addressed.
6.1.1  The effect  of different  MRTF  domains  in the interaction  with 
SRF
Both  the  MAL(fl)  and  MAL(BSAC)  isoforms form  SRF-dependent complexes  on  DNA 
fragments  containing  wild-type  SRF  binding  sites.  Efficient  formation  of  these 
complexes depends on the presence of the B1  and Q regions and GST-fusion proteins 
encompassing  these  regions  can  form  specific  complexes  with  recombinant  SRF 
(Chapter 3), showing that MAL directly contacts SRF. This contradicts a previous report 
where the inability to detect  MAL(BSAC)-SRF complexes lead to the proposal that an 
unknown  molecule  other than  SRF  was targeting  MAL to  CArG  box  containing  DNA 
(Sasazuki,  T.  et al.,  2002).  It  is  likely that the lack of  MAL(BSAC)-SRF complexes  in 
this study reflected  a combination of the different experimental conditions  used  in the 
gel  mobility-shift  assay  and  the  low  amounts  of  complex  formed  by  full-length  MAL 
proteins.
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6.1.1.1  Inhibition of complex formation by the RPEL domain
Different MAL forms that include the N-terminal  RPEL motifs only form small amounts 
of complex with SRF.  Removal of the extreme N-terminal sequences including  RPEL1 
increases SRF binding and this effect is further enhanced by deletion of the complete 
N-terminus of the protein.
How  could  the  N-terminal  region  of  MAL  affect  complex  formation  with  SRF?  One 
possibility is that inhibition of SRF binding is due to the interaction of the three RPEL 
motifs with actin present in the extracts. Dissociation of actin from MAL is a prerequisite 
for transcriptional activity of the protein, and preliminary data indicate that actin cannot 
interact with the MAL-SRF complex (Sebastian Guettler, personal communication).
The  different binding  competition  strategies employed to test this  possibility were  not 
fruitful.  Titration  of  RPEL  domain  in  order to  compete  with  full-length  MAL  for  actin 
binding had no effect on the  MAL-SRF complex.  It is conceivable however that due to 
the  abundance  of  actin  in  the  whole-cell  extracts  higher  concentrations  of  RPEL 
domain  are  required  to  alleviate  its  negative  effect on  the  MAL-SRF  interaction.  It  is 
noteworthy that titration  of Cytochalasin  D  in the  bandshift reactions  in  an  attempt to 
disrupt actin-MAL binding and increase complex formation with SRF also had no effect. 
The high actin protein levels in the extracts could also have influenced the outcome of 
this experiment.
Use  of  purified  actin  in  an  attempt  to  compete  with  SRF for  MAL  binding  was  also 
unsuccessful due to technical difficulties raised by the fact that the actin-polymerisation 
and  bandshift  conditions  coincide.  This  experiment  is  currently  being  repeated  with 
unpolymerisable actin forms that are still  able to interact with  MAL, such as the  R62D 
actin mutant (Posern, G.  et al, 2002) or actin purified in the presence of Latrunculin B, 
a drug that sequesters actin  monomers and  blocks the Rho pathway (Sotiropoulos, A. 
et al,  1999).  Latrunculin  B treated  actin  is  also  unable to  polymerise  but  retains the 
ability  to  bind  MAL.  The  issue  of  actin  interfering  with  MAL-SRF  binding  could  be 
unequivocally solved  by the  use  of purified  wild-type and  N-terminally truncated  MAL 
derivatives with recombinant SRF, in gel mobility-shift assays.  If actin is responsible for 
complex inhibition, the purified MAL proteins would be expected to form equal amounts 
of  complex  with  SRF,  irrespective  of  the  presence  of  the  RPEL  motifs.  Titration  of 
unpolymerisable actin would then be predicted to compete with SRF for MAL-binding.
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Although  the  competition  binding  experiments  could  neither  prove  nor  oppose  the 
possibility of an  actin-imposed  inhibition of MAL-SRF complex formation, two  lines of 
evidence make the involvement of actin unlikely.  MAL derivatives containing mutations 
in  the  RPEL  motifs  have  variable  effects  on  SRF  complex  formation,  despite  being 
equally  compromised  for  actin  binding.  Furthermore  N-terminal  truncations  of 
Myocardin,  whose  affinity  for  actin  is  minimal  (Sebastian  Guettler,  personal 
communication),  also exhibit enhanced  interaction with SRF.  It therefore appears that 
the  N-termini  of  MRTF  family  members  act  in  a  similar  way  to  inhibit  SRF  binding 
independently of their ability to bind actin.
One possibility is that the N-terminal domain is involved in intraprotein interactions that 
mask the  SRF-binding  surface  of  MAL.  It  should  be  noted  however that  attempts to 
investigate potential interactions between the RPEL domain and other regions of MAL 
by GST-pulldown  assays  have  not  produced  any  positive results  (Sebastian  Guettler, 
personal  communication).  Thus  although  the  data  so  far  show  that  the  structural 
integrity of the  N-terminal domain is required for the inhibition of MAL binding to SRF, 
they do not establish a mechanism for this effect.
6.1.1.2  The B1 box
Complex formation  between  SRF  and  MAL or  Myocardin depends on the  B1  region, 
which  is  required  for  direct  protein-protein  interactions  with  the  SRF  DNA-binding 
domain  (Chapters  2  and  3).  Alanine  scanning  mutagenesis  of  the  MAL  B1  box 
identified  a  seven-residue  sequence  that  is  critical  for  interaction  with  SRF. 
Furthermore the aromatic and planar properties of residues at key positions within this 
sequence are crucial for SRF binding (see also Section 6.1.2.1). This seven-amino acid 
stretch  is  conserved  between  MRTF  family  members  and  the  analogous  DM RTF 
sequence is able to substitute for that of MAL in the context of the murine MAL protein, 
indicating that the mode of  interaction of different  MRTFs with  SRF is  identical.  Short 
peptides  encompassing  this  core  sequence  are  sufficient  for  specific  SRF  binding, 
demonstrating that this conserved predominantly hydrophobic seven residue sequence 
constitutes the minimal SRF-interaction surface of the MRTFs.
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Peptide  competition  studies  indicate  that  basic  B1  residues  N-terminal  to  this  core 
sequence  contribute  to  the  affinity  of  complex  formation.  Nevertheless,  the  alanine 
scanning mutagenesis of the B1  box shows that individual basic residues in this region 
are dispensable for specific interaction with SRF.  Indeed alanine substitution of many 
of  these  residues  increases  rather  than  decreases  complex  formation  (discussed 
further in Section 6.1.3).
In  addition  to  its  role  in  SRF  complex  formation,  the  B1  region  affects  nuclear 
accumulation  of  MALAN.  Three  B1  residues,  K234,  K235  and  K237  are  required  for 
this  function.  These  functions  are  separable  since  the  ability  of  different  B1  mutant 
derivatives to bind SRF does not correlate with nuclear accumulation, with only residue 
K237 affecting both functions.  These observations indicate that the B1  sequence acts 
as a nuclear localisation signal,  as opposed to a nuclear export signal occluded upon 
SRF binding or a sequence promoting MAL nuclear retention through SRF interaction.
Functional studies demonstrate that residues  L236,  Y238,  H239 and Y241,  which are 
absolutely  required  for  in  vitro  complex  formation  with  SRF,  are  also  critical  for the 
interaction  in  intact  cells,  since  alanine  mutants  fail  to  activate  SRF-dependent 
transcription.  Substitutions,  which cause small reductions on complex formation  in the 
bandshift  assay,  do  not  exhibit  an  absolute  correlation  in  their  effects  on  SRF 
activation.  The  fact  that  their  impact  on  SRF  activation  is  more  noticeable  at  lower 
plasmid  inputs  implies  that  the  assay  is  easily  saturated  by  high  MAL  expression 
levels.
The  integrity of the  B1  region  is  also  required  for transcription of chromosomal  Rho- 
regulated SRF-dependent genes. This was demonstrated using an immunofluoresence 
approach to visualise  SRF-dependent  protein expression  in  intact cells.  Although this 
approach  involved  MAL overexpression  it succeeded  in  retaining  pathway specificity. 
Thus  wild-type  MAL  efficiently  induced  expression  of the  Rho-dependent  aSM-actin, 
whereas the expression of MAPK-controlled immediate early genes such as c-fos and 
egr-1 was unchanged.
Despite the successful use of chromatin immunoprecipitation to detect the recruitment 
of endogenous MAL to SRF target gene promoters (Miralles,  F.  et al., 2003),  attempts 
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binding  in  vivo  using  transiently  transfected  epitope-tagged  MAL  derivatives  were 
unsuccessful.  Although  different antibodies,  epitope tags  and  transfection techniques 
were  tested,  the  cause  of  this  is  unclear  since  other  studies  have  reported  the 
successful  chromatin  immunoprecipitation  of  transfected  Flag-Myocardin  with  SRF 
using similar conditions (Cao,  D.  etal., 2005). A further approach would be to evaluate 
cell-lines stably expressing tagged-MAL derivatives in order to ensure high MAL protein 
levels.
6.1.1.3  The Q box
Gel mobility-shift assays of MAL domain-deletion  mutants show that the lack of the  Q 
box decreases but does not abolish the MAL-SRF complex. This is corroborated by the 
reporter-gene  activation  data,  where  deletion  of  the  Q-box  has  a  minimal  effect  on 
transactivation potential in agreement with another report (Cen, B. et al., 2003).
In their original  Myocardin paper,  Wang  et. al. showed that both the B1  and Q regions 
of  Myocardin  were  necessary for complex formation with  SRF and  also  reported that 
Myocardin AB1  or AQ derivatives were unable to activate SRF-reporter genes  (Wang, 
D.  et al.,  2001).  The  results  described  here  partially confirm this  report,  since  neither 
AB1  nor  AQ  forms  of  Myocardin  interact  with  SRF  in  complex  formation  assays. 
However my results show that the  Myocardin AQ derivative can still  activate an  SRF- 
dependent  reporter  genes,  independently  of  the  Rho-actin  pathway.  The  failure  to 
visualise  MCAQ-SRF  complexes  despite  the  ability  of  these  proteins  to  interact 
functionally  could  be  a  result  of  the  Q  box  deletion  rendering  the  Myocardin-SRF 
interaction  too  weak  or  unstable  to  be  detectable  by  the  sensitivity  levels  of  the 
bandshift assay.
Further  analysis  of  the  MAL  Q  box  identified  a  number  of  conserved  hydrophobic 
residues within the Q box and  N-terminally to it that contribute to complex formation. In 
support  of  the  non-essential  role  of  the  Q  box  in  SRF  binding  removal  of  these 
sidechains  reduces  complex  formation  but  has  minimal  effects  on  transcriptional 
activation.
A  previous  study  identified  the  corresponding  Myocardin  residues  as  absolutely 
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equivalent to that of the TCF B box (Wang,  Z.  et al.,  2004).  Several  lines of evidence 
presented  here  contest  this  proposal.  The  Q  box  mutations  shown  to  affect  SRF 
binding  in  the  context  of  the  full-length  MAL  or  Myocardin  have  no  effect  on  the 
interaction  of  B1Q  peptides  with  SRF.  In  addition  the  integrity  of  the  Q  box  is  not 
sufficient to  mediate  peptide  binding to  SRF when the  B1  region  harbours  mutations 
that  abolish  the  complex.  Mutations  in  the  SRF  DNA-binding  domain  that  affect  the 
interaction with MAL do so irrespective of the presence of the Q-box, indicating that this 
region of MAL does not directly contact any surface on SRF. Moreover the Q box is not 
involved  in  contacting  DNA  within  the  ternary  complex  with  SRF,  since  efficient 
interaction  of  MAL  derivatives  with  SRF  remains  dependent on  the  DNA  sequences 
flanking the SRE irrespective of the presence of the Q region.  Despite the presence of 
hydrophobic residues in the regions roughly corresponding to the Q box in arthropods, 
this region is poorly conserved through evolution in contrast to B1  (Figure 6.1), and the 
Q residues important for complex formation cannot be satisfactorily aligned with those 
mediating the interaction of the TCF B box with SRF (Hassler,  M. et al., 2001; Ling, Y. 
eta!., 1997).
What could be the role of the Q box in the MRTF-SRF interaction if it does not involve 
contacts with SRF or DNA? One possibility is that the Q box is required to stabilise the 
interaction of the  B1  box  with  SRF,  perhaps by  making intraprotein contacts with this 
region.  Such  stabilising  interactions  are  seen  with  the  MATa2  repressor,  which 
contacts the  MCM1  p-sheet via a p-hairpin structure (see  Introduction;  (Tan,  S.  et al., 
1998)).
The Q box also inhibits the nuclear localisation of MAL, since in the MAL(met) context 
the  absence  of  this  region  results  in  nuclear  accumulation  under  basal  conditions 
(Miralles, F.  et al., 2003). Although there is no strict correlation between the Q-residues 
contributing to the SRF interaction and those affecting the subcellular localisation of the 
protein,  one  possibility  is that the  Q  box  interacts with the  B1  region  in  uncomplexed 
MAL  resulting  in  the  occlusion  of  the  nuclear  import  signal.  In  this  model  Q  box 
mutations  would  disrupt  this  interaction  and  expose  B1  residues  critical  for  nuclear 
import resulting in MAL nuclear accumulation.
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Figure 6.1  Sequence conservation in the B1  and Q regions of the MRTFs. Alignment of the B1  and Q regions of mouse MAL,  Myocardin and 
MALI 6. The B1  and Q boxes as defined by homology between the MAL and Myocardin regions are indicated by solid lines.  Identical residues are 
indicated by asterisks and conservative replacements by colons and dots above the sequence. The critical seven residue B1 sequence that mediates 
SRF binding is boxed in red. The Q box is grey. The conservation of the critical seven-residue  MAL sequence (red) and Q box-related sequence 
(indicated by grey lines) in bee {Apis Melifera) and fruitfly MRTFs are shown below. The basic region of the B1  box and the extended homology on the 
5’ side of B1  are indicated. Note that all B1  lysines are conserved in the B1  regions of the murine MRTFs.Chapter 6 Discussion
6.1.1.4  Dlmerisation of the MRTFs
All  MRTF family  members  contain  a region  resembling  a  leucine-zipper domain.  Co- 
immunoprecipitation  experiments  demonstrate  that  MAL  has  the  ability  to  self­
associate through  its  leucine-zipper domain.  Moreover MAL contacts SRF as a stable 
dimer,  as  shown  by  the  different  mobilities  of  MAL  LZ  mutants  in  gel  mobility-shift 
assays and also the inability of MAL to form monomeric SRF complexes on probes that 
lack critical DNA sequences on one side of the SRE (see later).
Despite the  presence  of  a  leucine-zipper-like  region  in  Myocardin,  this  protein  forms 
monomeric  complexes  with  SRF  in  bandshift  experiments.  Co-immunoprecipitation 
experiments  failed  to  show  self-association  of  Myocardin,  although  others  have 
reported  such  interactions  (Wang,  Z.  et al.,  2003).  The  discrepancy  between  these 
results could  be due to the sensitivity/stringency of the methods used.  Reporter gene 
activation  data  indicate  that  the  leucine-zipper  of  Myocardin  has  the  potential  to 
homodimerise, since its presence is required for full transactivation potential.  Moreover 
a  weak  Myocardin  dimer  can  be  detected  in  the  bandshift  assays,  the  presence  of 
which  is  dependent  on  the  leucine-zipper  motif.  Experiments  using  truncated  DNA 
probes  demonstrated  that  in  contrast  to  MAL,  Myocardin  is  an  unstable  dimer  in 
solution (Chapter 5).
The biological  significance of the  preferentially  monomeric state of  Myocardin  despite 
its  ability to  dimerise  remains  unclear.  Wang  et.  al.  have  proposed  that the  normally 
monomeric  Myocardin  homodimerises  upon  contacting  SRF dimers  on  neighbouring 
CArG  boxes  in the  promoters  of  muscle-specific genes  (Wang,  Z.  et al.,  2003).  They 
proposed that this  unmasks  an  otherwise cryptic activation domain of the  protein  and 
this step is required for muscle-gene activation, but this has yet to be substantiated.  It 
is  unclear  why  such  a  mechanism  would  be  in  place  since  the  MRTFs  are  able  to 
interact with both SRF subunits simultaneously (Chapters 3 and  5).  Moreover smooth 
muscle specific genes containing single CArG boxes are still responsive to  Myocardin 
activation (Zhou, J.  et at., 2005a) and multiple CArG boxes are not restricted to muscle 
gene  promoters  (Sun,  Q.  et al.,  2006)  and  hence  they  do  not  define  a  Myocardin- 
specific subset of SRF genes.
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Another possibility is that such a mechanism provides Myocardin with a wider range of 
gene  targets,  since  in  contrast  to  the  stable  MAL  dimer  the  interaction  of  the 
monomeric Myocardin with SRF does not depend on direct DNA contacts on both sides 
of the CArG box (see Section 6.1.3).  It is also conceivable that it reflects the interaction 
of  Myocardin  with  a  transcription  factor  other than  SRF,  which  is  not  possible  by  a 
dimeric  protein.  MEF2  has  recently  been  identified  as  a  partner  of  the  Myocardin 
cardiac specific monomer (Creemers,  E.  E.  et al., 2006). This protein does not provide 
an  MRTF interaction  surface  analogous to that presented  by SRF (see  Section  6.1.2 
and  the  Introduction),  and  it  would  be  of  interest  to  investigate  the  interaction  of 
Myocardin dimers with MEF2 and the possibility of Myocardin multimerisation on MEF2 
targets.
Leucine-zipper domains  are  described  in terms  of a heptad  repeat  in  which  residues 
are  designated  abcdefg.  In  this  repeating  pattern  residues  a   and  d   form  the 
dimerisation interface and  residues  e  and g  are thought to contribute to the stability of 
the interaction by forming interprotein salt-bridges (Baxevanis, A.  D.  et al.,  1993).  The 
charge  compatibility of positions  e   and  g   in  different  leucine zippers  defines the  “i+5 
rule” for the prediction of the specificity of leucine zipper partners (Vinson, C.  R.  et a/., 
1993).  According  to  this  rule  the  MAL  leucine-zipper  is  expected  to  homodimerise 
efficiently,  in contrast to that of Myocardin.  Furthermore the two proteins are predicted 
to heterodimerise. The results  presented  here broadly agree with the “i+5” predictions 
for  MRTF  dimerisation.  Furthermore  MALI 6  has  also  been  shown  to  homodimerise 
and heterodimerise with MAL, which also fits the “i+5” rule ((Selvaraj, A.  et al., 2003a); 
Cristina Perez-Sanchez, personal communication).
The  dimerisation  potentials of  MAL  and  Myocardin  cannot  be  interpreted  only on  the 
basis  of the  “i+5”  predictions  for  leucine-zipper interaction  as  shown  by the  use  of  a 
chimeric  MAL  construct  in  which  the  authentic  MAL  LZ  was  swapped  for  that  of 
Myocardin. The MAL(MC LZ) derivative formed both high- and low-mobility complexes 
with SRF, implying that rather than being a self-contained dimerisation unit, the leucine- 
zipper  of  Myocardin  displays  different  abilities  to  self-associate  depending  on  the 
protein  context.  So far,  no other region  in  MAL has been  shown to affect intraprotein 
interactions  although the  roles of conserved  regions such  as the  SAP domain  and  Q 
box still remain obscure.
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it should also be kept in mind that the potential interactions between residues g  and  e 
are not the only specificity determinants for leucine-zipper interaction.  Position a of the 
leucine zipper has also  been  implicated in dimerisation-partner selectivity (Baxevanis, 
A. D. etal., 1993; Lavigne, P. et al., 1995). Polar or charged residues are often found at 
these positions and are thought to provide further stability and specificity determinants 
(Alber,  T.,  1992;  Baxevanis,  A.  D.  et al.,  1993;  Lavigne,  P.  et al.,  1995).  A  closer 
inspection  of  the  MAL,  MALI 6  and  Myocardin  leucine-zippers  reveals  that  these 
positions are  largely occupied  by polar/charged  residues.  As yet,  it remains  unknown 
what, if any, significance these residues have in the ability of the MRTFs to partner with 
themselves and each other.
6.1.2  The MAL binding surface of SRF
6.1.2.1  The Interaction of cofactors with the hydrophobic groove of SRF
Functional studies have previously shown that physical interaction between the TCF B 
box and SRF inhibits the activity of the Rho-actin pathway (Murai, K. et al., 2002). Thus 
the prediction was formulated that the  Rho-regulated cofactor would compete with the 
TCFs  for  SRF  complex  formation.  This  was  confirmed  by  peptide  competition 
experiments,  which  demonstrated  that  the  TCF  B  box  and  MAL  contact  the  same 
surface on the SRF DNA-binding domain (Chapter 2).
The  TCF-binding  surface  of  SRF  corresponds  to  a  hydrophobic  groove  and  pocket 
formed by the pll-strand and all-helix of each SRF monomer ((Hassler, M.  et al., 2001; 
Ling, Y. etal.,  1998); see also Introduction and Chapter 4). The MAL-binding surface of 
SRF  was  also  mapped  along  this  groove  using  mutated  SRF  derivatives.  Mutations 
H193A,  V194E,  Y195D  and  T196E  disrupt  MAL-SRF  complex  formation  on  DNA 
fragments derived from the c-fos promoter.  In contrast in the  Elk-1-SRF complex only 
the V194E and T196E changes detectably impair interaction, consistent with the work 
of  Ling  et  al (Ling,  Y.  et al.,  1998).  In this study further changes that decrease  Elk-1- 
SRF complex formation  (E190A,  Y195D,  T199A,  Q203E,  and T207D),  were  identified 
by the use of a high affinity Ets DNA site to bind Elk1  and subsequently recruit SRF to 
a  weak  CArG  box,  which  presumably  renders  the  Elk-1  -   SRF  interaction  more 
sensitive to individual amino acid substitutions.
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TCF interacts with the hydrophobic groove of SRF by adding an antiparallel 0-strand to 
the central 0-sheet of the SRF DNA-binding domain (Hassler, M. etal., 2001). Although 
TCF B box residues  N- and C-terminal to the 0-strand sequence are also required for 
SRF  binding  due  to  their  interactions  with  the  SRF  al-helix  and  DNA,  and  all-helix 
respectively,  it is noteworthy that MATa2 complex formation with  MCM1  also depends 
on  the  addition  of  a  0-strand to  the  MCM1  DNA-binding  domain  (Hassler,  M.  et al., 
2001;  Ling,  Y.  et  al.,  1997;  Tan,  S.  et al.,  1998);  see  also  Introduction).  Moreover 
alanine  substitution  of  any  of  the  eight  residues  forming  the  0-strand  sequence  of 
MATa2  results  in  loss of interaction with  MCM1  in functional assays  (Mead,  J.  et al., 
1996).
Although the TCF and  MATa2 0-strands are added to SRF and  MCM1  respectively in 
opposite orientations, the interactions involved are highly conserved (Hassler,  M.  et al., 
2001;  Tan,  S.  et al.,  1998).  Central  to  the  interaction  of  SRF  with  the  TCFs  is  the 
insertion of an aromatic side-chain from the 0-strand in a deep hydrophobic pocket on 
the SRF DNA-binding domain,  defined by residues V194,  I206 and  1215 (Figure 6.2A; 
see  also  Chapter  4;  (Hassler,  M.  et al.,  2001)).  The  aromatic  character  of  the  TCF 
residue  inserted  in the  pocket  is crucial for complex formation  (Ling,  Y.  et al.,  1998). 
Such an interaction is also seen with  MCM1  and MATa2, and other MCM1  interacting 
proteins  have  been  implicated  in  interactions  with  residues  surrounding  the 
hydrophobic  pocket  (see  Introduction),  suggesting  that  this  represents  a  common 
cofactor-binding mechanism for Type-I MADS box transcription factors.
MAL  binding  to  SRF  also  involves  interactions  with  the  hydrophobic  pocket  as 
demonstrated by substitutions at positions I206 and 1215 that are predicted to alter the 
pocket  dimensions.  These  substitutions  affect complex formation  with  both  MAL  and 
Elk-1,  however  their  effects  on  the  MAL-SRF  and  TCF-SRF  interaction  are  not 
identical, indicating that the interactions of each cofactor with the SRF pocket are subtly 
different.  These observations  raise the possibility that MAL also  binds the  SRF  DNA- 
binding domain by adding a 0-strand to the central 0-sheet of the structure.  If 0-strand 
addition  is indeed the  mechanism of  MAL binding to SRF,  is this strand added to the 
SRF 0-sheet in an  antiparallel orientation as seen with TCF or in parallel as seen with 
MATa2 and MCM1?
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Figure 6.2 The MAL binding surface of SRF and the “(3-strand addition” cofactor binding model. (A) The SAP-1-SRF ternary complex (Hassler 
and Richmond, 2001) is shown: blue, SRF; green, DNA; yellow, SAP-1  B-box. Left, ribbon model, with secondary structure elements indicated. Centre, 
SRF and SAP-1 are shown in van der Waals and ribbon representations respectively. SRF residues implicated in MAL interaction are red (hydrophobic 
pocket), orange (pll-strand residues also contacting DNA), and pink (critical al-helix residues). Right, as centre but with DNA shown as van der Waals 
representation and SAP-1 aromatic side chains Y147 and F150 in backbone representation. Images were produced from the 1  hbx PDB file. (B) Poten­
tial sequence relationships between the critical MAL B1  region sequence and the (3-strand segments of the TCF B-box, and MATa2. The aromatic 
residues are highlighted in yellow. Note that the TCF (3-strand is added to the SRF (3-sheet in antiparallel orientation, whereas that of MATa2 is added 
to the MCM1  (3-sheet in paralell. Both cofactors insert a phenylalanine in the hydrophobic pocket of their MADS box partner protein.
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Both the TCF  B box  and  MAL B1  box contain two equally spaced aromatic residues, 
both of which are critical for binding to SRF (Chapter 3; (Hassler,  M.  et al., 2001; Ling, 
Y.  et  al.,  1998)).  In  the  case  of  TCF  one  of  these  aromatics  is  inserted  into  the 
hydrophobic  pocket,  raising  the  possibility  that  one  of  the  MAL  Y238  and  Y241 
residues fulfils the same role.
Substitutions  at these  positions aimed to identify the  MAL residue responsible for the 
pocket  interaction  were  not  successful  since  SRF  complex  formation  depends  on 
aromaticity at both the Y238 and Y241  positions (Chapter 3). Additionally experiments 
using  both  MAL  and  SRF  point  mutation  derivatives  in  an  attempt to  identify  mutant 
combinations  that  would  restore  MAL-SRF  binding  were  not  successful  (data  not 
shown).  Gel  mobility-shift assays containing  SRF hydrophobic  pocket  mutants,  which 
display  increased  interaction  with  MAL  such  as  I206A,  failed  to  restore  complex 
formation with the  MAL B1  mutants that do not interact with SRF.  Similarly bandshifts 
of MAL mutants, which strongly interact with SRF such as Y238F, did not compensate 
for the inability of SRF hydrophobic groove and pocket mutants to form a complex with 
MAL.
Thus although the data presented here are consistent with one of the MAL B1  aromatic 
residues  being  inserted  into  the  SRF  hydrophobic  pocket,  they  do  not  address  the 
direction  in  which  the  MAL  sequence  interacts  with  the  SRF  p-sheet,  since  either  a 
parallel or antiparallel orientation could provide an aromatic residue for insertion  in the 
pocket (Figure 6.2A).
A  number of  observations  suggest  but  do  not  prove that a  parallel  p-strand  addition 
mechanism  similar to  that  employed  by  MATa2  operates  in  the  MAL-SRF  complex, 
with MAL residue Y238 being inserted in the hydrophobic pocket. Alignment of the MAL 
B1  critical  region  in the opposite direction to the TCF p-strand,  which  is added to the 
SRF p-sheet in an antiparallel orientation, allows alignment of both  MAL Y238 with the 
TCF phenylalanine,  and  of the critical  MAL  L236 with a TCF residue  (L152  in  SAP-1 
and 1164 in Elk-1) required for interaction with the SRF all-helix (Figure 6.2A; Chapter 3 
and  (Hassler,  M.  et al.,  2001;  Ling,  Y.  et al.,  1997).  Moreover the Y238F substitution 
increases  MAL-SRF  complex  formation,  unlike  Y241F,  which  leaves  it  unaffected 
(Chapter  3),  suggesting  that  a  phenylalanine  at  position  238  facilitates  MAL-SRF
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interaction.  This  is  intriguing  in  light of the fact that the  residue  inserted  in  the  SRF 
hydrophobic  pocket  is  a  conserved  phenylalanine  in  all  three  TCFs  and  a 
phenylalanine also interacts with the pocket in the MATcx2-MCM1  complex (Hassler, M. 
etal., 2001; Ling, Y. eta/., 1997; Tan, S. eta/., 1998). Furthermore the DMRTF residue 
corresponding to MAL Y238 is a phenylalanine (Figure 6.1).
The  interaction of the  MAL  B1  region  with  SRF via a p-strand  mechanism could  also 
provide  an  explanation  for the  differential  effect of the  I206A substitution  at the  SRF 
hydrophobic  pocket,  on  the  MAL  and  TCF  interaction.  This  change  barely  affects 
complex formation with TCF, presumably because the B box residue in the vicinity is a 
serine  (S149  in  SAP-1),  whose  small  size does  not interfere with the long  isoleucine 
sidechain.  In  contrast  the  I206A  change  causes  a  striking  increase  of  MAL  binding, 
suggesting  that  the  isoleucine  sidechain  clashes  with  a  MAL  residue.  Assuming  that 
one of the  MAL tyrosines  is  inserted  in the hydrophobic  pocket,  the  residue closer to 
I206 would  be  H239 or Q240 depending on the orientation  of p-strand addition.  Both 
these amino acids have bulkier sidechains than serine,  which could  possibly interfere 
with  I206.  Such a  model would suggest that removal of the interfering MAL sidechain 
should also increase SRF binding. This is not the case however since mutation  H239A 
abolishes  binding,  and  Q240A  decreases  it,  indicating  that  these  residues  are  also 
involved in important interactions with the SRF DNA-binding domain.
6.1.3  The role of DNA in the MAL-SRF interaction
6.1.3.1  The role of DNA bending
Formation  of  the  MAL-SRF  complex  involves  the  N-terminal  sequences  of  the  SRF 
DNA-binding domain,  since  MAL does not interact with SRF.M2,  an  altered-specificity 
mutant that  contains  heterologous  N-terminal sequences.  This  requirement  seems  to 
be independent of the DNA sequence contacted by SRF, since MAL and SRF.M2 fail to 
form  a  complex  on  both  the  wild-type  SRE  and  the  SRF.M2  specific  SRE.M.  These 
results  confirm  and  extend  previous  findings  that  proposed  the  integrity  of  the  N- 
terminal  sequences  of the  SRF.DBD  as  a prerequisite for activation  through  the  Rho 
pathway (Hill, C. S. eta!.,  1994).
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Mutagenesis  analysis  based  on  the  SRF.M2  substitutions  that  do  not  affect  DNA 
specificity identified a group of four residues within the SRF al-helix whose mutation to 
the  analogous  residues  from  MCM1  abolished  MAL  binding.  In  contrast the  al-helix 
sequences  do  not  affect  the  TCF-SRF  complex,  which  is  also  weakly  formed  on 
SRF.M2.
The critical al-residues are located close to DNA in the binary SRF-DNA complex and 
two of them are known to interact with DNA directly (Hassler, M. et a/., 2001; Pellegrini, 
L.  et al.,  1995).  Furthermore,  the  cumulative  effect of  all four substituted  residues  is 
required to inhibit  MAL binding,  since  no individual substitution  has similar effects on 
MAL-SRF  complex  formation.  These  observations  suggest that the  inhibition  of  MAL 
binding  by  the  al-helix  derivative  does  not  involve  direct  protein-protein  contacts. 
Instead the effects of the SRF.M2 and al-helix mutations on MAL binding correlate with 
their effects on SRF-induced DNA bending.
The  ability  to  bend  their  DNA  sequences  is  a  well  characterised  property  of  Type-I 
SRF-like  MADS  box  transcription  factors  (see  Introduction).  Residues  within  the  al- 
helix  of  SRF  have  been  previously  implicated  in  DNA  bending  in  the  context  of the 
relaxed-specificity  METcoreS R F   construct  and  residues  within  the  analogous  region  of 
MCM1  have been shown to mediate DNA bending (Acton, T.  B.  et ah,  1997; Lim,  F.  L. 
et  al.,  2003;  West,  A.  G.  et  al.,  1997).  The  results  presented  here  confirm  the 
involvement of the SRF al-helix  in  DNA bending and  implicate this property of SRF in 
cofactor selectivity,  since  MAL but not TCF is sensitive to mutations that decrease the 
degree of DNA bending.
The identification of DNA bending as a possible determinant of cofactor interaction led 
me to test  other  residues  located  in the  al-helix  and  0-loop of the  SRF  DNA  binding 
domain previously reported to affect DNA bending through phosphate mediated effects 
on  DNA  binding  (West,  A.  G.  et  al.,  1999;  West,  A.  G.  et  a/.,  1997).  The  results 
presented  here  show  no  easily  interpreted  correlation  between  the  effects  of  these 
residues on  MAL binding  and  DNA bending. The alanine substitution of residue K154, 
previously  reported  to  be  a  major  bending  determinant  in  the context  of  METcoreS R F  
has  modest  effects  on  DNA  bending,  but  reduces  SRF complex  formation  with  both 
MAL  and  Elk-1.  It  is  possible  that  the  effect  on  Elk-1  complexes  reflects  altered 
interactions between SRF and the TCF ETS binding domain arising due to the spacing
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of  the  CArG  and  Ets  sites  in  the  c-fos promoter  probe  used  (Chapter  4;  see  also 
(Hassler, M. eta!'., 2001)).
Substitutions  of  the  p-loop  residues  T191  and  H193  had  striking  results  on  MAL 
binding,  which  were  accompanied  by small  effects on  DNA bending.  Although  this  is 
consistent with an effect on complex formation mediated by DNA bending,  it should be 
kept in mind that these residues are located close to the hydrophobic groove, which is 
the main MAL binding surface of SRF.  It is therefore not possible to determine whether 
the impairment of MAL binding is due to loss of DNA contacts and distortion, or due to 
disruption  of  protein-protein  contacts  with  MAL.  The  significant  effect  of  the  double 
T191/H193A  mutation  on  SRF-Elk-1  complex  formation  could  also  be  due  to  the 
proximity of these two  residues to  the TCF binding  surface.  The  reservations  on  the 
connection  between  the  effects  of  the  p-loop  residues  on  MAL  binding  and  DNA 
bending could in principle be dispelled by testing the ability of the mutant derivatives to 
bind MAL in the absence of DNA.  However as will be discussed later such an analysis 
was precluded by the required presence of DNA for efficient MAL-SRF interaction.
6.1.3.1.1  DNA bending in the MAL-SRF complex
In contrast to  its effect on  DNA  bending in the binary SRF-DNA complex,  the al-helix 
mutation does not alter the magnitude of DNA bending in the context of the MAL-SRF- 
DNA ternary complex. This suggests that formation of the MAL-SRF complex depends 
on the  induction of an  appropriate  DNA bend.  According to this view,  SRF  mutations 
compromised  for  DNA  bending  are  accompanied  by  the  impairment  of  MAL-SRF 
complex formation since they require  MAL to expend binding energy to further distort 
the DNA in the ternary complex.
Why would DNA bending be necessary for MAL binding to SRF? A simple model is that 
DNA  bending  or  distortion  facilitates  direct  contacts  between  MAL  and  DNA  in  the 
complex (see below) or that it induces an SRF conformation required for MAL binding. 
It  is  noteworthy that  appropriate  DNA  bending  has  been  proposed to  be  required  for 
correctly juxtaposing  MCM1  and  some of its cofactors,  such  as  Fkh2  and  MATal,  to 
achieve  optimal  complex  formation  (Lim,  F.  L.  et al.,  2003;  Mead,  J.  et  al.,  2002). 
Another possibility that is  not incompatible with the previous explanations  is that DNA 
bending  also  provides  a  specificity determinant for MAL target gene selection,  based
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on the inherent ability of a DNA sequence to bend. This could be a feature of the CArG 
box  itself,  since  the  central  A-T rich  sequence  has the  intrinsic tendency to  bend,  or 
sequences  adjacent  to  it,  as  seen  with  MCM1  and the  SQUA  protein  of Antirrhinum 
majus  (Acton,  T.  B.  et  al.,  1997;  West,  A.  G.  et  al.,  1999).  Binding  site  selection 
experiments  designed  to  investigate  this  possibility  were  not  successful  due  to 
technical issues (see Appendix for a detailed analysis).
It is important to note that although useful in identifying overall effects in DNA distortion 
within  a  nucleoprotein  complex,  circular  permutation  experiments  do  not  provide 
information on whether binding of a protein induces a DNA bend or simply an increase 
in  local  DNA  flexibility  (Kerppola,  T.  K.  et al,  1991).  Furthermore,  such  experiments 
cannot determine the  direction  of the  DNA bend.  In the case of the SRF-DNA  binary 
complex,  extensive  biochemical  and  crystallographic  analyses  have  determined  that 
SRF induces directional bending upon DNA binding (Hassier, M. et al, 2001; Pellegrini, 
L.  et al.,  1995; Sharrocks,  A.  D.  et al,  1995).  The results presented here however do 
not  address  the  effect  on  this  bend  of  MAL  binding  to  the  SRF-DNA  complex.  The 
present  analysis  involves  the  qualitative  comparison  of  the  effects  of  the  al-helix 
mutation on  DNA distortion  in the  MAL-SRF-DNA complex,  and thus the directionality 
of the DNA bend within the MAL-SRF-DNA complex was not a critical point.
Structural analysis of the SRF-MAL complex could resolve this issue,  but an additional 
way to tackle this would be to perform phasing analysis experiments (Crothers, D. M. et 
al.,  1991; Kerppola, T.  K.  et al.,  1991). This technique involves placing the binding site 
of the  protein  of  interest  at  different  locations  in  respect  with  an  intrinsic  DNA  bend 
induced  by  a  poly  A:T-tract,  such  that  the  spacing  between  the  two  bending  loci  is 
phased  over a helical  DNA turn.  The poly A:T tract will  bend  DNA towards the  minor 
groove,  and  if the  binding  of the  protein  of  interest  induces  an  in-phase  bend  to the 
same direction  the bends will cooperate to induce a maximum  DNA bend slowing the 
migration of the nucleoprotein complex through a native gel. If the protein induced bend 
is in the opposite orientation the two bends will counteract each other resulting in a fast 
moving  complex.  Calculation  of  the  relative  mobilities  of  the  complexed  versus  free 
DNA  as  a  function  of  the  distance  between  the  intrinsic  and  protein  induced  bend 
centres allows the determination of the orientation of the protein-induced bend.
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6.1.3.2  The Interaction of MAL with DNA In the ternary complex
The  mutagenesis  and  DNA  bending  experiments  discussed  in  the  previous  sections 
strongly  suggest  that  DNA  interactions  are  important  in  the  MAL-SRF  complex 
formation. Three lines of evidence show that this is indeed the case.  First, MAL binding 
to SRF results in symmetric DNA contacts at positions ±16 through ±21  with respect to 
the SRE dyad, as demonstrated by DNase I footprinting. Second, these interactions are 
required  for ternary  complex  formation  with  SRF,  since truncated  probes  lacking  the 
critical sequences flanking the SRE do not mediate MAL-SRF interaction. Third, DNA is 
required for efficient recovery of SRF with MAL in coimmunoprecipitation experiments. 
The data presented  here do not formally exclude the possibility of the additional  DNA 
contacts being mediated by SRF itself due to a conformational change induced by MAL 
binding.  The  solution  of  the  MAL-SRF-DNA  structure  will  unequivocally  resolve  this 
issue.  Nevertheless the simplest  interpretation of the data points to a  model  in  which 
MAL  binding  to  SRF  is  accompanied  by  symmetric  MAL-DNA  contacts  around  the 
SRE.
The  dimeric  nature  of  MAL  is  central  in  contacting  DNA  on  either  side  of  the  SRE 
monomeric  forms  of  MAL  and  Myocardin  show  a  decreased  dependence  on  the 
presence of the critical  DNA  regions.  This  result  in combination  with the  presence of 
two MAL binding surfaces on the SRF dimer and the ability of MAL B1  region peptides 
to  occupy  both  surfaces  at  the  same  time  (Chapters  3  and  4),  indicate  that  the 
formation  of  the  MAL-SRF  complex  involves  the  interaction  of  the  two  B1  boxes 
present in the  MAL dimer with the hydrophobic grooves of the two SRF subunits, with 
each  MAL subunit also  contacting  DNA.  This  model  also  provides  an  explanation for 
the  interference on  SRF activation  by the endogenous  MAL protein  under stimulated 
conditions observed with  MAL mutants that do not themselves bind SRF (Chapter 3). 
According  to  the  model  for  MAL-SRF  binding  delineated  above  heterodimerisation 
between the wild-type endogenous  MAL and overexpressed  mutated derivatives such 
as  Y238A  and  Y241A  would  be  expected  to  destabilise the  MAL-SRF-DNA complex 
due to the inability of one B1  box in the MAL dimer to bind SRF,  resulting in inefficient 
transcriptional activation.
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6 .1 .3.2.1  MAL-DNA contacts through the B1   region
The nested probe analysis of MAL-SRF complex formation reveals that the B1  region is 
most  likely  responsible  for  the  MAL-DNA  contacts,  since  GST-fusion  MAL  proteins 
encompassing only the B1  and Q regions require the appropriate DNA fragment length 
for efficient SRF-complex formation,  and this is not affected  by deletion of the Q box. 
Although the possibility that the region linking the B1  and Q boxes is somehow involved 
has  not been formally excluded,  several  lines of evidence support the  involvement of 
the  N-terminal  part  of the  B1  sequence  in formation of the  MAL-DNA contacts.  First, 
different  deletions  of  the  basic  B1  sequences  show  differences  in  their  abilities  to 
interact with the short nested  probes compared to the wild-type  MAL protein. Second, 
N-terminal truncations of the peptides encompassing the B1  box exhibit a drop in SRF 
binding  affinity  in  competition  assays.  Third,  B1  peptides  lacking  the  extreme  N- 
terminal  B1  residues  give  rise to  an  altered  DNase  I footprint,  directly implicating  the 
missing sequences in affecting MAL-DNA contacts.
Which B1  residue or residues could be responsible for DNA binding? Peptides lacking 
residues  224-228  from  the  N-terminal  part  of  the  B1  region  give  rise  to  an  altered 
footprint and removal of sequences 224-229 in the MALAN context increases the ability 
of MAL to interact with the shorter nested probes, implying that these sequences affect 
MAL-DNA contacts (Chapter 5).  One explanation for the effect of these sequences on 
MAL-SRF  complex  formation  is  that  their  involvement  in  the  MAL-DNA  contacts  is 
indirect, and that deletion of these sequences perturbs the authentic contacts between 
neighbouring  B1  residues  and  the  DNA.  On  the  other  hand  it  is  also  possible  that 
residues  224-229  are  themselves  involved  in  direct  DNA contacts  and  their deletion 
from  the  B1  peptides  results  in  the  loss  of  these  contacts,  but  also  induces  the 
formation of new or perturbation of pre-existing contacts by the remaining B1  residues. 
The results presented here do not exclude either scenario.
Deletion of residues 230-235 causes a decrease in the overall efficiency of MAL-SRF 
binding,  suggesting  that  it  reflects  the  loss  of  MAL-DNA  interactions  (Chapter  5). 
However  despite  removal  of  residues  K230  and  K232  from  the  MAL  B1  peptides 
resulting  in  marked  drops  in  SRF  binding  affinity,  these  peptides  produce  footprints 
apparently identical to the longer peptide A, indicating that these lysines do not directly 
interact  with  DNA  (Chapters  3  and  5).  This  does  not  exclude the  possibility  of other 
residues  such  as  K234  and  K235  being  responsible for  DNA contacts.  For example
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substitution  of  K234  with  alanine  in  the  context  of  MALAN  decreases  complex 
formation  with  SRF  (Chapter  2),  raising  the  possibility  that  this  lysine  interacts  with 
DNA.  Thus  the  results  presented  here  cannot  conclusively  identify  the  residues 
involved, since amino acids within either the 224-229 or 230-235 B1  sequences could 
be involved in DNA binding.
Removal  of  the  complete  N-terminal  half  of  the  B1  region  relieves  MAL  of  its 
dependence on the  DNA sequences flanking the SRE and the A224-235 derivative is 
able to bind all nested probes efficiently (Chapter 5). This result is surprising since the 
opposite effect would  be expected  if residues within the deleted  region  were  required 
for  direct  DNA  contacts  as  indicated  by  the  results  described  above.  One  possible 
explanation  is  that  the  224-235  deletion  brings  a  residue  close  to  the  SRF-binding 
region that is able to make a DNA contact closer to the core SRF-CArG box complex, 
thus sustaining binding. Interestingly the 224-235 deletion results in an arginine residue 
being brought to the position occupied by K234 in the wild-type protein.
A  second  possibility,  is  that  the  N-terminal  part  of  the  B1  box  occludes  the  seven- 
residue  sequence  mediating  binding  to  SRF,  and  the  MAL-DNA  contacts  act  to 
accommodate  the  basic  region  and  unmask  the  SRF-binding  stretch.  Deletion  of 
residues 224-235 relieves this masking effect resulting in the increased ability of MAL 
to bind SRF.  Although this scenario cannot be  ruled out,  it appears unlikely since the 
smaller  B1  deletions  would  be  expected  to  also  disrupt  such  an  autoinhibitory 
mechanism.  As already discussed  however these small deletions do not allow binding 
of MAL to the shorter nested probes.
A  third  and  more  attractive  explanation  is  that  the  multiple  lysines  in  the  B1  region 
compete with each other for DNA binding. According to this model deletion of the whole 
region  relieves this competition  and  increases the ability of MAL to interact with SRF. 
This suggestion  is also  supported  by the effects of alanine point  mutations of the  B1 
box lysines, where substitutions K227A, K230A, K232A and K235A increase MAL-SRF 
complex  formation  in  vitro,  implying  that these  lysine  side-chains  somehow  obstruct 
MAL-SRF binding (Chapter 3).
The data presented  here do  not address the possibility of sequence specificity in the 
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in the DNase I footprint,  in combination with the possible involvement of the B1  region 
lysines suggests that these contacts represent non-specific  interactions with the  DNA 
phosphate backbone.  However base-specific contacts within these  regions cannot be 
excluded.  Attempts  to  investigate  this  possibility  with  DNA  binding  site  selection 
experiments  using  MAL  and  SRF  were  not  brought  to  completion  due  to  time 
limitations.  Nevertheless  preliminary  results  indicate that  although  MAL  binding  may 
bias the sequence identity of the bases adjacent to the CArG box, there appears to be 
no specific sequence patterns enriched in the ±16 to ±22 regions contacted by MAL in 
the DNase I footprinting experiments (see Appendix).
The  data  discussed  in  this  section  and  the  presence  of  multiple  lysines  in  the  N- 
terminal half of the B1  box that are conserved between MRTF family members (Figure 
6.1)  make  it  tempting  to  speculate  that  more  than  one  of  these  residues  are 
responsible for interacting  with  DNA,  possibly by making phosphate contacts with the 
DNA backbone.  Further experiments are required to investigate this and to determine 
the MAL-DNA binding  mechanism.  The  use of  MAL derivatives or long  B1Q  peptides 
harbouring  single  or  multiple  lysine  to  alanine  substitutions  will  potentially  clarify  the 
puzzling  and  sometimes  contradicting  effects  of the  B1  region on  MAL-SRF complex 
formation.  MAL GST-fusion  derivatives containing  such  changes  were constructed  to 
address  these  issues,  however  preliminary  DNase  I  footprinting  and  nested  probe 
bandshift  experiments  were  inconclusive  and  could  not  be  completed  due  to  time 
constraints.
6.1.4  Conclusions: A model for the interaction of MAL and SRF
My  analysis  of the  mechanism  mediating  complex formation  between  MAL  and  SRF 
demonstrates that members  of the  MRTF and TCF families of SRF cofactors  interact 
with SRF using  related but distinct  mechanisms.  MAL contacts the same hydrophobic 
groove  on  the  SRF  DNA-binding  domain  as  members  of  the  TCF  family  of  SRF 
cofactors.  Interactions with a hydrophobic pocket on this surface of SRF are central for 
both MAL and TCF binding.  Formation of the MAL-SRF complex is mediated by a short 
predominantly  hydrophobic  core  sequence  within  the  conserved  MAL  B1  region. 
Although this sequence is sufficient for specific binding,  basic residues  N-terminal to it 
are thought to contribute to the  affinity of the interaction.  Hydrophobic  residues  in the 
neighbouring  Q-box also enhance  MAL-SRF complex formation  but these are unlikely
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to contact  SRF  directly.  MAL contacts  SRF  as  a dimer and  in  contrast to the  TCFs, 
mutations  in  the  SRF  al-helix  that  reduce  SRF-induced  DNA  bending  also  impair 
complex formation with MAL. These mutations however do not affect DNA distortion in 
the MAL-SRF complex.  Efficient MAL-SRF binding requires that SRF be bound to DNA 
and that MAL directly contacts DNA on either side of the CArG box.
My results support a model in which each MAL monomer adds a p-strand consisting of 
the core hydrophobic B1  sequence, to the p-sheet region in the middle layer of the SRF 
DNA-binding domain,  while simultaneously making direct DNA contacts with the  DNA 
flanking the CArG box. These DNA contacts are probably facilitated by the appropriate 
DNA  distortion  in  the  SRF-DNA  complex  and  mediated  by  basic  residues  in  the  B1 
region.
6.1.4.1  Implications of cofactor competition
“p-strand addition” is a common  interaction  mechanism  utilised by MADS  box factors, 
and is employed both for cofactor binding as exemplified by SRF and MCM1  (Hassler, 
M.  et al., 2001; Tan,  S.  et al.,  1998),  and also for dimerisation interactions as seen  in 
the extended contacts between the  MADS and  MEF2 domains of MEF2 factors  (Han, 
A.  et al.,  2003).  SRF utilises the overlapping surfaces to interact with the MRTFs and 
TCFs,  and the  same  is  observed  in  the  interactions of  MCM1  with  its  cofactors  (see 
Introduction for analysis). Although the p-strand addition mechanism is not available for 
cofactor binding in MEF2 factors, these proteins also use overlapping surfaces in their 
MEF2 domains to interact with the Cabin repressor and HDACs (Han, A.  et al., 2003). 
The  ability  to  recruit  many  different  interacting  proteins  via  the  same  binding 
mechanism expands the regulatory potential of MADS box transcription factors and the 
mutually exclusive interactions with their cofactors ensure specificity of their responses.
One  such  example  is  the  competition  between  MRTFs  and  TCFs  for  SRF  complex 
formation  presented  in  this  thesis.  MRTF-TCF  competition  has  been  shown  to  be 
relevant  in  vivo,  since  stimulation  of  the  MAPK  pathway  through  PDGF  in  smooth 
muscle cells results in Elk-1  activation and displacement of Myocardin from target gene 
promoters (Wang,  Z.  et at.,  2004).  Thus cofactor competition and exchange creates  a 
binary  switch  that  controls  SRF  responses  in  muscle  differentiation  and  cell 
proliferation.
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Although the  influence of SRF interaction with its cofactors  by signalling  inputs to the 
cofactors  themselves  is  well  established  (Hill,  C.  S.  et al.,  1993;  Miralles,  F.  et al., 
2003;  Murai,  K.  et  al.,  2002;  Wang,  Z.  et  al.,  2004),  it  remains  unclear  whether 
signalling to  SRF  itself affects cofactor selectivity.  Phosphorylation  of S162  in the al- 
helix  of  the  SRF  DNA-binding  domain  has  been  recently  implicated  in  selective 
inhibition  of  complex  formation  with  the  MRTFs  (Iyer,  D.  et  al.,  2006).  S162 
phosphorylation  by  PKCa  blocks  efficient  SRF-DNA  binding  resulting  in  inhibition  of 
Myocardin-SRF  complex  formation.  TCF-SRF complex  formation  remains  unaffected 
since TCF  binding  to  adjacent  Ets  sites facilitates  recruitment of the  phosphorylated 
SRF to the CArG box (Iyer,  D.  et at., 2006). The modulation of cofactor binding by this 
phosphorylation  event  has  been  implicated  in  the  control  of  the  myogenic  versus 
proliferative  response  of SRF,  and  such  phenomena involving  cofactor exchange via 
signalling to SRF will be interesting topics for future investigation.
6.1.4.2  Cofactor specificity of SRF target genes
An  additional  unresolved  issue  in  regulation  of  transcription  via  the  combinatorial 
interactions of SRF with its cofactors is the cofactor specificity of SRF target genes.  In 
the case of the TCFs  it is clear that the presence of an  Ets DNA site confers  MAPK- 
sensitivity on  SRF-dependent  genes  (Gineitis,  D.  et al.,  2001;  Murai,  K.  et al.,  2002; 
Zhou,  J.  et  al.,  2005b).  Nevertheless  it  is  not  possible  to  determine  the  TCF- 
responsiveness  of  SRF target  genes  based  on  the  DNA sequence  alone  due  to  the 
flexibility  observed  in  the  spacing  and  orientation  of the  Ets  site  with  respect  to  the 
CArG  box  (Treisman,  R.  et al.,  1992).  The  MRTFs  also  contact  DNA  in  the  ternary 
complex  with  SRF,  but  the  sequence-dependence  of  these  interactions  and  the 
influence of the DNA sequence of the CArG box and flanking regions on  MRTF target 
gene selection remain unresolved.
6.1 .4.2.1  Target gene specificity and functional diversity of the MRTFs
A  related  outstanding  question  is  what  determines  target  gene  specificity  between 
MRTF  family  members.  The  results  presented  in  this  thesis  and  the  sequence 
conservation of the MRTFs in the  B1  and Q regions (Figure 6.1)  indicate that different 
family  members  employ  the  same  mechanism  to  interact  with  SRF.  Moreover  the
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MRTFs  exhibit  distinct  but  overlapping  expression  patterns  in  mammals  and  all  are 
implicated in  muscle-specific gene expression (reviewed in (Pipes, G.  C.  et al., 2006); 
see  Introduction  for detailed  analysis).  Despite these  observations  and  indications of 
functional  redundancy,  in  vivo  data suggest that  different family  members  also  have 
discrete effects ((Li, S.  eta!., 2006; Li, S. etal., 2003; Oh, J.  eta!., 2005; Sun, Y. etal., 
2006); for analysis of the in vivo effects of different MRTFs see Introduction).
Different expression levels in diverse cell types and developmental stages are likely to 
affect recruitment of  MRTFs to target genes by competition for SRF binding.  It is also 
possible that the dimerisation state of the MRTFs plays a role in target gene selectivity. 
The requirement of dimeric MRTFs to contact DNA flanking both sides of the CArG box 
could limit accessibility to certain SRF genes due to competition with factors binding to 
DNA  elements  close  to  the  CArG  box,  as  indicated  by  the  inhibition  of  Rho-MAL 
signalling  by the  Ets and AP1/ATF sites flanking the CArG  box on the c-fos  promoter 
(Murai,  K.  et  a/.,  2002).  Fewer  restrictions  of  this  type  would  be  expected  for 
preferentially  monomeric  MRTFs  like  Myocardin,  since  these  only  require  SRF  and 
DNA contacts on one side of the SRF-DNA complex.
Another  as  yet  unexplored  possibility  is  that  additional  specificity  determinants  are 
imposed on  MRTF family members  by their interactions with proteins other than  SRF. 
Synergistic effects of SRF with myogenic factors such as GATA and MyoD have been 
widely reported (Belaguli,  N.  S.  et al., 2000; Groisman,  R.  etal.,  1996; Morin,  S.  et al., 
2001;  Nishida,  W.  et  al.,  2002).  Recent  studies  suggest  that  at  least  some  of  the 
GATA-mediated effects involve Myocardin (Yin,  F.  et a!., 2005),  although the promoter 
context  is  highly  significant  for  the  transcriptional  outcome  of  the  Myocardin-GATA 
interactions (Oh, J.  et al., 2004; Yin,  F.  et al., 2005). The extent to which these effects 
are restricted to Myocardin or involve other MRTF family members remains unknown.
The differential functional  roles of the  MRTFs could also  be  due to  SRF-independent 
transcription factor interactions,  as seen with the cardiac isoform of Myocardin,  which 
interacts with  MEF2  and  activates  MEF2-dependent gene targets  (Creemers,  E.  E.  et 
al.,  2006).  Thus  at least one  extra level of specificity exists  in the case of  Myocardin, 
and  it  remains  possible  that  the  other  MRTFs  also  interact  with  as  yet  unidentified 
partners.
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6.1.4.3  Future prospects
Several  outstanding  questions  remain  on  how  the  formation  and  modulation  of  the 
interactions  of  SRF  with  its  cofactors  determines  the  specificity  of  its  transcriptional 
responses depending on signalling inputs and cell type. The structural analysis of the 
MRTF-SRF complex,  the  investigation of the DNA sequence dependence  of complex 
formation  and  the  effects  of  cofactor  specific  SRF  derivatives  in  vivo  will  provide 
important  insights  into  the  mechanisms  via  which  SRF  fulfils  its  diverse  biological 
functions via combinatorial interactions with cofactors.
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7  Materials and Methods 
MATERIALS
7.1  Chemicals and reagents
This is a general  list of reagents.  Chemicals were purchased from  Sigma,  Merck  and 
Roche  unless  otherwise stated.  Those  reagents  used  specifically for one  method  are 
described in the relevant section.
Acrylamide/Bisacrylamide
37.5:1  and 19:1  solution AMRESCO
Agarose Gibco BRL
Ammonium persulphate Sigma
Ampicillin Sigma
Aprotinin Sigma
Benzamidine Sigma
Bromophenol Blue Biorad
BSA (acetylated) Sigma
Chloramphenicol Boehringer Mannheim
Complete protease inhibitor
cocktail tablets Roche
Coomassie Brilliant Blue Biorad
Cytochalasin D Calbiochem
Dithiothreitol (DTT) Calbiochem
Dimethyldichlorosilane solution BDH
Ethidium bromide Boehringer Mannheim
Glycogen Boehringer Mannheim
Kanamycin Sigma
Leupeptin Sigma
Linear Acrylamide Ambion
p-mercaptoethanol Sigma
milk powder Marvel
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dNTPs Pharmacia
Okadaic acid Calbiochem
Orange G Sigma
Pepstatin Sigma
Phenylmethyl-sulfonyl fluoride (PMSF) Sigma
Poly(dldC)*poly(dldC) Amersham
Protein assay reagent BtoRad
Revidue 32P dNTPs Amersham
Spermidine Sigma
TEMED Sigma
Trizma-base Sigma
Triton X-100 Sigma
Xylene cyanol Biorad
3MM paper Whatman
Restriction enzymes were purchased from New England Biolabs (NEB) and were used 
with  the  recommended  supplied  NEB  buffers  and  BSA  solution.  Additional  enzymes 
used were purchased from the following companies:
Biotaq Red DNA polymerase Bioline
Calf intestinal alkaline phosphatase NEB
DNase I Sigma
Klenow DNA polymerase NEB
Pfu turbo DNA polymerase Stratagene
Proofstart DNA polymerase Qiagen
Proteinase K Gibco BRL
RNase A Sigma
RNase inhibitor Boehringer Mannheim
T4 Polynucleotide kinase NEB
Where applicable, enzymes were used with the buffers supplied by the manufacturer.
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7.2  Buffers and solutions
All  buffers  and  solutions  were  made  with  deionised  water  (Milli-Q  plus  system, 
Millipore)  and,  where  appropriate  sterilised  by  filtration  on  a  0.2  ^m  vaccum-driven 
filtration  system  (Stericup).  A  list  of  the  most  commonly  used  solutions  follows. 
Solutions used specifically for one technique are listed in the relevant section.
PBS 0.17 mM NaCI
3 mM KCI
1  mM Na2HP04
1.8 mM KH2P04 pH 7.4
TBE 89 mM Tris Base
89 mM Boric acid
2 mM EDTA
TE 10 mM Tris pH 7.5,
1   mM EDTA pH 7.5
TEN 10 mM Tris pH 7.5,
1   mM EDTA pH 7.5
100 mM NaCI
7.3  Plasmids and oligonucleotides
7.3.1  Expression vectors
Protein expression In mammalian cells
MAL, SRF and Elk-1  cDNAs were expressed from the following vectors:
MLV.plink described in (Dalton, S. etal., 1992).
pEF.Flag derived from EF.plink (Hill, C. S. etal., 1995b), contains an 
N-terminal Flag epitope tag
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pEF.HA  derived from EF.plink (Hill, C. S. etal., 1995b), contains two
N-terminal HA epitope tags
Protein expression In reticulocyte lysate In vitro translation systems
SRF cDNAs were expressed from the following vector:
pFTX5  derived  from  T7Plink  (Howell,  M.  et al.,  1997)  has  an  N-
terminal Myc epitope tag
Protein expression In E. coll
MAL cDNAs were expressed as GST-fusion proteins from the following vector: 
pET41a  Novagen
7.3.1.1  Oligonucleotides
Oligonucleotide  primers  were  synthesised  by  the  in-house  Cancer  Research  UK 
oligonucleotide  synthesis service or from  Sigma.  All oligonucleotides were  purified  by 
reverse  phase  chromatography  (RP1)  unless  otherwise  stated.  Lyophilised 
oligonucleotides  were  dissolved  in  water  to  final  concentrations  of  10  or  100  pM. 
Details of oligonucleotide design for MAL and SRF derivative construction can be found 
in  section  7.7.4.4.  Oligonucleotides  used  to  generate  bandshift  probes  are  listed  in 
section 7.9.1.7.
7.4  Peptides
All  peptides  were  synthesised  by  the  Cancer  Research  UK  Peptide  Synthesis
Laboratory. Peptides were dissolved in water, or when they were too hydrophobic in 50
% acetonitrile/water solution.  After centrifuging for 10 minutes at maximum speed and
room  temperature  to  remove  undissolved  material  a  1/10  dilution  of  peptide  solution
was used to  measure the  absorbance of the peptide bond at 215  nm  in  a fluorimeter
using  Quartz cells.  The  absorbance  measurement was  used  to calculate the  peptide
concentration as follows:
(Absorbance x peptide dilution) + (number of peptide bonds) = A*
where A* =Absorbance units per peptide bond
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The peptide concentration was then worked out from the Beer-Lambert law:
A* s e c I
Where e = molar extinction coefficient (1000 l/M/cm for each peptide bond)
And I = cell path length, (3mm cells were used)
The pH of the peptide solutions was checked with pH indicator test strips and pH was 
brought to 7-8 with Tris-HCI pH 7.9.
The peptides were then buffered to a final concentration of 10 mM Tris-HCI pH 7.9,100 
mM NaCI and 25% acetonitrile. Peptide stock solutions were stored at -20°C and -80°C.
Peptide Name Peptide Sequence Residues
Elk-1  B box WT SSRNEYMRSGLYSTFTIQSLQ Elk-1  148-168
Elk-1  B box Y159A SSRNEYMRSGLASTFTIQSLQ Elk-1  148-168
MAL B1  A LKPKVKKLKYHQYIPPDQKQD MAL 229 - 249
MAL B1  B LKPKVKKLKYHQYIPPDQKQ MAL 229 - 248
MAL B1  C LKPKVKKLKYHQYIPPDQK MAL 229 - 247
MAL B1  D LKPKVKKLKYHQYIPPDQ MAL 229 - 246
MAL B1  E LKPKVKKLKYHQYIPPD MAL 229 - 245
MAL B1  F LKPKVKKLKYHQYIPP MAL 229 - 244
MAL B1  G LKPKVKKLKYHQYIP MAL 229 - 243
MAL B1  H KKLKYHQYIP MAL 234 - 243
MAL B1 J KKLKYHQYIPPDQKQD MAL 234 - 249
MAL B1  K VKKLKYHQYIPPDQKQD MAL 233 - 249
MAL B1  M KVKKLKYHQYIPPDQKQD MAL 232 - 249
MAL B1  N PKVKKLKYHQYI PPDQKQD MAL 231  - 249
MAL B1  P KPKVKKLKYHQYIPPDQKQD MAL 230 - 249
MAL B1  Q LKPKVKKLKAHQYIPPDQKQD MAL 229 - 249
MAL B1  R LKPKVKKLKYHQAIPPDQKQD MAL 229 - 249
MAL B1  S KKLKAHQYIP MAL 234 - 243
MAL B1Q KKAKELKPKVKKLKYHQYIPPDQKQDKGA
PATDSSYAKILQQQQLFLQLQILNQQQQQ
QQ
MAL 224 - 283
MAL B1Q Y238A KKAKELKPKVKKLKAHQYIPPDQKQDKGA MAL 224 - 283
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Peptide Name Peptide Sequence Reeldues
PATDSSYAKILQQQQLFLQLQILNQQQQQ
QQ
MAL B1Q3xA KKAKELKPKVKKLKYHQYIPPDQKQDKGA
PATDSSYAKIAQQQQLFAQLQALNQQQQ
QQQ
MAL 224 - 283
MC B1Q KKPKDPKPKVKKLKYHQYIPPDQKAEKSP 
PPM DS  A  Y  AR LLQQQQLFLQLQILSQQQQ 
QQQ
Myocardin 
247 - 306
MC B1QY261A KKPKDPKPKVKKLKAHQYIPPDQKAEKSP 
PPM DS  A  YAR LLQQQQLFLQLQILSQQQQ 
QQQ
Myocardin 
247 - 306
MC B1Q 3xA KKPKDPKPKVKKLKYHQYIPPDQKAEKSP
PPMDSAYARLAQQQQLFAQLQALSQQQQ
QQQ
Myocardin 
247 - 306
METHODS
All  water  used  was  deionised  on  a  Milli-Q  plus  system  (Millipore)  and,  where 
appropriate,  solutions  and  culture  media  were  sterilised  by  filtration  on  a  0.2  p,m
vaccum-driven filtration system (Stericup).
7.5  Bacterial Techniques
7.5.1  Bacterial media and plates
LB media  1% w/v Bacto-tryptone, 0.5% w/v Bacto-yeast extract,
1% w/v NaCI
LB agar  1% w/v Bacto-tryptone, 0.5% w/v Bacto-yeast extract,
1% w/v NaCI, 1.5% w/v Bacto-agar
217Chapter 7 Materials and Methods
Depending on plasmid antibiotic resistance 100 pg/ml Ampicillin, 30 pg/ml Kanamycin, 
or  34 pg/ml  Chloramphenicol  were  added  to  the  media  and  agar  plates  for  plasmid 
selection.
7.5.2  Bacterial strains
DH5a Invitrogen; used for all cloning manipulations
TOP10 Invitrogen; used for all cloning manipulations.
JM110 Stratagene; used for production of unmethylated DNA
Rosetta Novagen; used for expression of GST-fusion proteins
DE3 pLysS
7.5.3  Transformation of E. coli
7.5.3.1  Preparation of electrocompetent E. coll
A  single  colony  of  electrocompetent  E.  coli  previously grown  on  an  agar  plate,  was 
inoculated in a sterile flask containing  10 ml of LB media and grown overnight at 37°C 
at 200-220  rpm.  The  saturated  culture  was  divided  between two  1 1  flasks  containing 
500  ml of  LB  medium.  Cells  were  incubated  at  37°C with shaking  until they  reached 
ODeoo= 0.6.
The  cultures  were  then  chilled  on  ice  for  20  min  and  the  cells  were  collected  by 
centrifugation at 1200xg (4000 rpm) for 10 min at 4°C. The pellet was resuspended in 
ice-cold  10% glycerol  made  in  highly purified water and filtered  (resuspension volume 
was equal to the original culture volume) and incubated on ice for 20  min.  Cells were 
then  pelleted  by  centrifugation  at  4000  rpm  at  4°C  for  10  min.  The  wash  and 
centrifugation steps were repeated twice under the same conditions, reducing the pellet 
resuspension volume first to half and then to one quarter of the original culture volume. 
After the  third  wash  and  centrifugation  step,  as  much  supernatant  as  possible  was 
removed  and cells  were  gently  resuspended in  1/500 volume  (routinely 2ml  per  11  of 
original  bacterial  culture)  of  ice-cold  10%  glycerol.  This  bacterial  suspension  was
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divided into 40-200 \x\ aliquots in prechilled eppendorf tubes and snap-frozen on dry ice 
for 15 min before storing at -80°C.
7.5.3.2  Electroporation of DNA Into E. coll
40 pi of electrocompetent  bacteria were thawed on  ice and  mixed with  1pl of purified 
DNA dissolved in water or TE, or 1-2.5 pi of ligation mix. The suspension was placed in 
an  ice  cold  electroporation  cuvette  (BioRad  0.2  cm  separation)  and  cells  were 
subjected  to  an  electric  pulse  of  2.5  kV  (capacitance  setting  25  pF  and  resistance 
setting 200 Q) using  a  BioRad  Gene pulser with a pulse controller.  1   ml of LB  media 
was  immediately added to the cell  suspension which was incubated at 37°C for  1   hr. 
Cells  were  then  plated  on  LB  plates  containing  the  appropriate  concentration  of 
antibiotic, depending on plasmid antibiotic resistance.  For propagation of purified  DNA 
100 \i\ were plated.  For ligation samples, all the electroporated cell culture was plated: 
cells were pelleted by flash-spin centrifugation to 9000 rpm for 5 s and after removing 
all but 100-200 \i\ of media, cells were resuspended and plated.
7.5.3.3  Chemical Transformation of E. coll
Chemically  competent  E.  coli  JM110,  were  transformed  according  to  the 
manufacturer’s instructions (Stratagene).
7.6  Mammalian Cell culture
7.6.1  Cell culture media
E4 equivalent to DMEM
CRUK media production
Foetal Bovine Serum (FBS) Gibco BRL
OPTIMEM-1 Reduced Serum Medium, Gibco BRL
5 x Trypsin/Versene 2.5 g trypsin, 8 g NaCI,
1.15g Na2HP04,200 \ig KH2P04,
1  g versene (EDTA),
1.5 ml 1   % (w/v) phenol red
CRUK media production
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7.6.2  Cell lines
NIH3T3 A mouse fibroblast cell line 
(T  reisman Laboratory, CRUK)
SRE.FOS.HA An  NIH3T3  derived  cell  line  stably 
expressing  the  SRE.FOS.HA  construct. 
Described in (Alberts, A. S. etal., 1998).
7.6.3  General culture conditions
Cell lines were cultured on plastic dishes of tissue culture grade (Corning Incorporated 
and  Beckton  Dickinson) in an incubator (Innova Co-170,  New Brunswick Scientific) at 
37 °C and 10 % C02.  Cells were cultured in E4 supplemented with 10 % foetal bovine 
serum. All  media were warmed to 37 °C in a water bath before adding to the cells.  To 
remove cells from the flask, the cells were washed once with trypsin :versene and then 
incubated with trypsiniversene solution for 1-2 minutes at 37°C.
7.6.4  Transient cell transfection with Lipofectamine reagent
Transient cell transfections using the Lipofectamine reagent were performed according 
to  the  manufacturer’s  recommendations  (see  Table).  Transfections  for  luciferase 
assays and coverslip seeding for immunofluorescence assays were performed in 6-well 
plates, transfections for whole-cell extracts were in 60mm plates and transfections for 
co-immunoprecipitations in  10cm plates. Cells were seeded (see Table)  18-24 hr prior 
to  transfection,  in  E4  medium  supplemented  with  10%  FBS.  Transfections  were 
performed  the  following  day  as  follows:  the  DNA  and  Lipofectamine  Reagent  (see 
Table)  were  mixed  separately  with  Optimem-1  Reduced  Serum  Medium  and  left  at 
room  temperature  for  10  minutes.  After this  the  two  mixes  were  combined,  vortexed 
vigorously  and  allowed  to  incubate  at  room  temperature  for  30  minutes.  Cells  were 
washed twice in Optimem-1,  and the appropriate volume of Optimem-1  was added to 
each  dish  (see  Table).  The  transfection  mix  was  added  to  the  cells  and  they  were 
incubated  at  37°C  and  10%  C02 for  5  hr.  After 4-5  hr the transfection  solution  was
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replaced  with  starvation  media  (E4  +  0.3%  FCS).  Stimulations  of  cells  with  the 
appropriate stimuli were performed 18 - 24 hr later and prior to sample processing.
Plate
size
Number of 
cells per 
plate or well
[DNA]
Volume of 
Lipofectamine
Volume  of 
Optlmem
Volume of 
Optlmem on 
cells
6-well 1.5 x 105 1  1*9 6 p e l 200 pi 1500 pi
6 cm 3 x 105 2pg 12 pi 400pi 1500 pi
10 cm 1  x 106 2-4 ng 20 pi 1000 pi 4000 pi
7.6.5  Luciferase assay
Firefly  luciferase  was  measured  using  luciferase  reporter  assay  system  according 
manufacturer's recommendations  (Promega). Transfections for luciferase assays were 
performed using Lipofectamine reagent as described in section 7.6.4.  Routinely 40 ng 
3D.A.Iuc or 50 ng of the SRE.L2 or SRE.LM2 reporter plasmids were transfected with 
MAL or Myocardin expression plasmids (standard amounts were 50 ng).  150 ng of the 
MLV.IacZ reporter gene was co-transfected as an internal control for luciferase activity 
normalisation.  Each  experiment  included  a  sample  transfected  with  50  ng  of  the 
MLV.SRF.VP16,  for  normalisation  of  SRF  activity.  Where  necessary,  cells  were 
stimulated for 7 hr with the appropriate stimuli.  Cells were washed twice with  ice-cold 
PBS,  prior to  scraping  with  a  rubber  policeman  in  150  pi  1   x  Reporter  Lysis  Buffer 
(Promega).  After centrifugation at  13,000 rmp for 5 min to remove cell debris 20 //I of 
the supernatant was used to determine firefly luciferase activity. 45 pi Luciferase Assay 
Reagent  (Promega)  were  added  to  the  cell  lysates  in  a  Microtiter  plate  (Dynex 
Technologies,  Inc)  and  the  light  produced  was  measured  on  a  Microtiter  Plate 
Luminometer  (Dynex)  using  Revelation  Version  3.2  software.  The  activity  was 
normalised to  pgal  activity or to total  protein  measured with the  Biorad  protein  assay 
reagent (see section 7.8.2.1).
7.6.5.1  p-GAL assay
The  p-Galactosidase  assays for luciferase activity normalisation  were  performed  in  a 
96-well plate and contained 20 //I cell lysate,180 pi LacZ buffer (60 mM Na2HPO4.7H20,
221Chapter 7 Materials and Methods
40 mM NaH2P04 >   10 mM KCI, 1   mM MgS04, 2.7 ml/l B-mercaptoethanol) and 20 y\ of 4 
mg/ml O-Nitro-Phenyl-6-D-galactoside (ONPG).  Reactions were  incubated at 37°C for 
30  min,  or  until  the  colour  was  changed from  light to  dark yellow,  pgal  activity  was 
quantitated  spectrophotometrically  at  595  nm  using  a  SpectraMax  Plus
spectrophotometer (Molecular Devices).
LacZ buffer 60 mM NazHPO^HgO
40 mM NaH2P04
10 mM KCI
1   mM MgS04
2.7 ml/l p-mercaptoethanol
7.6.5.2  Mammalian reporter plasmids
3D.  A. LUC a  derivative  of 3D.ACAT (Mohun,  T.  et al.,  1987)  with  firefly 
luciferase  in  place  of the  CAT sequence.  Constructed  by  O. 
Geneste (Geneste, O. et al., 2002).
SREL2.LUC a  derivative  of  SRE.L2  (Hill,  C.  S.  et al.,  1994),  with  firefly 
luciferase  in  place  of  the  CAT  sequence.  Constructed  by 
Gemma Smith.
SRELM2.LUC a derivative  of  SRE.LM2  (Hill,  C.  S.  et al.,  1994),  with  firefly 
luciferase  in  place  of  the  CAT  sequence.  Constructed  by 
inserting  the  SRE.LM2  sequence  in  the  pGL3  (Clontech) 
luciferase reporter vector after digestion with Xho1.
MLVLacZ described in (Marais, R. etal., 1993).
7.6.6  Immunofluorescence assay
Cells were seeded in 6-well plates, each well containing 2-3 coverslips and transfected 
as described  in  section 7.6.4,  with  50 ng of MAL expression  plasmids.  Approximately 
24  hours  after  transfection  cells  were  stimulated  with  the  appropriate  stimuli  for  30 
minutes prior to processing.
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Cells were fixed in fresh 4% paraformaldehyde or formaldehyde in PBS, prewarmed to 
37°C,  for  15  min.  After washing  three times  with  PBS  cells  were  permeabilised  with 
0.2%  Triton  X-100  in  PBS  for  10  minutes.  Coverslips  were  blocked  with  Gelatin 
blocking solution for 30 min -  1   hr at room temperature and washed three times with 
0.2% Triton  X-100  in  PBS.  A piece of whatman  paper was  placed  in  a  plastic tissue 
culture  dish  and  after  wetting  it  with  water  a  piece  of  parafilm  was  placed  on  top. 
Primary  antibodies  were  diluted  in  Gelatin  blocking  solution  and  approximately  20  \i\ 
drops  were  placed  on  the  parafilm  sheet.  Each  coverslip  was  then  placed  on  the 
antibody solution  and  incubated for  1  hr at room temperature or 30  min  at 37°C.  After 
incubation coverslips were washed three times with 0.2% Triton X-100 in  PBS  before 
being  incubated  with  the  secondary  antibody  (and  other  staining  reagents  such  as 
phalloidin  and  DAPI)  following  the  procedure  described  for  the  primary  antibodies. 
Coverslips were washed three times with 0.2% Triton X-100 in PBS, followed by a final 
wash in water prior to mounting on glass slides. Slides were dried at 37°C for 1   hour or 
overnight  at  room  temperature.  Images  were  obtained  using  a  Zeiss  Axiovert 
microscope and Smart Capture system (Vysis  UK) and processed as PICT files  using 
Adobe photoshop CS2.
Endogenous gene expression  after MAL overexpression was performed  in essentially 
the same way,  with the exception that  150 ng of MALAN constructs were transfected, 
and cells were  kept under starvation conditions (1  mg/ml  BSA in  E4 media) for 48 hr 
prior to processing.
Immunofluorescence solutions
Gelatin blocking solution 1   % (v/v) Gelatin 
0.2 % (v/v) Triton X-100 
10 % FBS
10 % (w/v) Milk in PBS
mounting fluid 1  % (w/v) Mowiol 4-88 (Calbiochem)
2.5  %  (w/v)  1,4-diazabicyclo(2.2.2) 
octane antifade (Sigma)
25 % Glycerol
100 mM Tris-HCI pH 8.5
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Reagents used for Immunofluorescence analysis:
Primary antibodies
Antibody Specificity Species Concentration
Flag (Sigma) Flag Rabbit 1/300
M2 Flag (Sigma) Flag Mouse 1/200
SM a-actin (Sigma) SM a-actin Mouse 1/200
Egr-1  (Santa Cruz) Egr-1 Rabbit 1/50
Fos (Santa Cruz) Fos Rabbit 1/50
Secondary Antibodies
Antigen Conjugate Species Concentration
Rabbit IgG (Jackson Labs) FITC Goat 1/200
Mouse IgG (Jackson Labs) Cy2 Donkey 1/200
Rabbit IgG (Jackson Labs) Cy2 Donkey 1/200
Mouse IgG (Jackson Labs) Cy3 Donkey 1/500
Rabbit IgG (Jackson Labs) Cy3 Donkey 1/500
Cell staining reagents
Reagent Cell component Concentration
Phalloidin toxin 
TRITC-conjugated 
(Molecular Probes)
F-actin 1/100
4',6-diamidino-2-phenylindole 
stain (DAPI)
DNA 1/10000
7.7  Nucleic Acid Manipulations
7.7.1  Purification of plasmid DNA
To  prepare  plasmid  DNA,  a single  antibiotic-resistant colony was  picked  and  used to 
inoculate  either  4  ml  (small-scale  preparation,  miniprep)  or  200  ml  (large-scale 
preparation,  maxiprep)  of  LB  containing  the  appropriate  plasmid  selection  antibiotic. 
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using QIAprep spin  miniprep kit (Qiagen) according to the  Manufacturers’ instructions 
or by the CRUK Equipment Park Miniprep service using the Qiagen Biorobot 9600.  For 
maxipreps, the  DNA was  isolated using a Plasmid  Maxi  Kit (Qiagen) according to the 
Manufacturers’ instructions.
7.7.2  Quantitation of Nucleic Acid concentration
The concentration  of  purified  double  stranded  DNA was quantified  by  measuring  the 
OD  at  260nm  of  a  DNA  sample  diluted  by  1/100  in  water,  on  an  LKB  Biochrom 
Ultraspec  II  spectrophotometer.  1   absorbance  unit  at  260  nm  corresponds  to  a  50 
pg/ml  double  stranded  DNA  solution,  therefore  the  following  equation  was  used  to 
obtain the concentration of the DNA in pg/pl:
(OD reading x dilution factor x 50 ng/ml) + 1000 
The  purity  of  the  sample  was  estimated  by  measuring  the  OD  at  280.  A  ratio 
(ODzeo/ODzso) of ^ 1.8 but £ 2.0 is an indication of pure DNA.
7.7.3  Agarose gel electrophoresis
Agarose gels  (0.8-2.5%)  were  prepared  in  1xTBE with 0.5-2 ng/ml ethidium  bromide. 
The molten gel was poured into a sealed gel tray with the appropriate gel comb(s) and 
allowed to set at room temperature.  All gels were run in 1xTBE with a 1kb DNA ladder 
(New  England  Biolabs;  NEB)  at  120-150  volts  for  30min-1hr.  Visualisation  and 
photography of gels was by ultraviolet illumination using a UVP 2UV Transilluminator.
Agarose gel loading buffer 0.01  % w/v OrangeG
5 % Glycerol in TBE buffer
7.7.4  Cloning Techniques
For cDNA  subcloning,  the  appropriate  DNA fragments  were  generated  by  restriction 
enzyme  digestion  from  the  original  constructs  when  possible  and  ligated  into 
appropriately  R.E.  digested  vectors.  Otherwise for other cloning  procedures  including 
generation of mutants  by site-directed  mutagenesis, the desired  DNA fragments were 
produced  by  Polymerase  Chain  Reaction  (PCR)  with  oligonucleotides  containing 
appropriate  restriction  enzyme  sites,  and  ligated  into  the  chosen  vectors.  All  PCR-
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generated  fragments  were  verified  by  DNA  sequencing.  Descriptions  of  the  main 
methods used in all cloning procedures follow.
7.7.4.1  Purification of DNA fragments from enzymatic reactions
After  enzymatic  reactions,  such  as  PCR,  restriction  enzyme  digestion  and  DNA 
dephosphorylation,  DNA  fragments  were  purified  using  either  the  QIAquick™  or 
MinElute  PCR  purification  Kit  (Qiagen)  according  to  the  manufacturer’s 
recommendations.
7.7.4.2  Gel extraction of DNA fragments
Reactions  that  generated  more  than  one  DNA  species  were  electrophoresed  on 
agarose gels and the appropriate band excised from the gel with a scalpel using a low 
power UV lamp (365  nm).  The  DNA was extracted from the gel slice using either the 
QIAquick™  or  MinElute  Gel  Extraction  Kit  (Qiagen)  according  to  the  manufacturer’s 
recommendations.
7.7.4.3  Polymerase Chain Reaction
PCR was used to amplify cDNA for subcloning and also for the production of mutants 
by site-directed mutagenesis (see below). Oligonucleotide primers were designed to be 
21-36 mers depending on their purpose. Additionally,  some primers were designed to 
incorporate restriction sites or the desired changes for introducing mutations.
Standard 50 pi PCR reactions contained:
1   pi of 100 ng/pl template DNA 
1   pi each of 10 pmol forward and reverse primers 
4 pi of 2.5 mM dNTPS
2.5  units DNA polymerase (Pfu or Proofstart) 
in  1xPCR  buffer  (10  mM  KCI,  20  mM  Tris-HCI  pH8.8,  2  mM  MgS04,  10  mM 
(NH4)2SQ4,100pg/ml BSA, 0.1  % Triton X-100).
PCRs were carried out in a Biometra TRIO-thermoblock thermal cycler.
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Standard amplification conditions were as follows:
94°C 5 min
94°C 1 min 1
47-55°C 30 s -1  min \  x 30 cycles
72°C 1 min J
72°C 10 min
4°C 0 0
After  PCR,  1/10th   of the  reaction  were  run  on  an  agarose  gel  to  verify  PCR  product 
generation.  Depending on the expreriment the rest of the reaction was purified directly 
or gel extracted after agarose gel electrophoresis
7.7.4.4  Site directed mutagenesis
Primers  were  designed  on  both  strands  of  DNA  that  overlapped  the  region  to  be 
mutated.  The  mutation  was  centrally  located  within  a  primer,  and  was  flanked  either 
side by 15-18 bases of wild type sequence.  Primers were also designed at locations 5' 
and  3'  of  the  mutation  which  included  unique  restriction  enzyme  sites.  Two  PCR 
reactions  were  set  up  as  described  above,  in  both  cases  1   primer  containing  the 
mutation  and  the  corresponding  primer  containing  the  restriction  enzyme  site.  The 
products from the first  round  of  PCRs  were analysed  by agarose gel  electrophoresis, 
and purified in 10 \i\ final volume.  1   \x\ of each first round PCR was used as template for 
a  second  round  of  PCR  with  the  two  outer  primers  flanking  the  mutation  site.  This 
product  was  again  analysed  on  an  agarose  gel  and  the  correct  DNA  fragment  was 
purified.  After restriction  enzyme  digestion,  the  DNA fragment was purified again and 
ligated  into  the  appropriate  restriction  enzyme  digested  and  phosphatase  treated 
construct to generate a mutation within a wild type cDNA.
7.7.4.5  Restriction enzyme digestion
Restriction enzyme digestions were performed for 1-2 hr in the appropriate NEB buffer, 
at 37°C, unless recommended otherwise by the manufacturer.  10 pi of reaction mixture 
and  1   unit of enzyme were used  per microgram of DNA.  Cleavage was  monitored  by 
agarose gel electrophoresis.  If the  DNA fragment was required for further subcloning,
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the  reaction  was  either  purified  directly or electrophoresed  and  the correct fragment 
subsequently extracted from an agarose gel.
7.7.4.6  Dephosphorylation of DNA fragment ends
5' phosphate groups were removed from digested vectors that were going to be used 
for subcloning  in  order to  prevent religation using calf intestinal  alkaline  phosphatase 
(CIP). The enzyme was added to the DNA directly after restriction enzyme digestion in 
one of the NEB buffers recommended by the manufacturer and incubated for 30 min -  
1   hr at 37 °C prior to purification.
7.7.4.7 DNA Ligation
10 pi  ligation  reactions  were  carried  out  using  approximately  250  -  500  ng  of vector 
DNA, cut and treated with phosphatase, with a 3 fold molar excess of insert DNA and 
200 units of T4 DNA ligase in  1   x T4 DNA ligase buffer (NEB) at 16°C overnight or at 
room temperature for 30  min.  1.5-2.5  \i\  of the ligation  mixture were transformed  and 
plated on agar plates (see section 7.5.3.2). Colonies formed were cultured the following 
day  for  miniprep  DNA  purification.  Succesfuly  ligated  constructs  were  identified  by 
restriction enzyme digestion and/or sequencing of miniprep DNA.
7.7.4.8  Sequencing
Sequencing  reactions  were  carried  out  according  to  the  ABI  PRISM  Dye  terminator 
cycle sequencing kit. 150-200 ng of plasmid was mixed with 3.2 pmol of primer and 8 pi 
of Perkin Elmer Dirhodamine big dye terminator cycle mix (BDT versions 1.1  or 3.1) in 
a 20 pi reaction.
Thermal cycling was as follows:
96°C 5 min
96°C 30s 1
50°C 15s \ x 25 cycles
72°C 4 min J
4°C 0 0
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Unincorporated  dye terminators were removed from  sequencing  reactions  by ethanol 
precipitation:  2  pi  of 0.125  mM  EDTA and 2 pi of 3M  NaOAc  pH  5.2  and  50  pi  96% 
Ethanol  were  added  to  the  PCR  reactions  and  products  were  precipitated  at  room 
temperature for 15 min.  Samples were centrifuged at 4 °C for 30 min, washed in 50 pi 
70% ethanol and after a second centrifugation step the pellet was dried. Sequencing of 
precipitated  DNA  products  was  performed  by the  sequencing  service  of  the  Cancer 
Research  UK  Equipment  Park.  DNA sequences were analysed  using  an  ABI  PRISM 
377 DNA sequencer.  Sequence analysis was conducted with ABI Sequence Navigator 
and 4Peaks software.
7.8  Protein Manipulations
7.8.1  Protein production
7.6.1.1  Preparation of whole-cell extracts for gel moblllty-shlft assay
Transfections  for  whole-cell  extracts  used  in  bandshifts  were  performed  using 
Lipofectamine  reagent  as  described  in  section  7.6.3.  Routinely  1-2  pg  of  expression 
plasmids were transfected.  Where required stimulations of cells were performed for 30 
minutes  prior  to  extract  preparation.  Cells  were  washed  twice  with  ice-cold  PBS, 
ensuring  all  PBS  is  removed  after the  second  wash  before adding 80-100  pi  of  D0.4 
lysis  buffer to each  plate.  Cells were  scraped  into  1.5  ml  micro-centrifuge tubes,  and 
centrifuged at 13 000 rpm at 4°C for 5 min to remove cell debris. The supernatant was 
transferred  to  a  cold  microcentrifuge  tube  and  stored  at  -80°C.  Total  protein 
concentration was determined  using the  Bradford protein assay (see section 7.8.2.1). 
Concentrations  were  in  the  range  of  1.5-3  pg/pl  protein  solution.  Approximately  2 
pg/pl were used for electrophoretic mobility shift analysis. The expression levels of the 
proteins  of interest were verified  by  using  5-10  pi of extract for western  blot analysis 
(section 7.8.2.3).
D0.4 lysis buffer 20 mM HEPES pH 7.9
10% Glycerol
0.4 M KCI
0.4% tritonX-100
10 mM EGTA
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5 mM EDTA 
5 mM NaF 
1  mM DTT
Phosphatase and protease inhibitors and DTT were added fresh before use.
Protease/phosphatase inhibitors used were: 
Pepstatin, Leupeptin,
Aprotinin, Okadaic acid 10 mg/ml stock in water, 
used at 1/1000 dilution 
0.5mM stock in ethanol, 
used at 1/200 dilution
PMSF
7.8.1.2  Preparation of whole-cell extracts for western blot analysis
Transfections  for  whole-cell  extracts  used  in  western  blot  analysis  were  performed 
using  Lipofectamine  reagent  as  described  in  section  7.6.3.  Routinely  1-2  jig  of 
expression  plasmids  were transfected.  Cells  were washed  twice  using  ice-cold  PBS, 
80-100 /;l of 1x SDS sample buffer was added and the cells were scraped off the dish 
using a 'rubber policeman'.  5-10 /yl of extract was loaded per lane.
7.8.1.3  GST-fuslon protein production
A fresh transformant of the GST fusion protein was used to inoculate a 10 ml preculture 
of LB media containing the appropriate antibiotics (chloramphenicol and kanamycin for 
MAL  GST-fusions)  and  1   %  glucose  to  avoid  premature  induction.  The  culture  was 
grown  overnight  in  a shaking  incubator at 37  °C  and  was  diluted  1/200 the following 
day in the same  media.  This  large-scale culture was grown to an ODq o o  of 0.6 before 
induction  with  0.5  mM  IPTG  for  5  hr  at  25°C.  The  culture  was  then  centrifuged  at 
4000xg for 15 minutes at 4 °C, and the pellet was lysed in a suitable volume of ice cold 
Lysis  Buffer  (routinely  1/10  of  the  original  culture  volume)  and  was  sonicated  three 
times for  1   minute  on  ice  and  at  maximum energy,  on  a SANYO  Soniprep  150  MSE 
sonicator.  The  sonicated  culture  was  centrifuged  at  30,000xg  for  30  min  and  the 
supernatant was  respun  under the same conditions for a further 15  min to remove all 
cell  debris.  The supernatant  was  added to glutathione-agarose  bead  1:1  slurry  (1  ml 
per litre of culture) pre-equilibrated by washing twice with Lysis buffer and incubated on
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a rotor for 4 hours at 4 °C.  The beads were centrifuged at 1500 rpm for 1   minute at 4 
°C and washed twice with 10-15 ml of Lysis Buffer followed by a third wash with room 
temperature ATP  Buffer to remove the bacterial chaperone proteins.  The  beads were 
washed again with Lysis Buffer and 500 \i\ of Glutathione Elution buffer were added to 
the  beads  which  were  incubated  at  4°C  on  a  rotor  for  1   hour.  The  beads  were 
centrifuged  at  3500  rpm  for  1   minute at 4  °C,  the supernatant was transferred to  an 
eppendorf,  and  the  elution  procedure  was  repeated.  The  eluates  were  pooled  and 
dialysed  against  Dialysis  buffer  (1  litre of  Dialysis  buffer per  1  ml  of  protein  solution) 
using  Slide-A-Lyzer dialysis cassettes  (Pierce)  pre-equilibrated  in water.  Dialysis was 
overnight at 4°C with one  buffer change  and further dialysis for 4 hours the following 
day.  Proteins were then visualised  by Coomassie staining  after SDS electorphoresis. 
Protein  concentration  was  determined  by comparison  to  a set of  BSA standards  run 
alongside, using in parallel the Bradford assay (section 7.8.2.1).  Purified proteins were 
stored at -80°C.
GST Lysis Buffer 50 mM Tris-HCI pH 7.9 
100 mM NaCI 
1   % Triton X-100 
1 mM EDTA 
1  mM PMSF 
1   mM DTT
15 ng/ml Benzamidine
ATP wash Buffer 50 mM Tris-HCI pH 7.5 
50 mM KCI 
20 mM MgCI2  
5 mM ATP 
1   mM DTT
GST Elution Buffer 50 mM Tris-HCI pH 7.9 
100mM NaCI 
1  % Triton X-100 
1   mM EDTA 
1   mM PMSF 
1   mM DTT
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15 pg/ml Benzamidine
Dialysis Buffer 15 mM Tris-HCI pH 8.8 
100mM NaCI
10 mM Glutathione (30 mg/10 ml) 
1 mM DTT
Benzamldine at 10 mg/ml stock in water
ATP 0.2 M stock (in 200 mM NaOH and 
5 mM Tris pH 8.8)
7.8.1.4  In vitro protein translation with Reticulocyte lysate systems
Protein was  prepared  using the TNT Coupled  Reticulocyte  Lysate System  (Promega) 
according to the  manufacturer’s  instructions.  After in vitro translation  Ribonuclease  A 
(0.2 mg/ml final concentration) was added to the 50 pi reticulocyte lysate reactions, and 
samples were  incubated at 30°C for 5  minutes.  A sample of each  reaction  (3  pi)  was 
boiled  in  2x  SDS  sample  buffer  and  separated  on  a  16  %  SDS  gel  (see  section 
7.8.2.2).  Protein yield and integrity was analysed by western blotting (section 7.8.2.3). 
In vitro translated protein samples were stored at -80°C. 0.5-2 pi of sample were used 
in  gel  mobility-shift  assays,  while  co-immunoprecipitation  and  pulldown  assays 
contained whole 50 pi reactions.
7.8.2  Protein Analysis
7.8.2.1  Protein concentration quantitation (Bradford assay)
Protein  concentration  was  measured  using  200  pi  of  a  1   in  5  dilution  of  the  Biorad 
Protein Assay reagent. A standard curve was prepared by making dilutions of a stock 
BSA solution (NEB). 1   pi of the sample whose concentration was to be determined was 
used  in the assay,  which was  performed according to the  manufacturer’s instructions. 
The  OD  was  measured  at  595  nm  using  a  SpectraMax  Plus  spectrophotometer 
(Molecular  Devices).  The  protein  concentration  of  the  sample  was  then  determined 
from the BSA standard curve.
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7.B.2.2  SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Proteins  were  separated  according  to  their  size  by  SDS-PAGE  using  a  minigel 
apparatus  (ATTA).  6  ml  of  resolving gel  (9 or  10 % gels were  used  for  MAL  protein 
separation  and  16%  for  SRF  DNA  binding  domain  derivatives;  see  table  for 
composition)  was  poured  between  two  glass  plates  and  the  surface  overlaid  with 
methanol to ensure a level, air-free polymerisation interface.  Following polymerisation, 
the  methanol  was  removed,  the  stacking  gel  mix  (see  table  for  composition)  was 
poured on top of the resolving gel and a plastic comb was inserted between the plates 
to produce the wells.
Resolving gel Stacking gel
Percentage 9% 10% 16%
40% acrylamide/
bisacrylamide
(37.5:1)
3.38 ml 3.75 ml 6.0 ml 1.27 ml
1   M  Tris-HCI  (pH 
8.8)
5.65 ml 5.65 ml 5.65 ml
1   M  Tris-HCI  (pH 
6.8)
1.25 ml
10 % (w/v) SDS 150 |xl 150 \i\ 150 til 100 \i\
Water 5.66 ml 5.29 ml 3.05 ml 6.37 ml
50 % Glycerol - - - 0.9 ml
10 % (w/v) APS 150 jxl 150 \i\ 150 [il 100 \i\
TEMED 15 p -l ^5\l\ 15 til 10fil
After  polymerisation  the  comb  and  plastic  seals  were  removed  and  the  wells  were 
washed with water and  1   x SDS running buffer. Samples were boiled for 5 min in SDS 
sample  buffer to denature  proteins  before  loading.  Protein  molecular weight  markers 
(Rainbow markers: Amersham) were included in all experiments. Gels were run at 120- 
ISO V in SDS  running  buffer until the dye front was run off the gel.  After SDS-PAGE, 
gels were either stained with  Coomassie blue stain for 30 minutes and then destained 
(multiple washes with destain solution on a shaker) to visualise the proteins or used for 
Western blot analysis of the proteins (section7.8.2.3).
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SDS-PAGE buffers and solutions
1 x SDS running buffer 192 mM glycine 
25 mM Tris base pH 8.3 
0.1 % SDS
2 x SDS sample buffer 125 mM Tris-HCI pH 6.8 
4%  SDS 
20 % glycerol 
2% p-mercaptoethanol 
0.01  % w/v bromophenol blue
Coomassie stain 0.5 % (w/v) Coomassie blue dye 
40 % (v/v) methanol 
7 % (v/v) acetic acid
Destain solution 40 % (v/v) methanol 
7 % (v/v) acetic acid
7.8.2.3  Western Blot analysis
Following  electrophoresis,  proteins  were  transferred  onto  PVDF  membranes  (pre­
soaked in methanol; Amersham) or nitrocellulose membranes (Whattman) sandwiched 
between Whatmann 3MM paper.  Protein transfer was carried out at room temperature 
for  1   hr  at  250-300  mA  using  a  Mini  Trans-Blot  Cell  (Biorad)  with  western  blotting 
transfer buffer kept cool with an ice pack.
Following transfer the  membrane  was  incubated  in  5  %  milk-blocking  solution  for 30 
minutes at room temperature to block non-specific binding of antibody to filter. Next the 
membrane was incubated with the primary antibody in 2 % milk-biocking solution for 1  
hour at  room temperature  or overnight  at 4°C on  a  rocking  platform.  The  membrane 
was then washed twice for 15 minutes in 1   % milk-blocking solution prior to incubation 
with  a secondary antibody  conjugated to  horseradish  peroxidase  (HRP)  in  2  %  milk- 
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15  minutes  in  1   %  milk-blocking solution,  and then twice for  15  min  in  PBS  and the 
HRP  was  detected  with  ECL  Western  blotting  detection  reagents  (Amersham 
Pharmacia  Biotech).  ECL  solutions  A  and  B  were  mixed  at  1:1  ratio  and  5  ml  were 
added  to  the  membranes  for  1   min.  Excess  liquid  was  removed,  and  the  filter  was 
exposed to Amersham ECL Hyperfilm.
For  the  HRP-conjugated  primary  antibodies  (anti-HA-HRP  and  anti-Flag-HRP),  after 
blocking the membrane was incubated with the appropriate dilution of antibody for 1   hr 
at room temperature  or overnight at 4°C  before washing twice for  15  minutes  in  1   % 
milk-blocking  solution,  and  detection  with  ECL  Western  blotting  reagents  was  as 
described above.
Western blotting buffers and solutions
Western blotting transfer buffer 192 mM glycine
25 mM Tris base,
20 % methanol
5 % milk-blocking solution 5 % (w/v) milk powder (Marvel)
0.5 % (v/v) Triton X-100 in PBS
Antibodies used for western blotting analysis:
Primary antibodies
Antibody Specificity Species Concentration
9E10 (Cancer Research UK) Myc Mouse 1/1000
M2 Flag (Sigma) Flag Mouse 1/2000
Flag-HRP (Sigma) Flag Mouse 1/500
HA-HRP3F10 (Roche) HA Rat 1/500
Secondary Antibodies
Antigen Conjugate Species Concentration
Rabbit IgG (DAKO) HRP Goat 1/2000
Mouse IgG (DAKO) HRP Goat 1/2000
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7.8.2.4  Membrane stripping
To strip  membranes of antibodies, they were incubated  in glycine stripping  buffer (25 
mM  glycine,  pH  2.5,  0.1  %  SDS)  for  30  minutes  at  room  temperature  with  gentle 
agitation. The membrane was then washed twice for 15 minutes with PBS and blocked 
for 30  minutes  with  5  %  milk  blocking  solution,  before  proceeding  normally  with  the 
primary antibody.
7.Q.2.5 Protein co-immunoprecipitation assay
Cells in 10 cm dishes were lysed in 300 -1000 jil RIPA buffer containing freshly added 
protease  inhibitors  (Complete  protease  inhibitor  cocktail  -   Roche).  Lysates  were 
centrifuged at 13,000 rpm for 20 minutes at 4 °C. The supernatant was transferred to a 
sterile  pre-chilled  eppendorf and  diluted  1/2 with  1   % TX  buffer.  40  \i\  samples  were 
retained for use as controls.  The supernatant was then incubated with 20 nl Anti-Flag 
M2  or Anti-myc  Affinity  Gel  beads  (Sigma),  pre-equilibrated  in  1%  TX  buffer,  for 2-4 
hours  at 4 °C with  rotation.  The  beads were washed three times with  1   % TX  buffer, 
resuspended  in  2  x  SDS  sample  buffer and  Western  blotted  to  visualise  associated 
proteins.  MAL-SRF  co-immunoprecipitations  in  the  presence  of  DNA  included  non­
radioactive c-fos promoter PCR products produced as described in section 7.9.1.4 and 
purified as described in section 7.7.4.1.
Co-lmmunopreclpltatlon buffers
RIPA buffer 20 mM Tris-HCI pH 7.9 
150 mM NaCI 
1   mM EDTA 
5 % Glycerol 
1  % Triton X-100 
0.5 % Deoxycholate 
0.1 % SDS
1 % TX buffer 20 mM Tris-HCI pH 7.9 
150 mM NaCI 
1   mM EDTA 
5 % Glycerol 
1   % Triton X-100
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7.8.2.6  G ST-protein pulldow n assay
10pg of purified GST-MAL proteins (section 7.8.1.3) were incubated with  100pl in vitro 
translated SRF.DBD (section 7.8.1.4) and 30pl Glutathione Sepharose beads (washed 
once  in  pulldown  buffer)  in  500pl  pulldown  buffer  for  4hr  at  4°C  with  rotation.  After 
washing twice with 500 pi of pulldown buffer and discarding the supernatant the beads 
were  resuspended  in  20  pi  2x  SDS sample  buffer and  proteins  were fractionated  on 
16% gels as described in section 7.8.2.2. GST-MAL input was visualised by Ponceau S 
staining, and recovery of SRF.DBD by immunoblotting (section 7.8.2.3).
Pulldown buffer 50 mM Tris-HCI pH 7.9
150 mM NaCI
0.1 % Triton X-100
protease inhibitors were added fresh
Ponceau S solution 2 % (w/v) Ponceau S
30 % (v/v) trichloroacetic acid
7.9  Protein-DNA interaction analysis
7.9.1  Gel mobility-shift assay
Bandshift  assays  (Electrophoretic  Mobility  Shift  Assays  -   EMSA)  were  used  to 
investigate protein-DNA interactions.  Two glass plates (19 cm x 20 cm) one of which 
had  previously  been  siliconised  with  Dimethyldichlorosilane  solution  were  assembled 
with 1.5 mm plastic spacers and sealed with electrical tape. Non-denaturing acrylamide 
gel  mix (50  ml) was then  poured  between the plates and a  1.5 mm  plastic comb was 
inserted between the plates to produce the wells. 4% gels were routinely used for MAL 
whole-cell  extract  bandshifts,  circular  permutation  analysis  was  performed  with  5  % 
gels and 8 % gels were used for MAL peptide -  SRF.DBD bandshifts.
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Non-denaturing acrylamlde gel composition
Percentage 4% 5% 8%
40% (w/v) acrylamide 6 ml 7.5 ml 12 ml
1   x TBE 3 ml 3 ml 3 ml
Water 50 ml 49.5 ml 44 ml
10 % (w/v) APS 58 pi 58 pi 58 pi
TEMED 700 pi 700 pi 700 pi
After gel polymerisation the comb and tape were removed and the gels were mounted 
on the gel electrophoresis tanks (Cambridge). The wells were rinsed with 0.5 x TBE to 
removed unpolymerised gel mix.  Bandshift gels were pre-run at 170 Volts for 1-2 hours 
in 0.5 x TBE at room temperature prior to sample loading.
Bandshift binding  reactions containing different combinations of whole-cell extract (up 
to 2.5 pi cell extract; see section 7.8.1.1),  recombinant SRF DNA binding domain (5 -  
10 ng/pl) and in vitro translated proteins (usually 1   pi of reticulocyte lysate) were mixed 
with 5 pi 2 x DBB to a final volume of 9 pi. Recombinant SRF DNA-binding domain was 
either the  SRF  (residues  133-265)  fragment  (previously  produced  in  baculovirus  and 
purified in the Treisman lab) or the SRF(132-223) fragment ((Pellegrini,  L.  et al.,  1995) 
produced in E. coli from the pET3a vector and purified by the CRUK protein production 
lab).  Reactions  were  incubated  on  ice  for  5  min  before  addition  of  0.25  -  1   ng/pl 
radiolabelled  DNA  probe  and  further  incubation  for  15  min  at  room  temperature. 
Bandshift  loading  buffer  was  then  added,  and  samples  were  loaded  onto  the  non­
denaturing polyacrylamide gel.  Gels were run for the appropriate length of time at  170 
Volts before being transferred onto 3MM Whatman paper and dried on a gel drier at 80 
°C  for  45  minutes.  The  bandshift  was  visualised  by  overnight  exposure  on  KODAK 
Biomax Film at -80°C.
Bandshift buffers and solutions
2xDBB 2 mM EDTA
20 mM Tris-Hcl pH 7.9
100 mM NaCI,
1   mM DTT
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100 ng/ml BSA
50-200 ng/nl poly(dl-dC)*poly(dl-dC)
Bandshift loading buffer 60 % Glycerol
10 mM EDTA
0.01 % w/v Xylene cyanol
0.01 % w/v bromophenol blue
poly(dl-dC)* poly(dl-dC) 1  mg/ml stock made in TEN
The solution was heated to 72°C for 5-10 minutes to anneal and was allowed to cool
at  room  temperature  for  30  min  before  sonicating  twice  for  15  seconds  at  3/4
maximum energy to ensure fragment sizes between 200 -  400 bp
7.9.1.1  Supershift assays
Supershift  assays  were  performed  as  described  in  section  7.9.1.  Appropriate 
antibodies  were  added  to  bandshift  reactions  and  incubated  with  the  protein  for  10 
minutes on ice prior to addition of the DNA probe. The following antibodies were used: 
anti-Flag M2 (Sigma), anti-SRF (Santa Cruz), anti-MAL (raised against MAL residues 1  
- 170 by the CRUK antibody production facility (Miralles,  F.  et a/., 2003)).  0.2 -  0.4 ng 
of antibody was used per reaction.
7.9.1.2 Peptide competition bandshifts
Peptide competition bandshifts were performed as described in section 7.9.1.  Peptides 
were  added  to  bandshift  reactions  containing  the  proteins  of  interest  and  reactions 
were incubated for a further 5 minutes on ice prior to addition of the DNA probe.  For a 
description of the composition  of all  peptides used in  bandshift reactions,  see section
7.4.
7.9.1.3  MAL peptide -  SRF.DBD bandshifts
Peptide  bandshifts  were  performed  as  described  in  section  7.9.1.  Peptides 
(concentrations  ranging  from  0.014  -  20  jiM)  were  added  to  bandshift  reactions 
containing in vitro translated SRF.DBD and reactions were incubated for 5 minutes on
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ice prior to  addition  of the  DNA probe.  Complexes were  resolved  on 8%  native gels. 
For a  description  of the  composition of all  peptides  used  in  bandshift  reactions,  see 
section 7.4.
7.9.1.4  Generation of Bandshift DNA probes
Probes were labelled with [a^P] dCTP and generated by PCR.
20 pi PCR reactions contained:
2 pi 10 x Biotaq buffer (Bioline)
2 pi MgCI2 (15mM)
2 pl d(A, G and T)TP (500pM)
2 pl dCTP (200pM)
4 pl [a**P] dCTP (3000pCi)
2 pl Forward oligonucleotide (7pmol/pl)
2 pl Reverse oligonucleotide (7pmol/pl)
1  pl DNA template (50 ng/pl)
0.5 pl BioTaq polymerase (1  u/pl)
2.5  pl H20
Thermal cycling was:
95 °C 2 min
95 °C 1   min 1
65 °C 1  min ^   x 30cycles
72 °C 1   min J
72 °C 5 min
4 °C 0 0
The PCR product was precipitated  by incubation with an equal volume of 5M NH4OAc 
and 8 volumes of 95 % ethanol at -20°C for at least 1   hr. The precipitant was washed 
before loading on  a 5 - 7%  non-denaturing polyacrylamide gel  in TBE buffer.  The gel 
was run at 170 V for approximately 2 hours and then subjected to autoradiography with 
MXB  Film  (Kodak) for 1   -  2  minutes to identify the location of the  probe band on the 
gel.  Identified  probe  bands  were  excised  from  the  gel,  and  probe  was  extracted  by
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overnight  by  incubation  with  450  \i\  probe  extraction  buffer  at  37°C.  The  probe  was 
precipitated with 2.5 volumes of ethanol, washed with 70 % ethanol, air dried and then 
dissolved in TEN. The amount of hot probe was quantitated by Cerenkov counting of 1  
\i\ of the product. 0.5 -  1   ng/^l was used per electrophoretic mobility shift sample.
Bandshift probe loading buffer 60 % Glycerol
10 mM EDTA
0.01  % w/v Xylene cyanol
0.01  % w/v bromophenol blue
Probe Extraction buffer 0.5 M NH4OAc
1   mM EDTA
7.9.1.5  Probe Quantitation
The amount of PCR product was quantitated by calculating the Decay Factor of the 32P 
dCTP  stock:  Decay  Factor  32P  =  exp*-00485 x  x ).  This  was  then  used  to  calculate  the 
specific activity of the PCR product in cpm/pg using the following equation:
Specific Activity = 40 (ptCi) x 106 (Cerenkov cpm/^Ci) x Decay Factor
20 (nl) x 40 (pmol/ \i\) x 4 (dNTPs)
1   (xl of the resuspended probe was counted in a scintillation counter and the cpm value 
was divided by the specific activity to give the amount of probe in pg/fxl.
7.9.1.6  c-fos plasmids used for bandshift DNA probe construction
FOS.WT  pF711, described in (Treisman, R., 1985).
FOS.M  pF711  derivative, described in (Hill, C. S. etal.,  1995b).
FOS.L  pF711  derivative, described in (Hill, C. S. etal.,  1995b).
Also called FOS. ATCF
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7.9.7.7  Oligonucleotides used for bandshift DNA probe construction
The  table  that  follows  lists  the  oligonucleotides  used  to  generate  bandshift  probes, 
including  their  sequences  and  probe  names.  Oligonucleotide  pairs  used  for  circular 
permutation probes are numbered and designated F and R (forward and reverse). The 
wild-type  FOS  probe  generated  with  oligos  P10  and  P11  was  also  used  in  circular 
permutation analysis.  Generation of nested probes used forward oligos CP1  F,  CP1.3 
F, CP1.6 F, CP1.9 F and CP2 F with reverse oligo CP5 R for one set and forward oligo 
P10 with reverse oligos CP6 R, CP6.3 R, CP 6.6 R, CP6.9 R and CP7 R for the other 
set. Nested probes are named after the number of oligonucleotides between the centre 
of the SRF CArG box and the closest fragment end.
Probe Oligo pair Oligonucleotide sequence
FOS.(WT,  L, 
M and LM)
P10 (forward) CGCACTGCACCCTCGGTGTTGGCTGC
P11  (reverse) ATGGCTCCCCCCAGGGCTACAGGGAAA
CP1 CP1  F AC  ACAGG  AT  GTCC  ATATT  AGG  ACAT
CP1  R GAGCATTTCGCAGTTCCTGTCTCAG
CP2 CP2F CCT  CCCCCCTT  AC  ACAGG  AT  GTCC  A
CP2R AGTTCCTGTCTCAGAGGTCTCGTGG
CP3 CP3F TCCCGTCAATCCCTCCCCCCTTACA
CP3R CAGAGGTCTCGTGGGCCCCCCAAGA
CP4 CP4F CCGCGAGCAGTTCCCGTCAATCCCT
CP4R TGGGCCCCCCAAGATGAGGGGTTTC
CP5 CP5F TTGGCTGCAGCCCGCGAGCAGTTCC
CP5R AGATGAGGGGTTTCGGGGATGGCTC
CP6 CP6F CCGTTCCCGCCTCCCCTCCCCCAGC
CP6R GACGCAGATGTCCTAATATGGACAT
CP7 CP7F CCCCTCCCCCAGCCGCGGCCCCCGC
CP7R TGGAAACCTGCTGACGCAGATGTCC
CP8 CP8F GCCGCGGCCCCCGCCTCCCCCCGCA
CP8R GGGAAAGGCCGTGGAAACCTGCTGA
(-16) CP1  F AC  ACAGG  ATGTCCATATTAGG ACAT
CP5R AGATGAGGGGTTTCGGGGATGGCTC
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Probe Oligo pair Oligonucleotide sequence
(-19) CP1.3 F CTTACACAGG  ATGTCCAT  ATT  A
CP5R AGATGAGGGGTTTCGGGGATGGCTC
(-22) CP1.6 F CCCCTT  AC  ACAGG  AT  GTCC  ATA
CP5R AGATGAGGGGTTTCGGGGATGGCTC
(-25) CP1.9 F TCCCCCCTT  ACACAGGATGTCC
CP5R AGATGAGGGGTTTCGGGGATGGCTC
(-27) CP2F CCT  CCCCCCTTAC  ACAGG  AT  GTCC  A
CP5R AGATGAGGGGTTTCGGGGATGGCTC
(+16) P10 (forward) CGCACTGCACCCTCGGTGTTGGCTGC
CP6R G  ACGCAG ATGTCCT  AAT  AT  GGACAT
(+19) P10 (forward) CGCACTGCACCCTCGGTGTTGGCTGC
CP6.3 R GCTGACGCAGATGTCCTAATAT
(+22) P10 (forward) CGCACTGCACCCTCGGTGTTGGCTGC
CP6.6 R CCT  GCT  G  ACG C  AG  AT  GTCCT  AA
(+25) P10 (forward) CGCACTGCACCCTCGGTGTTGGCTGC
CP6.9 R AAACCTGCTGACGCAGATGTCC
(+28) P10 (forward) CGCACTGCACCCTCGGTGTTGGCTGC
CP7R TGGAAACCTGCTGACGCAGATGTCC
7.9.2  DNase I footprinting assay
DNase  I footprint  reactions contained  10,000cpm 5’ or 3’ radiolabelled  probe,  0.85ng
recombinant SRF(132-223) and 0.85-22.8ng GSTMAL(214-298) derivatives or 1.7 -  85
nM  MAL  peptides  in  1x  DNase  I  buffer with  2.5ng  poly(dl-dC)»poly(dl-dC)  and 3  mM
spermidine.  After incubating  at room temperature for 30min,  0.25 units  DNase  I were
added for 5min on  ice.  Reactions were stopped with Stop buffer at 50°C for 1  hr.  The
DNA was precipitated with  10 \i\ of 1M LiCI and 3 volumes 96% ethanol on dry ice for
30 minutes. After washing the DNA was pelleted and resuspended in 6^1 of formamide
loading  buffer.  Reactions  were  counted  in  a scintillation  counter and  equal cpm were
loaded on  a 8% polyacrylamide/8M  Urea sequencing gel, which  had been pre-run for
30  minutes.  Samples were  electrophoresed at  16mAmps for approximately 2  hr.  Gels
were transferred  onto  3MM  Whatman  paper and  dried  on  a gel  drier  at  80°C for 45
minutes. The footprint was visualised by overnight exposure on KODAK Biomax Film at
-80°C or by exposure to phosphorimager for 1  hr.
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DNase 1 footprint buffers and solutions
10x DNase I buffer 200 mM Tris-HCI pH 7.5 
500 mM NaCI,
30 mM MgCI2  
10 mM CaCI2  
20 mM DTT 
10 f*M ZnCI2  
20 % glycerol 
1   mg/ml BSA
protease inhibitors added fresh
DNase I stock solution 1   mg/ml (2 unrts/pl) 
in 10 mM Tris-HCI pH 7.5 
and 50 % glycerol 
kept at -20°C
Stop buffer 20mM Tris-HCI pH 7.5 
50 mM EDTA 
2 % SDS
0.25 mg.ml linear acrylamide 
0.2mg Proteinase K
Formamide loading buffer 95% formamide
20 mM EDTA
0.01 % w/v Xylene cyanol
0.01  % w/v bromophenol blue
8% denaturing gel solution 25ml 40% acrylamide/bisacrylamide
(19:1) solution
12.5 ml 10x TBE
62.5g Urea
42 ml H20
The mix was heated to 37°C, filtered 
and stored at 4°C until use.
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7.9.2.1  Generation of DNase I footprlntlng probes
Probes  were  generated  by  EcoRI  digestion  of  the  A(-363)  pF711  c-fos  promoter 
construct (Treisman,  R.,  1986) and labelling of either the 5’ end with y 32P-ATP and T4 
Polynucleotide  Kinase  or  the  3’  end  by  filling  in  with  a  “ P-dATP  and  Klenow 
Polymerase. The DNA was then digested with Notl to generate radiolabelled probes of 
245bp (5’label) and 251 bp (3’label). Probes were purified on native polyacrylamide gels 
and  Cerenkov  counted  in  a  scintillation  counter.  10,000cpm  of  probe  were  used  per 
DNase I footprinting reaction.
5 ’ end (top strand) labelling with T4 Polynucleotide Kinase
10  pg  of  DNA  were  digested  with  EcoRI  as  described  in  section  7.7.4.5.  An  equal 
volume  of  phenolichloroform  solution  was  added  to  the  reaction  and  after  vortexing 
centrifugation  was  at  maximum  speed  and  room  temperature  for  10  minutes.  The 
aqueous  phase  removed  and  DNA  was  ethanol  precipitated  with  1/10  volume  3M 
NaOAc  pH  5.2  and  2.5  volumes  96%  ethanol.  The  DNA  pellet  was  air  dried  and 
resuspended in 10 pl water.
5’ end phosphorylation reactions contained:
2 pl 10 x PNK buffer (NEB) 
5 pl [y^P] ATP (10 pCi/pl) 
10 pl EcoRI digested DNA
1  pl Polynucleotide kinase
2 pl H20
Reactions were incubated for 30 minutes at 37°C, followed by addition of 0.5 pl of PNK 
and  incubation  for  a  further  30  minutes  at  37°C.  PNK  was  heat-inactivated  for  20 
minutes at 65°C and 20 pl TE were added to neutralise the reaction, which was ethanol 
precipitated as described above in the presence of 10-20 pg/ml linear acrylamide. The 
pellet was  resuspended  in  20  pl  water and the  radiolabelled  DNA  was  digested  with 
Notl  as  described  in  section  7.7.4.5  to  release  the  radiolabelled  EcoRI-Notl  probe 
fragment. The reaction was ethanol precipitated and resuspended in  10 pl TE followed 
by DNA probe purification by native polyacrylamide gel electrophoresis as described in 
section 7.9.1.4.
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3 '  end (bottom strand) labelling with a 32P-dATP and Klenow Polymerase
10 pg of DNA were digested with EcoRI as described in section 7.7.4.5. The DNA was 
purified with the QIAQUICK reaction purification kit (section 7.7.4.1) and eluted in 30 pl 
water.
3* end labelling reactions contained:
5 pl 10 x NEB buffer 2 
5 pl [a32?] dATP (1 OpCi/pl)
1  pl d(C, G and T)TP (1mM)
30 pl EcoRI digested DNA
4 pl Klenow polymerase
5 pl H20
Reactions were incubated for 30 minutes at room temperature, followed by addition of 
1   pl  of  10mM  dNTPs  (A,  G,  C,  T)  and  incubation  for  a further  15  minutes  at  room 
temperature.  The  reaction,  was  ethanol  precipitated  as  described  above  in  the 
presence of 10-20 pg/ml linear acrylamide. The pellet was resuspended in 20 pl water 
and  the  radiolabelled  DNA  was digested  with  Notl  as described  in section  7.7.4.5 to 
release  the  radiolabelled  EcoRI-Notl  probe  fragment.  The  reaction  was  ethanol 
precipitated and resuspended in  10 pl TE followed by DNA probe purification by native 
polyacrylamide gel electrophoresis as described in section 7.9.1.4.
7.9.2.2  Preparation of AG marker for footprlntlng analysis
Maxam-Gilbert AG sequencing  reactions of the DNA probes were produced  by partial
depurination  of  DNA  with  formic  acid  and  subsequent  DNA  backbone  cleavage  with
piperidine,  and  were  used  as  DNA  marker  ladders.  50,000  -   100,000  cpm  of
radiolabelled  DNA  probe  were  mixed  with  1pg  Sonicated  Salmon  Sperm  DNA
(Stratagene) in TE buffer in a 10 pl final volume. After addition of 1  pl of 4% Formic Acid
the  mix  was  incubated  at 37°C  for 25  minutes  and then  placed  on  ice.  150  pl  of  1M
piperidine solution  were added  and the reaction was initially incubated at 90°C for 30
minutes and subsequently placed on ice for 5 minutes.  1   ml n-butanol was added and
the mix was vortexed vigorously and centrifuged for 2 minutes at maximum speed and
at room temperature to pellet the DNA. After removal of the supernatant 150 pl of  1  %
SDS  solution  and  1   ml  of  n-butanol  were  added  to  the  pellet and  the  vortexing  and
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centrifugation steps  were repeated. The supernatant was removed and the pellet was 
washed twice with 0.5 ml of n-butanol and dried under vacuum for 10 minutes.  10 \i\ of 
formamide  loading  dye  were  added  and the  recovery of  DNA  marker was  measured 
with  a  scintillation  counter  before  storing  at  -20°C.  Approximately  5,000  cpm  of  AG 
marker were loaded per experiment.
7.9.3  In vitro selection of transcription factor DNA binding sites
Binding  site  selection  was  carried  out  essentially  as  described  in  (Pollock,  R.  et a/., 
1990).
7.9.3.1  Oligonucleotides used In Binding Site Selection
Binding  site  selection  oligos  were  designed  to  contain  a  random  oligonucleotide 
sequence  flanked  by  primers  that  included  restriction  enzyme  sites  for  cloning  and 
analysis of selected  sites.  Oligo SS1  32N contained 32 random  nucleotides,  whereas 
oligo  SS2  conSRE  included  a  partially  set  SRE  (CCWWAWWWGG)  flanked  by  21 
random nucleotides on either side, thus constraining SRF binding to the middle of the 
sequence.
Oligonucleotide name Oligonucleotide sequence
SS1  32N CAGGTCAGTTCAGCGAATTCTGTCG(N)32GAGGC
AAGCTTAGTGCAACTGCAGC
SS1  32N EcoRI F CAGGTCAGTTCAGCGAATTCTGTCG
SS1  32N Hindlll R GCTGCAGTTGCACTAAGCTTGCCTC
SS2 conSRE CAGTTCAGCGAATTCTGATG 
(N)21CC(W)2A(W)3GG (N)* 
CAGCGAAGCTTAGTGCTACT
SS2 conSRE EcoRI F CAGTTCAGCGAATTCTGATG
SS2 conSRE Hindlll R AGTAGCACTAAGCTTCGCTG
7.9.3.2  Preparation of double stranded oligonucleotide randomer
The oligonucleotide  randomer was rendered  double stranded  and  labelled  with  [a32P] 
dCTP by PCR.
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20 i*l PCR reactions contained:
2 |il 10 x Biotaq buffer (Bioline)
2 i*l MgCI2  (15mM)
2 |il d(A, G and T)TP (500|iM)
2 |il dCTP (40fiM)
5 pl [cPP] dCTP (10 |iCi/|il)
2 |il Reverse primer SS1  R or SS2 R (80ng/|il) 
2 |il oligonucleotide randomer (50 ng/|il)
1  |il BioTaq polymerase (1  u/|il)
2 |il H20
The following PCR cycle was performed once:
94 °C 1  min
62 °C 3 min
72 °C 10 min
2 \iI of 0.5 mM cold dCTP were added and reactions were incubated at
72 °C 10 min
The product was purified on  an 8% native polyacrylamide gel as described  in section
7.9.1.4.  The  final  DNA  pellet  was  resuspended  in  20  |il  water  and  after  Cerenkov 
counting and amount quantitation  (see section 7.9.3.5) the ds oligo was diluted to 0.1 
ng/|il in water.
7.9.3.3  Binding and Recovery of oligonucleotides
Reaction  buffers  and  conditions  including  protein  amounts  were  kept  as  similar  as
possible to the known  MAL-SRF bandshift conditions (section 7.9.1).  The  binding site
selection using SS1  32N as the starting oligo pool was performed by GST-pulldown of
GST.MAL(214-298)  and  recombinant  SRF(132-223).  Binding  reactions  contained  6
ng/|il  GST  fusion  proteins,  1.36  ng/|il  SRF(132-223)  (both  diluted  in  buffer  D0.4
described  in  section  7.8.1.1).  The  binding  site  selection  using  SS2  conSRE  as  the
starting  oligo  pool  was  performed  by  immunoprecipitation  of  whole-cell  extracts
expressing flag-tagged MALAN and MALANAB1  with untagged SRF whole-cell extract.
Mock-transfected extracts combined with untagged SRF were used as negative control
and flag-tagged SRF extract was used as a positive control.
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Binding  reactions were set up in 0.5 ml tubes and  included 0.2  ng/jxl  of radiolabelled 
oligonucleotide  (0.4  ng/^l  in  the  first  round  of  selection)  in  1x  SS  Binding  Buffer. 
Reactions were incubated for 30 minutes at room temperature before addition of 20 nl 
GST-sepharose  bead  slurry  (washed  once  in  SS  wash  buffer).  Samples  were 
incubated  on  a  rotor  at 4°C for 2.5  hours.  The supernatant was  removed  and  beads 
were  washed  twice  with  SS  wash  buffer.  Selected  oligonucleotides  were  eluted  by 
addition of 200 [l\ elution buffer and incubation at 45 °C for 1   hour. After extraction with 
an  equal  volume  of  phenolichloroform  solution  the  selected  oligos  were  ethanol 
precipitated.  Pellets  were  dissolved  in  10  nl  water  and  recovery  was  quantitated  by 
Cerenkov counting to work out the concentration of selected DNA (section 7.9.3.5).
Binding site selection buffers
2x SS Binding Buffer  40 mM Hepes pH 7.9
200 mM NaCI 
0.4 mM EDTA 
0.4 mM EGTA 
20 % glycerol 
100 ng/ml BSA
16 ng/nl poly(dl-dC)#poly(dl-dC)
0.2 % Triton X-100 
2 mM DTT 
6 mM spermidine
protease inhibitor cocktail  (Roche)
SS wash buffer  20 mM Hepes pH 7.9
100 mM NaCI 
0.2 mM EDTA 
0.2 mM EGTA 
0.1 % Triton X-100 
1  mM DTT
protease inhibitor cocktail  (Roche)
Buffers were stored at 4°C.  poly(dl-dC)«poly(dl-dC),  spermidine,  DTT and  protease 
inhibitors were added fresh prior to use.
249Chaptec? Materials and Methods
SS Elution solution 50 mM Tris pH 7.9
100 mM NaOAcI
5 mM EDTA
0.5 % SDS
7.9.3.4  Amplification of selected oligonucleotides
1  pg of selected DNA was amplified for use in subsequent rounds of selection.
20 pi PCR reactions contained:
2 pi 10 x Biotaq buffer (Bioline)
2 pi MgCI2 (15mM)
3.2  pi d(A, G and T)TP (500pM)
2 pi dCTP (40pM)
1  pi [c^P] dCTP (10 pCi/pl)
2 pi Forward primer SS1  F or SS2 F (80ng/pl)
2 pi Reverse primer SS1  R or SS2 R (80ng/pl)
1   pi selected oligonucleotide (1  pg/pl)
0.5 pi BioTaq polymerase (1  u/pl)
2 pi H20
The following PCR programme was used:
94 °C 30 sec i
62 °C 30 sec [•  x 17 cycles
72 °C 30 sec J
72 °C 2 min
The product was  purified  on  an  8% native polyacrylamide gel  as described  in section
7.9.1.4.  The  final  DNA  pellet  was  resuspended  in  10  pi  water  and  after  Cerenkov 
counting and amount quantitation (see section 7.9.3.5) the selected DNA was diluted to 
0.1  ng/pl in water.
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7.9.3.5  Quantitation of oligonucleotides
The  amount  of  double  stranded  oligonucleotide  material  produced  for  use  as  the 
original sequence pool was determined as follows:
1  \x\ of the radiolabelled DNA was Cerenkov counted in a scintillation counter. The ratio 
of  hot/total  dCTP  that  can  be  incorporated  by  the  double  stranding  reaction  was 
calculated  for  each  oligonucleotide,  to  allow  an  estimation  of  the  original  specific 
activity of the sample.
The specific activity of the synthesised DNA was then calculated using the radioactive 
decay equation: N/No =e-°0 4 8 5 x 1
where No= the original specific activity of the sample, and N= the specific activity after 
time t.
Assuming that  1x106cpm  is approximately equal to  1j*Ci, the Specific Activity can  be 
converted into moles and using the  MW of each oligonucleotide this can be converted 
into  grammes,  thus  allowing  the  estimation  of  the  concentration  of  the  1^1  sample 
counted originally.
The same method was used to quantitate the amouns of amplified selected DNA, with 
the exception that the hot/total dCTP ratio was different in this case.
7.9.3.6  Recovery of selected DNA by gel moblllty-shlft assay and analysis 
by cloning and sequencing
After four rounds of selection the selected probes were used in gel mobility-shift assays 
(section 7.9.1) with the selecting proteins and appropriate controls. After drying and the 
gel  was  exposed  to  film  to  visualise.  Specific  bands formed  between  the  protein  of 
interest and the DNA were excised and soaked in 70-100 fil water at 37°C overnight.
10-20 til of this were used in a 30 \i\ PCR reaction:
3 jaI  10 x Biotaq buffer (Bioline)
3 *il MgCI2 (15mM)
2.5 m-I d(A, G and T)TP (1  mM)
1  (jlI dCTP (120*iM)
1.5 p ,l [a32P] dCTP (10 |iCi/|il)
3 til Forward primer SS1  F or SS2 F (80ng/fil) 
3 \i\ Reverse primer SS1  R or SS2 R (80ng/nl)
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10 fil selected oligonucleotide (1  pg/^l) 
0.5 i*l BioTaq polymerase (1  u/pl)
2.5  nl H2 0
The following PCR programme was used:
94 °C 1 min
62 °C 1 min x 17 cycles
72 °C 1 min J
72 °C 5 min
The  PCR  product  was  purified  as  described  in  section  7.9.1.4,  including  a  phenol 
extraction step prior to the final ethanol precipitation. The DNA pellet was resuspended 
in  20  i*l  water  and  digested  with  the  appropriate  restriction  enzymes  (EcoRI  and 
Hindlll) as described in section 7.7.4.5. After phenol extraction with an equal volume of 
phenol:chloroform  solution  and  subsequent  ethanol  precipitation  the  pellet  was 
dissolved  in  water  and  ligated  (see  section  7.7.4.7)  into  the  pBSKS+  vector 
(Stratagene),  which  had  previously been digested with  EcoRI and  Hindlll  and treated 
with  alkaline  phosphatase  (sections  7.7.4.5  and  7.7.4.6).  E.  coli  were  subsequently 
transformed with ligated DNA and individual colonies were grown into miniprep cultures 
(sections  7.5.3  and  7.7.1).  Purified  DNA  was  sequenced  as  described  in  section 
7.7.4.8.
7.9.3.7  Analysis of selected oligonucleotides
Selected  oligonucleotides  were  analysed  manually  for  the  SS1  32N  experiments. 
Details are explained  in the text of Chapter 8/Appendix.  The sequences derived from 
the SS conSRE experiments were analysed by Mike Mitchell of the CRUK Cgal facility, 
using the Improbizer programme, a tool specialised in searching sets of sequences for 
motifs.  Improbizer  randomly  samples the  input sequences  many times  searching  for 
over-represented  sub-sequences,  scoring  the  identified  matrix  according  to 
conservation.  Improbizer will  start with  motifs of the  specified  size  and  allow them to 
grow  if  the  conservation  extends  outside  of  the  initial  high  scoring  region.  The 
sequence motif images for the SS2 conSRE selected sequences were  made by  Mike 
Mitchell using the Weblogo programme.
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8  Appendix
8.1  Binding site selection aims
The results described in the preceding chapters highlight the central role of DNA in the 
interaction  of  MAL  with  SRF  and  raise the  question  of the  significance  of the  CArG 
sequence  itself for the formation  of the ternary MAL-SRF-DNA complex.  Additionally, 
the  discovery  that  the  SRF-induced  DNA  distortion  serves  to  facilitate  direct 
interactions between MAL and the DNA sequences flanking the SRE raises the issue of 
specificity  in  the  formation  of  these  MAL-DNA  contacts.  In  the  present  chapter  I 
describe  my  preliminary  attempts to  investigate  the  SRE  specificity of the  MAL-SRF 
complex and also the possible sequence dependence of the MAL-DNA contacts within 
the MAL-SRF-DNA complex.
8.2  Site  selection  1:  selection  of  MAL-SRF  specific  DNA 
binding sites
To explore the possibility that the  MAL-SRF complex  recognises  DNA sites deviating 
from  the  SRF  consensus  I  employed  an  in  vitro  binding  site  selection  technique 
(Pollock,  R.  et al.,  1990;  Thiesen,  H.  J.  et al.,  1990).  This technique involves  using  a 
pool of random sequence oligonucleotides as the source of potential binding sites.  To 
facilitate amplification the random sequence is flanked on either side by specific primer 
sequences, which contain the desired restriction enzyme sites for cloning and analysis 
of the  selected  sequences.  After  incubation  of the  double  stranded  oligonucleotides 
with  the  protein  of  interest  the  formed  nucleoprotein  complexes  are  isolated  by 
precipitation on affinity beads. The selected  DNA is then recovered and PCR amplified 
for use in subsequent rounds of selection.  After a few selection  rounds the recovered 
DNA is used in  a gel mobility-shift assay with the selecting protein and specific bands 
are excised  in order to extract selected  protein-bound  DNA.  This  DNA is then cloned 
into an appropriate vector and analysed by sequencing. This technique has been used 
successfully  in  the  past  to  identify  the  consensus  binding  sites  of  many  proteins 
including  SRF,  MCM1  and  of  Elk-1  in  complex  with  SRF  ((Pollock,  R.  et al.,  1990; 
Treisman,  R.  et  al.,  1992;  Wynne,  J.  et al.,  1992);  see  also  Section  1.2.2.1  of  the 
Introduction).
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The experimental design of the MAL-SRF binding site selection experiment is outlined 
in  Figure  8.1.  SS1  32N,  the  oligonucleotide  designed  for  the  experiment  included  a 
random  32  nucleotide  sequence.  MAL-SRF  specific  DNA  sites  were  selected  with 
purified proteins to avoid non-specific binding effects from other proteins in cell extracts 
and  were  isolated  using  a  GST-pulldown  assay.  Binding  conditions  and  protein 
concentrations were identical to those used in the standard MAL-SRF gel mobility-shift 
assay.
To  identify  DNA  sites  specified  by  the  minimal  MAL  and  SRF  regions  required  for 
complex formation  I  used  the  GST.MAL(214-298) fusion  protein that contains the  B1 
and  Q  regions  and  the  recombinant  SRF  DNA-binding  domain  SRF(132-223).  A 
sample of GST.MAL(214-298) alone was also included to test whether the B1-Q region 
of  MAL  has  the  ability  to  bind  DNA  specifically  in  the  absence  of  other  proteins. 
Samples containing empty GST and empty GST combined with SRF(132-223) served 
as  negative  controls.  Given  the  well  characterised  SRF binding  consensus  my  initial 
experiments  did  not  include  GST.SRF(132-223)  fusion  protein  as  a  positive  control. 
The initial oligonucleotide pool and the DNA samples recovered after each amplification 
step were radiolabelled to facilitate analysis by EMSA.
After four rounds of selection the recovered  DNA from each sample was tested  in gel 
mobility  shift  assays  for  the  formation  of  specifically  enriched  complexes  with  the 
selecting proteins (Figure 8.2, the red line under each bandshift specifies the reactions 
where specifically enriched complexes might be found).
Selection  with  GST.MAL(214-298)  in the absence of SRF did  not enrich for DNA that 
generated  specific  complexes.  Thus the  B1-Q regions of  MAL are  not competent for 
autonomous  DNA  binding  under  these  binding  conditions  (Figure  8.2,  lanes  1-5), 
although  this  does  not  exclude  the  possibility  that  they  might  make  specific  DNA 
contacts within a ternary complex with SRF. A non-specific band was present in  most 
reactions including those containing starting DNA material (Round 0).
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Figure 8.1. Experimental design of DNA binding site selection using with the SS1 
32N random oligo pool. The sequence of the SS1 32N oligo which contains 32 random 
oligonucleotides  (designated  N)  is  shown.  Binding  site  selection  reactions  contained 
GST.MAL(214-298)  with  or  without  recombinant  SRF(132-223)  (samples  1   and  2)  or 
empty GST protein with or without recombinant SRF(132-223) (samples 3 and 4).
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Selection  using  GST.MAL-SRF.DBD  in  combination,  enriched  for  DNA  that  could 
efficiently be bound by MAL-SRF complexes (Figure 8.2, lanes 26-30; the binary SRF- 
DNA  and  ternary  MAL-SRF-DNA  complexes  are  indicated  by  black  and  red  arrows 
respectively. See also Figure 8.3A, where the MAL-SRF enriched complexes are better 
visible).  The  SRF.DBD  appeared to bind also  Round  0  DNA,  however a  non-specific 
band  was  also  present  in  these  samples  and  was  migrated  roughly  at  the  same 
position  as  the  binary  SRF.DBD-DNA  complex,  complicating  interpretation  of  this 
observation (Figure 8.2, compare lanes 21-25 and 31-35 where no SRF is present, with 
lanes 26-30 and 36-40 which contain SRF; discussed below).
Selection with GST alone, or GST in combination with SRF(132-223) (samples (3) and 
(4) respectively) did not result in enriched DNA-bound complexes (Figure 8.2, lanes 51- 
55 and 76-80). SRF.DBD appeared to bind weakly to both the initial and selected DNA 
(Figure  8.2,  lanes  46-50,  56-60,  66-70  and  76-80).  This  cannot  be  due  to  spurious 
binding  of  SRF-DNA  complexes  to  the  GST-beads  during  the  GST-pulldown,  since 
SRF was not included in the sample (3) selection reactions.
Interpretation  of the apparent  weak  binding  of SRF to  DNA from  all  selection  rounds 
phenomenon  is  complicated  by  the  non-specific  bands  that  co-migrate  with  the 
SRF.DBD  and  were also  present in  bandshifts (3) and  (4).  One possibility is that the 
SRF.DBD  can  bind  the  starting  Round  0  oligonucleotide  material.  In  principle  this 
should not happen with a completely random oligonucleotide pool,  however it is likely 
that this results from the 3’ primer sequence of the SS1  32N oligonucleotide providing a 
GAGG tetranucleotide adjacent to the  randomised  sequence which  was  utilised  as  a 
partial SRF site (Figure 8.1 A; see below).
8.2.1  Analysis of the MAL-SRF selected binding sites from the SS1
32N oligonucleotide pool
To  analyse  MAL-SRF  specific  DNA  binding  sites  the  DNA  present  in  MAL-SRF 
complexes formed  with  Round  4  DNA was recovered,  cloned  and sequenced  (Figure 
8.3A, the band is indicated by an arrow).
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1   2  3  4  5  6  7  8  9  10  11 12 13 14  1S 19 17  18 19  20  21  22 23  24  2S 26  27 28 29 30  31 32 33  34 35 36 37  38 39  40
selection
with: (3)  GST (4)  GST+ SRF(132-223)
bandshlft
GST:  + + + + + + +  +  +  +  + + + + + + +  +  +  +
GST.MAL:  +♦♦+++++++  +++  +   +   +   +   +  +  +
SRFDBD:  + + ♦ ♦ +   +♦  +  +  +  ♦ + + + +  ++  +  +  +
SS round: 0   1  2   3   4  0   I  2   3   4  01 2   3   4   0  1  2  3 4   012340123401234012 3 4
41  42 43 44  45 46  47 48 49 50 51 52  53 54 55 56  57 58 59  80  81  62 63  64 65  66 87 68 69  70 71 72  73 74 75 76  77 78 79  80
Figure  8.2.  Gel  mobility-shlft  assays  of  the  selected  SS1  32N  DNA from  four 
selection rounds. The selecting proteins for each enriched DNA sample are indicated 
over each gel.  Each gel  mobility-shift assay included  reactions with the starting  DNA 
(SS round 0), and enriched DNA samples (SS rounds 1  -4), assayed for complex forma­
tion with GST-MAL(214-298) or empty GST, with or without recombinant SRF (residues 
132-223).  The  reactions  assaying  selected  DNA with  the  selecting  proteins,  where 
specifically enriched complexes  might  arise  are  indicated  by  red  lines.  The  specific 
complexes of GST.MAL(214-298) and SRF(132-223) in gel (2) are indicated by arrows: 
red  arrow  GST.MAL-SRF-DNA complex,  black  arrow  SRF-DNA complex.  Note  that 
non-specific bands are seen in all gels at the same position as SRF(132-223), which 
may represent degraded probe DNA or contamination of the DNA samples with smaller 
fragments during the DNA purification step.
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Of  the  182  cloned  oligonucleotides,  142  represented  unique  sequences,  with  the 
remaining  40  sequences  representing  oligonucleotides  recovered  more  than  once 
(results summarised  in  Figure 8.3B). The identification of multiple identical sequences 
shows  that  after  four  rounds  of  selection  the  complexity  of  the  original  randomised 
oligonucleotide  pool  has  been  significantly decreased,  indicating  that the  experiment 
had effectively been taken to completion.
Only 8 of the selected  sequences  matched the  CC(AfT)2A(A/T)3GG  CArG  consensus 
found  in  natural  SRF  sites  and  of  these  only  one  matched  the  more  stringent 
CC(A/T)TATA(A/T)GG  high  affinity consensus derived in the original SRF binding site 
selection  study  (Figure  8.4;  (Pollock,  R.  et al.,  1990)  and  also Section  1.2.2.1  of the 
Introduction).  The  majority  of  selected  sequences  contained  sites  with  one  or  more 
mismatches  in  the  CArG  consensus  (Figure  8.4;  summarised  in  Figure  8.3).  For 
discussion  purposes  hereafter  sites  that  match  the  CC(A/T)2A(A/T)3GG  SRF  binding 
consensus will be classed as CArG sequences, while those that contain mismatches in 
the 10bp SRF-binding sequence will be referred to as CArG-like.
50  of the  selected  oligonucleotides  contained  sites  overlapping  the  3’  GAGG  primer 
sequence,  and  half  of  these  contained  further  mismatches  within  the  CArG-like  site 
(Figure  8.8;  see  Section  8.2.1.2).  21  of  the  selected  oligonucleotides  contained  two 
10bp sequences resembling CArG sites and were thus classed separately (Figure 8.9). 
Five oligonucleotides did not contain a sequence resembling a CArG box.
8.2.1.1  Analysis  of  the  MAL-SRF  selected  CArG-llke  sites  located 
completely In the random oligonucleotide sequences
The  sequential  rounds  of oligonucleotide  recovery and  amplification  are  set to  select 
high  affinity  sites.  Thus  the  identification  of  predominantly  mismatched  CArG  like 
sequences  was  surprising,  since  even  single  mismatches  reduce  the  affinity  of  SRF 
binding by tenfold and CArG sites containing two or more mismatches are predicted to 
have negligible affinity for SRF (Leung, S. etai, 1989; Wynne, J. etal., 1992).
Nevertheless  high  affinity  binding  does  not  always  correlate  with  functional 
significance.  Many CArG boxes found in natural promoters contain mismatches in one
258B
DNA selected with:  (2) GST.MAL(214-298) + SRF(132-223) 
GST:
GST.MAL(214-298)
SRF(132-223)
SRF.DBD
GST.MAL:
SRF.DBD
SS round:  1234 1234 1234 1234
Round 4 sites selected with GST.MAL(214-298) + SRF(132-223)
unique sequences 142
1  CArG-like sequence 117
CArG (consensus) 8
CArG-like (1  mismatch) 35
CArG-like (>1  mismatch) 24
CArG with GAGG primer overlap 50
>1  CArG-like sequence 21
without primer overlap 1
with GAGG primer overlap 16
with other primer overlap 4
no obvious CArG 5
CAGGTCAGTTCAGCGAATTCTGTCG  (N )32  GAGGCAAGCTTAGTGCAACTGCAGC
Figure 8.3.  [GST.MAL+SRF.DBD]  selected  DNA sites from the SS1  32N  random 
oligo pool.  (A) Gel  mobility-shift assay of the DNA selected with GST.MAL(214-298) 
and SRF(132-223).  Bandshift reactions contained GST-MAL(214-298) or empty GST, 
with  or  without  recombinant  SRF(132-223),  and  DNA  from  the  indicated  selection 
rounds.  The  band  corresponding  to  the  GST.MAL-SRF.DBD  complex  with  Round  4 
DNA (indicated by arrow) was excised and DNA was amplified and cloned for sequence 
analysis.  (B)  Summary of the  binding  site selection  results  after sequence  analysis. 
CArG  (consensus)  sequences  match  the  CC(A/T)3A(A/T)2GG  consensus.  CArG-like 
sequences contain  one  or  more  non-consensus change.  CArGs with  primer overlap 
utilise the the 3’ primer sequence GAGG. The SS1 32N oligo sequence is shown below 
with the 3’ GAGG primer sequence underlined. Oligonucleotides containing more than 
one CArG-like sequences are listed separately.
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of the 10bp of the SRF-binding sequence (Miano, J. M., 2003; Selvaraj, A.  et al., 2004; 
Zhang,  S.  X.  et al.,  2005).  Although  the  biological  relevance  of this  phenomenon  is 
unknown they have been suggested to represent a mechanism to regulate SRF activity 
by imposing a threshold for SRF binding perhaps due to the requirement of a cofactor. 
Hence the fact that the combination of the minimal MAL-SRF binding domains selected 
predominantly  mismatched  sites  raised the possibility that the  DNA specificity of the 
MAL-SRF  complex  deviates  from  the  CC(A/T)eGG  consensus.  I  thus  proceeded  to 
analyse the selected sequences in order to define potential MAL-SRF specific patterns.
Inspection of the CArG and CArG-like sites with one or more mismatches did not reveal 
clear  sequence  patterns  (Figure  8.4).  The  consensus  CArG  sites  were  too  few  to 
attempt sequence analysis, whereas the CArG-like sites with more than one mismatch 
could  not  be  divided  into  groups  since  many  different  combinations  of  mismatch 
position and identity were observed.
Alignment  of  the  single  mismatched  sites  at  the  CArG  box  so  that  non-consensus 
bases  were  contained  on  the  right  CArG  halfsite,  revealed  no  clear  grouping  of  the 
mismatched sites (Figure 8.4,  middle group), since they contained G/C changes in the 
central  A/T tract and  also  mismatches  in the flanking  C-G  residues  with  not  obvious 
base or position bias.
Similarly grouping of the  CArG  boxes containing one or no  mismatches  according to 
their conserved  halfsite  sequence  (e.g.  TTAGG  versus  TATGG)  did  not  identify  any 
bias  in the position or base identity of the non-consensus changes,  or patterns in the 
sequences flanking the 10bp core site (Figure 8.5).
The original SRF binding site selection which derived the CArG box consensus with the 
central  invariant  A/T  tract  flanked  by  C-G  residues,  had  also  revealed  that  the 
sequence specificity of the prefferred SRF binding sites extended further from the 10bp 
core  to  the  flanking  sequences  on  either side  (Pollock,  R.  et al.,  1990).  This  study 
established  that  SRF  selects  asymmetric  sites  with  a  well-conserved  ATGC 
tetranucleotide directly adjacent to the 5’ side of the CArG  box and a  less conserved 
sequence  on  the  3’  side  and  determined  the  SRF  binding  consensus  halfsite  as  5- 
ATG(not G)CC(A/T)TA-3\
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92-  gaattctgtcgGATTATAACGGGCCATATAAGGTTTTCTTTGGgaggcaagctt
23-  aagcttgcctcGGAAGGGCACACAAGCCATTTATGGTAACCAAcgacagaattc
13-  gaattctgtcgTGGGTACCATTTATGGTATCCAATCACTGCCTgaggcaagctt
86-  aagcttgcctcCCACACCATTTAAGGCTGGCAGTGTATTCCAGcgacagaattc
5  4  -  gaattctgtcgGGAACCCCAT  ATTTGGTCTTCGCGGGGGCTCCcgacagaattc
78-  gaattctgtcgATGCTTGTCCAATTTTGGGCTTATGAGTACGCgaggcaagctt
47  -  gaattctgtcgGGGGTAGAATCTTTCCAAATTTGGTGGCCATCgaggcaagctt
21-  gaattctgtcgCCGGCAGACGGAATATACCTTTTTTGGTCATCgaggcaagctt
CArG-IIKe with one non-consensus change
13b-  gaattctgtcgGAGCTAATGGCTTATAAGGTCTCGATGTCGGGgaggcaagctt
13o-  gaattctgtcgGGGGGCTTAAAAGGTTTTCGGTAGGATACTTAgaggcaagctt
27-  aagcttgcctcAAGGGCATAAATGGCAACCTAGTTCACGGGGTcgacagaattc
12-  aagcttgcctcTCAGCCACACCGCCCACTGTCATATAAGGCTGcgacagaattc
5-  gaattctgtcgCACGGGTGCCTGCCTGTCTTTATAGGGAGGTgaggcaagctt
18-  aagcttgcctcGGGACATATAAGGGCCCGACGACGAAAAACGCcgacagaattc
36-  gaattctgtcgACATATTTGGTGTATACGCGGGGGTGGGCCCCgaggcaagctt
31-  aagcttgcctcCAGACAACTATATAAGGGTACGGGACTCGCCAcgacagaattc
28-  gaattctgtcgACAGCATCAGCTATATAAGGTGTTGTCGCCCGgaggcaagctt
59-  gaattctgtcgGCCGTTTCATAACTAAATATGGAGAGGTTCTTgaggcaagctt
35-  aagcttgcctcGAGATAATACTATAAAAGGCTCAAAAAGACTTcgacagaattc
84-  gaattctgtcgAGAGTGGGCGGGGCTATAAATGGTTATATTOCgaggcaagctt
33-  gaattctgtcgTTCGGATGGCGAGGCTTGTCTTAATTTGGTCCgaggcaagctt
19b-  gaattctgtcgTCTGTGGCCGTTTAAGGCGCTTATTAGCTTAGgaggcaagctt
17  -  gaattctgtcgGTGAATCGTTTGTATGCCGTAAAAGGCATGGGgaggcaagctt
2  3o-  gaattctgtcgGTATGTTGTTTTCATCCGAAAATGGTAACTAAgaggcaagctt
42-  aagcttgcctcCTGTCAGCTACCCTTTATGGTTATCAGTATGTcgacagaattc
23b-  aagcttgcctcTACGACCAGCTGAGACCGACCCTAAAAGGCCCcgacagaattc
19-  aagcttgcctcACGTACCCTAAAAGGCATCCATCAGCACCAAcgacagaattc
11  -  aagcttgcctcCTACCCCCACATAAGGTAAAAACGTCTTATAAcgacagaattc
66-  gaattctgtcgCCACATAAGGTTCGATTTGATGCTACTCAGTgaggcaagctt
4-  aagcttgcctcATAATCACACCAATTACCAGCACCACTTATGGcgacagaattc
2  lb-  aagcttgcctcAAAGCACTCCACGACATACCTCTTATGGATACcgacagaattc
4  9  -  aagcttgcctcAATCACTTC  CTC  AAAAGGAAATGCTGCTcgacagaattc
10-  aagcttgcctcCTGAGCTTCAATCACCTTGTAAGGCATTCCAAcgacagaattc
8  3  -  aagcttgcctcGACTAGCCTTGTAAGGCACTAGCAATAGACCAcgacagaattc
21c-  gaattctgtcgTATGGCCTAGTTAGGGTAGATTGCCGTTTAGGgaggcaagctt
7  -  gaattctgtcgTGGGATATTCACCTAGACCATGTATGGTTCCTgaggcaagctt
34-  gaattctgtcgCCTTGTAAGGTGGTATCCGAGGTGCCGTCGCGgaggcaagctt
8-  gaattctgtcgCATCAGGTCCATGTTTGGTTTOATGTGTGAGGgaggcaagctt
56-  gaattctgtcgTGTGGCCTAGTTAGGGTAGATTGCCGTTTAGGgaggcaagctt
30-  gaattctgtcgTGAGTCGGAGTACCTTCTAAGGGTTGGGACTgaggcaagctt
30b-  gaattctgtcgAATGGCGCGATGCACCCTTCTAAGGGCGGAACgaggcaagctt
2  -  aagcttgcctcACCCGGTATACCTTACCTTCAATGGACACCAAcgacagaattc
27  -  gaattctgtcgGGGGGTGTGTCCTTCAAAGGGTTGGGGAGGCTgaggcaagctt
CArG-like with more than one non-consensus change
79-  gaattctgtcgTCGGTATAGATTTTTGACTATATATGTCGCCTgaggcaagctt
20-  gaattctgtcgGAAGTGGATCAAAACTGGACTCATATGGGCGTgaggcaagctt
90-  aagcttgcctcACCACGGCGACCTATATGGACACTAATCTCGCcgacagaattc
95-  gaattctgtcgAGACTGTATTGGTCTTGTTAATCTCTCGCTTCgaggcaagctt
88.1-  aagcttgcctcAGGAGGTCCCGAGACACTATAGCTACAAAAGGcgacagaattc
34c-  gaattctgtcgTCGCJlGCATTGTGCCTATGTTTGGGTGTTTGTgaggcaagctt
42b-  gaattctgtcgGGGGGCTCGTAAGTCTAATCATGGTGTGCGOTgaggcaagctt
45-  gaattctgtcgATGTACGCCTTTATACGGGTGTAGTCGGGGCgaggcaagctt
38-  gaattctgtcgGGATGGATGTAATGACTGTATAAGGTCACTGTgaggcaagctt
1-  gaattctgtcgCTTATGGTGATTCTTCTGTTTATGGTTAGAAGgaggcaagctt
89-  gaattctgtcgGGGAGGGACGATTAAGGTTATAGTAGTCAGTGgaggcaagctt
11c-  gaattctgtcgTGCAAGGCACCGTAGTTGGTAGTCGTGTTGGGgaggcaagctt
55-  gaattctgtcgAGCGATATGTGTCGGGCTATGTAGGGGCCTCTgaggcaagctt
35b-  gaattctgtcgTCATAGATGGTCACGGACTGCTTTGGGTATGGgaggcaagctt
82.2-  aagcttgcctc&AGACCCTACAAGGAAATAAAGTAGGACACAGcgacagaattc
36b-  aagcttgcctcCCTGACAACTTAAACCCTACAAGGTCAAAGAAcgacagaattc
26-  aagcttgcctcACTCAAAGATAACCCTACTTGGCTCCATCAGAcgacagaattc
34b-  aagcttgcctcACAAACACCCAAACATAGGCACAATGCTGCGAcgacagaattc
62-  gaattctgtcgCCTCATCTGGGGTTTTCTATGTTTAAATAAGgaggcaagctt
51-  gaattctgtcgTATTGTCCACTTTCGGGCCGAGTTTGTAGCGTgaggcaagctt
10-b  gaattctgtcgGTGCATATAGGGATGCATCGGCGTGGTTTCGgaggcaagctt
82.1-  gaattctgtcgTATGCCTTAAGTACGAATTTGGGCATGTTTCAgaggcaagctt
14-  gaattctgtcgATTGCCCTTTAGGGTGATATTTACGTCATTCTgaggcaagctt
lib-  gaattctgtcgGAGACGACCGTGTAGGGGTGCGGGGCTCACTGgaggcaagctt
Figure 8.4. [GST.MAL(214-298) + SRF(132-223)] selected  binding sites  in which 
the CArG box is within  the random SS1 32N sequence. The sequences of 65 bind­
ing  sites containing  one  CArG-like  site completely within the  random  sequence  and 
derived  by  four  rounds  of  selection  are  shown  below  the  consensus  CArG  site. 
Sequences  were  aligned  at  the  CArG  box,  so  that  CArG-like  sequences  with  one 
mismatch contained non-consensus bases in the same half-site. CArG-like sequences 
with more than one mismatches cannot be divided in clear subclasses. Blue: bases that 
match the CArG consensus; red: non-consensus bases; primer sequences are shown 
in lowercase letters.
261CArG halfsite
TAAGG
92-
12-
18-
31-
28-
11-
66 -
86 -
13b-
10-
83-
30-
30b-
34-
19b-
gaattctgtcgGATTATAACGGGCCATATAAGGTTTTCTTTGGgaggcaagctt
aagcttgcctcTCAGCCACACCGCCCACTGTCATATAAGGCTGcgacagaattc
aagcttgcctcGGGACATATAAGGGCCCGACGACGAAAAACGCcgacagaattc
aagcttgcctcCAGACAACTATATAAGGGTACGGGACTCGCCAcgacagaattc
gaattctgtcgACAGCATCAGCTATATAAGGTGTTGTCGCCCGgaggcaagctt
aagcttgcctcCTACCCCCACATAAGGTAAAAACGTCTTATAAcgacagaattc
gaattctgtcgCCACATAAGGTTCGATTTGATGCTACTCAGTgaggcaagctt
aa
gaattc
gcttgcctcCCACAC  i  ATTTAAOGCTGGCAGTGTATTCCAGcgacaga 
tgtcgGAGCTAATGGCTTATAAGGTCTCGATGTCGGGgaggcaagctt
aattc
Igaggcaagctt
gaattctgtcgCCTTGTAAGGTGGTATCCGAGGTGCCGTCGCGgaggcaagctt 
gaattctgtcgTCTGTGGCCGTTTAAGGCGCTTATTAGCTTAGgaggcaagctt
TATGG
4-
23-
13-
7-
42-
21b-
59-
aagcttgcctcATAATGACACCAATTACCAGCACCACTTATGGcgacagaattc
aagcttgcctcGGAAGGGCACACAAG  .'i  A.(GTAACCAAcgocagaattc
gaattctgtcgTGGGTACCATTTATGGTATCCAATCACTGCCTgaggcaagctt
gaattctgtcgTGGGATATTCACCTAGACCATGTATGGTTCCTgaggcaagctt
aagcttgcctcCTGTCAGCTACCCTTTATGGTTATCAGTATGTcgacagaattc
aagcttgcctcAAAGCACTCCACGACATACCTCTTATGGATACcgacagaattc
gaattctgtcgGCCGTTTCATAACTAAATATGGAGAGGTTCTTgaggcaagctt
AAAGG
49-
35-
13c-
17-
23b-
19-
27-
aagcttgcctcAATCACTTCCTCAAAAGGAAATGCTGCTcgacagaattc
aagcttgcctcGAGATAATACTATAAAAGGCTCAAAAAGACTTcgacagaattc
gaattctgtcgGGGGGCTTAAAAGGTTTTCGGTAGGATACTTAgaggcaagctt
gaattctgtcgGTGAATCGTTTGTATGCCGTAAAAGGCATGGGgaggcaagctt
aagcttgcctcTACGACCAGCTGAGACCGACCCTAAAAGGCCCcgacagaattc
aagcttgcctcACGTACCCTAAAAGGCATCCATCAGCACCAAcgacagaattc
gaattctgtcgGGGGGTGTGTCCTTCAAAGGGTTGGGGAGGCTgaggcaagctt
TUGG
54-  gaattctgtcgGGAACCCCATATTTGGTCTTCGCGGGGGCTCCcgacagaattc
36-  gaattctgtcgACATATTTGGTGTATACGCGGGGGTGGGCCCCgaggcaagctt
8-  gaattctgtcgCATCAGGTCCATGTTTGGTTTGATGTGTQAGGgaggcaagctt
21-  gaattctgtcgCCGGCAGACGGAATATACCTTTTTTGGTCATCgaggcaagctt
78-  gaattctgtcgATGCTTGTCCAATTTTGGGCTTATGAGTACGCgaggcaagctt
47-  gaattctgtcgGGGGTAGAATCTTTOCAAATTTGGTGGCCATCgaggcaagctt
33-  gaattctgtcgTTCGGATGGCGAGGCTTGTCTTAATTTGGTCCgaggcaagctt
AATGG
27-
84-
23c-
aagcttgcctcACCCGGTATACCTTACCTTCAATGGACACCAAcgacagaattc
aagcttgcctcAAGG(;  CAACCTAGTTCACGGGGTcgacagaattc
gaattctgtcgAGAGTGGGCGGGGCTAJAAATGGTTATATTGCgaggcaagctt 
gaattctgtcgGTATGTTGTTTTCATCCGAAAATGGTAACTAAgaggcaagctt
TTAGG
21c-
56-
gaattctgtcgTATGGCCTAGTTAGGGTAGATTGCCGTTTAGGgaggcaagctt
gaattctgtcgTGTGGCCTAGTTAGGGTAGATTGCCGTTTAGGgaggcaagctt
ATAGG
5- gaattctgtcgCACGGGTGCCTGCCTGTCTTTATAGGGAGGTgaggcaagctt
Figure 8.5. The CArG-like sequences selected by [GST.MAL(214-298)+SRF(132- 
223)] do not belong to distinct subclasses depending on CArG halfsite identity.
The sequences of 43 binding sites containing one CArG-like site  with no or a single 
mismatch were grouped according to CArG half-site identity. Sequences were aligned 
at the CArG  box so that non-consensus bases were on the right halfsite.  Light blue: 
bases that follow the perfect CArG consensus sequence; red: non-consensus bases; 
primer sequences are shown in lowercase letters.
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Despite no such obvious 5’ flanking sequence specificity in the MAL-SRF selected sites 
I  attempted  to  align  them  according  to  the  best  match  to  the  flanking  SRF  halfsite 
consensus  (ATG-not  G)  in  order  to  discover  the  degree  of  variability  between  the 
originally  derived  SRF  consensus  site  and  that  of the  GST.MAL(214-298)-SRF(132- 
223) selected sites.  Sequences were aligned so that the maximum matches would be 
on the 5’ side of the CArG box (Figure 8.6). Oligonucleotides where the central 10 and 
flanking 4  bp on  either side  impinged on primer sequences were  ignored  in order to 
derive an extended consensus binding sequence.
Although  this  consensus  broadly  agreed  with  the  one  derived  in  the  original  SRF 
binding  site  selection,  significant  differences  were  apparent.  The  MAL-SRF  derived 
consensus contained mismatches in all  10 positions of the CArG box, with the highest 
number of changes at positions ±1  and ±3 (Figure 8.6), in contrast to the original SRF 
consensus where the flanking C-G and central A-T bases are invariant.
Furthermore  although  in the extended  MAL-SRF derived consensus there  appears to 
be a preference for ATG at positions -9 to -7 and an overall asymmetry in the flanking 
sequence selection, when the data are combined into the halfsite consensus positions 
±9 to ± 6 do  not  display any strong  specificity  bias for any sequence  pattern  (Figure 
8.6).  Thus  it  would  appear  that  under  the  conditions  used  the  minimal  MAL-SRF 
complex  displays  more  relaxed  specificity  in  the  DNA  sequence  it  recognises. 
Nevertheless,  the  possibility that the  relaxed  specificity observed  is  a property of the 
minimal  SRF  DNA-binding  domain  cannot be  excluded,  due to the lack of  a positive 
control  dataset.  The  previous  SRF  DNA  binding  site  selections  were  performed  with 
full-length SRF (Pollock,  R.  et al.,  1990), and although SRF(132-223) has been widely 
used in biochemical and crystallographic analyses its wild-type DNA specificity has not 
been confirmed.
To investigate whether the mismatched CArG like sequences represent genuine MAL- 
SRF  specific  sites,  I  tested  their  ability  to  interact  with  SRF  and  form  a  MAL-SRF 
complex was tested. Radiolabelled probes were produced from four cloned oligos, one 
containing a single G mismatch in the A-T core and three containing two mismatches at 
different position of the CArG-like box (Figure 8.7A).  These were used in gel  mobility- 
shift  assays  with  MAL  and  SRF derivatives,  in  parallel  with  a c-fos  promoter derived 
DNA probe, which contains a high affinity SRF site.
263extended SRF halfslte consensus:  A(T/A)G(notG^CC(A/DTA
(Pollock and Treisman 1990)
21-  aagcttgcctcGATGACCAAAAAAGGTATATTCCGTCTGCCGGcgacagaattc
54-  aagcttgcctcGGAGCCCCCGCGAAGACCAAATATGGGGTTCCcgacagaattc
78-  aagcttgcctcGCGTACTCATAAGCCCAAAATTGGACAAGCATcgacagaattc
9  2  -  aagcttgcctcCCAAAGAAAACCTTATATGGCCCGTTATAATCcgacagaattc
23-  gaattctgtcgTTGOTTACCATAAATGGCTTGTGTGCCCTTCCgaggcaagctt
13-  aagcttgcctcAGGCAGTGATTGGATACCATAAATGGTACCCAcgacagaattc
86-  gaattctgtcgCTGGAATACACTGCCAGCCTTAAATGGTGTGGgaggcaagctt
47  -  gaattctgtcgGGGGTAGAATCTTTCCAAATTTGGTGGCCATCgaggcaagctt
10-  gaattctgtcgTTGGAATGCCTTACAAGGTGATTGAAGCTCAGgaggcaagctt
13b-  gaattctgtcguAGCTAATGGCTTATAAGGTCTCGATGTCGGGgaggcaagctt
35-  aagcttgcctcGAGATAATACTATAAAAGGCTCAAAAAGACTTcgacagaattc
27  -  aagcttgcctcAAGGGCATAAATGGCAACCTAGTTCACGGGGTcgacagaattc
13c-  aagcttgcctcTAAGTATCCTACCGAAAACCTTTTAAGCCCCCcgacagaattc
28-  AAGCTTGCCTCCGGGCGACAACACCTTATATAGCTGATGCTGTCGACAGAATTC
21c-  gaattctgtcgTATGGCCTAGTTAGGGTAGATTGCCGTTTAGGgaggcaagctt
49-  gaattctgtcgCGAGCAGCATTTCCTTTTGAGGAAGTGATTgaggcaagctt
84-  AAGCTTGCCTCGCAATATAAC  CATTTATAGCCCCGCCCACTCTCGACAGAATTC
59-  gaattctgtcgGCCGTTTCATAACTAAATATGGAGAGGTTCTTgaggcaagctt
42-  gaattctgtcgACATACTGATAACCATAAAGGGTAGCTGACAGgaggcaagctt
8-  gaattctgtcgCATCAGGT  .  i ,   TTTGATGTGTGAGGgaggcaagctt
30-  gaattctgtcgTGAGTCGGAGTACCTTCTAAGGGTTGGGACTgaggcaagctt
83-  gaattctgtcgTGGTCTATTGCTAGTGCCTTACAAGGCTAGTCgaggcaagctt
31-  aagcttgcctcCAGACAACTATATAAGGGTACGGGACTCGCCAcgacagaattc
2-  gaattctgtcgTTGGTGT:   G  .   TAAGGTATACCGGGTgaggcaagctt
19b-  gaattctgtcgTCTGTGGCCGTTTAAGGCGCTTATTAGCTTAGgaggcaagctt
27-  gaattctgtcgGGGGGTGTGTCCTTCAAAGGGTTGGGGAGGCTgaggcaagctt
56-  gaattctgtcgTGTGGCCTAGTTAGGGTAGATTGCCGTTTAGGgaggcaagctt
2  3c-  aagcttgcctcTfAGTTACCATTTTCGGATGAAAACAACATACcgacagaatSc
19-  gaattctgtcgTTGGTGCTGATGGATGCCTTTTAGGGTACGTgaggcaagctt
30b-  gaattctgtcgAATGGCGCGATGCACCCTTCTAAGGGCGGAACgaggcaagctt
18-  GAATTCTGTCGGCGTTTTTCGTCGTCGGGCCCTTATATGTCCCGAGGCAAGCTT
5-  gaattctgtcgCACGGGTGCCTGCCTGTCTTTATAGGGAGGTgaggcaagctt
2  lb-  aagcttgcctcAAAGCACTCCACGACATACCTCTTATGGATACcgacagaattc
17  -  aagcttgcctcCCCATGCCTTTTACGGCATACAAACGATTCACcgacagaattc
7-  gaattctgtcgTGGGATATTCACCTAGACC  ATGTATC  GTTCCTgaggcaagctt
11-  gaattctgtcgTTATAAGACGTTTTTACCTTATGTGGGGGTAGgaggcaagctt
14-  gaattctgtcgATTGCCCTTTAGGGTGATATTTACGTCATTCTgaggcaagctt
82.2-  gaattctgtcgCTGTGTCCTACTTTATTTCCTTGTAGGGTCTCgaggcaagctt
38-  gaattctgtcgGGATGGATGTAATGACTGTATAAGGTCACTGTgaggcaagctt
26-  aagcttgcctcACTCAAAGATAACCCTACTTGGCTCCATCAGAcgacagaattc
11c-  aagcttgcctcCCCAACACGACTACCAACTACGGTGCCTTGCAcgacagaattc
lib-  gaattctgtcgGAGACGACCGTGTAGGGGTGCGGGGCTCACTGgaggcaagctt
45-  gaattctgtcgATGTACGCCTTTATACGGGTGTAGTCGGGGCgaggcaagctt
42b-  gaattctgtcgGGGGGCTCGTAAGTCTAATCATGGTGTGCGGTgaggcaagctt
89-  gaattctgtcgGGGAGGGACGATTAAGGTTATAGTAGTCAGTGgaggcaagctt
82.1-  gaattctgtcgTATGCCTTAAGTA G  -   c ;   CATGTTTCAgaggcaagctt
36b-  aagcttgcctcCCTGACAACTTAAACCCTACAAGGTCAAAGAAcgacagaattc
1-  GAATTCTGTCGCTTATGGTGATTCTTCTGT  T T  AT GGTTAGAAGGAGGCAAGCTT
55-  gaattctgtcgAGCGATATGTGTCGGGCTATGTAGGGGCCTCTgaggcaagctt
51  -  gaattctgtcgTATTGTCCAC  TTTCGGGCCGAGTTTGTAGCGTgaggcaagctt
79-  gaattctgtcgTCGGTATAGATTTTTGACTATATATGTCGCCTgaggcaagctt
90-  aagcttgcctcACCACGGCGACCTATATGGACACTAATCTCGCcgacagaattc
34c-  GAATTCTGTCGTCGCAGCATTGTGCCTATGTTTGGGTGTTTGTGAGGCAAGCTT
34b-  aagcttgcctcACAAACACCCAAACATAGGCACAATGCTGCGAcgacagaattc
20-  gaattctgtcgGAAGTGGATCAAAACTGGACTCATATGGGCGTgaggcaagctt
CArG  p o s itio n   -9   -8   -7   -6   -5   -4   -3   -2   -1   +1  +2  +3  +4  +5  +6  +7  +8  +9
A  29  17  10  23  4  1  22  14  25  12  39  22  2  -   6  11  16  8
G  12  7  21  17  3  1  5  -   7  2  2  6  52  53  15  11  13  19
C  7  9  3  6  47  45  4  3  5  5  -   5  -   1  14  14  14  18
T  7  22  21  9  1  8  24  38  18  36  14  22  1  1  20  19  12  10
consensus  A X f e G t t X & C   C  X / A   T  A / T   T   A A / T G   G   T   N   N G / G
A T   G /C
HALTS ITE__________ ±9  ±8  ±7  ±6  ±5  ±4  ±3  ±2  ±1
A  39  29  29  43  5  2  44  28  61
G  30  21  35  31  4  1  10  -   12
C  26  22  14  21  100  97  10  5  7
T  15  38  32  15  1  10  46  77  30
consensus  (T )  N  (C )  (T )  C  C  T/A  T  A
A  T
Figure  8.6.  Derivation  of  a  consensus  DNA  binding  sequence  for  [MAL(214- 
298)+SRF(132-223)].  The 55 sequences listed contain  the CArG box and  four flank­
ing  nucleotides on  either side completely within the randomised  sequence and were 
used  to  derive  an  extended  DNA  binding  consensus  sequence.  CArG  boxes  were 
aligned for  maximum match to the extended SRF halfsite consensus [shown at the top; 
(Pollock and Treisman, 1990)] was on the 5’ side of the CArG box. Blue: CArG consen­
sus  bases;  red:  non-consensus  bases;  lowercase  letters:  primer  sequences.  The 
derived  [MAL(214-298)+SRF(132-223)]  consensus  is  shown  at  the  bottom.  Bases 
separated  by  forward  slash  are  interchangeable;  bases  shown  one  over  the  other 
denote preference for the top base; brackets denote least favoured bases.
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The  probes  were  first  tested  for their interaction  with  different  sized  SRF derivatives 
(Figure  8.7B).  The  efficiency  of  complex  formation  between  each  probe  and  the 
different  SRF  forms  is  not  directly  comparable,  due  to  the  different  source  of  the 
proteins:  SRF(132-223)  was  purified from  of  E.  coli,  SRF(120-265)  was  produced  in 
reticulocyte  lysates,  whereas  SRF(fl)  was  expressed  in  whole-cell  extracts. 
Nevertheless  the  ability  of  each  SRF derivative  to  bind  the  different  probes  can  be 
correlated to  its high affinity interaction with the c-fos probe (Figure 8.7B,  lanes  1,11 
and 16).
All  three  SRF  derivatives  tested  bound  the  mismatched  sites  with  lower  efficiency 
compared to their interaction  with the c-fos probe (Figure 8.7B),  and  phosphorimager 
analysis  revealed  that  irrespective  of  their  length,  the  different  SRF  derivatives 
displayed 5 to 10-fold lower affinities for the mismatched probes (data not shown), thus 
excluding the possibility of SRF(132-223) recognising non-consensus sites.
Inclusion of MALAN in the reactions containing the c-fos probe gave rise to substantial 
amounts  of  complex  with  all  three  SRF  forms  (Figure  8.7C).  In  contrast  complex 
formation between  MALAN and either full-length SRF or SRF(120-265) with probes A, 
B,  C and  D was greatly reduced (Figure 8.7C, compare lanes  12-15 with lane  11  and 
lanes 7-10  with  lane  6)  and  was shown  to correspond to  10-20% of the  c-fos  probe 
binding activity by phosphorimager analysis (data not shown). Surprisingly MALAN was 
more  competent  in  binding  the  mismatched  probes  when  complexed  with  SRF(132- 
223) (Figure 8.7C,  lanes 2-4).  In this case, the complex formation efficiency was in the 
range of 20-40% compared to the wild-type complex formed with the c-fos probe.
Thus the altered DNA specificity observed in the MAL-SRF selected sequences is not a 
genuine  property  of  the  MAL-SRF  complex,  since  in  that  case  MAL  should  have 
recruited  all  SRF  forms  into  high  affinity  ternary  complexes.  In  contrast  this  result 
appears to imply that MAL has more relaxed DNA binding specificity when bound to the 
minimal SRF DNA-binding domain compared to when  it interacts with longer forms of 
SRF. SRF(132-223) encompasses only the MADS and SAM domains required for DNA 
binding and dimerisation.  Although the sequences preceding the N-terminal extension 
are  not thought to affect  DNA binding it is conceivable that their absence  renders the 
MAL-SRF more flexible conformationally increasing the ability of SRF to  interact with 
non-consensus sites.
265A
F  fos  .   .   .ATCCCTCCCCCCTTACACAGGATGTCCATATTAGGACATCTGCOTCAGCAGGTTTCC.  ..
A   42  ...  gaattctgtcgACATACTGATAACCATAAAGGGTAGCTGACAGgaggcaagctt.  .  .
B  34c  .  .   .   gaattctgtcGTCGCAGCATTGTGCCTATGTTTGGGTGTTTGTgaggcaagctt.  .  .
C l   ...  gaattctgtcgCTTATGGTGATTCTTCTGTTTATGGTTAGAAGgaggcaagctt...
D  20  ...  gaattctgtcgGAAGTGGATCAAAACTGGACTCATATGGGCGTgaggcaagctt...
B SRF:  (132-223)  (120-265)  (fl) 
probe:  fabcdfabcdfabcd
SRF(fl)
SRF(120-265) 
SRF(132-223)-►
1  2  3  4  5  6  7  8  9  10 11  12  13 14 15
C  _________ MALAN__________
SRF:  (132-223)  (120-265)  (fl) 
probe: f   abcd f   abcdf abcd
MALAN-SRF 
SRF(fl)
SRF(120-265)
S RF(132-223)-►
1234 5678  9  1011 12  131415
Figure  8.7.  Characterisation  of  [MAL(214-298)+SRF(132-223)]  non-consensus 
CArG  selected  sites  for  SRF  binding  and  MAL-SRF  complex  formation.  (A)
Sequences of the cloned sites that were used as probes in bandshift assays. Probe F is 
the  wild-type  c-fos  CArG  sequence.  Blue:  bases  that  follow  the  CArG  consensus 
sequence;  red:  non-consensus  bases;  primer  sequences  are  shown  in  lowercase 
letters.  Only part of the  sequences is shown.  (B)  Gel  mobility-shift assays contained 
purified SRF(132-223) or in vitro translated SRF(120-265) or whole-cell extract express­
ing  full-length  SRF,  combined  with  the  indicated  probes.  The  red  arrows  indicate the 
SRF-DNA complexes formed by the three different size SRF derivatives. (C) Gel-mobility 
shift assays were as in B, with reactions also including MALAN whole-cell extract.
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However,  despite  the  increased  ability  of  the  MAL-SRF(132-223)  to  bind  the 
mismatched sites, the amounts of complex formed with the c-fos probe are still  much 
higher,  indicating  that  the  wild-type  consensus  CArG  sequence  still  represents  the 
preferred  binding  site  of  the  complex,  compared  to  the  ones  selected  in  this 
experiment. This indicates that binding to mismatched CArG box might not represent a 
bona fide property of the MAL-SRF complex, and implies that other factors might have 
influenced the selection process.
The  interpretation  of  these  results  is  further  complicated  by  the  lack  of  a  positive 
GST.SRF(132-223) control. Although in principle binding site selections should always 
recover sites conforming to the  same consensus for a given  protein,  the actual  sites 
selected depend on many parameters. These include the stringency of the binding and 
washing conditions, the manner of oligonucleotide recovery, the purity of the selecting 
protein,  and  also  the  quality  of  the  randomised  oligonucleotide  synthesis.  The 
concentration  of  the  selecting  proteins  is  a  critical  parameter  of  binding  selection 
experiments.  Identification of high affinity sites requires that the starting  random  DNA 
pool be in excess compared with the selecting protein so that high affinity sites can be 
preferentially bound and amplified for the subsequent protein binding steps.
Although the binding conditions  of the  MAL-SRF site selection were  kept as close to 
those used to produce efficient complexes in bandshift experiments,  it is possible that 
an  aspect  of  the  experimental  setup  influenced  the  site  selection  procedure.  The 
amount  of  SRF(132-223)  used  in  the  binding  site  selection  was  identical  to  that 
included  in  the  gel  mobility  shift  assay  in  Figure  8.7B  (lanes  1-5).  The  substantial 
amounts of complex formed even with the low affinity probes raise the  possibility that 
the protein concentration in the site selection was too high, thus saturating the binding 
reactions  and  lowering  the  specificity  threshold  of  SRF  binding.  As  a  result  lower 
affinity  SRF  sites  were  bound  and  these  were  subsequently  carried  through  the 
selection rounds.
8.2.1.2  The CArG-like sites utilising the primer GAGG sequences
In light of the results presented in the previous section it is perhaps not surprising that 
the  combination  of  purified  MAL(214-298)  and  SRF(132-223)  recognised  the  GAGG 
primer sequence as a CArG-like halfsite (Figure 8.8).  It is noteworthy that the utilisation
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of a GAGG primer sequence as a half-site had been previously observed in binding site 
selection  studies  with  MCM1  and  MCM1  hybrids  containing  the  SRF  SAM  domain 
(Wynne,  J.  et al.,  1992),  but  not  with  wild-type  SRF  (Pollock,  R.  et al.,  1990).  The 
MCM1  consensus  is  more  relaxed  within the A-T rich tract compared to that of SRF 
due to the unconstrained conformation of residue R18, which allows the presence of G- 
C base pairs  (see Section  1.2.3.3.1  of the Introduction).  Thus in selecting the GAGG- 
halfsite sequences, the minimal MAL-SRF complex displays a DNA specificity closer to 
that of MCM1  than SRF. Although such a marked change in the DNA specificity of SRF 
when complexed with  MAL is an  intriguing idea, the experimental weaknesses of this 
binding site selection discussed in the previous sections indicate that recognition of the 
GAGG halfsite resulted from inordinately high amounts of SRF in the binding reactions.
The  fortuitous  utilisation  of the  GAGG  primer tetranucleotide  resulted  in  constraining 
the CArG-like sites at one end of the random 32-nucleotide sequence. Since MAL itself 
contacts DNA between positions ±13 and ±22, the -13 and -22 regions of the selected 
oligos  were  inspected  for  sequence  specific  patterns  (Figure  8.8),  however  no 
sequence specificity was apparent. The inability to identify sequence specific motifs on 
the 5’  region of the GAGG  halfsite sequences does  not unequivocally  preclude  MAL- 
DNA specific  contacts.  It  is  possible  for  instance  that the  result was  affected  by the 
relaxed specificity of the sites selected  by the minimal  MAL-SRF complex or the fact 
that the MAL-DNA contacts were constrained to the primer sequences on the 3’ side of 
the CArG box.
8.2.1.3  The oligonucleotides containing two CArG-like sites
The  double  CArG-like  selected  sites  represent  15%  of  the  total  unique  sequences 
identified.  Although  the  majority  of these  included  more than  one  mismatches  in  the 
core 10bp,  most of the sequences recovered multiple times belonged in this category, 
implying  that  possibly  both  sites  could  be  recognised  by  the  MAL-SRF  complexes 
(Figure 8.9).
Multiple functional  CArG  sites  are  often found  in  SRF controlled  promoters,  however 
these are well spaced from each other, and some times are located hundreds of base 
pairs apart  (Miano,  J.  M.  et al.,  2004;  Selvaraj,  A.  et al.,  2004;  Sun,  Q.  et al.,  2006). 
The  footprint of the minimal SRF DNA-binding  domain covers the area to  nucleotidesgeneral CArG box consensus:  cc(a /T)  6GG
perfect CArG consensus:  cc(A /T)TA TA (A /T)G G
-30  -25  -20  -15  -10  -5  0
■  ■  ■  ■  ■  ■  ■
46-  gaattctgtcgGGGTGGGATTCTGGTGGAATCTGTGTCCTTATgaggcaagctt
44-  gaattCtgtcgGGAGAGGATTTGGTCACGATACGCAACCATATgaggcaagctt
29-  gaattctgtcgGCGGAACTTGACTAGTTAAACGAATCCCTTATgaqgcaagctt
36b-  gaattctgtcgTGTTATGCAGTGAATGATGGCAGTACCCTTATgaggcaagctt
71-  gaattctgtcgACGTACGGTCCCCCGTTCATGTGTGGCCTTATgaggcaagctt
60-  gaattctgtcgGCAACGAGAAAATGGGCCTCTGGCACCCTTATgaggoaagctt
50-  gaattctgtcgTGCGTGGCGGGGAGCAGATTGTGTTACCTATTgaggcaagctt
3-  gaattctgtcgGTCATTTAGGGTATTCTTCGAACTAGCCTTATgaggcaagctt
1-  gaattctgtcgGCAACGAGAAAATGGGCCTCTGGCACCCTTATgaggcaagctt
13d-  gaattctgtcgAGTTTGCGTGAGGGGTGTGTATCCCGCCTTTTgaggcaagctt
25-  gaattctgtcgGGGTAATATACAGAGCATCATGCCTGCCTTTTgaggoaagctt
16-  gaattctgtcgGGCTGGTGTAGCTGTCCCCGTCGTGTCCTTTTgaggcaagctt
77-  gaattctgtcgTGGATGGGCAGGGATCTCGTATACGCCCATTTgaggcaagctt
65-  gaattctgtcgTAGGCCCTATGAATATTACTAGATTACCATTTgaggcaagctt
18b-  gaattctgtcgGTTGTGCAGCAAAGCGTGGGTTGTGCCCATTTgaggcaagctt
60b-  gaattctgtcgGGGTAATATACAGAGCATCATGTCTGCCTTTTguggcaagctt
55b-  gaattctgtcgGGTTTGGACATACCTACGAGTTGTATCCATAAgaggcaagctt
33b-  gaattctgtcgATTCACGCGTTCGTGTGAGTGGATGCCCATAAgaggcaagctt
31-  gaattctgtcgAGTGGTGTGGTCGGTGTACCTTGAGGCCTAATgaggcaagctt
52-  gaattctgtcgGGGGCGTACTGCTGAATGAGTTATCTCCTAATgaggcaagctt
9-  gaattctgtcgCTAAGGTGCGGTGGGCGTTTACATTTCCAATTgaggcaagctt
4  8-  gaattctgtcgCGGGGGTCTCGGCTCGTGTGACATTTCCAATTg  a  ggcaagctt
37-  gaattctgtcgGCGGGTTCCAGATGCGTGGGAGGATGCCAAAAgaggcaagctt
12b-  gaattctgtcgCTAAGGTGCGGTGGGCGTTTATATTTCCAATTgaggcaagctt
34c-  gaattctgtcgGGGGAGAAAGCACCGTATATTACTGACCTTGTgaggcaagctt
24-  gaattctgtcgAATAGGTAATAATACGCCCTCCTAGACCTTGTgaggcaagctt
28b-  gaattctgtcgTCATGGAGGGGGGGGCACTTCGGTGGCCATGTgaggcaagctt
88.2-  gaattctgtcgAGTAGCGGTATGCGGcTCGTCTATTGCCTTGTgaggcaagctt
5b-  gaattctgtcgTAACTCAGTGGTGGGTTACACTCTGTCCATACgaggcaagctt
29-  gaattctgtcgGGGTAGCTAAAAATTACAGCTTTTTACCTTTCgaggcaagctt
29b-  gaattctgtcgTGGGGAGGCTGGGGGATGACTGAATGCCTTACgaggcaagctt
22-  gaattctgtcgGCGGGTGCCTATCTAAGCCCATACGACCTTACgaggcaagctt
28c-  gaattctgtcgTAGAAGGACATGTAATTGGACAGTTCCCATAGgaggcaagctt
7b-  gaattctgtcgGATTGGAGGCGTGGCCTGGGTTACGTCCGTATgaggcaagctt
45b-  gaattctgtcgTGGCGGATCACTATGCGGTACAGTTGCCGTATgaggcaagctt
17b-  gaattctgtcgTAACTGAAACACTGATGTAAATAGCGCCGTATgaggcaagctt
49b-  gaattctgtcgTTATAAAAGATCGCCATTGGTCCTTACCCTAAgaggcaagctt
85-  gaattctgtcgCGGTGGACCAAACTGCGGATATGACACCCTAAgaggcaagctt
36c-  gaattctgtcgTGTAGAGAGCTGGTGTTACTTTAGTCCCCTATgaggcaagctt
39-  gaattctgtcgGGTCTAAGGTGCAACCTCGGGTATGGCCCTATgaggcaagctt
40-  gaattctgtcgCTGTTTGGGTGTGGTGAGATAAGTGACTTTATgaggcaagctt
10c-  gaattctgtcgGTTGATGCCAGTGCGCGAGAGTGCGGCTATATgc.  ggcaagctt
96-  gaattctgtcgTAAAATCGGTGTGCAGAGGTGGGTGTCTATTTg  a ggcaagctt
5c-  gaattctgtcgGAGGTCGTGTGTGGGCGATTATCCGCCTATTTgaggcaagctt
80-  gaattctgtcgGCGTAGCGCGGCACTTTAATAGACTACTTAATgaggcaagctt
46b-  gaattctgtcgGGTGTTGTAATCAAGGCTACGCGTGACTATTTgaggcaagctt
48-  gaattctgtcgGGGTTTTTAAGGCTGCGCGGACATGACCCTACgaggcaagctt
32-  gaattctgtcgTAGCCCGGGTCTGGTCATATAGGGGTCGTGTTgaggcaagctt
6-  gaattctgtcgTGGGGGCAGCTCGTGGATGATTTGACCATAACg- :   .caagctt
37-  gaattctgtcgTGGTGGCCCACGTCTTAGAGTATGTCCATACAgaggcaagctt
■  ■  ■  ■  ■  ■  ■
-30  -25  -20  -15  -10  -5  0
Figure  8.8.Selected  binding  sites  for  GST.MAL(214-298)  and  SRF(132-223)  in 
which the CArG box overlaps the 3’ primer sequence. The sequences of 50 oligo­
nucleotides containing one CArG-like site that utilises the 3’ GAGG  primer sequence 
are shown below the consensus CArG site. Sites were recovered after four rounds of 
selection  and  are aligned on the fixed  GAGG  sequence.  Blue:  bases that follow the 
perfect CArG consensus sequence; red: non-consensus bases; primer sequences are 
shown in lowercase letters.  Nucleotides in the random sequence are numbered from 
the centre of the CArG box. The solid lines represent the area of MAL-DNA contacts as 
defined by DNase I footprinting and nested probe analysis.
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±14 from the centre of the SRE (Chapter 5;  Figures 5.2 and 5.3).  Hence it is formally 
possible for some of the selected sites that two SRF dimers were bound on the same 
DNA molecule  at the same time  (Figure 8.9).  The  DNA-binding  requirements of  MAL 
make  it  unlikely that two  MAL dimers  could  be contacting them  simultaneously  (see 
Chapter 5). One possibility is that each MAL subunit could be interacting with a distinct 
SRF dimer,  as  previously suggested for the  Myocardin  interaction with  multiple CArG 
boxes  (Wang,  Z.  et al.,  2004),  but this  has  not  been tested  and  is  not supported  by 
concrete data.
Thus,  although the possibility that the double sites are a genuine feature of the  MAL- 
SRF complex has not been excluded,  it is more likely that the extended  length of the 
random  sequence  (32  nucleotides)  and  the  fact  that  the  flanking  primer  sequences 
were  used  as  part  of  the  CArG  site,  lead  to  the  independent  parallel  selection  of 
sequences that contained more than one possible sites. Time restrictions did not allow 
testing  of  the  affinities  of  the  different  sites  and  this  set  of  data  was  not  analysed 
further.
8.3  Site selection 2
During the course of the first binding site selection experiment it became apparent that 
MAL-SRF complex formation depended on  MAL-DNA contacts outside the core CArG 
sequence (Chapter 5).  I therefore designed a second binding site selection experiment 
to  investigate  the  possibility  of  sequence  specificity  in  these  MAL-DNA  contacts. 
DNase I footprinting and nested probe analysis located the DNA regions contacted by 
MAL to positions ±12 to ±22 from the centre of the CArG box, requiring a long random 
oligonucleotide sequence to identify the extensive sequence covered by the MAL and 
SRF  complex.  To  avoid  complications  by  CArG  boxes  located  at  varying  positions 
within  the  randomer  and  to  avoid  selecting  multiple  CArG  boxes  by  chance  the 
oligonucleotide was designed to contain a partially set CArG box, where the flanking C 
and  G  bases  and  a  central  adenine  were  invariant,  and  the  rest  of  the  core  was 
constrained  for A or T  (Figure  8.10).  This  partially  set  CArG  box  was  flanked  by  21 
random nucleotides, thus constraining SRF binding to the middle of the sequence and 
including  long  enough  randomers on either side for  MAL  binding.  Care  was taken to 
avoid primer sequences that could be recognised as halfsites.
27018-gaattctgt  cgAATTTGGCAACTGTGTGCGGAGATGTCTTTTTgaggcaagctt 
70-gaattctgtcgTTTAAGGACATGCCCCAAGGATAAGTCTGCAAgaggcaagctt 
3x  47  -gaattctgtcgTAAAAGGGCAGGCGTACGTTATAGTACCAAAGgaggcaagctt 
5x  7  3-gaattctgtcgAGATTAGGTCATGAGACTTTGTGAGTCCTAATgaggcaagctt 
8  x  11-gaattctgtcgTGTATGGTATTATTGCCATTTGTGGTCCTGAAgaggcaagctt 
3  4-gaattctgtcgACCAGCTAGGAAGTCGGACTATTTGACCATTAgaggcaagctt
20-gaattctgtcgCCATATTAGGGGCGGTAAAAGGTGGGCCTCAAgaggcaagctt
87-gaattctgtcgCCATATATGAGAGCGGAGGGACGTGGCCATGTgaggcaagctt 
16-gaattctgtcgGTGCTTAAAAGGAAATTCGTCTGTGCCCATAGg  aggcaagctt
72-gaattctgtcgGCTTATATGGGTTGAAACGGTCAAGTCCGTTTgaggcaagctt
6-gaattctgtcgGCTTATATGGGTAGGGGAACTATTATCCTTACgaggcaagctt
26-gaattctgtcgCCCATTTTGGTGTTTATGCGATCACTCCTTTTgaggcaagctt
43-gaattctgtcgCATAATACCATATATAGGTTCGCTGTCCGTCTgaggcaagctt 
2x  24-gaattctgtcgCCTAAGGATCAGTTATGGTGTTTTCTCCTTCTgaggcaagctt
30-gaattctgtcgACTTCCAGTCATGGGTCGAACGGTGACCTTATgaggcaagctt
15-gaattctgtcgTGCCCGGGTTGCCTTTCCAAACTGGGCCTTGTgaggcaagctt
50-gaattctgtcgTAGGTGCTTGGGCACGTACATGGCCTTATCGGgaggcaagctt
2x  31-gaattctgtcgTGTGGCCTAGTTAGGGTAGATTGCCGTTTAGGgaggcaagctt
21—gaattctgtccGTGGATTATTAGTTCCGTTTAGGGCGTTTTTAgaggcaagctt 
1-gaattctgtcgCTTATGGTGATTCTTCTGTTTATGGTTAGAAGgaggcaagctt
31-gaattctgtcgGTCATCCTCATTTCGCTCCTATTTTAGGCCTAgaggcaagctt 
lOx  19-gaattctgtcgTTATAAGGCGTTTTTACCTTATGTGGGGGTAGgaggcaagctt
Figure 8.9.  [GST.MAL+SRF.DBD] selected oligonucleotides after four rounds of 
selection containing more than one potential CArG site. Potential CArG sequences 
are shown in blue with mismatches in red. The red numbers next to some sequences 
indicate the number of times these were recovered during the sequencing process.
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Due to the complications encountered using purified short forms of MAL and SRF and 
isolating oligonucleotides by GST-pulldown (see previous section) I opted to use whole 
cell  extracts  expressing  transfected  full-length  proteins  and  recover  sequences  by 
immunoprecipitation  (Figure  8.11).  Four  selection  conditions  were  set:  1)  mock- 
transfected  empty  Flag  vector  with  untagged  SRF,  2)  Flag-tagged  MALAN  with 
untagged SRF,  3)  Flag-tagged  MALANAB1  with  untagged SRF as a negative control, 
4) Flag-tagged SRF as a positive control.
After four  rounds  of  selection  recovered  DNA  samples  were  assayed  alongside  the 
starting  DNA  material  in  bandshifts for specific  complex formation  with  the  selecting 
extracts (Figure 8.11, the red line  under each  bandshift specifies the reactions where 
enriched complexes might arise).
Selection with empty Flag.vector and SRF did not enrich DNA able to generate specific 
complexes  (Figure  8.11,  lanes  1-5).  Although  both  SRF  and  MAL-SRF  complexes 
could bind DNA from all selection rounds due to the presence of the set CArG box, the 
DNA in the complexes was not enriched.
In contrast sequential  rounds of selection with  Flag-tagged  MALAN and SRF enriched 
MAL-SRF specific sites as can be seen by the progressive increase in the amounts of 
SRF-DNA  and  MAL-SRF-DNA  complexes  (Figure  8.11,  lanes  26-30).  Similar 
enrichment was seen  in the  Flag.SRF recovered  DNA  (Figure 8.11,  lanes 61-65).  As 
expected  this  was  not  observed  with  the  DNA  selected  in  the  presence  of  the 
MALANAB1  derivative that cannot bind SRF (Figure 8.11, lanes 51-55).
8.3.1  Analysis  of the  MAL-SRF  and  SRF selected  sequences from
the SS2 (conSRE) oligonucleotide pool
To analyse MAL-SRF specific DNA sites, DNA from round four bound by the MAL-SRF 
complex, was recovered, cloned and sequenced (Figure 8.11, lanes 30 band indicated 
by  red  arrow).  A  complex  formed  by  SRF  and  round  four  specific  DNA  was  also 
processed to provide a control SRF specific dataset (Figure 8.11, lane 65).
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Figure 8.10.  Binding  site selection experimental design with  the SS2 (conSRE) 
random oligo pool. (A) The sequence of the SS2 (conSRE) oligo is shown (N denotes 
any nucleotide and W denotes A or T). The double stranded oligonucleotide pool was 
incubated with whole-cell extracts expressing untagged SRF with  Flag-tagged  MALAN 
wild-type (sample 2) or Flag-tagged MALANAB1  (sample 3). Extract (v) was mock trans­
fected with empty Flag.vector and combined with untagged SRF was used as a negative 
control (sample 1). Flag-tagged SRF was used as a positive control (sample 4).
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Figure 8.11. Bandshifts of the selected SS2 (conSRE)  DNA after four rounds. The
selecting proteins for each enriched DNA sample are indicated over each gel. Each gel 
mobility-shift assay included reactions with the starting DNA (SS round 0), and enriched 
DNA  samples  (SS  rounds  1-4),  assayed  for  complex  formation  with  the  following 
whole-cell extract combinations: [mock-transfected Flag.vector and SRF], [MALAN and 
SRF],  [MALANAB1  and  SRF],  [mock-transfected  Flag.vector].The  reactions assaying 
selected DNA with the selecting proteins, where specifically enriched complexes might 
arise are indicated by  red lines. The specific complexes of [MALAN and SRF] in gel (2) 
and  SRF alone  in gel  (4) that were excised for further analysis are  indicated  by red 
arrows. (The empty Flag vector is designated Flag.v)
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131  unique MAL-selected sequences were obtained, with two sequences arising twice 
indicating  that  the  sequence  diversity  of  the  DNA  molecules  has  been  substantially 
reduced  after four selection  rounds.  The  MAL sequences were grouped  according to 
the  central  A-T  tract  of  the  CArG  motif  (Figure  8.12).  Visual  inspection  of  the 
sequences  revealed  a predominance of G  and T residues in the randomised  regions 
(see below). Although sequence homology was apparent in the region bordering the 5’ 
side of the CArG box, no specific sequence motifs were immediately discernable in the 
areas of the MAL-DNA contacts.
Table 8.1  Base composition of the random sequences flanking the CArG  box in 
the MAL-SRF selected sites
Base composition of 21N sequence on the 
left of the CArG box
Base composition of 21N sequence on 
the right of the CArG box
A 13.3% A 12.5%
C 8.1   % C 12.8%
G 34.5% G 18.7%
T 44.1  % T 56.0 %
64 unique SRF-selected sequences were compiled as a control dataset (Figure 8.13). 
Like the MAL-SRF selected oligos, the SRF dataset also contained significant G-T bias. 
Grouping  of these according to the A-T CArG  box  core  also  revealed the  5’ flanking 
sequence  conservation.  However  there  was  substantial  sequence  variation  in  this 
region, in contrast to the consensus derived by Pollock and Treisman where the ATGC 
tetranucleotide bordering the 5’ side of the CArG box was almost invariant (Pollock,  R. 
etal., 1990).
The  G-T  bias  observed  in  the  control  SRF selected  sequences  is  unexpected  since 
SRF  has  not  been  shown  to  have  such  a  preference  in  the  flanking  sequences  it 
recognises.  It is thus possible that this represents an error in oligonucleotide synthesis. 
Ideally  selected  oligonucleotides  from  earlier  rounds  and  samples  from  the  starting 
oligo  pool  would  have  been  sequenced  to  resolve  this  issue,  however  this  was  not 
possible due to time constraints.  It therefore remains possible that the motifs identified 
from these datasets do not represent bona fide consensus sequences but are
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TTATAT  (n = 60)
208a-GCACTTQTQTTCTTTTCATAGCCTTATATQQCATTGCTOGTCGTTTGTATOT 
2  4-ACTCCCATTQCTTQTTGTTAGCCTTATATGOTOTTTTOTTTOTTTTTTOCGT 
37  c-GOGGTGGTGGAAGGGTTTTATCCTTAIATGQQTATTTTATQTGTTTTTGTTT 
208b-GTCCCCCACCQTGGCQCATATCCTTATATGGTATGGTTTTGTTTQTQGTtTA 
203-GTTTTTATGTGTTTGTTTTGTCCTTATATGGTGTTTTTGGTGTTTCTCTCTT
12c-TTTTOGGGTTACCATTTTTGTCCTTATATGQGGTTTTCTTTAOTGTATTCTT
15-  TGTTGATGGGT  ATTGTTGTGGCCTTATA1  k™  ^  vj  t a i i i n n i i v r a n m  
49c-  TTTTTGTCTTTGT  ATGTGTGGCCTTATATQGTGOTATTQTGTTTQQTTTQTT 
218b-TGTTTGGGTGTTGGGTATTTTCCTTATATQQTGGGQTTCATQTCGTAATTAC 
2-QCTQTTTGTGCTGGTGTTTTTCCTTATATGGTCAGAATTTTGTQCCTATTTT 
217  -QOGQCQAGATCTTTGTTATTTCCTTATATGGATAGGCCGCCGCCCCCACCTC
207-C
208C-1  _____________
3  7  a-TTGTTGTCGGCACTTTTGCTTCCTTATATGGTGGTTTTGTGCGTTGGGTGTT
7  5-t t g g t t t t t g g t g t a c t o c t t c c t t a t a t o o t t t o t o o c t o g t a c t o t t t t t
51  -GGGTTGTTTTTGGTTTTTTTGCCTTATATGGTGTTGTGTTTTTCCATATTQA 
31  -  GGTTTGTQTGTTTGGTTTTTQCCTTATATQGTGTTTTQGTTTTTGQCQTTTT
3-TATATGTTCTQATGTGTTTTGCCTTATA^TOTCGTQTTCTQTCGATQTTQCT 
210-GCCGTTAGTGTQTATTTGTTGCCTTATATGQGCTTTTQGTTGTAQTTCTTTT
215b-GGAAATTTGTQTTTTTTGTTQCCTTATATQGTTATTTCTTTTGGTTGGTQTA 
72a-TGTTTTTTATGTAGGGGATTGCCTTATATGGGCATTCTTTTGTTATTGGTTC 
40c  -  AATQTGOCGQGOOGATTATTOCCTTATATOGGTTOTTTTTQTTOTT7TTCTT
11  -GGTTTQTCATT^TTGTTATTQCCTTATA^TOTTQTQQTTQOTTTOTTOTTTT 
2  3  -  TQGTGTTGTGTTQQGTTATTQCCTTATATQGTQATTTGTTTATTQTTTCTTA 
2  50-GCTTTTGQQTCQTTGTTATTQCCTTATATQQTTCTQTTTTQTCTGTTGTTTT 
12  b-QGGGTGCGTGTATGTTTATTGCCTTATATGGTGTTTTGGGTTATGTTTTTGT 
4  9  b-GTTGTTTTTGOTTATTTATTGCCTTATATGGTCCCTCTTTTCCGACCTTTTA 
7  8b-GGTACGTQTGTTTQTTTATTQCCTTATATOGTTATTTAGTTTTTTACGATTC 
6  2  -  TGTTTTTTATGTAGGGGATTGCCTTATATGGGCATTCTTTTGTTATTGGTTC 
17  -  TQQQTGTGGGT  ATTGQGATTQCCTTATATGGGTATTATTTTACTQTTTTTQT
202-GCCCATGGGTGTTQTTTGTTACCTTATATQGTCATTTTTQQATTTTTTGQTC 
7  8  c  -TTGOCTOTATTTOGTTTTTT  ACCTTATATOGTOTOGGTTTCCTOCQGTAATC
2  3  O-GTTCTGTTACGAACTCTTTTACCTTATATQQTCACGTQTQCACCTTATTTTC 
10-GGGAATOGGGCQTOGTTATGACCTT  ATATGGTTACATT  ATGTTGTGTTTTTT 
2  0  -  TOCOTTTGTTGTTOGCGATGACCTTATATGGATTTOTTTOOOTTTGTTTTTA
248-1
249-C  ____   ______
218c-AAAAAAACOTAAAAAACAACACCCTATATGOATACAAAACAACAGCCACCAC
3  3c-GTAATQTTQCGCTATACAACACCTTATATGGTGCQTTTTQTQCTQCTGTTTT 
2  05  -OQTTOGOQOOCTOOQATAATACCTTATATOOTOQTTTATTTTOTQTOTTTTC
14-GTTTTCGCGCGAAGAAAAGTACCTTATATGGTAATACGTTQCTACCCATGTC 
8-TOTTTOTCGTGTOOTTTACGCCCTTATATGGAGTTTTTTTQTTTQTTTTTTT 
2  2b-TGGTTGTT  ATGGGCTTT  ATGGCCTTATATGGCAGTGTTTTTGTACTAT  ATTT
216b-TQTCQQTTTTQTTQTTTTATQCCTTATATGQATQTGTTTOTTTGTTQCTCTT
215  a  -GTOTTGOCTTQTAOATTTCTTCCTTATATOOTQTOOOOCTCACGCCTCTCTC 
213-TOTTTOTCTOTOTTTTTOTCOCCTTATATOOTATCTTTTTTTTTOOTTATTT
ATATTT  (n -8 )
226a-GGOCOTOTTOTGGTAAOATGACCATATTTOOqCATCTTTGCAQTQTQTCQQT 
7-QQQQOQQOCQTTOCGTTTTQACCATATTTQOTTQTCTTATTTTAQTTTTTTT 
6  5-GQOTTGOGTGTATTTATAAQTCCATATTTOGOCATTTTTCQTTTGTCTTTTT 
1  -TQQGTACCGTAGTTTTTATQTCCATATTTQQTQCTCTTTQGTAQCTQTTTTT 
5  4-AGOOOGGGAGGGOGGTTATGCCCATATTTOGAGCGTTTTTTAAGTTTTCTTT 
7  2  C-TQGCAGGTGGT  AATTTTATQCCCATATTTQOTCATTGTTTATTTATTGTGTT 
26c-GTGTGGGGGCAGCGGTTATATCCATATTTGGTAATGTTTTAGGTCCTTTTGT
TTATTT  (n=30)
7 3-GOGGOGTCTTTTOTGATGTTTCCTTATTTOOTQTTQTTGTTOTTTTTTCTAT 
5  0 -GGGTOQTTTTTTQ TGTTGTTTCCTTATTTGGTCTQTOTTGTGATTTTTTTTC 
26b-GGGCTTGTGTTGQTATTATTTCCTTATTTGGTQTTTTTATGTTTTTTTGTTT 
231  -TCTACTGCAACACCQTCATTTCCTTATTTGGTQTTGTTGGTGTAGTTTTGTT 
2  7  -QOOGTOTGGTAQOGQATATTTCCTTATTTGOTO TTTTTTGTTTTOTTTTCTT
2  40-  GGTGGGTTTGTTTTGTTTTGTCCTTATTTOGTCATTTC  T  AGATTC  C  GTTTTT
3  3  a-OTTQCGTGOTAACTTTT  ATGTCCTTATTTGOTOTTTTQTTTTCAOTTTTTTC 
22a-QGQqGQGQAQQGCGTTTATGTCCTTATTTGGTCATTTTTTTATTGTTTTTTC 
2  37  -  OOTTTOTGTOOGATOTT  ATOTCCTTATTTGOT  ATTCTTCAQAOCAGTTTTTT
216c-TGTTTTGGTTGTTGGTGATGTCCTTATTTGGGTGTGTTTTGTTTAGTTGTTC 
2  4  7  -  GTGGTGTGGGGTTGGGGGTTGCCTTATTTGGGC  ATTTTGTGTTGTGTTTTTT 
2  2  c-GTTGTGTGGQGTGGGTTTTTGCCTTATTTQQTATTGTAGTTGCTTTTTTTTT
2  5-GGGGGAGTGATCGTGTTTTGGCCTTATTTGGTAATGGTTTTTGGTTTGTGTT
3  5-TAAQOGOQAGCQATQTTATTGCCTTATTTGQTGTTGTTTTTOCTGTTTTTTT 
7  8a-GTTTTTGCACTTTTGTTATTGCCTTATTTGGTATTAAAATATGGGCTCATAC 
239  -  GGGCQTQTQGQTGTGTT  ATTGCCTT  ATTTGGTCTCTCAATOTGTTTTTGTTT 
211  -GOTCOTTCAAGTGTOTTATTGCCTTATTTGGTTGTGTTTTTOTCTTTGTTTT
4  7  -  GGGGTGTGTT  ATGGTTTGTT  ACCTTATTTGGTGTTTTTGTGTTTGGTTTTTT 
80c-GGGGTGTGTTGTGTGTTATTACCTTATTTGGGTGTTtATTTGGTTTGTTTTC 
20  4  -  TGTOTGTQGTTQT  AQGATTTACCTT  ATTTGGTCATTTGGTGTTTTQXGTTTT 
229-TGTTGTCCATTTTGQGTATGACCTTATTTGGTOTTTTTQTGTACTQTCTTTT 
80b-TTATGTTGtGGTAGGTTTTGACCTTATTTGGTATTATTTGTCCACTTGCgTT
243  b-QTOTOTTTTTTTTTOTTTTGACCTTATTTGOTGTTTTATCCATTCACCTTTC 
219-GGTTGGAGTTCGTGTTTGTOCCCTTATTTGGTCTTTTTTGTTTCTTTATTCT 
223  -  TGTGTG  TQGTTGT  T  T  T  T  ATGC  C  C  TTATTTGG  TTC  TT  T  1‘   T  GG  TT'1‘   T  T  T1‘   GG  TT 
234-TTQTTGGQTQTOTOTTTATQCCCTTATTTGOTAGTOTTTGTTTGCTTTGGTC 
80  a  -  TGTTTTTOTTCTCCTTTQTATCCTTATTTGGACATTTTTTQCTTCAGTTTAT 
3  9-CGTCAACG0CCTACATCGCTACCTTATTTGGGCATGATTTTTA0TCTTTCCC 
9  -OOGAGGOQAQAAAGAAGAQTTCCTTATTTOOGTATOTTTTTTTTTOTTOTTT
ATATAT  (n = 2 5 )
2  3  2-TTGGTGCQTTGTGTTTTATTQCCATATATGGTCGTTTTTTQAGTCQATTTGC 
4  3-GATTCTTTTTTTTAGTTGTTGCCATATATGGTGGTGTTTGGCTTATGTTGGT 
216  a  -GGGGGTCGTGTTGAAGTGTTGCCATATATGGTTTGTTTGGTATTTTTTGTTT 
244C-1
12  a-TTTQTTGAGTGGCAAAAATAGCCATATATGGGCATTATCATAGCGCTTTACT
6  8  b-ACATGACTGTTCCAAAGGATACCATATATGGAAGAACAAATGCTAGGGGTTG
7  2  b-AAAAATAAAACCAAAACAATACCATATATQGCCCGAAAAAATCCCCCTCACC 
41  -TOQATTTQAGACGGAATATAACCATATATGOCAACAACCTAGCOCCCCCCGC
2  4  4b-AAAAGAAATGAAACAAT  ATCACCATAT  ATGGAAATAATACAQCTAAAACCCA
5  5  -TGGGGGTTTGGTTTCTTTTGACCATATATGGTAGTGTTGTCTGTGTGTGGTT 
4  0  a  -  TGTGATTCQGAATOGTTTTQACCAT  ATATGGTGATTTGTGTATCCTGTGGTT 
4  2  c-GTTCGATCATCTTTTTTTTTACCATATATGGCAAAACTAGAATGACQACCCC 
225  -GOGOTTTGTQTTTTTTTAAOTCCATATATGGTCATTTCGQTTTTTTGCTGTA 
226c  -  GATGTGGGAGGQGTTTTATGTCCATATATGGTAGGAATGTTOTTTGTTTTTT 
214  -  TGCGTGACGGGTTGTTTATGTCCATATATGGGTGTGTTTATTTGGGTTGTTT 
7  7  -TGOOCACQQTGTOAATTATGTCCATATATGGGTGTTTATOQTOTGTOTTTTT 
7  4-GOGTTGGGGGCTGTGTTTTGTCCATATATGGATATTTTTATGTTTGTTTCTT 
3  0  -  GTOTOQTTTGCTTQTGTTTGTCCAT  AT  ATOG  t  TGTGrTTCTTTQTTTQTTTT 
228C-GGT  ATTGOQTCTTTTTTATCTCCATATATOOOTATTTTTCGTTTCTTCTCOT 
7  9-GAGGATTGTTTGTGGGTATATCCATATATGGCCCCCTTTTCGCGCCTGGGTC 
233-TTTGGTTCCTTOTCQTCCCCATCCATATATGQTATQTTTTQTTCTGTTAQTOT 
22  8a-GGOQOTTTGGTQTAGGOCACTCCATATATQQTGGTTTATTQTTQATTQTQTT 
222b-ACACAAAQCQT  ACAAAACACCCCAT  AT  ATGGTCAAAOGAT  ACATGAAACAAA 
4  2  a-COTATTTGAOTOTTTTTTTTCCCATATATGGTTATTATTCCTCTGTGTTTTT
TAATAT  (n -3 )
201-TGTGTOTTATCQCQTTTATOCCCTAATATGQTCA1 rGGTTAGGTTGA
TTATAA  (n -2 )
228b-  GTGOOTOTQAGGATOTCATGTCCTT  A1
243C-TQATTTGAQTOTTTTTTATATCCTTATAAGOCTATAAOCTOCCCCQTACTCC
2  4  3  a  -  TGTQTGTTATCQCGTTTATGCCCTAATATGGTCATTTTTTTOGTTAGOTTGA 
2  6  a-TTQGGGAOQATTQOTTTGTGTCCTAATATOGTAATGTTTCTTTATATQTTQT
TAATAA  (n -1 )
2  2  6b -GACAATAAGTAACCGAAATGACCTAATAAGGTAAAAACTACCAACCCACCAC
TAATTT  (n -1 )
2  41  -TTTATCAGOATCAQTTTATTCCCTAATTTOGTCATTTTTGTQCCGTAGTTTC
ATAAAA  (n = l)
71  -TAAAACAAGOTTGTAGACTGCCCATAAAAGGAAGATCTCACACACCCATATC
Figure  8.12.  MAL-SRF  selected  oligonucleotides  from  the  SS2(conSRE)  oligo 
pool after four rounds of selection.  The 131  unique oligonucleotides are grouped 
depending on the core A-T tract of the CArG box. Sequences have been aligned so that 
maximum  match  is  on  the  5’  flanking  region  of  the  CArG  box.  Only  the  random 
sequences with the central partially set CArG box are shown. The CArG box is under­
lined. The SS2(conSRE) oligonucleotide is shown at the top (the letter N denotes any 
nucleotide and W denotes A or T).
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Table 8.2  Base composition of the random sequences flanking the CArG  box in 
the control SRF selected sites
Base composition of 21N sequence on the 
left of the CArG box
Base composition of 21N  sequence  on 
the right of the CArG box
A 19.0% A 14.5%
C 12.5% C 25.5 %
G 35.4 % G 18.8%
T 33.1  % T 41.2%
influenced  by the  excess  presence of  certain  nucleotides  in  what should  have  been 
completely randomised sequences.
It should be noted however that despite the possible bias in the synthesis of the original 
oligonucleotide  pool,  the  MAL-SRF selected  DNA appears to further enriched for the 
presence  of thymines  on  either side of the  CArG  box  compared  to the control  SRF- 
selected  oligonucleotides  (compare  Table  8.1  and  Table  8.2).  This  observation  is 
intriguing  in  light  of  the  intrinsic  bending  properties  of  A-T  rich  sequences  and  the 
dependence of  MAL-SRF binding  on  DNA bending,  since  it  raises the possibility that 
MAL  preferentially  binds  SRF  on  CArG  sites  the  surrounding  sequences  of  which 
display  increased  flexibility.  This  line  of  enquiry was  not further  pursued  due  to time 
limitations.
8.3.1.1  Analysis of the randomised sequences flanking the central CArG 
box of the SS2 (con SRE) samples
Despite these concerns the two datasets were used to identify MAL-specific sequence 
preferences.  The  Improbizer  motif  recognition  programme  was  used  to  analyse  the 
sequence  motif  content  of  each  dataset,  however  this  approach  only  identified  the 
partially  set  CArG  box  with  confidence.  Smaller  patterns  isolated  in  the  randomised 
regions  were  barely  above  the  cut-off for nucleotide  combinations  arising  by chance 
(data not shown).
Attempts to refine the search for MAL-specific motifs in the randomised regions using 
the  SRF  selected  oligos or  human and  mouse genomic  sequences as  background
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TTATAT  (n -3 6 )
310c-GTATTTOTTTACAQTQCOTOCCCTTATATOOTTAOQCTOTCACTQTCCATCA
177-OQOOTOTTOOQACTQTATTOCCCTTATATOGOTOTGTTGTQTOTOQGAGTTA
162-GGGOGGGGCTGTCGTCAATOCCCTTATATQOOTATTTGTTTTTGGGTTATTT 
165  -GGTGTGGTGTOGTGTTCATGCCCTTATATOGAGTATGGTTATCTGTGACACA
188-QQTCQQAQTQQTQGGATATGCCCTTATATGGTATTOTQTQCGTATOTOTQTT 
164  a  -  GGTT  AT  AATGT  ATTCTT  ATGCCCTT  ATATGGQTCTTTAGATCTCQGCTGQCT 
164c-GCGCGAAGOOOTOTOTTATGCCCTTAXATOOTOOTTTTATQATTCTOTTTTT 
166  c-GQTCTTATTTT  ATCGTTATQCCCTTATATGGAGTTGTTTTOGCTCAAACTTC
198-TTOTGOQTAGTTTTTTATCTOCCTTATATOGTGTTQGCAGTTCTTOTGTTTA 
307  -GGOOTOOCTGTTGTGOTOTToCCTTATATOGTOTTTTTGTTGTGTTTTTATT 
19  6  a  -  TTACQOOTTCOACQOTTGTTGCCrrATATGQTATOTTCCTTT  AQATCQTTTC
163-TGAGGTGGTGAGGCOGTATTGCCTTATATGGTCATTTOGTCATTTACCCATC 
4  9b-QTTGTTTTTGQTTATTTATTGCCTTATATOOTCCCTCTTTTCCQACCTTTTA
200a  -  TTTQTGGCCTOTAGOQT  ATQOCCTTATATOOOTOTGTGTTTTAOTCCTATAC 
171c-TGAGAGCTGTGTAGTTTAACGCCTTATATGGTAGTGCTTTTTGTGOTTGTTT 
306  -  TATGCCCQATGCTGAGCACCGCCTTATATGQQCATTCTCCCqCAGCCCCCCC 
184  -OAGTOTTOTCTACCCOQATTTCCTTATATOOOCAACAOOOTCOTCCCCCCTC 
6  -OTTTTTTGOTGTTATATATTTCCTTATATGGCTCCTCCTQCACQCCCACACC
5  2-OOGOOOCOGCGTGGGTTATTTCCTTATATGQTTQTTTATTTTOTGTQOTOTT 
161  -GGGTTGTGTTGTTTOCTATOTCCTTATATOOOCACTGACTCCTTOCCCTTCA 
17  3  -  TTTOTTTTATTAQCGGCCAGTCCTTATATGGTCACAACTTCCCCCATGTCCC 
167  -GTTTGATOCATTCTGGATACTCCTTATATGGACTTGTTTTTOTGGQTGTTOC
310a-TQGGGTTCTGTTGGGTTATGACCTTATATGGATTTTCTTGQGTTCACTTCTC 
183-TATTGCCQGTGTCQCTGATTACCTTATATGOTCTOQTGTTGTTTGCTTTATT
6  3  -OATCATTOTTATOTTCTATTACCTTATATOOATATACTCCTGACOACCCCCC 
192-OCOOTOTTTATGOGOOTQTQACCTTATATOGTCATATOGACTTTACCGOCTC 
168-TTAGCATGTGGTTAGAQAOCACCTTATATGGOTATCTCTTACTTCTCGTTGT
1 8 9 -TCAOqCTTACTATOCTAATACCCTTATATGGTCATQTOTTGTCTCCOOTCCC
164b-  TATOTGTGAGGGGTOTTTTGTCCTTATATOOTGTTOCTTCTCTTTGTGTTTT 
16  6b-TGCCTAT  AGTCGATQTT  ATGCCCTT  AT  ATGGAGTGGCGGTACTCCCACTTCC 
2  OOb-GCACCAAAGGTATCATAAACACCATATAAGGAGATGTTCACCCCACGGCAAA 
40b-TTTGCCGTOGOOTGAACATCTCCTTATATOQTQTTTATGATACCTTTGOTOC 
14-GTTTTCOCGCGAAGAAAAOTACCTTATATGOTAATACOTTOCTACCCATGTC 
196  b-QAQAQQQGGGTGCAACGATGACCTTATATQGTCAGACGTTATGGCCTQTCCC
ATATAT  (n -1 4 )
178-CTAACOGAACAGCCOTCACTACCATATATOOAOTCACCACCACOCACCCCCA
16  6a-OGATTAGAAGCAAGACCATGACCATATATGGCAATACATTCGCACCCTCCCC 
17  4  -GGOTOGTGTGTCATGTTATOACCATAT  ATOQTQTTTTGCGCCCQCTCTQCTC 
19  5  -  TOGTQGAOTTTTGQOGGATQACCATATATOOTATOQTOTGCACCCCAOOTTC 
1   90-  QQQGGGQTTQAQGQGTTTTGACCATAT  ATGGTOTT  ATGTTQGTTTTGTQCTT 
3  0  8  -  QGQTGGCTTTTGTGTTTTTAACCATATATGOTOCTOGAGAOTTTTTTTGGTT
303  -GGAGTTTQTTTQTTTQTOTATCCATATATGOOCATQTTCCGTOCCTTTTTTT
17  lb-TQQTOQQQQTQQGTTCOTTQCCCATATATGOTOTGATATTTCCATOTQTGTG
193  -QGTOOCOTOOTAQAQTTATOCCCATATATQOATOTTTTTTTCATOATAATTC
301  -QQQQTQQCCTTTGTQTTATQCCCATATATGGTCTTOTQTTTTATOOTTTOTT 
18  6  -  QQQGCGQCAQAQQQTOTAACQCC  ATATATGOTCATTTTQCTTTTOTGTTTTT
3  lOb-aaaAAAACCAAACQAACACACCCATATATGQACATAACCCAATACCACCGCC
TTATTT  (n -8 )
17  6-GCQGATGGATOTAQCQTATQCCCTTATTTGOOTATOGGTGGTCTAAGATGTT 
200c-TQQQGCQTTQTTOTQCTATTACCTT  ATTTQOGCATCGATTGTCATTTTTTTT 
aOc-QQGGTOTQTTGTQTQTTATTACCTTATTTGOOTOTTtATTTQOTTTGTTTTC 
2  6b-OOOCTTGTGTTGGTATTATTTCCTTATTTOOTGTTTTTATOTTTTTTTQTTT 
2  7  -QGOGTQTOGTAQGGGATATTTCCTTATAAGOTOTTTTTTOTTTTGTTTTCTT
302  -TCACACACOCOOCACOCACTTCCTTATTTQOTCATOTCTTTCGAQTOOTCTC 
9  -QGQAGOGGAGAAAGAAQAGTTCCTTATTTGQOTATOTTTTTTTTTGTTGTTT
19  6c-GGOTOOOTTGOTCGOTATQTOCCTTATTTOOOCCGOCTACAAATACCCCCAC
TTATAA  (n = 4)
17  O-TATCQAAQTTOTTOTATCTTOCCTTATAAOOOCATOTTOCTCACCOAAOGCC
175-OTATTOTGCOTTAQAATATOCCCTTATAAOOCTCQTTATOOGAQTCACTCCC 
187  -QGGQQQTTTGAATTQTTATOCCCTTATAAOGOTTTTTQTTOOTTCGTTOTTC
ATATTT  (n -1 )
2  6c-QTQTQQQQGCAGCGGTTAT  ATCCATATTTOGT  AATOTTTTAQQTCCTTTTQT
ATATTA  (n -1 )
26a-ACAACATATAAAGAAACATTACCATATTAOGACACAAACCAATCCTCCCCAA
Figure  8.13.  SRF  selected  oligonucleotides  from  the  SS2(conSRE)  oligo  pool 
after four rounds of selection.  The 64 unique oligonucleotides are grouped depend­
ing on the core A-T tract of the CArG box. Sequences have been aligned so that maxi­
mum match is on the 5’ flanking region of the CArG box. Only the random sequences 
with the central  partially set CArG  box are shown.  The CArG  box  is underlined. The 
SS2(conSRE) oligonucleotide is shown at the top (the letter W denotes A or T).
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populations not thought to contain MAL-specific motifs, also only recognised the central 
CArG box with the flanking sequences scoring as random (data not shown).
To simplify the analysis,  only  16bp fragments of the randomised regions of both  MAL 
and  SRF selected  oligos,  which  included the  MAL-DNA contact region,  were  used to 
search  for  motifs.  Searches  containing  the  right  or  left  randomised  sequences 
separately did not identify anything above the cut-off for patterns occurring by chance. 
Assuming that potential specific motifs might be symmetric and combining the two sets 
of random sequences as forward (left set) and reverse complementary (right set) also 
produced no results.
Attempts  were  also  made to  use  known  MAL-dependent genes  reported  by  Selvaraj 
and  coworkers  for comparison  (Selvaraj,  A.  et at.,  2004),  but this  approach  was  not 
informative.  It is unclear whether that reflected the absence of specific motifs in these 
promoters.  The  only  published  study  of  MAL-dependent  SRF  target  genes  used  a 
dominant negative  MAL that  indiscriminately  blocks  MRTF and  TCF interactions  with 
SRF ((Selvaraj,  A.  et at.,  2004);  see  also  Introduction)  and  as  a result  it  is  not clear 
whether all  reported  genes  are genuinely  MAL dependent.  Similarly there  is  no clear 
MAL-independent population to compare the MAL-SRF derived sequences.
Thus  it  appears  that  at  least  under  the  conditions  used  and  with  oligonucleotides 
containing  a partially set CArG  box MAL does not recognise sequence specific motifs 
in the MAL-DNA contact regions. Nevertheless the possibility remains that a nucleotide 
bias  during  the  oligonucleotide  synthesis  has  obscured  any  low complexity  patterns. 
Another possibility is that setting the CArG box to CCWWAWWWGG was too stringent 
to  select  optimal  MAL  sites,  or  that  this  sequence  that  matches  the  known  SRF 
consensus is not the preferred MAL-SRF binding site.
8.3.1.2  Investigation  of the  differences  In  the  central  CArG  sequences 
selected by SRF versus MAL-SRF
As  discussed  previously the  original  SRF binding  site  selection  derived  an  extended 
SRE  consensus that  included the CArG  box  halfsite  and the  sequences  immediately 
adjacent to it ((Pollock,  R.  et a/.,  1990); see Section 8.2.1.1).  Although the ATG(notG) 
consensus  flanking  the  CArG  box  identified  in  that  study  does  not  appear  to  be
279Chapter 8 Appendix
conserved in either the SRF or the SRF-MAL datasets, there appears to be sequence 
bias  in this  region  (Figure 8.12 and  Figure 8.13).  I therefore proceeded to  investigate 
the sequence  preference of the  MAL-SRF and SRF selected oligos in the nucleotides 
immediately adjacent to CArG  box.  The fact that the CArG  box  has been  partially set 
limits the potential observable differences that might be observed within the core 10bp 
of the site.
The  Improbizer  programme  was  used  to  search  for  sequence  preferences  in  the 
regions bordering the CArG box and a plot of nucleotide frequency was produced. The 
extended motif derived from the SRF dataset broadly matched that identified by Pollock 
and  Treisman  ((Pollock,  R.  et  al.,  1990);  Figure  8.14,  compare  panels  A  and  B), 
although in contrast to the invariance of the ATGC tetranucleotide on the 5’ side in the 
original study, the base usage in the SRF motif derived here varied greatly.
The  process was  repeated for the  MAL-SRF dataset and  a nucleotide frequency plot 
was produced (Figure 8.14C). This differed from that of SRF at positions -7 and -6. At 
position -7 MAL selected predominantly T followed by G, while SRF selected G and T 
with roughly equal frequencies. At position -6 SRF showed no nucleotide bias whereas 
MAL showed  preference for T or G.  Differences were also seen at position +7 where 
MAL showed no preference, while SRF displayed a small bias for C or T.
In order to identify the consensus halfsites for each dataset, the oligonucleotides were 
divided  in  half  and  the  right  side  was  combined  with  the  reverse  complementary 
version of the left side.  The halfsite motifs identified by the Improbizer programme for 
the  SRF  and  MAL-SRF  selected  sequences  varied  only  in  position  ±7  where  SRF 
selected  predominantly  G,  while  MAL selected  mainly T.  It should  be  noted  however 
that the selection  frequencies  of the  predominant bases  in  either case  are quite  low. 
Thus although small differences can be identified in the CArG box flanking sequences 
selected  by  SRF  and  the  MAL-SRF  complex,  these  are  not  striking.  This  does  not 
preclude a possible significance of these differences in the formation of MAL-SRF-DNA 
complexes.  For instance DNA bending and cofactor selection by MCM1  depends to an 
extent on the sequences directly flanking the MCM1  site (Acton, T. B. et al.,  1997; Lim,
F.  L.  et  al.,  2003).  The  importance  of  these  differences  was  not  investigated 
experimentally due to time limitations.
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Figure 8.14. Consensus motifs derived from the MAL-SRF and SRF selected SS2.(conSRE) oligonucleotides. (A) The extended consensus and 
halfsite consensus derived by (Pollock and Treisman, 1990). Bases shown one over the other denote preference for the top base. (B) Extended and 
halfsite consensus motif derived from the SRF dataset. The size of the letters represents their frequency at each position. The preset CArG sequence 
within the random oligonucleotide is shown in black under the motif. The letter W designates A or T. The extended consensus motifs were derived with 
the  Improbizer programme, searching for sequence bias extending on either side of the  10bp CArG  motif. The halfsites were derived in the same 
manner by dividing the oligos in half and combining the forward (left side) and reverse complement (right side) sequences. Motif images were made 
with the weblogo programme. (C) Extended and halfsite consensus motif derived from the MAL-SRF dataset. Motifs were derived as in B.Chapter 8 Appendix
8.4  Evaluation  of  the  site  selection  experiments  and  future 
directions
The two binding site selection experiments presented in this section do not conclusively 
address the  sequence dependence  of the  MAL-SRF complex  formation.  Attempts  to 
select MAL-SRF specific sites from a completely random oligonucleotide pool in order 
to investigate whether the sequence of the CArG box  itself affected MAL-SRF complex 
formation,  were  unsuccessful  due  to  technical  problems.  The  subsequent  discovery 
that MAL contacts DNA flanking the main SRF-CArG complex, and that these contacts 
are  required  for  efficient  MAL-SRF  complex  formation  increased  the  length  of  the 
sequences  that  would  have  to  be  examined  in  order to  identify  authentic  MAL-SRF 
DNA  specificity.  The  second  binding  site  selection  approach  involved  including  a 
partially set CArG  box  in the  middle of the  random sequence in  order to  explore the 
sequence specificity of the MAL-DNA interactions. The results of this experiment were 
inconclusive,  since  time  constraints  did  not  allow  completion  of  the  data  analysis. 
Analysis  of the  preliminary  data  indicates that  despite  the  possibility of  a  nucleotide 
bias  in  the  original  oligonucleotide  pool,  the  MAL-SRF  selected  sequences  exhibit  a 
preference for T-tracts on either side of the CArG box. These sequences did not reveal 
specific patterns, but this could be due to the biased oligonucleotide synthesis. It would 
be  interesting  to  pursue this  observation  further  in  order to  investigate  whether  MAL 
selects CArG sites located within intrinsically more flexible sequences. A starting point 
to  achieve  this  would  be  using  a  similar  binding  site  selection  approach.  Control 
procedures should be added to ensure the unbiased synthesis of the original  random 
oligonucleotide  material.  This could be easily achieved  by sequencing samples of the 
original double-stranded  DNA.  This  experiment could also  be  modified to  explore the 
sequence  specificity  of  MAL-SRF  selected  CArG  boxes,  by  constraining  fewer 
nucleotides in the central random sequence to the CArG box consensus.
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